"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Fourth Quarter 2015 Earnings Conference Call. My name is Candace, and I'll be your operator for today. [Operator Instructions] And as a reminder, this conference call is b",63,"Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Fourth Quarter 2015 Earnings Conference Call. My name is Candace, and I'll be your operator for today. [Operator Instructions] And as a reminder, this conference call is being recorded. I would now like to turn the call over to Patrick O'Brien, Vice President of Investor Relations. Please go ahead."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Candance, and good afternoon, everyone. Just after market closed today, a press release was issued with earnings results for the fourth quarter and full year 2015. The press release and detailed slides are available on the Investor Relations se",232,"Thank you, Candance, and good afternoon, everyone. Just after market closed today, a press release was issued with earnings results for the fourth quarter and full year 2015. The press release and detailed slides are available on the Investor Relations section of the Gilead Sciences website. 
Joining today's call will be John Martin, Chairman and Chief Executive Officer; John Milligan, President and Chief Operating Officer; Norbert Bischofberger, Executive Vice President of Research and Development and Chief Scientific Officer; Paul Carter, Executive Vice President commercial operations; and Robin Washington, Executive Vice President and Chief Financial Officer. 
Before beginning formal remarks, let me remind you that we'll be making forward-looking statements, including plans and expectations with respect to products, product candidates, financial projections and the use of capital, all of which involve certain assumptions, risks and uncertainties that are beyond our control and could cause actual results to differ materially from these statements. A description of these risks can be found in the latest SEC disclosure documents and recent press releases. 
In addition, Gilead does not undertake any obligation to update any forward-looking statements made during this call. 
Non-GAAP financial measures will be used to help you understand the company's underlying business performance. The GAAP to non-GAAP reconciliations are provided in the earnings release, press release as well as on the Gilead Sciences website. 
I will now turn the call over to John Martin."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Patrick, and thank you, everyone, for joining us today. 2015 was an exceptional year for Gilead, with progress in a number of therapeutic areas, most notably in the development of TAF-based therapies for HIV and hepatitis B and new agents for",226,"Thank you, Patrick, and thank you, everyone, for joining us today. 
2015 was an exceptional year for Gilead, with progress in a number of therapeutic areas, most notably in the development of TAF-based therapies for HIV and hepatitis B and new agents for the treatment of liver disease. Gilead is entering 2016 from a position of financial strength, a portfolio of 20 marketed products that address significant segment medical needs, including Genvoya, the most recent to be introduced; and the growing pipeline with multiple programs for which milestones are expected during the coming year, including regulatory decisions on 2 products for HIV and one each for HCV and HPV. 
As you all know, we announced on Friday that John Milligan will be appointed CEO, a role he will assume in a few weeks. I will be taking on the role of Executive Chairman and will continue to be actively engaged in the company. John Milligan has been with Gilead for more than 25 years and, over that time, has built expertise in every functional area of the company's operations. The Board and I are confident that this is the right time for this transition and that John is the right person to lead Gilead in the next few years of evolution. 
John, congratulations. I'll now turn the call over to you to make a few remarks."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, John. I'm honored and excited by the opportunity to lead this company and the great team we have. In my new role, I will continue to work hard to help Gilead's business grow beyond antivirals imaging and enter new therapeutic areas for the betterm",1158,"Thanks, John. I'm honored and excited by the opportunity to lead this company and the great team we have. In my new role, I will continue to work hard to help Gilead's business grow beyond antivirals imaging and enter new therapeutic areas for the betterment of patients. 
[indiscernible] Greatly appreciated that John Merman closely involved as the Executive Chairman. 
Turning to the business and result of the quarter. Genvoya, the company's first TAFs single-tablet original for the treatment of HIV-1 infection, is approved in the U.S. and Europe. Genvoya achieved preferred status in the U.S. Department of Health and Human Services treatment guidelines within the first 2 weeks after approval, which speaks to the profile of the product and the important needs it addresses. 
Two other TAF-based regimens are pending regulatory approval in the U.S. and EU. F/TAF has been assigned a PDUFA date of April 7 and in the EU, a CHMP opinion could be adopted in the first quarter of this year. RF/TAF has been assigned a PDUFA date of March 1, and a CHMP opinion is expected in the second half of this year. This means that Gilead could launch 2 new TAF is in a products in the coming months giving patients a wider range of options for the treatment of their HIV. 
During the last quarter, 4 Phase III studies of GS 9883, Gilead proprietary integrase inhibitor, combined in a single-tablet cover with F/TAF were initiated. Two studies will evaluate the safety and efficacy of GS 9883F F/TAF in HIV-1-infected treatment-naive adults. One will compare GS 983 F/TAF to Triumeq, and the other will compare GS 9883 F/TAF to [indiscernible] plus F/TAF. 
Two other studies will evaluate patients who switched from Triumeq or a boosted PI to GS 9883 F/TAF. 
Phase II data on GS 9883 F/TAF will be presented later conference in the safety enough to their activity over 48 weeks of treatment. Analysis of the data through 24 weeks indicated that an FCR of GS 9883 F/TAF may represent a valuable option for many patients. And based on current timelines, the U.S. NDA and EU MAA could be filed in the second half of next year. 
Last month, Gilead submitted a new drug application in the U.S. and a Marketing Authorization Application in the EU for TAF as a treatment for chronic hepatitis B. Regulatory submissions are also expected in Japan, Korea, Taiwan and India this year and China in the first half of 2017. 
Phase III study results reflect high efficacy and improved renal and bone safety parameters, similar to those seen in the clinical studies evaluating TAF-based regimens for HIV. 
Beyond TAF for HCV, several ongoing research programs are focused on therapies with finite duration of dosing that achieved long-term viral suppression. The first-in-human approach where multiple programs are evaluating different ways to activate immune system to eliminate  infected effective hepatocytes. The most advanced is our TLR-7 agonist, GS-9620, which is currently in 2 Phase II studies. Other approaches include the combination of novel direct-acting antiviral and agents that modulate cccDNA transcription. Two of these new programs may enter into clinical trials in the first half of 2016. 
In hepatitis C, Gilead's focus remains on advancing care of people with disease regardless of genotypes or disease severity. This launch Sovaldi December 2013 and Harvoni in October 2014, more than 770,000 individuals around the world have been treated with sofosbuvir-based regimen. 
In November, FDA approved Harvoni for expanded use in patients with genotype 4, 5 and 6 chronic HCV infection and patients co-infected with HIV. In addition, Harvoni plus [indiscernible] for 12 weeks was approved as an alternate therapy to 24 weeks of Harvoni for treatment experience genotype-1 patients with sclerosis. 
Investigational once-daily pan-genotypic combinations studied for the treatment of genotypes 1 through 6 chronic HCV infection, including patients with compensated and decompensated sclerosis. FDA granted priority review and has set a PDUFA date of June 28, 2016. 
Additionally, ledipasvir/sofosbuvir has been granted accelerated assessment in the EU. If approved, sofosbuvir/velpatasvir will represent a significant step forward, particularly for genotype 3 patients, and will also become the first and only regimen offering high SVR8 which 12 weeks of treatment of all for patients with HCV genotypes. 
The advances in treatment of HCV with Sovaldi and Harvoni over the past 2 years have allowed Gilead to work with governments and public health experts on eradication strategies amongst specific populations and geographies. Programs such as those ongoing in the Republic of Georgia and Iceland could serve as examples for other governments around the world seeking to eradicate HCV. 
Public-health programs to prevent HIV transmission are also underway, including efforts to raise awareness about the use of Truvada for PrEP. Today, more than 40,000 patients in the U.S. are receiving Truvada for preventive indication. Yesterday, the MAA was validated for Gilead's type 2 variation of Truvada for PrEP, and it is now under evaluation by the EMA. 
Gilead continues its R&D effort in NASH, or nonalcoholic hepatitis. Phase II studies of [indiscernible], a targeting antibody, are ongoing in patients with NASH and also primary sclerosing cholangitis. The data Monitoring Committee for these studies recently met and recommends the continuation of the studies, which have a 96-week endpoint. 
Additionally, clinical studies of the FXR agonist, GS 9674, have been initiated, with the first patients receiving treatment in Q4 of last year. 
Moving to oncology. Gilead continues to study [indiscernible] in several hematological disorders. Phase III study results show adding [indiscernible] to [indiscernible] and rituximab provides statistically significant and clinically meaningful improvements in progression-free and overall survival compared to the domestic and rituximab alone. 
Supplemental regulatory filings are planned in the U.S. and Europe early this year to include these important new data. 
Beyond [indiscernible], Gilead also is exploring novel combinations of investigational therapies for a range of cancers, including 4 classes of kinase inhibitors through PI3K, 6 Jack and BTK, that each target different signaling pathways. 
Progress has been made in inflammation as well. Gilead entered into a global partnership with Galapagos [ph] late last year for the development and commercialization of [indiscernible], a JAK 1 inhibitor for rheumatoid arthritis and other inflammatory diseases. Phase II trial data shows that [indiscernible] has the potential to be an effective and well-tolerated oral therapy for patients with RA and Crohn's disease. Phase III studies of [indiscernible] in RA and Crohn's are planned to start later this year. 
In summary, Gilead's substantial pipeline offers numerous opportunities for continued growth, both in the short and longer term, and the financial strength of the company allows us to be thoughtful and opportunistic in pursuing partnerships or acquisitions that will further expand the future portfolio of products. 
2016 will be a busy year for Gilead, and I want to take this opportunity to thank all of our employees for the support in this transition and for their continued hard work and dedication. Paul Carter will now provide a commercial update."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, John, and good afternoon, everyone. Gilead achieved $8.4 billion in net product revenue in the fourth quarter, representing 16% year-over-year growth. U.S. product revenue reached $4.8 billion in the fourth quarter, which is down 14% from the thir",1320,"Thanks, John, and good afternoon, everyone. Gilead achieved $8.4 billion in net product revenue in the fourth quarter, representing 16% year-over-year growth. U.S. product revenue reached $4.8 billion in the fourth quarter, which is down 14% from the third quarter and down 12% on a year-over-year basis, largely due to a decrease of HCV revenue. 
European product revenue reached $1.7 billion in the quarter, which was in line with the prior quarter and up 22% on a year-over-year basis despite the negative 11% foreign exchange impact. 
For the rest of the world, product revenues were $1.9 billion for the full quarter and $3.8 billion for the full year, driven largely by HCV launches in Japan. 
Beginning with hepatitis C. Total HCV product revenue reached $4.9 billion in the fourth quarter. 
In the next few minutes, I'll describe the results for the quarter 4 by region and also describe how we're thinking about the year ahead. 
In the United States, HCV product revenue totaled $2.4 billion, which is down 27% from the third quarter. This decline was impacted by substantially lower VA sales in the fourth quarter. 
In quarter 3, Congress allocated an additional $500 million to the VA for HCV treatment, and this was fully utilized in quarter 3. New patients in the VA were very limited during quarter 4 due to the uncertainty of future funding at that time. Congress has since allocated substantial funding of $1.5 billion for the fiscal year, which will allow treatments in the VA to resume in this quarter. 
In terms of patient numbers in 2015, nearly 250,000 U.S. HCV patients started treatment, with more than 90% of these patients receiving Gilead HCV therapies. 
As I commented last quarter, there were an unusually large number of patient starts in the U.S. in the first quarter of last year, indicative of the rapid initiation of treatment to many warehouse patients, followed by a flattening of patients in the remaining quarters of the year. 
Looking to the future, even with nearly 400,000 patients treated since the launch of Sovaldi, there remain more than 3 million HCV-infected individuals in the U.S. who have let yet to be treated, approximately half of whom are diagnosed according to recent CDC data. 
Long-term education and awareness efforts to increase rates of diagnosis and the flow of HCV-infected patients into treated care are important and will play out over many years, as we know from our experience in HIV. 
Turning to Europe. Hepatitis C revenue was $846 million in the fourth quarter, and we estimate that more than 110,000 patients were treated wit sofosbuvir-based regiments in 2015. 
Following the normal summer seasonality in quarter 3, there was an increase of patient starts throughout Europe in quarter 4, including in the U.K. following the final appraisal determination for Harvoni from Nice. A number of countries in Europe have volume-based incentives of Sovaldi and Harvoni, encourage a high number of patients being treated. 
In quarter 4, the growth in revenues did not match the growth in patient starts because of the impact of certain volume-based agreements, combined with adverse foreign exchange movements. 
In Japan, hepatitis C revenues for the fourth quarter were $1.4 billion. Since the launch of Sovaldi in May and the launch of Harvoni in September, sales of $1.9 billion have been generated in Japan, with Harvoni representing more than $1 billion of that number. 
In late December, pricing and reimbursement negotiations of Sovaldi and Harvoni in Australia were finalized. 
There were a number of variables to consider when thinking about HCV patient numbers and revenues for 2016. Patient starts in the U.S. will likely be similar to 2015 existing levels both observed in the second half and extrapolated for the full year, while the Europe numbers will continue to grow as early launch markets stabilize and new markets ramp up treatment. 
In Japan, patient numbers are difficult to predict because launches are still in the early stages, and to some extent, we are likely seeing the impact of warehoused patients. 
In the rest of the world, we're excited to bring -- to reach new patients in several new markets, notably in Asia-Pacific and in Latin America. 
As we think about revenue, we anticipate that variables to consider include potential shortage duration of treatment, the full year effect of payer contracts in the U.S. and buy Price volume deals in some European markets, which may allow more patients to be treated at a lower per-patient cost. 
We also anticipate that payer mix in the U.S. may shake slightly towards public payers, while in Japan, new legislation will likely result in lower pricing for Sovaldi and Harvoni. 
We are confident in the long-term sustainability of HCV markets worldwide. Despite the number of patients treated today, there are still millions of HCV-infected individuals who have yet to be treated and many that have yet to be diagnosed. There are significant efforts underway by industry, governments and patient organizations to increase rates of diagnosis and linkage to care. 
We're also confident in our competitive position as we enter 2016. Sovaldi and Harvoni are breakthrough therapies that set the bar with cure rates of up to 99%. Data presented at ASLD in November showed real world cure rates with Harvoni that met or exceeded what was predicted by clinical trials, including the 8-week duration of therapy. 
We also look forward to launching our next HCV product, sofosbuvir/velpatasvir, in due course around the world starting later this year. 
Turning to HIV. HIV product revenue reached $3 billion in the fourth quarter. In the U.S., revenues were $2 billion, a 3% increase from the third quarter and up 5% on a year-over-year basis, driven by the continued demand for Stribild, [indiscernible], Truvada and the recent launch of Genvoya. 
Stribild has a strong underlying prescription demand, with year-on-year growth of 40% and 12%, respectively. 
7 out of 10 HIV patients in the U.S. initiate therapy with a Gilead product, and nearly 6 in 10 receive a Gilead single-tablet regimen. 
Genvoya sales have been very encouraging in the first few weeks of launch. Revenues for the quarter were $44 million, with early product uptake well ahead of the launch of Stribild at the same time points. 
Access and reimbursement have been consistent with historical norms in HIV, and the rapid addition of Genvoya to the DHS gap treatment guidelines as a preferred first-line treatment reinforces the safety and efficacy profile observed in clinical trials and reflected in nonproduct label. 
In Europe, HIV revenues were $747 million for the quarter, up 4% from the third quarter, driven by the sales of Stribild and [indiscernible], with a slight decline year-over-year caused by foreign exchange. 
7 out of 10 patients in Europe also started on Truvada-based backbone in 2015. 
Genvoya was launched in Europe in November. Similar to the U.S., we have seen encouraging early product uptake in the 6 countries launched during the fourth quarter. 
A final comment on HIV is that the commercial organization is getting ready to execute the launches of RF/TAF and F/TAF in the next months. 
Turning to other therapy areas. Total revenue for product outside of HIV and HCV, which includes [indiscernible], AmBisome, [indiscernible], Letairis and Ranexa, totaled $1.9 billion in 2015 and grew 16% year-over-year. 
Over the last quarter, progress has been made in the area of cardiovascular disease. Since the inclusion of the ambition data in the Letairis label, we've seen a great deal of interest in engagement from  the medical community. 
Revenue for the full year for Letairis received -- reached $700 million, and market share for the products among patients initiating therapy is nearly 50%. 
In closing, Gilead had a remarkable 2015. The commercial organization's excited about the opportunities across all of Gilead's therapeutic areas, both in the near  term and over the longer term, to help many more patients around the world. 
And I'll now turn the call over to Robin."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Paul, and good afternoon, everyone. We are pleased to share full year and fourth quarter 2015 financial results and provide 2016 guidance. For the fourth quarter, total revenues were $8.5 billion, up 16% compared to the fourth quarter of 2014",1033,"Thank you, Paul, and good afternoon, everyone. We are pleased to share full year and fourth quarter 2015 financial results and provide 2016 guidance. 
For the fourth quarter, total revenues were $8.5 billion, up 16% compared to the fourth quarter of 2014. Net income for the quarter was $4.7 billion or $3.18 per diluted share compared to $3.5 billion or $2.18 per diluted share for the fourth quarter of 2014. 
Non-GAAP diluted EPS for the fourth quarter was $3.32 per share, up 37% compared to the fourth quarter of 2014. 
Turning to fiscal year 2015. Full year total revenues were $32.6 billion, up 31% year-over-year. 
Net income for the year was $18.1 billion or $11.91 per diluted share compared to $21 billion or $7.35 per diluted share for 2014. 
Non-GAAP diluted EPS was $12.61 per share for the year, up 56% year-over-year. 
Product sales during the year were $32.2 billion, up 31% year-over-year. HCV product sales increased year-over-year to $19.1 billion, up 54%. And non-HCV product sales increased year-over-year to $13 billion, up 8%. 
The increase in HCV product sales for the year was primarily driven by sales of Harvoni, which launched in October 2014. Further, the annualized HCV gross-to-net- estimate that was shared with you during the Q4 earnings call a year ago is on target and reflected in our 2015 results. 
Non-HCV product sales growth for the year was primarily driven by Stribild and Complera [indiscernible], partially offset by [indiscernible]. 
Turning to expenses for the full year 2015. Non-GAAP R&D expenses were $2.8 billion, up 10% compared to the prior year, reflecting the continued progression of our product pipeline. Non-GAAP SG&A expenses were $3.2 billion, up 17% compared to the prior year, driven by expenses to support our growth and geographic expansion. 
The non-GAAP effective tax rate for the full year was 16.2%, which was lower compared to guidance due to the permanent extension of the federal R&D credit that was passed in December. If you recall, the permanent extension of the credit was not included in 2015 guidance. 
Cash flows from operations were $20.3 billion for the full year 2015 and $4.9 billion for the fourth quarter. 
With respect to shareholder return, $3.1 billion in cash was utilized to repurchase 29 million shares during the quarter, bringing total 2015 share repurchases to 10,095,000,000 [ph] shares. Including the Q2 2015 warrant settlement of $3.9 billion dividends and share repurchases, Gilead has returned more than $15 billion in cash to shareholders in 2015. 
Earlier today, we announced an increase of the quarterly dividend from $0.43 per share to $0.47 per share, which will become effective in the second quarter of 2016, subject to a declaration by the Board of Directors. 
Additionally, the Board authorized a new $12 billion share repurchase program to be initiated after the completion of the current $15 billion program, which, as of December 31, 2015, had $8 billion remaining. 
Also announced was the utilization of $5 billion of the current program to enter into an accelerated share repurchase agreement, which is expected to be completed in the next 3 months. This is in addition to the ongoing open-market share repurchases that have continued under the current share repurchase program since January of this year. 
The increase in the dividend and increased level of share repurchases underscore the confidence of the Board and management in the strength of the business and future cash flows. 
Since 2010, in addition to financing ongoing R&D programs and business development activities, more than 75% of free cash flows were returned to shareholders, and share count was reduced in excess of 20% while maintaining and improving investment-grade credit ratings, which Gilead values. 
Looking forward, the plan is to continue to return a significant component of free cash flow to shareholders via share repurchases and increases to our dividend over time. 
As in the past, there could be future periods of time when share repurchases are reduced due to acquisitions and other pipeline investments that are prioritized to drive future long-term growth. This strategy provides agility and financial flexibility to support R&D investments as well as any future acquisitions or partnership opportunities we may consider. 
Finally, I would like to cover full year 2016 non-GAAP financial guidance summarized on Slide 51 in the earnings presentation available on the Gilead website. 
Product sales are expected to be in the range of $30 billion to $31 billion. Guides for product sales is subject to a number of uncertainties, including an uncertain global macroeconomic environment, adoption of additional pricing measures to reduce HCV spending; volatility in foreign currency exchange rates; inaccuracy and HCV patients start estimates; additional competitive launches in HCV; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers and a larger-than-anticipated shift in payer mix to more highly discounted payer segments, such as PAS, FSS, Medicaid and the VA. 
Non-GAAP product gross margins are expected to be in the range of 88% to 90%. Non-GAAP R&D expenses are expected to be in the range of $3.2 billion to $3.5 billion as a result of the continued investment in our product pipeline. This includes the financial impact of the Galapagos calibration, or collaboration, which closed in January. 
Non-GAAP SG&A expenses are expected to be in the range of $3.3 billion to $3.6 billion. This reflects an estimated $200 million increase for the U.S.-branded prescription drug fee. Please note that 2015 included a favorable adjustment of approximately $100 million based on the receipt of the 2015 invoice from the IRS. 
For the full year, the non-GAAP effective tax rate is expected to be in the range of 18% to 20%. This includes the impact of the federal R&D tax credit, which was permanently extended at the end of 2015 and the increase for the U.S.-branded prescription drug fee, which is not tax-deductible. 
Full year diluted EPS impact of acquisition-related restructuring and stock-based compensation expenses is expected to be in the range of $1.10 to $1.16 per share. 
In closing, we are pleased with 2015 accomplishments across the organization. Thank you, and we look forward to updating you on our progress. 
Let's now open the call for questions. Operator?"
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","[Operator Instructions] And our first question comes from Geoff Meacham of Barclays.",12,"[Operator Instructions] And our first question comes from Geoff Meacham of Barclays."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","With regards to 2016 guidance, how we should think about the top line guidance and what it implies for any loosening of restrictions in the lower fibrosis core groups or any changes in their pricing? And maybe that's a more detailed than you're ready to g",62,"With regards to 2016 guidance, how we should think about the top line guidance and what it implies for any loosening of restrictions in the lower fibrosis core groups or any changes in their pricing? And maybe that's a more detailed than you're ready to go maybe give us frame how we should think about these levers in 2016 relative to 2015."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Okay. So I think I said in the script that we should anticipate in the United States that 2016 revenues should be more or less based on the second half of 2015 extrapolated for the year. I also mentioned that we had some lumpiness in the second half of th",607,"Okay. So I think I said in the script that we should anticipate in the United States that 2016 revenues should be more or less based on the second half of 2015 extrapolated for the year. I also mentioned that we had some lumpiness in the second half of the year due to the purchasing profile of the VA. And we anticipate that, that will smooth out during the course of this year. I've also said numerous times before that in quarter 1 last year we had a very large bogus of warehoused patients being treated which, of course, we're unlikely to see again. But to some extent, that gets substituted as the payers, commercial payers, that we are well-known are beginning to loosen restrictions. So there's a few dynamics in the U.S., but I think the way that I would look at it is a fairly flat stable, perhaps more generally growing number of patients going into treatment. If we see public players stepping up like Medicaid and perhaps a correctional facility to start treating more patients, then patients down could go higher than that in 2016. There's a few other factors, which I also mentioned as we think about the revenue aspect as opposed to just patient numbers. The next 6 [ph] patients, GT1 patients are qualified are more likely to be using the 8-week HARVONI treatment duration. And of course, therefore, revenue per patient will come down proportionately. Having said that, the offset is that budgets for treating patients go up, and we would like to think that more patients could be treated. So I think that's sort of the main thing. I think from a competitive point of view, we feel very confident that our label is very strong and that we are very much supported by the real world data that we've seen since the launch of Harvoni and with very high SVR rates and  a very strong safety profile, at least as good, if not better, than the one that was used in our registrational trials. So I think we feel good about the year. The U.S. is fairly steady and possibly could even grow, as I said with, some restrictions, loosen and from them in public payers step up. Around the world, as I mentioned, we expect patient numbers to grow in Europe. They started to stabilize in the major markets now and again following more or less the shape of the curve in the U.S., where there is a large lump because of warehoused operations being treated initially with. That is smoothing out now. And many of the smaller markets are now beginning to come on onstream. And so we should see a number of patients in the U.S. but the same thing, we'll like to see more patients be treated with shorter durations. And I also mentioned, we have a number of price and volume agreements in place, which are delivered in incentive wise to encourage high volumes of patients being treated but at a lower revenue per patient, if you like. So we should think about that. And then around the rest of the world, Japan, I mentioned, very early days. We're still in that warehousing phase, I think, in Japan, although we're very pleased with the launch of their so far. And then there are various other small markets around the world and medium-sized markets, Canada, Australia being one of the medium-sized markets that are yet to launch here. So we have plenty of patients around the world, but there are some other dynamics, as I said, around shorter treatment and, of course, the competitive situation."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Mark Schoenebaum from Evercore ISI.",11,"And our next question comes from Mark Schoenebaum from Evercore ISI."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","[indiscernible] On behalf of Mark Schoenebaum. I have a question about [indiscernible] specific JAK 1, the one you got from Galapagos. Just curious thoughts, talks, conference as well as whether your base case will be 200 milligrams daily dose going forwa",64,"[indiscernible] On behalf of Mark Schoenebaum. I have a question about [indiscernible] specific JAK 1, the one you got from Galapagos. Just curious thoughts, talks, conference as well as whether your base case will be 200 milligrams daily dose going forward in the U.S. And sort of somewhat related question. What's exactly impacting your 2016 guidance of -- on R&D expenses from Galapagos collaboration?"
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. So maybe I could enter the first few questions. So we were very excited about [indiscernible] because of the clinical profile. As you know, they have now data. Galapagos has generated data in our aid and also in Crohn's. Both of those have remarkable",136,"Yes. So maybe I could enter the first few questions. So we were very excited about [indiscernible] because of the clinical profile. As you know, they have now data. Galapagos has generated data in our aid and also in Crohn's. Both of those have remarkable efficacy. And also importantly, we think that [indiscernible] can be distinguished from competitors because of its safety profile, in particular, the lack of hemoglobin decreases and the very low infection rates. The other thing you asked about, the dose, that still needs to be negotiated with the FDA. We actually have a meeting coming up in the next couple of months, where we will talk about, in detail, the Phase III program designed, including the doses. So it's really, at this point, too early to say what the dose will be."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","And this is Robin, to answer the second part of your question. We really have included, relative to the collaboration, the --  some of the upfront milestone payments as well as the costs associated with some of the Phase III trials that Norbert just spoke",74,"And this is Robin, to answer the second part of your question. We really have included, relative to the collaboration, the --  some of the upfront milestone payments as well as the costs associated with some of the Phase III trials that Norbert just spoke about. So we don't break it out in detail, but I would assume a couple of hundred million incremental to 2015 included in our guidance to support those projects."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Matt Roden of UBS.",10,"And our next question comes from Matt Roden of UBS."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Congrats to John Martin for an amazing 20 years at the helm here. So I have a big picture question. Seems like a good time to ask it, I guess, with the transition. Over the last 2 years, you've tripled your revenues. You've increased your earnings by abou",140,"Congrats to John Martin for an amazing 20 years at the helm here. So I have a big picture question. Seems like a good time to ask it, I guess, with the transition. Over the last 2 years, you've tripled your revenues. You've increased your earnings by about sixfold over that period. But the market seems to be discussed your ability to grow the business from here. Just wanted to see whether you can lay out a vision of the development to the various franchise that you have. You have -- a lot's going on in cancer, you've added to the inflammation franchise. You have TAF, 9883 in HIV. Just wondering if he could maybe shine a light on how you visualize the growth up to, say, 2020 something like that. It would be really helpful to hear your thoughts."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Matt, it's John Madigan. I assume the question is not for me, not the congratulatory one to John Martin. So it's a very good question. Whoever will take it. Well, I'll take it. I'd be happy to. It's a very good question. You're right, we are facing extrao",568,"Matt, it's John Madigan. I assume the question is not for me, not the congratulatory one to John Martin. So it's a very good question. Whoever will take it. Well, I'll take it. I'd be happy to. It's a very good question. You're right, we are facing extraordinary time when we've been able to triple revenue over the last couple of years, which is a very unusual thing for an organization to be able to do. And we're moving our pipeline along as fast as we can, and as we mentioned, there's some very interesting opportunities for us. So we do see very good opportunities in organic growth, and I have great confidence in HIV portfolio that with the 3 STRSs  we talked about on the call today and the other STR being developed by our partner, Johnson, that will have very -- a meaningful continued growth of both patients and revenues in the future in HIV. I think that's a very important thing for us. We're continuing to accelerate HCV to bring it SOF/VEL to market and work in  more countries than we ever have before. So those are important additions and some things current markets. We're very excited about [indiscernible].. I think there's good opportunities in inflammatory diseases. We have spoken about is very much in the past, and sort of quietly, we've been investigating our MMP-9 antibody, 5745, which we didn't talk about on this call, which now has positive data in 3 of the 4 indications we've looked at an in inflammatory diseases, with the fourth under investigation. And so not only do we have [indiscernible] potentially for our inflammatory disease, but we have an antibody, which has a mechanism, which is very refractory to current care and could be a very good beginning to inflammatory disease franchise. Of course, you mentioned the kinase inhibitor that we have for oncology. There's always a potential that those could be useful in various diseases in combination with [indiscernible] as well, and we will explore that, although I still think the best value of it is the fact that it's a very good-looking drug and some very positive data in Crohn's disease. So we are going down the pathway of inflammatory disease by virtue of the successes we have in our pipeline and successes in licensing. Oncology, it's -- [indiscernible] has been a good start for us. We really need to continue to try to ramp up our efforts in this area and to continue to broaden the areas we want to work in. It's pretty clear we have to do additional partnerships or find other avenues to broaden the revenu stream there for the future. And as Robin mentioned, with our balance sheet, we have to create flexibly of the new partnerships or acquisitions that could get us there, so that would be an important consideration for us. That may not be the only avenue. We also look at other areas where we can bring in different programs, potentially accelerating the revenue as soon as possible in some of those areas when those things are available. And if the environment has shifted dramatically in our favor, we're doing those sorts of partnerships and whatnot. So that's a good -- 2016, I believe, will be a good year for us because of the strengths of the underlying business and the economic uncertainty that's driving the market today."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","John, can I add something maybe? I would like to reiterate what Robin said in her script. If you look back at the last 6 years, it has been very remarkable. We have done many, many deals in [indiscernible], [indiscernible], Galapagos. And yet, we were abl",83,"John, can I add something maybe? I would like to reiterate what Robin said in her script. If you look back at the last 6 years, it has been very remarkable. We have done many, many deals in [indiscernible], [indiscernible], Galapagos. And yet, we were able to return 70% of the free cash flow to shareholders. So I think that is a good way to think about the future, to in-license the collaborative efforts while, at the same time, returning money to shareholders."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Michael Yee of RBC Capital Markets.",12,"And our next question comes from Michael Yee of RBC Capital Markets."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","My congrats to John Milligan as well. Looking forward to a new era. I wanted to ask a bit of a 2-part question. One is you gave some guidance here. And remarkably, like the last question, it actually looks like you're a little flattish or whatnot this yea",134,"My congrats to John Milligan as well. Looking forward to a new era. I wanted to ask a bit of a 2-part question. One is you gave some guidance here. And remarkably, like the last question, it actually looks like you're a little flattish or whatnot this year. Do you expect, qualitatively, to be growing over the next year? And two, do you expect that this is a bit of a trough revenue here? I just want to get your view on that. And importantly, when you look at managed care, given that there's any competitor onboard, do you expect minimal to no changes or minimal changes in terms of access and things like that? Just given new competition, can you talk a little bit about about that [indiscernible] how that can change [indiscernible]."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","It's Michael [indiscernible]. First of all, thank you for the congratulations. The second of all, unfortunately, we can't tell you about revenue growth beyond. We have a lot of opportunities, but obviously, we don't give 2017 or beyond guidance. We, in th",141,"It's Michael [indiscernible]. First of all, thank you for the congratulations. The second of all, unfortunately, we can't tell you about revenue growth beyond. We have a lot of opportunities, but obviously, we don't give 2017 or beyond guidance. We, in this business, you almost have to take things 1 year at a, time especially in hepatitis C, as we understand the rate of diagnosis for patients coming to care, which is great opportunity out there with 1.5 million patients, as Paul mentioned, still being diagnosed but not yet under care, so really good opportunities for us. With regard to the competition coming to market, we have a very, very strong position, but I'm going to turn this over to Paul because he'd like to give you some of his thoughts on what the competitive landscape looks like versus Harvoni."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. Thanks, John. I mean, think we've our minds about 12 months. We had the first competitive coming to the hepatitis C space. And I think the managed care view at that time was that these products were interchangeable and could be treated by commodities",238,"Yes. Thanks, John. I mean, think we've our minds about 12 months. We had the first competitive coming to the hepatitis C space. And I think the managed care view at that time was that these products were interchangeable and could be treated by commodities, to some extent, which really triggered the pricing and negotiations we saw in early part of last year. That has been proven to be a totally incorrect view of the hepatitis C products. And what we've seen, fortunately, with Harvoni, in particular, is a real-world data really strengthened its position and people's understanding what our product does. It has curious people with an incredibly high SVR rates, and the safety profile has been extremely good and in line, if not better, than its label. That hasn't been the case of competitive products so far. In fact, we've seen safety warnings added to labels, and we've seen a differentiation. And that's played out in the market. So I think as we see our new competitors are coming into the market, now payers are really thinking this through. There isn't any kind of sort of instinctive reactions. People have been very thoughtful, and we noticed because we have a very close discussions with the managed care main players. And we're working with them as they think through this. And I think we feel pretty confident that we'll maintain a strong position as we enter 2016."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Matthew Harrison of Morgan Stanley.",11,"And our next question comes from Matthew Harrison of Morgan Stanley."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","And my congratulations to both John. I thought if I could just ask 2 related specific questions. So first, Paul, maybe, I just want to make sure I understand what you're trying to say with respect to U.S. HCV volumes. If we look at the 2 volumes, the numb",163,"And my congratulations to both John. I thought if I could just ask 2 related specific questions. So first, Paul, maybe, I just want to make sure I understand what you're trying to say with respect to U.S. HCV volumes. If we look at the 2 volumes, the numbers you've given up in the third and the fourth quarter, it's about 105,000 patients together, which is about 210 on a full-year basis, which is below the 236 you guys reported. And if we take the low end of the 47,000, which it sounds like because of being from the fourth quarter, that 188,000 and you might -- just if you can give us some direction, I'm sure you're not going to tell us a number, around those numbers, just so we're clear on exactly what you're trying to say. And then maybe related to that, can you just specifically address where you think access is going to for Medicaid in [indiscernible] this year?"
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Sure. So if you've got your pencil ready, these are numbers that, I think, happened last year. In fact, thank you but even to quarter 4, quarter third [ph], quarter 4 2014 where we think 46,000 HCV starts were in the market. These are total starts, by the",286,"Sure. So if you've got your pencil ready, these are numbers that, I think, happened last year. In fact, thank you but even to quarter 4, quarter third [ph], quarter 4 2014 where we think 46,000 HCV starts were in the market. These are total starts, by the way. In quarter 1, 2015, there were 72, and that really was the peak of this warehoused patient  part of the curve, then dropped down into quarter 2 of 65,000. There were still some of those warehoused patients coming through. And then quarter 3 was 62,000, and quarter 4 was 50,000. We know that in quarter 3, a lot of patients were treated by the VA who, by the way, seems to be incredibly efficient in getting patients into treatment. And we know that in quarter 4, very few patients were initiated by the VA. So I think if you do the basic math on that, you get up to about 230-something-thousand forecasting that forward into 2016 if you assume the VA picks up. Then I think this sort of merges into the second part of your question, which is what happens with Medicaid and other public payers who, today, have really treated very, very few people. So our assumption is they're still not going to treat that many more patients this year, it's the way we're thinking forward, but we're hopeful that, that will be a trend that improves over time, that people start to see how effective these drugs are, and particularly, the 8-week usage of Harvoni, which, as I mentioned, in the real world seems to be incredibly effective and offers very good value. So that's how we're thinking about it. I hope that's clear."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Cory Kasimov of JPMorgan.",10,"And our next question comes from Cory Kasimov of JPMorgan."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Also my congrats to both John and John on a great run and a great opportunity. So I wanted to ask about longer-term trends, the evolution of the HCV market. I know it's hard for everyone to get their hands around, but you indicated again there were about",163,"Also my congrats to both John and John on a great run and a great opportunity. So I wanted to ask about longer-term trends, the evolution of the HCV market. I know it's hard for everyone to get their hands around, but you indicated again there were about 3 million HCV patients in the U.S. that have yet to be treated. About half of those are diagnosed. In terms of new patients that are entering the system, how similar or different are they from the existing patients or those that have already been cured in terms of, I guess, the overall motivation to be treated fibrosis score insurance coverage, we get a lot of questions on our in the legitimate candidates in terms of being under the care of a doc, not IV drug users, et cetera. So could you just comment, try to give us a little more comfort and how we should be thinking about this longer-term evolution in the U.S.?"
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","So Cory, I've mentioned before that we have some proprietary research that we do to try and monitor the patients into treated care, and that means people who are diagnosed with hepatitis C and are registered with a hepatitis C prescriber. And that number",240,"So Cory, I've mentioned before that we have some proprietary research that we do to try and monitor the patients into treated care, and that means people who are diagnosed with hepatitis C and are registered with a hepatitis C prescriber. And that number has been remarkably consistent at around -- we have actually 3 different sources of data, and it's around high 20s to 30,000 patients a month have been fully in that category. So they're diagnosed with HCV and they're registered with a treater. So if you do the math on that, clearly, that 360,000 patients coming into treatment a year, and we're seeing treatment levels are lower than that. And what that speaks to is the types of patients are different amongst that 360,000 group. And that sort of pathway to actual treatment varies considerably. But that does appear, again, doing the math and assuming the research is correct, that there is a line at the door of patients that still need to be treated and are acceptable. I don't think those are the people that are, let's say, out of society or -- these are people that are accessible and for one reason or another reason, that they haven't started treatment yet. But there's a strong flow of patients still out there, and I don't think we're anywhere near getting to the point where we're dealing with patients that are extremely difficult, let's say, to manage."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Phil Nadeau of Cowen & Company.",11,"And our next question comes from Phil Nadeau of Cowen & Company."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","John Milligan, a question for you. I found it interesting that in your prepared remarks, wherever you're introduced, you mentioned that you wanted to take Gilead into therapeutic areas outside of antivirals. And I know, in an answer to a prior question, y",85,"John Milligan, a question for you. I found it interesting that in your prepared remarks, wherever you're introduced, you mentioned that you wanted to take Gilead into therapeutic areas outside of antivirals. And I know, in an answer to a prior question, you went through the assets you have  in other areas. I'm curious whether you're signaling a need for even more assets in those areas. And in particular, if you had a shopping list, which areas will be on the top of your list?"
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","So I mean, it's pretty clear we've done some great things in HIV and HCV. But for the company to grow, we have to work in other areas. That doesn't mean that were not going to get to continue to work at hepatitis B, which is important to us and there is a",434,"So I mean, it's pretty clear we've done some great things in HIV and HCV. But for the company to grow, we have to work in other areas. That doesn't mean that were not going to get to continue to work at hepatitis B, which is important to us and there is a potential to cure the disease. We all recognize that is a hard thing to do as well as curing HIV, which is an equally harder thing to do, perhaps. So that does imply that we have to go outside of antivirals for continued growth, and we're interested in doing that as we've been hiring and growing with new things in our portfolio for a number of years. I think the good fortune to can help us grow into those areas. And so the answer is yes, we're very interested in acquiring assets through partnerships potentially acquisition that could help us grow in those areas. And with the tripling of our revenue over the last 2 years, the need to do so sooner rather than later is high. That being said, we want to get the right assets at the right price. And so we have the flexibilities are to be to manage the  balance sheet, can manage to be patient to not be forced in doing something before we want to. And so we are looking in the area of oncology. We're looking at an additional things in inflammatory diseases, things that are adjacent to there, to see what opportunities might fit within our portfolio so that we could create a really strong franchise like we have in HIV and HCV with multiple options for success in those areas. Some will depend on what happens in our portfolio this year as we make progress with our MMP-9 antibody or not. Obviously, we're looking heavily in NASH with the FXR agonist. We're very interested in liver diseases, so that's a very important area for us. And we'll continue to try to bolster those to make sure that the company has the assets necessary to have the progress in the future. Is there a shopping list? There's always a list that you have in your mind or sometimes on paper. That's probably dangerous. So it rests on my mind in which I think about things that will be important for us or things that could have the right opportunity at the right price. Whether or not those things ever come to fruition depends on a lot of factors, but clearly, we're going to be very interested in taking a look at this year."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","And with the assets having sold off pretty aggressively in the public markets over the last several months, does that make things more attractive to you? Or is it really about getting the right assets that's derisked and prices secondary?",40,"And with the assets having sold off pretty aggressively in the public markets over the last several months, does that make things more attractive to you? Or is it really about getting the right assets that's derisked and prices secondary?"
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Well, it makes much more attractive. There's no question.",9,"Well, it makes much more attractive. There's no question."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Ying Huang of Bank of America Merrill Lynch.",14,"And our next question comes from Ying Huang of Bank of America Merrill Lynch."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","First one on maybe pricing trend. If my math is right, if you take about $5.5 billion [ph] you booked in the second half, divide it by about 112,000 [ph] patients starting patients, you're looking at roughly 15,000 per patient revenue in the U.S. in the s",105,"First one on maybe pricing trend. If my math is right, if you take about $5.5 billion [ph] you booked in the second half, divide it by about 112,000 [ph] patients starting patients, you're looking at roughly 15,000 per patient revenue in the U.S. in the second half of 2015. So now with Merck's new drug launch in HCV, how should we think about pricing trend in the marketing in 2016? And then I also have a question about diagnoses rate. Based on experience you have in the field, can you provide a little more color on the rate of nearly diagnosed patients in HCV?"
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Maybe I'll talk about pricing, first of all. I mean, I think everyone knows this, but it's really net prices of the important number here for payers in the U.S. and, indeed, in Europe. So there seems to be over the last few days a somewhat misinformationa",143,"Maybe I'll talk about pricing, first of all. I mean, I think everyone knows this, but it's really net prices of the important number here for payers in the U.S. and, indeed, in Europe. So there seems to be over the last few days a somewhat misinformational confusion around the whack price and discounts. So we feel that our pricing is extremely competitive and offers very, very good value, given the competitive set. And as I said earlier, payers is in the U.S., this time around, taking a much more thoughtful look at the labels and trying to make sure they do the right thing for their clients. And so we feel pretty strong, and I'm pretty confident in the solid base, let's say, of our price in the U.S. market. And the second question was about HCV presented nearly diagnosed patients."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","I think that's a hard thing to get at. We still see about 30,000 patients coming into care every month so that's been an interesting metric for us, just more patients are coming to care that are being treated. We don't know how many are newly diagnosed an",215,"I think that's a hard thing to get at. We still see about 30,000 patients coming into care every month so that's been an interesting metric for us, just more patients are coming to care that are being treated. We don't know how many are newly diagnosed and how many are coming out a bucket of diagnosed patients. But it is interesting to note that our most recent data still suggests there's about 1.5 million patients diagnosed in America, which means that -- and that was about 1.6 million when we launched Sovaldi. So that implies that there has been a refilling of that bucket, a replenishment, if you will, but it's right away by this category of patient as more patients are being diagnosed and working their way through the system. So we don't have a firm handle on the exact numbers, so that's the closest approximation I can give you. But it does suggest that there's a pretty good flow of patients were now becoming aware in coming to at least be diagnosed. We don't know that characterization of those patients are as earlier question about the weather patients eligible for treatment since many of the Medicaid are not treating many patients, and that's something we are 20 figure out right now."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","And Ying, I may want to add that there is the CDC recommendation about general diagnoses. We have a number of projects in a number of American cities to look at subpopulations that we test and we demonstrate that you can actually fairly high diagnoses rat",73,"And Ying, I may want to add that there is the CDC recommendation about general diagnoses. We have a number of projects in a number of American cities to look at subpopulations that we test and we demonstrate that you can actually fairly high diagnoses rates up to 20% in some of these populations. And I think as people become aware of these things, I think the diagnosis will increase. That's our belief."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Olivia  Young of Credit Suisse.",11,"And our next question comes from Olivia  Young of Credit Suisse."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","And to both John, congrats on a great history and a great future. Two questions, rather short of one quick. In Japan, can you just help us understand like how to think about whether it's a 12% or maybe perhaps the larger kind of 50% range of discount, I m",113,"And to both John, congrats on a great history and a great future. Two questions, rather short of one quick. In Japan, can you just help us understand like how to think about whether it's a 12% or maybe perhaps the larger kind of 50% range of discount, I mean, when it comes to what kind of pricing discount will happen? And then also just on Genvoya. indiscernible] was that a little little bit and you start until this year. I just wanted to understand if you think the lion share are coming from Iraq, there's some maybe are triple kind of new starts or maybe switch coming in with the Genvoya launch?"
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","I'll comment on Japan. We're fully aware of the new pricing regulation that actions been introduced in Japan. We are, let's say, highly confident that, that will affect Harvoni and Sovaldi in Japan. We are not totally first yet on the number or the timing",66,"I'll comment on Japan. We're fully aware of the new pricing regulation that actions been introduced in Japan. We are, let's say, highly confident that, that will affect Harvoni and Sovaldi in Japan. We are not totally first yet on the number or the timing of that likely price cut, but we have factored that into our guidance. And the second question was on Stribild."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Genvoya.",1,"Genvoya."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes, yes. Well, Genvoya has got a really good start. We think that about 80% of the Genvoya business today is from switches. And we think that the majority of those switches are actually from Stribild so far. So that probably accounts for the Stribild sha",87,"Yes, yes. Well, Genvoya has got a really good start. We think that about 80% of the Genvoya business today is from switches. And we think that the majority of those switches are actually from Stribild so far. So that probably accounts for the Stribild share number. We think thing of the switches to Genvoya, about 10% of those switches and for have come from non-Gilead products. So we're pleased with the phase of switching, and we're pleased that we're all so better get some incremental growth."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Brian Abrahams of Jefferies.",10,"And our next question comes from Brian Abrahams of Jefferies."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","My congratulations to John Martin on all your accomplishments as CEO and to John Milligan on your well-deserved new role. So a question on related to inflammatory franchise. Historically, you guys have had a lot of success developing and commercializing p",122,"My congratulations to John Martin on all your accomplishments as CEO and to John Milligan on your well-deserved new role. So a question on related to inflammatory franchise. Historically, you guys have had a lot of success developing and commercializing products with best-in-class features on efficacy, safety and dosing that through really dominated space such as in HIV and hep C. The majority diseases are bit different, a lot more crowded. Wonder if you could talk a little bit about some other ways your thing about conducting the the moment that for 5745 to maximize differentiation? Perhaps, you could talk about commission opportunities there and how this ties into your long-term commercial strategy as you enter into this new therapeutic areas."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","And so, Brian, as I've said before, we believe [indiscernible], by itself, if you compare it with other JAK inhibitors, is a very valuable franchise. It has a good efficacy, and it could have safety advantages. And I'm saying it could have because I'm mak",199,"And so, Brian, as I've said before, we believe [indiscernible], by itself, if you compare it with other JAK inhibitors, is a very valuable franchise. It has a good efficacy, and it could have safety advantages. And I'm saying it could have because I'm making across study comparisons. So until we do a large Phase III program, we don't really know that for certain. But then as you putted out where we afterwards very quickly want to go with [indiscernible] is in combination therapy. We believe that the majority of all disease and auto are a, there's a huge unmet need still. If you look at some of the ACR 20 responses, they up to 80%, but ACR70s are only in the teens or 20% at most. So that means there's a huge improvement left to be done, and that, we believe, could be done with combination therapies. We're  going to go ahead and combine our JAK inhibitor with our MMP-9. That's going to be the first thing. And afterwards, also, the 6 [ph] compounds and the BTK inhibitor. So that's where we think we could have a big impact on the future of the treatment of inflammatory conditions."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Brian Skorney of Robert W. Baird.",12,"And our next question comes from Brian Skorney of Robert W. Baird."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Congratulations to John and John. Just two, I guess. I guess, the first question is in terms of Japanese sales, I understand there is a government-mandated rates, given the revenue that Sovaldi and Harvoni are generating. Can you just through how that as",149,"Congratulations to John and John. Just two, I guess. I guess, the first question is in terms of Japanese sales, I understand there is a government-mandated rates, given the revenue that Sovaldi and Harvoni are generating. Can you just through how that as of Jan 1? And can you give us a scale we should expect further price cut? And then just to dig down a little more on Merck's pricing and how it impacts you guys. I think we're all surprised by the quickness and the gross discount that AbbVie and you had applied for the initial launches. I guess, the question as we are clearly going to take a substantial discount versus what you guys have out. Are you at a point where you're comfortable enough in the profile that you're drawing a line in the sand to say you're essentially not going to be discounting anymore?"
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Let me start by talking about Japan. We're not going to say what our assumption is around the tax outcome. I mean, I think I've already said before. We understand the rule is pretty clear what the range is, and we're going to be somewhere in that range. A",186,"Let me start by talking about Japan. We're not going to say what our assumption is around the tax outcome. I mean, I think I've already said before. We understand the rule is pretty clear what the range is, and we're going to be somewhere in that range. And we're also not sure exactly the timing of that. So but we have -- we built an assumption into our guidance that we've given, and I can't really comment further on that at this point. Then on the gross to net, I mean, I think your question is are we confident enough to walk away. And I think the answer is yes, we are. But we're hopeful that our close discussions with payers and the strength of our label and the strengths of the relative strength of our label compared to the competitors and, of course, its enormous wealth real-world data that we've got gives us a position where we sincerely hope the right thing have been done for patients and patients can access to our medicines. So I think that's the way we think about it."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","And Brian, other than the cost of the drug, you should also consider, of course, the cost of treatment. There is a genotype required for genotype 1a. The resistance test will cost about $700 and incurs some time delay. There is test for ALTs at 8 weeks an",116,"And Brian, other than the cost of the drug, you should also consider, of course, the cost of treatment. There is a genotype required for genotype 1a. The resistance test will cost about $700 and incurs some time delay. There is test for ALTs at 8 weeks and the 12 weeks if you have a dose for 16 weeks. And also, it's possible that, well, a fairly significant number of the genotype 1A patients,  and those are 50% U.S. able requires 16 weeks with ribavirin. So that's not -- it's more than 12 -- it increases the treatment cost per portion of the compared to  to 12 weeks or 8 weeks in our case, with Harvoni."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","And I think the good news, just to reemphasize is that the payers across the United States have been very cognizant of this and thinking carefully the full implications and not being dazzled by the headlines of a low back price.",41,"And I think the good news, just to reemphasize is that the payers across the United States have been very cognizant of this and thinking carefully the full implications and not being dazzled by the headlines of a low back price."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","We have time for one more question. Our final question comes from the line of Terence Flynn of Goldman Sachs.",20,"We have time for one more question. Our final question comes from the line of Terence Flynn of Goldman Sachs."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I have 2 because I'm guessing now you might not want to answer the first one. But just for Robin on capital allocation. You mentioned 77% of free cash flow return from 2010 through 2015. As you look forward, do you guys have a target payout ratio in mind?",96,"I have 2 because I'm guessing now you might not want to answer the first one. But just for Robin on capital allocation. You mentioned 77% of free cash flow return from 2010 through 2015. As you look forward, do you guys have a target payout ratio in mind? And then the second one  was just on EU hep C patient volumes in '16. Paul, you gave us a lot of context for U.S. but maybe just if you could be a little bit more specific in terms of actually thinking about volumes in Europe."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Sure, Terrence. I'll take the first one. You're right. I'm not going to give a specific number. And as I mentioned on the call, I think it varies based on the other investments we're making. And the numbers we gave you were on average. There have been per",84,"Sure, Terrence. I'll take the first one. You're right. I'm not going to give a specific number. And as I mentioned on the call, I think it varies based on the other investments we're making. And the numbers we gave you were on average. There have been periods where we've been higher and periods we've been lower. But by using the word substantial, I think you can assume it remains significant. It could vary period -- or year-to-year. That's how I look at it."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","And on the EU volumes, we estimated that in the EU, I should say, so the 28 countries in the EU where the product's been launched so far in 2015 around about 140 patients in total are treated. We have a slightly lower market share in Europe than we do in",278,"And on the EU volumes, we estimated that in the EU, I should say, so the 28 countries in the EU where the product's been launched so far in 2015 around about 140 patients in total are treated. We have a slightly lower market share in Europe than we do in the U.S., and that's because of their type arrangements that our competitors got to place. The range of market share ranges from 70% to 90%. But I would say the average would be about 80% of that 140. All of the main countries, the big countries in Europe have now gone through their sort of warehouse points of the launch tried to do with the patient flow and are getting more stable patient flows, but are growing. So I think that's my main point. We anticipate higher numbers of patients in 2016 over '15. And countries like the U.K. really didn't treat very many patients at all so far, but they are now beginning to ramp up. And then some of the smaller countries, Netherlands, Australia, are beginning to grow patient numbers. Having said that, I also mentioned earlier price volume agreements. These are set up to try to encourage more patients being treated. But obviously, the flipside to those arrangements is that the price for patient comes down, and there's better value to treat more patients. The other thing, I think, is a real-world data with 8 weeks of Harvoni treatment. It looks stronger and stronger and is more convincing to European payers. And therefore, they will also use that opportunity to try and treat more patients, but of course, at a lower revenue per patient."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Candace, and thank you all for joining us. We appreciate your continued interest in Gilead, and the team here looks forward to providing you with updates on our future progress.",32,"Thank you, Candace, and thank you all for joining us. We appreciate your continued interest in Gilead, and the team here looks forward to providing you with updates on our future progress."
29002,322206567,924942,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for participating today's conference. This concludes the program and you may all now disconnect. Have a good day, everyone.",24,"Ladies and gentlemen, thank you for participating today's conference. This concludes the program and you may all now disconnect. Have a good day, everyone."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Fourth Quarter 2015 Earnings Conference Call. My name is Candice, and I'll be your operator for today. [Operator Instructions] And as a reminder, this conference call is b",63,"Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Fourth Quarter 2015 Earnings Conference Call. My name is Candice, and I'll be your operator for today. [Operator Instructions] And as a reminder, this conference call is being recorded.
I would now like to turn the call over to Patrick O'Brien, Vice President of Investor Relations. Please go ahead."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Candice, and good afternoon, everyone. Just after market close today, a press release was issued with earnings results for the fourth quarter and full year 2015. The press release and detailed slides are available on the Investor Relations sect",233,"Thank you, Candice, and good afternoon, everyone. Just after market close today, a press release was issued with earnings results for the fourth quarter and full year 2015. The press release and detailed slides are available on the Investor Relations section of the Gilead Sciences' website. 
Joining today's call will be John Martin, Chairman and Chief Executive Officer; John Milligan, President and Chief Operating Officer; Norbert Bischofberger, Executive Vice President of Research and Development and Chief Scientific Officer; Paul Carter, Executive Vice President of Commercial Operations; and Robin Washington, Executive Vice President and Chief Financial Officer. 
Before beginning formal remarks, let me remind you that we'll be making forward-looking statements, including plans and expectations with respect to products, product candidates, financial projections and the use of capital, all of which involve certain assumptions, risks and uncertainties that are beyond our control and could cause actual results to differ materially from these statements. A description of these risks can be found in the latest SEC disclosure documents and recent press releases. In addition, Gilead does not undertake any obligation to update any forward-looking statements made during this call. 
Non-GAAP financial measures will be used to help you understand the company's underlying business performance. The GAAP to non-GAAP reconciliations are provided in the earnings release, press release as well as on the Gilead Sciences' website. 
I will now turn the call over to John Martin."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Patrick, and thank you, everyone, for joining us today. 2015 was an exceptional year for Gilead, with progress in a number of therapeutic areas, most notably in the development of TAF-based therapies for HIV and hepatitis B and new agents for",226,"Thank you, Patrick, and thank you, everyone, for joining us today. 
2015 was an exceptional year for Gilead, with progress in a number of therapeutic areas, most notably in the development of TAF-based therapies for HIV and hepatitis B and new agents for the treatment of liver disease. Gilead is entering 2016 from a position of financial strength, a portfolio of 20 marketed products that address significant unmet medical needs, including Genvoya, the most recent product to be introduced, and the growing pipeline with multiple programs for which milestones are expected during the coming year, including regulatory decisions on 2 products for HIV and one each for HCV and HPV. 
As you all know, we announced on Friday that John Milligan will be appointed CEO, a role he'll assume in a few weeks. I will be taking on the role of Executive Chairman and will continue to be actively engaged in the company. John Milligan has been with Gilead for more than 25 years and, over that time, has built expertise in every functional area of the company's operations. The board and I are confident that this is the right time for this transition and that John is the right person to lead Gilead in the next few years of evolution. 
John, congratulations. I'll now turn the call over to you to make a few remarks."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, John. I'm honored and excited by the opportunity to lead this company and the great team we have. In my new role, I will continue to work hard to help Gilead's business grow beyond antivirals and into new therapeutic areas for the betterment of pa",1159,"Thanks, John. I'm honored and excited by the opportunity to lead this company and the great team we have. In my new role, I will continue to work hard to help Gilead's business grow beyond antivirals and into new therapeutic areas for the betterment of patients.
I'm also greatly appreciative to have that John will remain closely involved as the Executive Chairman. 
Turning to the business and results of the quarter. Genvoya, the company's first TAF-based single-tablet regimen for the treatment of HIV-1 infection, is approved in the U.S. and Europe. Genvoya achieved preferred status in the U.S. Department of Health and Human Services treatment guidelines within the first 2 weeks after approval, which speaks to the profile of the product and the important need it addresses. 
Two other TAF-based regimens are pending regulatory approval in the U.S. and EU. F/TAF has been assigned a PDUFA date of April 7. And in the EU, a CHMP opinion could be adopted in the first quarter of this year. R/F/TAF has been assigned a PDUFA date of March 1, and a CHMP opinion is expected in the second half of this year. This means that Gilead could launch 2 new TAF-containing products in the coming months, giving patients a wider range of options for the treatment of their HIV. 
During the last quarter, 4 Phase III studies of GS-9883, Gilead's proprietary integrase inhibitor combined in the single-tablet regimen with F/TAF were initiated. Two studies will evaluate the safety and efficacy of GS-9883/F/TAF in HIV-1-infected treatment-naive adults. One will compare GS-9883/F/TAF to Triumeq, and the other will compare GS-9883/F/TAF to dolutegravir plus F/TAF. Two other studies will evaluate patients who switch from Triumeq or a boosted PI to GS-9883/F/TAF. 
Phase II data on GS-9883/F/TAF will be presented later this year at a medical conference describing the safety and antiviral activity over 48 weeks of treatment. Analysis of the data through 24 weeks indicated that an FCR of GS-9883/F/TAF may represent a valuable option for many patients. And based on current time lines, the U.S. NDA and EU MAA could be filed in the second half of next year. 
Last month, Gilead submitted a new drug application in the U.S. and a Marketing Authorization Application in the EU for TAF as a treatment for chronic hepatitis B. Regulatory submissions are also expected in Japan, Korea, Taiwan and India this year and China in the first half of 2017. 
Phase III study results reflect high efficacy and improved renal and bone safety parameters, similar to those seen in the clinical studies evaluating TAF-based regimens for HIV. 
Beyond TAF for HPV, several ongoing research programs are focused on therapies with finite duration of dosing that achieve long-term viral suppression. The first is an immunomodulatory approach, where multiple programs are evaluating different ways to activate immune system to eliminate infected hepatocytes. The most advanced is our TLR-7 agonist, GS-9620, which is currently in 2 Phase II studies. Other approaches include the combination of novel direct-acting antivirals and agents that modulate cccDNA transcription. Two of these new programs may enter into clinical trials in the first half of 2016. 
In hepatitis C, Gilead's focus remains on advancing care of people with the disease regardless of genotype or disease severity. With the launch of Sovaldi in December 2013 and Harvoni in October 2014, more than 770,000 individuals around the world have been treated with sofosbuvir-based regimen.
In November, FDA approved Harvoni for expanded use in patients with genotype 4, 5 and 6 chronic HCV infection and the patients co-infected with HIV. In addition, Harvoni plus ribavirin for 12 weeks was approved as an alternate therapy to 24 weeks of Harvoni for treatment experience genotype-1 patients with cirrhosis. 
Sofosbuvir and Velpatasvir is an investigational once-daily pan-genotypic combinations studied for the treatment of genotype 1 through 6 chronic HCV infection, including patients with compensated and decompensated cirrhosis. FDA granted priority review and has set a PDUFA date of June 28, 2016.
Additionally, sofosbuvir/velpatasvir has been granted accelerated assessment in the EU. If approved, sofosbuvir/velpatasvir will represent a significant step forward, particularly for genotype 3 patients. It would also become the first and only regimen offering high SVR8, with 12 weeks of treatment for patients with all HCV genotypes. 
The advances in treatment of HCV with Sovaldi and Harvoni over the past 2 years have allowed Gilead to work with governments and public health experts on eradication strategies among specific populations and geographies. Programs such as those ongoing in the Republic of Georgia and Iceland could serve as examples for other governments around the world seeking to eradicate HCV. 
Public-health programs to prevent HIV transmission are also underway, including efforts to raise awareness about the use of Truvada for PrEP. Today, more than 40,000 patients in the U.S. are receiving Truvada for its preventive indication. Yesterday, the MAA was validated for Gilead's type 2 variation of Truvada for PrEP, and it is now under evaluation by the EMA. 
Gilead continues its R&D efforts in NASH, or non-alcoholic steatohepatitis. Phase II studies of simtuzumab, a LOXL2 targeting antibody, are ongoing in patients with NASH and also primary sclerosing cholangitis. The data monitoring committee for these studies recently met and recommended the continuation of the studies, which have a 96-week endpoint. 
Additionally, clinical studies of the FXR agonist, GS-9674, have been initiated, with the first patients receiving treatment in Q4 of last year. 
Moving to oncology. Gilead continues to study Zydelig in several hematological disorders. Phase III study results show adding Zydelig to bendamustine and rituximab provides statistically significant and clinically meaningful improvements in progression-free and overall survival compared to bendamustine and rituximab alone. 
Supplemental regulatory filings are planned in the U.S. and Europe early this year to include these important new data. 
Beyond Zydelig, Gilead also is exploring novel combinations of investigational therapies for a range of cancers, including 4 classes of kinase inhibitors through PI3K, Syk, JAK and BTK, that each target different signaling pathways. 
Progress has been made in inflammation as well. Gilead entered into a global partnership with Galapagos late last year for the development and commercialization of filgotinib, a JAK1 inhibitor for rheumatoid arthritis and other inflammatory diseases. Phase II trial data shows that filgotinib has the potential to be an effective and well-tolerated oral therapy for patients with RA and Crohn's disease. Phase III studies of filgotinib in RA and Crohn's are planned to start later this year. 
In summary, Gilead's substantial pipeline offers numerous opportunities for continued growth, both in the short and longer term, and the financial strength of the company allows us to be thoughtful and opportunistic in pursuing partnerships or acquisitions that will further expand the future portfolio of products.
2016 will be a busy year for Gilead, and I want to take this opportunity to thank all of our employees for the support in this transition and for their continued hard work and dedication.
Paul Carter will now provide a commercial update."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, John, and good afternoon, everyone. Gilead achieved $8.4 billion in net product revenue in the fourth quarter, representing 16% year-over-year growth. U.S. product revenue reached $4.8 billion in the fourth quarter, which is down 14% from the thir",1326,"Thanks, John, and good afternoon, everyone. Gilead achieved $8.4 billion in net product revenue in the fourth quarter, representing 16% year-over-year growth. U.S. product revenue reached $4.8 billion in the fourth quarter, which is down 14% from the third quarter and down 12% on a year-over-year basis, largely due to a decrease of HCV revenue.
European product revenue reached $1.7 billion in the quarter, which was in line with the prior quarter and up 22% on a year-over-year basis despite the negative 11% foreign exchange impact. 
For the rest of the world, product revenues were $1.9 billion for the fourth quarter and $3.8 billion for the full year, driven largely by HCV launches in Japan. 
Beginning with hepatitis C. Total HCV product revenue reached $4.9 billion in the fourth quarter. 
In the next few minutes, I'll describe the results for the quarter 4 by region and also describe how we're thinking about the year ahead. 
In the United States, HCV product revenue totaled $2.4 billion, which is down 27% from the third quarter. This decline was impacted by substantially lower VA sales in the fourth quarter. 
In quarter 3, Congress allocated an additional $500 million to the VA for HCV treatment, and this was fully utilized in quarter 3. New patient starts in the VA were very limited during quarter 4 due to the uncertainty of future funding at that time. Congress have since allocated substantial funding of $1.5 billion for the fiscal year, which will allow treatments in the VA to resume in this quarter. 
In terms of patient numbers, in 2015, nearly 250,000 U.S. HCV patients started treatment, with more than 90% of these patients receiving Gilead HCV therapies. As I commented last quarter, there were an unusually large number of patient starts in the U.S. in the first quarter of last year, indicative of the rapid initiation of treatment for many warehouse patients, followed by a flattening of patients in the remaining quarters of the year. 
Looking to the future, even with nearly 400,000 patients treated since the launch of Sovaldi, there remain more than 3 million HCV-infected individuals in the U.S., who have let yet to be treated, approximately half of whom are diagnosed according to recent CDC data. 
Long-term education and awareness efforts to increase rates of diagnosis and the flow of HCV-infected patients into treated care are important and will play out over many years, as we know from our experience in HIV. 
Turning to Europe. Hepatitis C revenue was $846 million in the fourth quarter, and we estimate that more than 110,000 patients were treated with sofosbuvir-based regimens in 2015.
Following the normal sound seasonality in quarter 3, there was an increase of patient starts throughout Europe in quarter 4, including in the U.K. following the final appraisal determination for Harvoni from NICE. A number of countries in Europe have volume-based incentives of Sovaldi and Harvoni, which serve to encourage a high number of patients being treated. 
In quarter 4, the growth in revenues did not match the growth in patient starts because of the impact of certain volume-based agreements, combined with adverse foreign exchange movements. 
In Japan, hepatitis C revenues for the fourth quarter were $1.4 billion. Since the launch of Sovaldi in May and the launch of Harvoni in September, sales of $1.9 billion have been generated in Japan, with Harvoni representing more than $1 billion of that number. In late December, pricing and reimbursement negotiations for Sovaldi and Harvoni in Australia were finalized.
There were a number of variables to consider when thinking about HCV patient numbers and revenues for 2016. Patient starts in the U.S. will likely be similar to 2015 levels of observed in the second half and extrapolated for the full year. While the Europe numbers will continue to grow as early launch markets stabilize and new markets ramp up treatment.
In Japan, patient numbers are difficult to predict because launches are still in the early stages, and to some extent, we are likely seeing the impact of warehoused patients. 
In the rest of the world, we're excited to bring -- to reach new patients in several new markets, notably in Asia Pacific and in Latin America. 
As we think about revenue, we anticipate that variables to consider include potential shortage durations of treatment, the full year effect of payer contracts in the U.S. and by price volume deals and some European markets, which may allow more patients to be treated at a lower per patient cost. 
We also anticipate that payer mix in the U.S. may shift slightly towards public payers, while in Japan, new legislation will likely result in lower pricing for Sovaldi and Harvoni. 
We're confident in the long-term sustainability of HCV markets worldwide. Despite the number of patients treated to-date, there are still millions of HCV-infected individuals, who've yet to be treated and many other that are yet to be diagnosed. There are significant efforts underway by industry, governments and patient organizations to increase rates of diagnosis and linkage to care. 
We're also confident in our competitive position as we enter 2016. Sovaldi and Harvoni are breakthrough therapies that set the bar with cure rates of up to 99%. Data presented at ASLD in November showed real world cure rates with Harvoni that met or exceeded what was predicted by clinical trials, including the 8-week duration of therapy.  We also look forward to launching our next HCV product, sofosbuvir/velpatasvir, in due course around the world starting later this year. 
Turning to HIV. HIV product revenue reached $3 billion in the fourth quarter. In the U.S., revenues were $2 billion, a 3% increase from the third quarter and up 5% on a year-over-year basis, driven by the continued demand for Stribild, Complera, Truvada and the recent launch of Genvoya. 
Stribild and Complera has a strong underlying prescription demand, with year-on-year growth of 40% and 12%, respectively. 
7 out of 10 HIV patients in the U.S. initiate therapy with a Gilead product, and nearly 6 in 10 receive a Gilead single-tablet regimen. 
Genvoya sales have been very encouraging in the first few weeks of launch. Revenues for the quarter were $44 million, with early product uptake well ahead of the launch of Stribild at the same time point. 
Access and reimbursement have been consistent with historical norms in HIV, and the rapid addition of Genvoya to the DHS gap treatment guidelines as a preferred first-line treatment reinforces the safety and efficacy profile observed in clinical trials and reflected in non-product label. 
In Europe, HIV revenues were $747 million for the quarter, up 4% from the third quarter, driven by the sales of Stribild and Eviplera, with a slight decline year-over-year caused by foreign exchange. 7 out of 10 patients in Europe also started on Truvada-based backbone in 2015. 
Genvoya was launched in Europe in November. Similar to the U.S., we have seen encouraging early product uptake in the 6 countries launched during the fourth quarter. 
A final comment on HIV is that the commercial organization is getting ready to execute the launches of RF/TAF and F/TAF in the next months. 
Turning to other therapy areas. Total revenue for product outside of HIV and HCV, which includes Zydelig, AmBisome, Cayston, Letairis and Ranexa, totaled $1.9 billion in 2015 and grew 16% year-over-year. 
Over the last quarter, progress has been made in the area of cardiovascular disease. Since the inclusion of the AMBITION data in the Letairis label, we've seen a great deal of interest in engagement from  the medical community. 
Revenue for the full year for Letairis received -- reached $700 million, and market share for the products among patients initiating therapy is nearly 50%. 
In closing, Gilead had a remarkable 2015. The commercial organization's excited about the opportunities across all of Gilead's therapeutic areas, both in the near term and over the longer term, to help many more patients around the world. 
And I'll now turn the call over to Robin."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Paul, and good afternoon, everyone. We are pleased to share full year and fourth quarter 2015 financial results and provide 2016 guidance. For the fourth quarter, total revenues were $8.5 billion, up 16% compared to the fourth quarter of 2014",1034,"Thank you, Paul, and good afternoon, everyone. We are pleased to share full year and fourth quarter 2015 financial results and provide 2016 guidance. 
For the fourth quarter, total revenues were $8.5 billion, up 16% compared to the fourth quarter of 2014. Net income for the quarter was $4.7 billion or $3.18 per diluted share compared to $3.5 billion or $2.18 per diluted share for the fourth quarter of 2014. Non-GAAP diluted EPS for the fourth quarter was $3.32 per share, up 37% compared to the fourth quarter of 2014. 
Turning to fiscal year 2015. Full year total revenues were $32.6 billion, up 31% year-over-year. Net income for the year was $18.1 billion or $11.91 per diluted share compared to $12.1 billion or $7.35 per diluted share for 2014. 
Non-GAAP diluted EPS was $12.61 per share for the year, up 56% year-over-year. 
Product sales during the year were $32.2 billion, up 31% year-over-year. HCV product sales increased year-over-year to $19.1 billion, up 54%. And non-HCV product sales increased year-over-year to $13 billion, up 8%. 
The increase in HCV product sales for the year was primarily driven by sales of Harvoni, which launched in October 2014. Further, the annualized HCV gross-to-net estimate that was shared with you during the Q4 earnings call a year ago is on target and reflected in our 2015 results. 
Non-HCV product sales growth for the year was primarily driven by Stribild and Complera, Eviplera partially offset by ATRIPLA.
Turning to expenses for the full year 2015. Non-GAAP R&D expenses were $2.8 billion, up 10% compared to the prior year, reflecting the continued progression of our product pipeline. Non-GAAP SG&A expenses were $3.2 billion, up 17% compared to the prior year, driven by expenses to support our growth and geographic expansion. 
The non-GAAP effective tax rate for the full year was 16.2%, which was lower compared to guidance due to the permanent extension of the federal R&D credit that was passed in December. If you recall, the permanent extension of the credit was not included in 2015 guidance. 
Cash flows from operations were $20.3 billion for the full year 2015 and $4.9 billion for the fourth quarter. 
With respect to shareholder return, $3.1 billion in cash was utilized to repurchase 29 million shares during the quarter, bringing total 2015 share repurchases to 10,095,000,000, shares. Including the Q2 2015 warrant settlement of $3.9 billion dividends and share repurchases, Gilead has returned more than $15 billion in cash to shareholders in 2015. 
Earlier today, we announced an increase of the quarterly dividend from $0.43 per share to $0.47 per share, which will become effective in the second quarter of 2016, subject to a declaration by the Board of Directors. 
Additionally, the board authorized a new $12 billion share repurchase program to be initiated after the completion of the current $15 billion program, which, as of December 31, 2015, had $8 billion remaining. 
Also announced was the utilization of $5 billion of the current program to enter into an accelerated share repurchase agreement, which is expected to be completed in the next 3 months. This is in addition to the ongoing open market share repurchases that have continued under the current share repurchase bulk program since January of this year. 
The increase in the dividend and increased level of share repurchases underscore the confidence of the board and management in the strength of the business and future cash flows. 
Since 2010, in addition to financing ongoing R&D programs and business development activities, more than 75% of free cash flows were returned to shareholders, and share count was reduced in excess of 20% while maintaining and improving investment-grade credit ratings, which Gilead values. 
Looking forward, the plan is to continue to return a significant component of free cash flows to shareholders via share repurchases and increases to our dividend over time. 
As in the past, there could be future periods of time when share repurchases are reduced due to acquisitions and other pipeline investments that are prioritized to drive future long-term growth. This strategy provides agility and financial flexibility to support R&D investments as well as any future acquisitions or partnership opportunities we may consider. 
Finally, I would like to cover full year 2016 non-GAAP financial guidance summarized on Slide 51 in the earnings presentation available on the Gilead website. 
Product sales are expected to be in the range of $30 billion to $31 billion. Guidance for product sales is subject to a number of uncertainties, including an uncertain global macroeconomic environment, adoption of additional pricing measures to reduce HCV spending, volatility in foreign currency exchange rates; inaccuracy and HCV patients start estimates; additional competitive launches in HCV; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers and a larger-than-anticipated shift in payer mix to more highly discounted payer segments, such as PHS, FFS, Medicaid and the VA. 
Non-GAAP product gross margins are expected to be in the range of 88% to 90%. Non-GAAP R&D expenses are expected to be in the range of $3.2 billion to $3.5 billion as a result of the continued investment in our product pipeline. This includes the financial impact of the Galapagos calibration, or collaboration, which closed in January. 
Non-GAAP SG&A expenses are expected to be in the range of $3.3 billion to $3.6 billion. This reflects an estimated $200 million increase for the U.S.-branded prescription drug fee. Please note that 2015 included a favorable adjustment of approximately $100 million based on the receipt of the 2015 invoice from the IRS. 
For the full year, the non-GAAP effective tax rate is expected to be in the range of 18% to 20%. This includes the impact of the federal R&D tax credit, which was permanently extended at the end of 2015, and the increase for the U.S.-branded prescription drug fee, which is not tax-deductible. 
Full year diluted EPS impact of acquisition-related restructuring and stock-based compensation expenses is expected to be in the range of $1.10 to $1.16 per share. 
In closing, we are pleased with 2015 accomplishments across the organization. Thank you, and we look forward to updating you on our progress. 
Let's now open the call for questions. Operator?"
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","[Operator Instructions] And our first question comes from Geoff Meacham of Barclays.",12,"[Operator Instructions] And our first question comes from Geoff Meacham of Barclays."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","This is Carter Gould on for Geoff. Congrats on the quarter. With regards to 2016 guidance, how should we think about the top line guidance and what that implies for any loosening of restrictions in the lower fibrosis-core groups or any changes in net pric",76,"This is Carter Gould on for Geoff. Congrats on the quarter. With regards to 2016 guidance, how should we think about the top line guidance and what that implies for any loosening of restrictions in the lower fibrosis-core groups or any changes in net pricing and if maybe that's a little more detail than you're ready to go into maybe you can just frame how we should think about these levers in 2016 relative to 2015?"
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Okay. So I think I said in the script that we should anticipate in the United States that 2016 revenues should be more or less based on the second half of 2015 extrapolated for the year. I also mentioned that we had some lumpiness in the second half of th",597,"Okay. So I think I said in the script that we should anticipate in the United States that 2016 revenues should be more or less based on the second half of 2015 extrapolated for the year. I also mentioned that we had some lumpiness in the second half of the year due to the purchasing profile of the VA. And we anticipate that, that will smooth out during the course of this year. I've also said numerous times before that in quarter 1 last year, we had a very large bogus of warehouse patients being treated which, of course, we're unlikely to see again. But to some extent, that gets substituted as the payers, commercial payers, that we are well-known are beginning to loosen restrictions. So there's a few dynamics in the U.S., but I think the way that I would look at it is a fairly flat stable, perhaps marginally growing a number of patients flowing into treatment. If we see public payers stepping up like Medicaid and perhaps a correctional facility to start treating more patients, then patient numbers could go higher than that in 2016. There's a few other factors, which I also mentioned as we think about the revenue aspect as opposed to just patient numbers. The less-sick patients, GT1 patients that qualify, are more likely to be using the 8-week Harvoni treatment duration. And of course, therefore, revenue per patient would come down proportionately. Having said that, the offset is that budgets for treating patients go up, and we would like to think that more patients could be treated. So I think that's sort of the main thing. I think from a competitive point of view, we feel very confident that our label is very strong and that we are very much supported by the real-world data we've seen since the launch of Harvoni and with very high SVR rates anda very strong safety profile, at least as good, if not better, than the one that was used in our registrational trials. So I think we feel good about the year. The U.S. is fairly steady and possibly could even grow, as I said, with some restrictions loosens and public payers step up. Around the world, as I mentioned, we expect patient numbers to grow in Europe. They started to stabilize in the major markets now, again, following more or less the shape of the curve in the U.S., where there is a large lump because of warehoused patients being treated initially. That is smoothing out now. And many of the smaller markets are now beginning to come on onstream. And so we should see higher of patients in the Europe. But the same thing, we'll like to see more patients being treated with shorter durations. And as I also mentioned, we do have a number of price volume agreements in place, which are delivered in incentive wise to encourage high volumes of patients being treated but at a lower revenue per patient, if you like. So we should think about that. And then around the rest of the world, Japan, I mentioned, very early days. We're still in that warehousing phase, I think, in Japan, although we're very pleased with the launch of that so far. And then there were various other small markets around the world and medium-size markets, Canada, Australia being one of the medium-sized markets that are yet to launch here. So we have plenty of patients around the world, but there are some other dynamics, as I said, around shorter treatment and, of course, the competitive situation."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Mark Schoenebaum of Evercore.",10,"And our next question comes from Mark Schoenebaum of Evercore."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","It's actually Vlad Nikolenko on behalf of Mark Schoenebaum. I have a question about filgotinib specific JAK1 inhibitor, the one you got from Galapagos. Just curious, your thoughts about testicular talks concerns on filgotinib as well as whether your base",73,"It's actually Vlad Nikolenko on behalf of Mark Schoenebaum. I have a question about filgotinib specific JAK1 inhibitor, the one you got from Galapagos. Just curious, your thoughts about testicular talks concerns on filgotinib as well as whether your base case will be 200 milligrams daily dose going forward in the U.S.? And sort of somewhat related question. What's exactly impacting your 2016 guidance of -- on R&D expenses from Galapagos collaboration?"
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. So maybe I could answer the first few questions. So we were very excited about filgotinib because of the clinical profile. As you know, they have now data. Galapagos has generated data in RA and also in Crohn's. Both of those have remarkable efficacy",134,"Yes. So maybe I could answer the first few questions. So we were very excited about filgotinib because of the clinical profile. As you know, they have now data. Galapagos has generated data in RA and also in Crohn's. Both of those have remarkable efficacy. And also importantly, we think that filgotinib can be distinguished from competitors because of its safety profile, in particular, the lack of hemoglobin decreases, and very low infection rates. The other thing you asked about the dose. That still needs to be negotiated with the FDA. We actually have a meeting coming up in the next couple of months, where we will talk about, in detail, the Phase III program design, including the doses. So it's really, at this point, too early to say what the dose will be."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","And this is Robin. To answer the second part of your question, we really have included, relative to the collaboration, the -- some of the upfront milestone payments as well as the costs associated with some of the Phase III trials that Norbert just spoke",74,"And this is Robin. To answer the second part of your question, we really have included, relative to the collaboration, the -- some of the upfront milestone payments as well as the costs associated with some of the Phase III trials that Norbert just spoke about. So we don't break it out in detail, but I would assume a couple of hundred million incremental to 2015 included in our guidance to support those projects."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Matt Roden of UBS.",10,"And our next question comes from Matt Roden of UBS."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Congrats to John Martin for an amazing 20 years at the helm here. So I have a big picture question. Seems like a good time to ask it, I guess, with the transition is, over the last 2 years, you've tripled your revenues. You've increased your earnings by a",142,"Congrats to John Martin for an amazing 20 years at the helm here. So I have a big picture question. Seems like a good time to ask it, I guess, with the transition is, over the last 2 years, you've tripled your revenues. You've increased your earnings by about sixfold over that period. But the market seems to be discounting your ability to grow the business from here. Just wanted to see if you can maybe lay out a vision of the development of various franchises that you have. You have -- a lot's going on in cancer. You've added to the inflammation franchise. You have TAF, 9883 in HIV. Just wondering if he could just maybe shine the light on how you visualize the growth up to, say, 2020 something like that? It would be really helpful to hear your thoughts."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Matt, it's John Milligan. I assume the question's for me, not the congratulatory one to John Martin. So it's a very good question.",23,"Matt, it's John Milligan. I assume the question's for me, not the congratulatory one to John Martin. So it's a very good question."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Whoever want to take it",5,"Whoever want to take it"
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Whoever will take it. Well, I'll take it. I'd be happy to. So it's a really good question. So you're right. We have -- we faced an extraordinary time when we've been able to triple revenue over the last couple of years, which is a very unusual thing for a",555,"Whoever will take it. Well, I'll take it. I'd be happy to. So it's a really good question. So you're right. We have -- we faced an extraordinary time when we've been able to triple revenue over the last couple of years, which is a very unusual thing for an organization to be able to do. And we're moving our pipeline along as fast as we can. And as we mentioned, there's some very interesting opportunities for us. So we do see very good opportunities in organic growth. And I have great confidence in HIV portfolio that with the 3 STRs  we talked about on the call today and the other STR being developed by our partner, Johnson, that will have very -- a meaningful continued growth of both patients and revenues in the future in HIV. I think that's a very important thing for us. We're continuing to accelerate HCV to bring SOF/VEL [indiscernible] to market and try to work in  more countries than we ever have before. So those are important initiatives and things that are current to market. We're very excited about filgotnib. I think there's great opportunities for us in inflammatory diseases. We hadn't spoken about it very much in the past, and sort of quietly, we've been investigating our MMP-9 antibody, 5745, which we didn't talk about on this call, which now has positive data in 3 of the 4 indications we've looked at in inflammatory diseases, with the fourth under investigation. And so not only do we have filgotnib potentially for RA and inflammatory diseases, but we have an antibody, which has a mechanism, which is very refractory to current care and could be a very good beginning to inflammatory disease franchise. Of course, you mentioned the kinase inhibitors that we have for oncology. There's always a potential that those could be useful in various diseases in combination with filgotnib as well, and we will explore that, although I still think the best value of it is the fact that it's a very good-looking drug and some very positive data in Crohn's disease. So we are going down the pathway of inflammatory diseases by virtue of the successes we've had in our pipeline and successes in licensing. Oncology, it's -- Zydelig has been a good start for us. We really need to continue to try to ramp up our efforts in this area and to continue to broaden the areas we want to work in. It's pretty clear we have to do additional partnerships or find other avenues to broaden the revenue stream there for the future. As Robin mentioned, with our balance sheet, we have to create flexibly of the new partnerships or acquisitions that could get us there, and so that would be an important consideration for us. That may not be the only avenue. We also look at other areas where we could can bring in different programs, potentially accelerating the revenue as soon as possible in some of those areas when those things are available. And if the environment has shifted dramatically in our favor, we're doing those sorts of partnerships and whatnot. So that's a good -- 2016, I believe, will be a good year for us because of the strengths of the underlying business and the economic uncertainty that's driving the market today."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","John, can I add something maybe? I would like to reiterate what Robin said in her script. If you look back at the last 6 years, it has been remarkable. We have done many, many deals CGI, Arresto, Calistoga, Pharmasset, Galapagos, and yet, we were able to",83,"John, can I add something maybe? I would like to reiterate what Robin said in her script. If you look back at the last 6 years, it has been remarkable. We have done many, many deals CGI, Arresto, Calistoga, Pharmasset, Galapagos, and yet, we were able to return 70% of the free cash flow to shareholders. So I think that is a good way to think about the future, to in-license through collaborative efforts while, at the same time, returning money to shareholders."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Michael Yee of RBC Capital Markets.",12,"And our next question comes from Michael Yee of RBC Capital Markets."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","My congrats to John Milligan as well. Looking forward to a new era. I wanted to ask a bit of a 2-part question. One was you gave some guidance here. And remarkably, like the last question, it actually looks like you're a little flattish or whatnot this ye",155,"My congrats to John Milligan as well. Looking forward to a new era. I wanted to ask a bit of a 2-part question. One was you gave some guidance here. And remarkably, like the last question, it actually looks like you're a little flattish or whatnot this year. Do you expect, qualitatively, to be growing over the next year? And two, do you expect that this is a bit of trough revenue here? I just wanted to get your view on that. And importantly, when you look at managed care -- second part of the question, look at managed care, given that there's a new competitor onboard, do you expect minimal to no changes or minimal changes in terms of access and things like that? Just given the new competition, can you talk a little bit about that and there's a little bit of nervousness on how that may change things on the payer front?"
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","So Michael, it's John Milligan. First of all, thank you for the congratulations. Second of all, unfortunately, we can't tell you about revenue growth beyond. We have a lot of opportunities, but we -- obviously, we don't give 2017 or beyond guidance. We'll",148,"So Michael, it's John Milligan. First of all, thank you for the congratulations. Second of all, unfortunately, we can't tell you about revenue growth beyond. We have a lot of opportunities, but we -- obviously, we don't give 2017 or beyond guidance. We'll -- we, in this business, you almost have to take things 1 year at a time, especially in hepatitis C, as we understand the rate of diagnosis and patients coming in to care, which is there's great opportunity out there with 1.5 million patients, as Paul mentioned, still being diagnosed but not yet under care, so really good opportunities for us. With regard to the competition coming to market, we have a very, very, very strong position. But I'm going to turn this over to Paul because he'd like to give you some of his thoughts on what the competitive landscape looks like versus Harvoni."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. Thanks, John. I mean, I think if we tossed our minds back 12 months, we had the first competitor coming in to the hepatitis C space. And I think the managed care view at that time was that these products were interchangeable and could be treated by c",245,"Yes. Thanks, John. I mean, I think if we tossed our minds back 12 months, we had the first competitor coming in to the hepatitis C space. And I think the managed care view at that time was that these products were interchangeable and could be treated by commodities, to some extent, which really triggered off the pricing and negotiations we saw in early part of last year. That has been proven to be a totally incorrect view of the hepatitis C products. And what we've seen, fortunately, with Harvoni, in particular, is the real-world data has really strengthened its position and people's understanding of what that product does. It has -- it cures people at an incredibly high SVR rates, and the safety profile has been extremely good and in line, if not better, than its label. That hasn't been the case of competitor products so far. In fact, we've seen safety warnings added to labels, and we've seen a differentiation. And that's played out in the market. So I think as we see a new competitor coming into the market, now payers are really thinking this through. There isn't any kind of sort of instinctive reactions. People have been very thoughtful, and we noticed because we have very close discussions with the managed care main players. And we're working with them as they think through this. And I think we feel pretty confident that we'll maintain a strong position as we enter 2016."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Matthew Harrison of Morgan Stanley.",11,"And our next question comes from Matthew Harrison of Morgan Stanley."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","And I might extend congratulations to both Johns. I thought if I could just ask 2 related specific questions. So first, Paul, maybe, I just want to make sure I understand what you're trying to say with respect to U.S. HCV volumes. If we look at the 2 volu",174,"And I might extend congratulations to both Johns. I thought if I could just ask 2 related specific questions. So first, Paul, maybe, I just want to make sure I understand what you're trying to say with respect to U.S. HCV volumes. If we look at the 2 volumes, the numbers you've given up in the third and the fourth quarter, it's about 105,000 patients together, which is about 210 on a full-year basis, which is below the 236 you guys reported. And if I take the low end of the 47,000, which it sounds like you're saying is too low because of the VA from the fourth quarter, that's 188,000 annualized. So I just -- if you can just give us some direction on -- I'm sure you're not going to tell us a number, around those numbers, just so we're clear on exactly what you're trying to say. And then maybe related to that, can you just specifically address where you think Access is going to go for Medicaid [indiscernible] this year?"
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Sure. So if you've got your pencil ready, these are the numbers that, I think, happened last year. In fact, I'll take you back even into quarter 4, 2014 where we think 46,000 HCV starts were in the market. These are total starts, by the way. In quarter 1,",286,"Sure. So if you've got your pencil ready, these are the numbers that, I think, happened last year. In fact, I'll take you back even into quarter 4, 2014 where we think 46,000 HCV starts were in the market. These are total starts, by the way. In quarter 1, 2015, there were 72. And that really was the peak of this warehoused patient  part of the curve, then dropped down into quarter 2 of 65,000. There were still some of those warehoused patients coming through. And in quarter 3 was 62,000, and quarter 4 was 50,000. We know that in quarter 3, a lot of patients were treated by the VA who, by the way, seems to be incredibly efficient at getting patients into treatment. And we know that in quarter 4, very few patients were initiated by the VA. So I think if you do the basic math on that, you would get up to about 230-something-thousand forecasting that forward into 2016 if you assume that VA picks up. Then I think this sort of merges into the second part of your question, which is what happens with Medicaid and other public payers who, to date, have really treated very, very few people. So our assumption is they're still not going to treat that many more patients this year, is the way we're thinking forward. But we are hopeful that, that will be a trend that improves over time as people start to see how effective these drugs are and, particularly, 8-week usage of Harvoni which, as I mentioned, in the real world, it seems to be incredibly effective and offers very good value. So that's how we're thinking about it. I hope that's clear."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Cory Kasimov of JPMorgan.",10,"And our next question comes from Cory Kasimov of JPMorgan."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Also my congrats to both John and John on a great run and a great opportunity. So I wanted to ask about longer-term trends, the evolution of the HCV market. I know it's hard for everyone to get their hands around, but you indicated again there are about 3",166,"Also my congrats to both John and John on a great run and a great opportunity. So I wanted to ask about longer-term trends, the evolution of the HCV market. I know it's hard for everyone to get their hands around, but you indicated again there are about 3 million HCV patients in the U.S. that have yet to be treated. About half of those are diagnosed. In terms of new patients that are entering the system, how similar or different are they from the existing patients or those that have already been cured in terms of, I guess, the overall motivation to be treated, fibrosis score insurance coverage. We get a lot of questions on are these future patients actually legitimate candidates in terms of being under the care of a doc, not IV drug users, et cetera. So can you just comment, try to give us a little bit more comfort in how we can be thinking about this longer-term evolution in the U.S.?"
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","So Cory, I've mentioned before that we have some proprietary research that we do to try and monitor the flow of patients into treated care, and that means people who are diagnosed with hepatitis C and are registered with a hepatitis C prescriber. And that",241,"So Cory, I've mentioned before that we have some proprietary research that we do to try and monitor the flow of patients into treated care, and that means people who are diagnosed with hepatitis C and are registered with a hepatitis C prescriber. And that number has been remarkably consistent at around -- we have actually 3 different sources of data, and it's around high 20s to 30,000 patients a month have been falling into that category. So they're diagnosed with HCV, and they're registered with a treater. So if you do the math on that, clearly, that's 360,000 patients coming into treatment a year, and we're seeing treatment levels are lower than that. And what that speaks to is the types of patients are different amongst that 360,000 group, and their sort of pathway to actual treatment varies considerably. But it does appear, again, doing the math and assuming the research is correct, that there is a line at the door of patients that still need to be treated and are accessible. I don't think those are the people that are, let's say, out of society or -- these are people that are accessible and for one reason or another reason, they haven't started treatment yet. But there's a strong flow of patients still out there, and I don't think we're anywhere near getting to the point where we're dealing with patients that are extremely difficult, let's say, to manage."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Phil Nadeau of Cowen & Company.",11,"And our next question comes from Phil Nadeau of Cowen & Company."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Let me add my congratulations to John Martin and John Milligan. John Milligan, a question for you. I found it interesting that in your prepared remarks, right after you were introduced, you mentioned that you wanted to take Gilead into therapeutic areas o",99,"Let me add my congratulations to John Martin and John Milligan. John Milligan, a question for you. I found it interesting that in your prepared remarks, right after you were introduced, you mentioned that you wanted to take Gilead into therapeutic areas outside of antivirals. And I know, in an answer to a prior question, you went through the assets you have in other areas. And I'm curious whether you're signaling a need for even more assets in those areas and, in particular, if you had a shopping list, which areas will be on the top of your list?"
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","So I mean, it's pretty clear we've done some great things in HIV and HCV. But for the company to grow, we have to work in other areas. That doesn't mean that we're not going to continue to work at hepatitis B, which is important to us, and there is the po",439,"So I mean, it's pretty clear we've done some great things in HIV and HCV. But for the company to grow, we have to work in other areas. That doesn't mean that we're not going to continue to work at hepatitis B, which is important to us, and there is the potential to cure that disease. We all recognize that as a hard thing to do as well as curing HIV, which is an equally or harder thing to do, perhaps. So that does imply that we have to go outside of antivirals for continued growth, and we're interested in doing that as we've been hiring and growing with new things in our portfolio over a number of years. I think we have some good core teams that can help us grow into those areas. And so the answer is yes, we're very interested in acquiring assets through partnerships or potentially acquisitions that could help us grow in those areas. And with the tripling of our revenue over the last 2 years, the need to do so sooner rather than later is hyped. That being said, we want to get the right assets at the right price. And so we have the flexibilities certainly with our balance sheet in that current business to be patient to get things to not be forced into doing something before we want to. And so we are looking in the area of oncology. We are looking at additional things in inflammatory diseases, things that are adjacent to there, to see what opportunities might fit within our portfolio so that we could create a really strong franchise like we have in HIV and HCV with multiple options for success in those areas. Some of it will depend on what happens in our portfolio this year as we make progress with our MMP-9 antibody or not. Obviously, we're looking heavily at NASH with the FXR agonists. We're very interested in liver diseases, so that's a very important area for us. And we'll continue to try to bolster those to make sure that the company has the assets necessary to have the progress for the future. Is there a shopping list? There's always a list that you have in your mind or sometimes on paper. That's probably dangerous. So mine's in my mind with which I think about things that would be important for us or things that could have the right opportunity at the right price. Whether or not those things ever come to fruition depends on a lot of factors. But clearly, we're going to be very interested in taking a look this year."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","And with the assets having sold off pretty aggressively in the public markets over the last several months, does that make things more attractive to you? Or is it really about getting the right assets that's derisked and price is secondary?",41,"And with the assets having sold off pretty aggressively in the public markets over the last several months, does that make things more attractive to you? Or is it really about getting the right assets that's derisked and price is secondary?"
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Well, it makes it more attractive. There's no question.",9,"Well, it makes it more attractive. There's no question."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Ying Huang of Bank of America Merrill Lynch.",14,"And our next question comes from Ying Huang of Bank of America Merrill Lynch."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","First one on maybe pricing trend. If my math is right, if you take about $5.5 billion you booked in the second half, divided by about 112,000 patients starting patients, you're looking at roughly 50,000 per patient revenue in the U.S. in the second half o",103,"First one on maybe pricing trend. If my math is right, if you take about $5.5 billion you booked in the second half, divided by about 112,000 patients starting patients, you're looking at roughly 50,000 per patient revenue in the U.S. in the second half of 2015. So now with Merck's new drug launch in HCV, how should we think about pricing trend in the market in 2016? And then, I also have a question about diagnosis rate. Based on experience you have in the field, can you provide a little bit more color on the rate of nearly diagnosed patients in HCV?"
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Well, maybe I'll talk about pricing, first of all. I mean, I think everyone knows this, but it's really net price is the important number here for payers in the U.S. and, indeed, in Europe. So there seems to be over the last few days a somewhat of misinfo",145,"Well, maybe I'll talk about pricing, first of all. I mean, I think everyone knows this, but it's really net price is the important number here for payers in the U.S. and, indeed, in Europe. So there seems to be over the last few days a somewhat of misinformational confusion around the WACC price and discounts. So we feel that our pricing is extremely competitive and offers very, very good value, given the competitive set. And as I said earlier, payers in the U.S., this time around, are taking a very much more thoughtful look at the labels and trying to make sure they do the right thing for their clients. And so we feel pretty strong and pretty confident in the solid bases, let's say, of our price in the U.S. market. And the second question was about HCV presented to nearly diagnosed patients."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","I think that's a hard thing to get at. We still see about 30,000 patients coming into care every month so that's been an interesting metric for us, because more patients are coming into care than are being treated. We don't know how many are newly diagnos",227,"I think that's a hard thing to get at. We still see about 30,000 patients coming into care every month so that's been an interesting metric for us, because more patients are coming into care than are being treated. We don't know how many are newly diagnosed and how many are coming out of a bucket of diagnosed patients. But it is interesting to note that our most recent data still suggests there's about 1.5 million patients diagnosed in America, which means that -- and that was about 1.6 million when we launched Sovaldi. So that implies that there has been a refilling of that bucket, a replenishment, if you will. I don't know if buckets are the right term [ph] here. But it is category of patient as more patients are being diagnosed and working their way through the system. So we don't have a firm handle on exact numbers, so that's the closest approximation I can give you. But it does suggest that there's a pretty good flow of patients who are now becoming aware and coming in to at least be diagnosed. We don't know the characterization of those patients. There was an earlier question about whether those are patients eligible for treatment since many of the Medicaids are not treating many patients. And that's something we're trying to figure out right now."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","And Ying, I may want to add that there is the CDC recommendation about general diagnosis. We have a number of projects in a number of American cities to look at, subpopulations that we test and we demonstrate that you can actually have fairly high diagnos",74,"And Ying, I may want to add that there is the CDC recommendation about general diagnosis. We have a number of projects in a number of American cities to look at, subpopulations that we test and we demonstrate that you can actually have fairly high diagnosis rates up to 20% in some of these populations. And I think as people become aware of these things, I think the diagnosis will increase. That's our belief."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Alethia Young of Credit Suisse.",11,"And our next question comes from Alethia Young of Credit Suisse."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","To both Johns, congrats on a great history and a great future. Two questions, the shorter ones quick. In Japan, can you just help us understand like kind of how to think about this whether it's a 12% or maybe perhaps the larger kind of 50% range of discou",128,"To both Johns, congrats on a great history and a great future. Two questions, the shorter ones quick. In Japan, can you just help us understand like kind of how to think about this whether it's a 12% or maybe perhaps the larger kind of 50% range of discounts, I mean, when it comes to what's kind of the pricing discount will happen? And then also just on Genvoya. I was just -- I saw Stribild was down a little bit in new start and total share. So I just wanted to understand if you think the total lion's share is coming from Stribild or do you think there's like some maybe a triple of kind of new starts or maybe switches coming in with the Genvoya launch?"
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Okay, maybe I'll comment on Japan. We are fully aware of the new pricing regulation that's just been introduced in Japan. We are, let's say, highly confident that, that will affect Harvoni and Sovaldi in Japan. We are not totally [indiscernible] yet on th",69,"Okay, maybe I'll comment on Japan. We are fully aware of the new pricing regulation that's just been introduced in Japan. We are, let's say, highly confident that, that will affect Harvoni and Sovaldi in Japan. We are not totally [indiscernible] yet on the number or the timing of that likely price cut. But we have factored that in to our guidance. And the second question was on Stribild."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","And switches on Genvoya.",4,"And switches on Genvoya."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","And Genvoya.",2,"And Genvoya."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","And switches, yes, yes. Well, Genvoya has gone off to a really good start. We think that about 80% of the Genvoya business today is from switches. And we think that the majority of those switches are actually from Stribild so far. So that probably account",88,"And switches, yes, yes. Well, Genvoya has gone off to a really good start. We think that about 80% of the Genvoya business today is from switches. And we think that the majority of those switches are actually from Stribild so far. So that probably accounts for the Stribild share number. We think, of the switches to Genvoya, about 10% of those switches so far have come from non-Gilead products. So we're pleased with the phase of switching, and we're pleased that we're also getting some incremental growth."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Brian Abrahams of Jefferies.",10,"And our next question comes from Brian Abrahams of Jefferies."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","My congratulations to John Martin on all your accomplishments as CEO and to John Milligan on your well-deserved new role. So a question related to the inflammatory franchise. Historically, you guys have had a lot of success developing and commercializing",133,"My congratulations to John Martin on all your accomplishments as CEO and to John Milligan on your well-deserved new role. So a question related to the inflammatory franchise. Historically, you guys have had a lot of success developing and commercializing products with best-in-class features along efficacy, safety and dosing that enable you to really dominate a space such as in HIV and hep C. RA and inflammatory valve diseases are a little bit different, they're a lot more crowded. Wonder if you could talk a little bit about some of the ways you're thinking about conducting the development paths for drugs like filgotinib and 5745 to maximize differentiation? Perhaps, you could talk about combination opportunities there and how this ties into your long-term commercial strategy as you enter these new therapeutic areas."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes so, Brian, as I've said before, we believe filgotinib, by itself, if you compare it with other JAK inhibitors, is a very valuable franchise. It has good efficacy and it could have safety advantages. And I'm saying it could have because I'm making cros",196,"Yes so, Brian, as I've said before, we believe filgotinib, by itself, if you compare it with other JAK inhibitors, is a very valuable franchise. It has good efficacy and it could have safety advantages. And I'm saying it could have because I'm making cross-study comparisons. So until we do a large Phase III program, we don't really know that for certain. But then as you pointed out where we afterwards fairly quickly want to go with filgotinib is in combination therapy. We believe that in inflammatory valve disease and also RA, there is a huge unmet need still. If you look at some of the ACR20 responses, they are up to 80%, but ACR70s are only in the teens or 20% at most. So that means there's a huge improvement left to be done, and that, we believe, could be done with combination therapies. We're going to go ahead and combine our JAK inhibitor with our MMP-9. That's going to be the first thing. And afterwards, also [indiscernible] the zinc compounds and the BTK inhibitor. So that's where we think we could have a big impact on the future of the treatment of inflammatory conditions."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Brian Skorney of Robert W. Baird.",12,"And our next question comes from Brian Skorney of Robert W. Baird."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","My congratulations to John and John. Just 2, I guess. I guess the first question is in terms of Japanese sales, I understand there's a government-mandated price cut given the revenue that Sovaldi and Harvoni are generating. Can you just walk us through ho",159,"My congratulations to John and John. Just 2, I guess. I guess the first question is in terms of Japanese sales, I understand there's a government-mandated price cut given the revenue that Sovaldi and Harvoni are generating. Can you just walk us through how that flows as of January 1? And can you give us a scale of what we should expect further price cut? And then just to dig down a little more on Merck's pricing and how it impacts you guys. I think we're all surprised by the quickness in the gross to net discount that AbbVie and you had applied for the initial launches. I guess, the question is Merck clearly is going to take a pretty substantial discount versus what you guys have out. Or are you at a point where you're comfortable enough in the profile that you're drawing a line in the sand to say you're essentially not going to be discounting anymore?"
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Let me start by talking about Japan. We're not going to say what our assumption is around the tax outcome. I mean, I think I already said before. We understand the rules. It's pretty clear what the range is, and we're going to be somewhere in that range.",188,"Let me start by talking about Japan. We're not going to say what our assumption is around the tax outcome. I mean, I think I already said before. We understand the rules. It's pretty clear what the range is, and we're going to be somewhere in that range. And we're also not sure exactly the timing of that. So but we have -- we built an assumption into our guidance that we've given, and I can't really comment further on that at this point. Then on the gross to net, I mean, I think your question is are we confident enough to walk away. And I think the answer is yes, we are. But we're hopeful that our close discussions with payers and the strength of our label and the strength of the -- the relative strength of our labels compared to the competitors and, of course, this enormous wealth of real-world data that we've got gives us a position where we sincerely hope the right thing is done for patients and patients get access to our medicines. So I think that's the way we think about it."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","And Brian, other than the cost of drug, you should also consider, of course, the cost of treatment. There is a genotype required for genotype 1a. The resistance test will cost about $700 and incurs some time delay. There is a test for ALTs at 8 weeks and",114,"And Brian, other than the cost of drug, you should also consider, of course, the cost of treatment. There is a genotype required for genotype 1a. The resistance test will cost about $700 and incurs some time delay. There is a test for ALTs at 8 weeks and at 12 weeks so you have to dose for 16 weeks. And also, it's possible that, well, a fairly significant number of the genotype 1a patients, and those are 50% in U.S., they will require 16 weeks with ribavirin. So that's not -- it's more than 12 -- it increases the treatment cost proportionately compared to 12 weeks or 8 weeks in our case, with Harvoni."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","But I think the good news, just to reemphasize, is that the payers across the United States have been very cognizant of this and thinking carefully the full implications and not being dazzled by the headlines of a low back price.",41,"But I think the good news, just to reemphasize, is that the payers across the United States have been very cognizant of this and thinking carefully the full implications and not being dazzled by the headlines of a low back price."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And we have time for one more question. Our final question comes from the line of Terence Flynn of Goldman Sachs.",21,"And we have time for one more question. Our final question comes from the line of Terence Flynn of Goldman Sachs."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I have 2 because I'm guessing now you might not want to answer the first one. But just for Robin on capital allocation, you mentioned 77% of free cash flow return from 2010 through 2015. As you look forward, do you guys have a target payout ratio in mind?",96,"I have 2 because I'm guessing now you might not want to answer the first one. But just for Robin on capital allocation, you mentioned 77% of free cash flow return from 2010 through 2015. As you look forward, do you guys have a target payout ratio in mind? And then, the second one was just on EU hep C patient volumes in '16. Paul, you gave us a lot of context for U.S., but maybe just if you could be a little bit more specific in terms of actually thinking about volumes in Europe."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Sure, Terence. I'll take the first one. You're right. I'm not going to give a specific number. And as I mentioned on the call, I think it varies based on the other investments we're making. And the numbers we gave you were on average. There have been peri",87,"Sure, Terence. I'll take the first one. You're right. I'm not going to give a specific number. And as I mentioned on the call, I think it varies based on the other investments we're making. And the numbers we gave you were on average. There have been periods where we've been higher and periods we've been lower. But by using the word substantial, I think you can assume it to remain significant, but could vary period from period -- or year-to-year. That's how I'd look at it."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","And on the EU volumes, we estimated that in the EU, I should say, so the 28 countries in the EU where the product's been launched so far in 2015, around about 140 patients in total were treated. We have a slightly lower market share in Europe than we do i",278,"And on the EU volumes, we estimated that in the EU, I should say, so the 28 countries in the EU where the product's been launched so far in 2015, around about 140 patients in total were treated. We have a slightly lower market share in Europe than we do in the U.S., and that's because of payer type arrangements that our competitors got in place. The range of market share ranges from 70% to 90%. But I would say on the average would be about 80% of that 140. All of the main countries, the big countries in Europe have now gone through their sort of warehoused points of the launch trajectory with the patient flow and are getting into more stable patient flows, but are growing. So I think that's my main point. We anticipate higher numbers of patients in 2016 over '15. And countries like the U.K. really didn't treat very many patients at all so far, but they are now beginning to ramp up. And then, some of the smaller countries, Netherlands, Austria, are beginning to grow patient numbers. Having said that, I also mentioned earlier price volume agreements. These are set up to try and encourage more patients being treated. But obviously, the flipside to those arrangements is that the price per patient comes down, and there's better value to treat more patients. The other thing, I think, it's the real-world data with 8 weeks of Harvoni treatment. It looks stronger and stronger and is more convincing to European payers. And therefore, they will also use that opportunity to try and treat more patients, but of course, at a lower revenue per patient."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Candace, and thank you all for joining us today. We appreciate your continued interest in Gilead. And the team here looks forward to providing you with updates on our future progress.",33,"Thank you, Candace, and thank you all for joining us today. We appreciate your continued interest in Gilead. And the team here looks forward to providing you with updates on our future progress."
29002,322206567,925047,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This concludes the program, and you may all disconnect. Have a great day, everyone.",24,"Ladies and gentlemen, thank you for participating in today's conference. This concludes the program, and you may all disconnect. Have a great day, everyone."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Fourth Quarter 2015 Earnings Conference Call. My name is Candice, and I'll be your operator for today. [Operator Instructions] And as a reminder, this conference call is b",63,"Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Fourth Quarter 2015 Earnings Conference Call. My name is Candice, and I'll be your operator for today. [Operator Instructions] And as a reminder, this conference call is being recorded.
I would now like to turn the call over to Patrick O'Brien, Vice President of Investor Relations. Please go ahead."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Candice, and good afternoon, everyone. Just after market close today, a press release was issued with earnings results for the fourth quarter and full year 2015. The press release and detailed slides are available on the Investor Relations sect",233,"Thank you, Candice, and good afternoon, everyone. Just after market close today, a press release was issued with earnings results for the fourth quarter and full year 2015. The press release and detailed slides are available on the Investor Relations section of the Gilead Sciences' website. 
Joining today's call will be John Martin, Chairman and Chief Executive Officer; John Milligan, President and Chief Operating Officer; Norbert Bischofberger, Executive Vice President of Research and Development and Chief Scientific Officer; Paul Carter, Executive Vice President of Commercial Operations; and Robin Washington, Executive Vice President and Chief Financial Officer. 
Before beginning formal remarks, let me remind you that we'll be making forward-looking statements, including plans and expectations with respect to products, product candidates, financial projections and the use of capital, all of which involve certain assumptions, risks and uncertainties that are beyond our control and could cause actual results to differ materially from these statements. A description of these risks can be found in the latest SEC disclosure documents and recent press releases. In addition, Gilead does not undertake any obligation to update any forward-looking statements made during this call. 
Non-GAAP financial measures will be used to help you understand the company's underlying business performance. The GAAP to non-GAAP reconciliations are provided in the earnings release, press release as well as on the Gilead Sciences' website. 
I will now turn the call over to John Martin."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Patrick, and thank you, everyone, for joining us today. 2015 was an exceptional year for Gilead, with progress in a number of therapeutic areas, most notably in the development of TAF-based therapies for HIV and hepatitis B and new agents for",226,"Thank you, Patrick, and thank you, everyone, for joining us today. 
2015 was an exceptional year for Gilead, with progress in a number of therapeutic areas, most notably in the development of TAF-based therapies for HIV and hepatitis B and new agents for the treatment of liver disease. Gilead is entering 2016 from a position of financial strength, a portfolio of 20 marketed products that address significant unmet medical needs, including Genvoya, the most recent product to be introduced, and the growing pipeline with multiple programs for which milestones are expected during the coming year, including regulatory decisions on 2 products for HIV and one each for HCV and HPV. 
As you all know, we announced on Friday that John Milligan will be appointed CEO, a role he'll assume in a few weeks. I will be taking on the role of Executive Chairman and will continue to be actively engaged in the company. John Milligan has been with Gilead for more than 25 years and, over that time, has built expertise in every functional area of the company's operations. The board and I are confident that this is the right time for this transition and that John is the right person to lead Gilead in the next few years of evolution. 
John, congratulations. I'll now turn the call over to you to make a few remarks."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, John. I'm honored and excited by the opportunity to lead this company and the great team we have. In my new role, I will continue to work hard to help Gilead's business grow beyond antivirals and into new therapeutic areas for the betterment of pa",1160,"Thanks, John. I'm honored and excited by the opportunity to lead this company and the great team we have. In my new role, I will continue to work hard to help Gilead's business grow beyond antivirals and into new therapeutic areas for the betterment of patients.
I'm also greatly appreciative to have that John will remain closely involved as the Executive Chairman. 
Turning to the business and results of the quarter. Genvoya, the company's first TAF-based single-tablet regimen for the treatment of HIV-1 infection, is now approved in the U.S. and Europe. Genvoya achieved preferred status in the U.S. Department of Health and Human Services treatment guidelines within the first 2 weeks after approval, which speaks to the profile of the product and the important need it addresses. 
Two other TAF-based regimens are pending regulatory approval in the U.S. and EU. F/TAF has been assigned a PDUFA date of April 7. And in the EU, a CHMP opinion could be adopted in the first quarter of this year. R/F/TAF has been assigned a PDUFA date of March 1, and a CHMP opinion is expected in the second half of this year. This means that Gilead could launch 2 new TAF-containing products in the coming months, giving patients a wider range of options for the treatment of their HIV. 
During the last quarter, 4 Phase III studies of GS-9883, Gilead's proprietary integrase inhibitor combined in the single-tablet regimen with F/TAF were initiated. Two studies will evaluate the safety and efficacy of GS-9883/F/TAF in HIV-1-infected treatment-naive adults. One will compare GS-9883/F/TAF to Triumeq, and the other will compare GS-9883/F/TAF to dolutegravir plus F/TAF. Two other studies will evaluate patients who switch from Triumeq or a boosted PI to GS-9883/F/TAF. 
Phase II data on GS-9883/F/TAF will be presented later this year at a medical conference describing the safety and antiviral activity over 48 weeks of treatment. Analysis of the data through 24 weeks indicated that an FCR of GS-9883/F/TAF may represent a valuable option for many patients. And based on current time lines, the U.S. NDA and EU MAA could be filed in the second half of next year. 
Last month, Gilead submitted a new drug application in the U.S. and a Marketing Authorization Application in the EU for TAF as a treatment for chronic hepatitis B. Regulatory submissions are also expected in Japan, Korea, Taiwan and India this year and China in the first half of 2017. 
Phase III study results reflect high efficacy and improved renal and bone safety parameters, similar to those seen in the clinical studies evaluating TAF-based regimens for HIV. 
Beyond TAF for HPV, several ongoing research programs are focused on therapies with finite duration of dosing that achieve long-term viral suppression. The first is an immunomodulatory approach, where multiple programs are evaluating different ways to activate immune system to eliminate infected hepatocytes. The most advanced is our TLR-7 agonist, GS-9620, which is currently in 2 Phase II studies. Other approaches include the combination of novel direct-acting antivirals and agents that modulate cccDNA transcription. Two of these new programs may enter into clinical trials in the first half of 2016. 
In hepatitis C, Gilead's focus remains on advancing care of people with the disease regardless of genotype or disease severity. With the launch of Sovaldi in December 2013 and Harvoni in October 2014, more than 770,000 individuals around the world have been treated with sofosbuvir-based regimen.
In November, FDA approved Harvoni for expanded use in patients with genotype 4, 5 and 6 chronic HCV infection and the patients co-infected with HIV. In addition, Harvoni plus ribavirin for 12 weeks was approved as an alternate therapy to 24 weeks of Harvoni for treatment experience genotype-1 patients with cirrhosis. 
Sofosbuvir and Velpatasvir is an investigational once-daily pan-genotypic combinations studied for the treatment of genotype 1 through 6 chronic HCV infection, including patients with compensated and decompensated cirrhosis. FDA granted priority review and has set a PDUFA date of June 28, 2016.
Additionally, sofosbuvir/velpatasvir has been granted accelerated assessment in the EU. If approved, sofosbuvir/velpatasvir will represent a significant step forward, particularly for genotype 3 patients. It would also become the first and only regimen offering high SVR8, with 12 weeks of treatment for patients with all HCV genotypes. 
The advances in treatment of HCV with Sovaldi and Harvoni over the past 2 years have allowed Gilead to work with governments and public health experts on eradication strategies among specific populations and geographies. Programs such as those ongoing in the Republic of Georgia and Iceland could serve as examples for other governments around the world seeking to eradicate HCV. 
Public-health programs to prevent HIV transmission are also underway, including efforts to raise awareness about the use of Truvada for PrEP. Today, more than 40,000 patients in the U.S. are receiving Truvada for its preventive indication. Yesterday, the MAA was validated for Gilead's type 2 variation of Truvada for PrEP, and it is now under evaluation by the EMA. 
Gilead continues its R&D efforts in NASH, or non-alcoholic steatohepatitis. Phase II studies of simtuzumab, a LOXL2 targeting antibody, are ongoing in patients with NASH and also primary sclerosing cholangitis. The data monitoring committee for these studies recently met and recommended the continuation of the studies, which have a 96-week endpoint. 
Additionally, clinical studies of the FXR agonist, GS-9674, have been initiated, with the first patients receiving treatment in Q4 of last year. 
Moving to oncology. Gilead continues to study Zydelig in several hematological disorders. Phase III study results show adding Zydelig to bendamustine and rituximab provides statistically significant and clinically meaningful improvements in progression-free and overall survival compared to bendamustine and rituximab alone. 
Supplemental regulatory filings are planned in the U.S. and Europe early this year to include these important new data. 
Beyond Zydelig, Gilead also is exploring novel combinations of investigational therapies for a range of cancers, including 4 classes of kinase inhibitors through PI3K, Syk, JAK and BTK, that each target different signaling pathways. 
Progress has been made in inflammation as well. Gilead entered into a global partnership with Galapagos late last year for the development and commercialization of filgotinib, a JAK1 inhibitor for rheumatoid arthritis and other inflammatory diseases. Phase II trial data shows that filgotinib has the potential to be an effective and  well-tolerated oral therapy for patients with RA and Crohn's disease. Phase III studies of filgotinib in RA and Crohn's are planned to start later this year. 
In summary, Gilead's substantial pipeline offers numerous opportunities for continued growth, both in the short and longer term, and the financial strength of the company allows us to be thoughtful and opportunistic in pursuing partnerships or acquisitions that will further expand the future portfolio of products.
2016 will be a busy year for Gilead, and I want to take this opportunity to thank all of our employees for the support in this transition and for their continued hard work and dedication.
Paul Carter will now provide a commercial update."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, John, and good afternoon, everyone. Gilead achieved $8.4 billion in net product revenue in the fourth quarter, representing 16% year-over-year growth. U.S. product revenue reached $4.8 billion in the fourth quarter, which is down 14% from the thir",1324,"Thanks, John, and good afternoon, everyone. Gilead achieved $8.4 billion in net product revenue in the fourth quarter, representing 16% year-over-year growth. U.S. product revenue reached $4.8 billion in the fourth quarter, which is down 14% from the third quarter and down 12% on a year-over-year basis, largely due to a decrease of HCV revenue.
European product revenue reached $1.7 billion in the quarter, which was in line with the prior quarter and up 22% on a year-over-year basis despite the negative 11% foreign exchange impact. 
For the rest of the world, product revenues were $1.9 billion for the fourth quarter and $3.8 billion for the full year, driven largely by HCV launches in Japan. 
Beginning with hepatitis C. Total HCV product revenue reached $4.9 billion in the fourth quarter. 
In the next few minutes, I'll describe the results for the quarter 4 by region and also describe how we're thinking about the year ahead. 
In the United States, HCV product revenue totaled $2.4 billion, which is down 27% from the third quarter. This decline was impacted by substantially lower VA sales in the fourth quarter. 
In quarter 3, Congress allocated an additional $500 million to the VA for HCV treatment, and this was fully utilized in quarter 3. New patient starts in the VA were very limited during quarter 4 due to the uncertainty of future funding at that time. Congress have since allocated substantial funding of $1.5 billion for the fiscal year, which will allow treatments in the VA to resume this quarter. 
In terms of patient numbers, in 2015, nearly 250,000 U.S. HCV patients started treatment, with more than 90% of these patients receiving Gilead HCV therapies. As I commented last quarter, there were an unusually large number of patient starts in the U.S. in the first quarter of last year, indicative of the rapid initiation of treatment for many warehouse patients, followed by a flattening of patients in the remaining quarters of the year. 
Looking to the future, even with nearly 400,000 patients treated since the launch of Sovaldi, there remain more than 3 million HCV-infected individuals in the U.S., who have let yet to be treated, approximately half of whom are diagnosed according to recent CDC data. 
Long-term education and awareness efforts to increase rates of diagnosis and the flow of HCV-infected patients into treated care are important and will play out over many years, as we know from our experience in HIV. 
Turning to Europe. Hepatitis C revenue was $846 million in the fourth quarter, and we estimate that more than 110,000 patients were treated with sofosbuvir-based regimens in 2015.
Following the normal summer seasonality in quarter 3, there was an increase of patient starts throughout Europe in quarter 4, including in the U.K. following the final appraisal determination for Harvoni from NICE. A number of countries in Europe have volume-based incentives of Sovaldi and Harvoni, which serve to encourage a high number of patients being treated. 
In quarter 4, the growth in revenues did not match the growth in patient starts because of the impact of certain volume-based agreements, combined with adverse foreign exchange movements. 
In Japan, hepatitis C revenues for the fourth quarter were $1.4 billion. Since the launch of Sovaldi in May and the launch of Harvoni in September, sales of $1.9 billion have been generated in Japan, with Harvoni representing more than $1 billion of that number. In late December, pricing and reimbursement negotiations for Sovaldi and Harvoni in Australia were finalized.
There were a number of variables to consider when thinking about HCV patient numbers and revenues for 2016. Patient starts in the U.S. will likely be similar to 2015 levels observed in the second half and extrapolated for the full year, while the Europe numbers will continue to grow as early launch markets stabilize and new markets ramp up treatment.
In Japan, patient numbers are difficult to predict because launches are still in the early stages, and to some extent, we are likely seeing the impact of warehoused patients. 
In the rest of the world, we're excited to bring -- to reach new patients in several new markets, notably in Asia Pacific and in Latin America. 
As we think about revenue, we anticipate that variables to consider include potential shorter durations of treatment, the full year effect of payer contracts in the U.S. and by price volume deals in some European markets, which may allow more patients to be treated at a lower per patient cost. 
We also anticipate that payer mix in the U.S. may shift slightly towards public payers, while in Japan, new legislation will likely result in lower pricing for Sovaldi and Harvoni. 
We're confident in the long-term sustainability of HCV markets worldwide. Despite the number of patients treated to-date, there are still millions of HCV-infected individuals, who've yet to be treated and many other that have yet to be diagnosed. There are significant efforts underway by industry, governments and patient organizations to increase rates of diagnosis and linkage to care. 
We're also confident in our competitive position as we enter 2016. Sovaldi and Harvoni are breakthrough therapies that set the bar with cure rates of up to 99%. Data presented at AASLD in November showed real world cure rates with Harvoni that met or exceeded what was predicted by clinical trials, including the 8-week duration of therapy.  We also look forward to launching our next HCV product, sofosbuvir/velpatasvir, in due course around the world starting later this year. 
Turning to HIV. HIV product revenue reached $3 billion in the fourth quarter. In the U.S., revenues were $2 billion, a 3% increase from the third quarter and up 5% on a year-over-year basis, driven by the continued demand for Stribild, Complera, Truvada and the recent launch of Genvoya. 
Stribild and Complera has a strong underlying prescription demand, with year-on-year growth of 40% and 12%, respectively. 
7 out of 10 HIV patients in the U.S. initiate therapy with a Gilead product, and nearly 6 in 10 receive a Gilead single-tablet regimen. 
Genvoya sales have been very encouraging in the first few weeks of launch. Revenues for the quarter were $44 million, with early product uptake well ahead of the launch of Stribild at the same time point. 
Access and reimbursement have been consistent with historical norms in HIV, and the rapid addition of Genvoya to the DHS gap treatment guidelines as a preferred first-line treatment reinforces the safety and efficacy profile observed in clinical trials and reflected in non-product label. 
In Europe, HIV revenues were $747 million for the quarter, up 4% from the third quarter, driven by the sales of Stribild and Eviplera, with a slight decline year-over-year caused by foreign exchange. 7 out of 10 patients in Europe also started on Truvada-based backbone in 2015. 
Genvoya was launched in Europe in November. Similar to the U.S., we have seen encouraging early product uptake in the 6 countries launched during the fourth quarter. 
A final comment on HIV is that the commercial organization is getting ready to execute the launches of R/F/TAF and F/TAF in the next months. 
Turning to other therapy areas. Total revenue for product outside of HIV and HCV, which includes Zydelig, AmBisome, Cayston, Letairis and Ranexa, totaled $1.9 billion in 2015 and grew 16% year-over-year. 
Over the last quarter, progress has been made in the area of cardiovascular disease. Since the inclusion of the AMBITION data in the Letairis label, we've seen a great deal of interest in engagement from  the medical community. 
Revenue for the full year for Letairis received -- reached $700 million, and market share for the products among patients initiating therapy is nearly 50%. 
In closing, Gilead had a remarkable 2015. The commercial organization's excited about the opportunities across all of Gilead's therapeutic areas, both in the near term and over the longer term, to help many more patients around the world. 
And I'll now turn the call over to Robin."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Paul, and good afternoon, everyone. We are pleased to share full year and fourth quarter 2015 financial results and provide 2016 guidance. For the fourth quarter, total revenues were $8.5 billion, up 16% compared to the fourth quarter of 2014",1034,"Thank you, Paul, and good afternoon, everyone. We are pleased to share full year and fourth quarter 2015 financial results and provide 2016 guidance. 
For the fourth quarter, total revenues were $8.5 billion, up 16% compared to the fourth quarter of 2014. Net income for the quarter was $4.7 billion or $3.18 per diluted share compared to $3.5 billion or $2.18 per diluted share for the fourth quarter of 2014. Non-GAAP diluted EPS for the fourth quarter was $3.32 per share, up 37% compared to the fourth quarter of 2014. 
Turning to fiscal year 2015. Full year total revenues were $32.6 billion, up 31% year-over-year. Net income for the year was $18.1 billion or $11.91 per diluted share compared to $12.1 billion or $7.35 per diluted share for 2014. 
Non-GAAP diluted EPS was $12.61 per share for the year, up 56% year-over-year. 
Product sales during the year were $32.2 billion, up 31% year-over-year. HCV product sales increased year-over-year to $19.1 billion, up 54%. And non-HCV product sales increased year-over-year to $13 billion, up 8%. 
The increase in HCV product sales for the year was primarily driven by sales of Harvoni, which launched in October 2014. Further, the annualized HCV gross-to-net estimate that was shared with you during the Q4 earnings call a year ago is on target and reflected in our 2015 results. 
Non-HCV product sales growth for the year was primarily driven by Stribild and Complera, Eviplera partially offset by ATRIPLA.
Turning to expenses for the full year 2015. Non-GAAP R&D expenses were $2.8 billion, up 10% compared to the prior year, reflecting the continued progression of our product pipeline. Non-GAAP SG&A expenses were $3.2 billion, up 17% compared to the prior year, driven by expenses to support our growth and geographic expansion. 
The non-GAAP effective tax rate for the full year was 16.2%, which was lower compared to guidance due to the permanent extension of the federal R&D credit that was passed in December. If you recall, the permanent extension of the credit was not included in 2015 guidance. 
Cash flows from operations were $20.3 billion for the full year 2015 and $4.9 billion for the fourth quarter. 
With respect to shareholder return, $3.1 billion in cash was utilized to repurchase 29 million shares during the quarter, bringing total 2015 share repurchases to 10,095,000,000, shares. Including the Q2 2015 warrant settlement of $3.9 billion dividends and share repurchases, Gilead has returned more than $15 billion in cash to shareholders in 2015. 
Earlier today, we announced an increase of the quarterly dividend from $0.43 per share to $0.47 per share, which will become effective in the second quarter of 2016, subject to a declaration by the Board of Directors. 
Additionally, the board authorized a new $12 billion share repurchase program to be initiated after the completion of the current $15 billion program, which, as of December 31, 2015, had $8 billion remaining. 
Also announced was the utilization of $5 billion of the current program to enter into an accelerated share repurchase agreement, which is expected to be completed in the next 3 months. This is in addition to the ongoing open market share repurchases that have continued under the current share repurchase bulk program since January of this year. 
The increase in the dividend and increased level of share repurchases underscore the confidence of the board and management in the strength of the business and future cash flows. 
Since 2010, in addition to financing ongoing R&D programs and business development activities, more than 75% of free cash flows were returned to shareholders, and share count was reduced in excess of 20% while maintaining and improving investment-grade credit ratings, which Gilead values. 
Looking forward, the plan is to continue to return a significant component of free cash flows to shareholders via share repurchases and increases to our dividend over time. 
As in the past, there could be future periods of time when share repurchases are reduced due to acquisitions and other pipeline investments that are prioritized to drive future long-term growth. This strategy provides agility and financial flexibility to support R&D investments as well as any future acquisitions or partnership opportunities we may consider. 
Finally, I would like to cover full year 2016 non-GAAP financial guidance summarized on Slide 51 in the earnings presentation available on the Gilead website. 
Product sales are expected to be in the range of $30 billion to $31 billion. Guidance for product sales is subject to a number of uncertainties, including an uncertain global macroeconomic environment, adoption of additional pricing measures to reduce HCV spending, volatility in foreign currency exchange rates; inaccuracy in HCV patients start estimates; additional competitive launches in HCV; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers and a larger-than-anticipated shift in payer mix to more highly discounted payer segments, such as PHS, FFS, Medicaid and the VA. 
Non-GAAP product gross margins are expected to be in the range of 88% to 90%. Non-GAAP R&D expenses are expected to be in the range of $3.2 billion to $3.5 billion as a result of the continued investment in our product pipeline. This includes the financial impact of the Galapagos calibration, or collaboration, which closed in January. 
Non-GAAP SG&A expenses are expected to be in the range of $3.3 billion to $3.6 billion. This reflects an estimated $200 million increase for the U.S.-branded prescription drug fee. Please note that 2015 included a favorable adjustment of approximately $100 million based on the receipt of the 2015 invoice from the IRS. 
For the full year, the non-GAAP effective tax rate is expected to be in the range of 18% to 20%. This includes the impact of the federal R&D tax credit, which was permanently extended at the end of 2015, and the increase for the U.S.-branded prescription drug fee, which is not tax-deductible. 
Full year diluted EPS impact of acquisition-related restructuring and stock-based compensation expenses is expected to be in the range of $1.10 to $1.16 per share. 
In closing, we are pleased with 2015 accomplishments across the organization. Thank you, and we look forward to updating you on our progress. 
Let's now open the call for questions. Operator?"
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","[Operator Instructions] And our first question comes from Geoff Meacham of Barclays.",12,"[Operator Instructions] And our first question comes from Geoff Meacham of Barclays."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","This is Carter Gould on for Geoff. Congrats on the quarter. With regards to 2016 guidance, how should we think about the top line guidance and what that implies for any loosening of restrictions in the lower fibrosis-core groups or any changes in net pric",76,"This is Carter Gould on for Geoff. Congrats on the quarter. With regards to 2016 guidance, how should we think about the top line guidance and what that implies for any loosening of restrictions in the lower fibrosis-core groups or any changes in net pricing and if maybe that's a little more detail than you're ready to go into maybe you can just frame how we should think about these levers in 2016 relative to 2015?"
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Okay. So I think I said in the script that we should anticipate in the United States that 2016 revenues should be more or less based on the second half of 2015 extrapolated for the year. I also mentioned that we had some lumpiness in the second half of th",596,"Okay. So I think I said in the script that we should anticipate in the United States that 2016 revenues should be more or less based on the second half of 2015 extrapolated for the year. I also mentioned that we had some lumpiness in the second half of the year due to the purchasing profile of the VA. And we anticipate that, that will smooth out during the course of this year. I've also said numerous times before that in quarter 1 last year, we had a very large bulbous of warehouse patients being treated which, of course, we're unlikely to see again. But to some extent, that gets substituted as the payers, commercial payers, that we are well-known are beginning to loosen restrictions. So there's a few dynamics in the U.S., but I think the way that I would look at it is a fairly flat stable, perhaps marginally growing a number of patients flowing into treatment. If we see public payers stepping up like Medicaid and perhaps a correctional facility to start treating more patients, then patient numbers could go higher than that in 2016. There's a few other factors, which I also mentioned, as we think about the revenue aspect as opposed to just patient numbers. The less-sick patients, GT1 patients that qualify, are more likely to be using the 8-week Harvoni treatment duration. And of course, therefore, revenue per patient would come down proportionately. Having said that, the offset is that budgets for treating patients go up, and we would like to think that more patients could be treated. So I think that's sort of the main thing. I think from a competitive point of view, we feel very confident that our label is very strong and that we are very much supported by the real-world data we've seen since the launch of Harvoni and with very high SVR rates and a very strong safety profile, at least as good, if not better, than the one that was used in our registrational trials. So I think we feel good about the year. The U.S. is fairly steady and possibly could even grow, as I said, if some restrictions loosens and public payers step up. Around the world, as I mentioned, we expect patient numbers to grow in Europe. They started to stabilize in the major markets now, again, following more or less the shape of the curve in the U.S., where there is a large lump because of warehoused patients being treated initially. That is smoothing out now. And many of the smaller markets are now beginning to come on onstream. And so we should see higher number of patients in Europe. But the same thing, we're likely to see more patients being treated with shorter durations. And as I also mentioned, we do have a number of price volume agreements in place, which are delivered incentive wise to encourage high volumes of patients being treated but at a lower revenue per patient, if you like. So we should think about that. And then around the rest of the world, Japan, I mentioned, very early days. We're still in that warehousing phase, I think, in Japan, although we're very pleased with the launch there so far. And then there were various other small markets around the world and medium-size markets, Canada, Australia being one of the medium-sized markets that are yet to launch yet. So we have plenty of patients around the world, but there are some other dynamics, as I said, around shorter treatment and, of course, the competitive situation."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Mark Schoenebaum of Evercore.",10,"And our next question comes from Mark Schoenebaum of Evercore."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","It's actually Vlad Nikolenko on behalf of Mark Schoenebaum. I have a question about filgotinib specific JAK1 inhibitor, the one you got from Galapagos. Just curious, your thoughts about testicular talks concerns on filgotinib as well as whether your base",73,"It's actually Vlad Nikolenko on behalf of Mark Schoenebaum. I have a question about filgotinib specific JAK1 inhibitor, the one you got from Galapagos. Just curious, your thoughts about testicular talks concerns on filgotinib as well as whether your base case will be 200 milligrams daily dose going forward in the U.S.? And sort of somewhat related question. What's exactly impacting your 2016 guidance of -- on R&D expenses from Galapagos collaboration?"
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. So maybe I could answer the first few questions. So we were very excited about filgotinib because of the clinical profile. As you know, they have now data. Galapagos has generated data in RA and also in Crohn's. Both of those have very remarkable eff",135,"Yes. So maybe I could answer the first few questions. So we were very excited about filgotinib because of the clinical profile. As you know, they have now data. Galapagos has generated data in RA and also in Crohn's. Both of those have very remarkable efficacy. And also importantly, we think that filgotinib can be distinguished from competitors because of its safety profile, in particular, the lack of hemoglobin decreases, and very low infection rates. The other thing you asked about the dose. That still needs to be negotiated with the FDA. We actually have a meeting coming up in the next couple of months, where we will talk about, in detail, the Phase III program design, including the doses. So it's really, at this point, too early to say what the dose will be."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","And this is Robin. To answer the second part of your question, we really have included, relative to the collaboration, the -- some of the upfront milestone payments as well as the costs associated with some of the Phase III trials that Norbert just spoke",74,"And this is Robin. To answer the second part of your question, we really have included, relative to the collaboration, the -- some of the upfront milestone payments as well as the costs associated with some of the Phase III trials that Norbert just spoke about. So we don't break it out in detail, but I would assume a couple of hundred million incremental to 2015 included in our guidance to support those projects."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Matt Roden of UBS.",10,"And our next question comes from Matt Roden of UBS."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Congrats to John Martin for an amazing 20 years at the helm here. So I have a big picture question. Seems like a good time to ask it, I guess, with the transition is, over the last 2 years, you've tripled your revenues. You've increased your earnings by a",142,"Congrats to John Martin for an amazing 20 years at the helm here. So I have a big picture question. Seems like a good time to ask it, I guess, with the transition is, over the last 2 years, you've tripled your revenues. You've increased your earnings by about sixfold over that period. But the market seems to be discounting your ability to grow the business from here. Just wanted to see if you can maybe lay out a vision of the development of various franchises that you have. You have -- a lot's going on in cancer. You've added to the inflammation franchise. You have TAF, 9883 in HIV. Just wondering if you could just maybe shine the light on how you visualize the growth out to, say, 2020 something like that? It would be really helpful to hear your thoughts."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Matt, it's John Milligan. I assume the question's for me, not the congratulatory one to John Martin. So it's a very good question.",23,"Matt, it's John Milligan. I assume the question's for me, not the congratulatory one to John Martin. So it's a very good question."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Whoever want to take it.",5,"Whoever want to take it."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Whoever will take it. Well, I'll take it. I'd be happy to. So it's a really good question. So you're right. We have -- we faced an extraordinary time when we've been able to triple revenue over the last couple of years, which is a very unusual thing for a",555,"Whoever will take it. Well, I'll take it. I'd be happy to. So it's a really good question. So you're right. We have -- we faced an extraordinary time when we've been able to triple revenue over the last couple of years, which is a very unusual thing for an organization to be able to do. And we're moving our pipeline along as fast as we can. And as we mentioned, there's some very interesting opportunities for us. So we do see very good opportunities in organic growth. And I have great confidence in HIV portfolio that with the 3 STRs we talked about on the call today and the other STR being developed by our partner, Johnson, that will have very -- a meaningful continued growth of both patients and revenues in the future in HIV. I think that's a very important thing for us. We're continuing to accelerate HCV to bring SOF/Velpatasvir to market and try to work in more countries than we ever have before. So those are important initiatives and things that are current to market. We're very excited about filgotinib. I think there's great opportunities for us in inflammatory diseases. We hadn't spoken about it very much in the past, and sort of quietly, we've been investigating our MMP-9 antibody, 5745, which we didn't talk about on this call, which now has positive data in 3 of the 4 indications we've looked at in inflammatory diseases, with the fourth under investigation. And so not only do we have filgotinib potentially for RA and inflammatory diseases, but we have an antibody, which has a mechanism, which is very refractory to current care and could be a very good beginning to a inflammatory disease franchise. Of course, you mentioned the kinase inhibitors that we have for oncology. There's always a potential that those could be useful in various diseases in combination with filgotinib as well, and we will explore that, although I still think the best value of it is the fact that it's a very good-looking drug and some very positive data in Crohn's disease. So we are going down the pathway of inflammatory diseases by virtue of the successes we've had in our pipeline and successes in licensing. In oncology, it's -- Zydelig has been a good start for us. We really need to continue to try to ramp up our efforts in this area and to continue to broaden the areas we want to work in. It's pretty clear we have to do additional partnerships or find other avenues to broaden the revenue stream there for the future. As Robin mentioned, with our balance sheet, we have to create flexibility of the new partnerships or acquisitions that could get us there, and so that would be an important consideration for us. That may not be the only avenue. We also look at other areas where we can bring in different programs, potentially accelerating the revenue as soon as possible in some of those areas when those things are available. And as the environment has shifted dramatically in our favor, we're doing those sorts of partnerships and whatnot. So that's a good -- 2016, I believe, will be a good year for us because of the strengths of the underlying business and the economic uncertainty that's driving the market today."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","John, can I add something maybe? I would like to reiterate what Robin said in her script. If you look back at the last 6 years, it has been remarkable. We have done many, many deals CGI, Arresto, Calistoga, Pharmasset, Galapagos, and yet, we were able to",83,"John, can I add something maybe? I would like to reiterate what Robin said in her script. If you look back at the last 6 years, it has been remarkable. We have done many, many deals CGI, Arresto, Calistoga, Pharmasset, Galapagos, and yet, we were able to return 70% of the free cash flow to shareholders. So I think that is a good way to think about the future, to in-license through collaborative efforts while, at the same time, returning money to shareholders."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Michael Yee of RBC Capital Markets.",12,"And our next question comes from Michael Yee of RBC Capital Markets."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","My congrats to John Milligan as well. Looking forward to a new era. I wanted to ask a bit of a 2-part question. One was you gave some guidance here. And remarkably, like the last question, it actually looks like you're a little bit flattish or whatnot thi",156,"My congrats to John Milligan as well. Looking forward to a new era. I wanted to ask a bit of a 2-part question. One was you gave some guidance here. And remarkably, like the last question, it actually looks like you're a little bit flattish or whatnot this year. Do you expect, qualitatively, to be growing over the next year? And two, do you expect that this is a bit of trough revenue here? I just wanted to get your view on that. And importantly, when you look at managed care -- second part of the question, look at managed care, given that there's a new competitor onboard, do you expect minimal to no changes or minimal changes in terms of access and things like that? Just given the new competition, can you talk a little bit about that and there's a little bit of nervousness on how that may change things on the payer front?"
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","So Michael, it's John Milligan. First of all, thank you for the congratulations. Second of all, unfortunately, we can't tell you about revenue growth beyond. We have a lot of opportunities, but we -- obviously, we don't give 2017 or beyond guidance. We'll",148,"So Michael, it's John Milligan. First of all, thank you for the congratulations. Second of all, unfortunately, we can't tell you about revenue growth beyond. We have a lot of opportunities, but we -- obviously, we don't give 2017 or beyond guidance. We'll -- we, in this business, you almost have to take things 1 year at a time, especially in hepatitis C, as we understand the rate of diagnosis and patients coming in to care, which is there's great opportunity out there with 1.5 million patients, as Paul mentioned, still being diagnosed but not yet under care, so really good opportunities for us. With regard to the competition coming to market, we have a very, very, very strong position. But I'm going to turn this over to Paul because he'd like to give you some of his thoughts on what the competitive landscape looks like versus Harvoni."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. Thanks, John. I mean, I think if we tossed our minds back 12 months, we had the first competitor coming in to the hepatitis C space. And I think the managed care view at that time was that these products were interchangeable and could be treated by c",245,"Yes. Thanks, John. I mean, I think if we tossed our minds back 12 months, we had the first competitor coming in to the hepatitis C space. And I think the managed care view at that time was that these products were interchangeable and could be treated by commodities, to some extent, which really triggered off the pricing and negotiations we saw in early part of last year. That has been proven to be a totally incorrect view of the hepatitis C products. And what we've seen, fortunately, with Harvoni, in particular, is the real-world data has really strengthened its position and people's understanding of what that product does. It has -- it cures people with an incredibly high SVR rate, and the safety profile has been extremely good and in line, if not better, than its label. That hasn't been the case of competitor products so far. In fact, we've seen safety warnings added to labels, and we've seen a differentiation. And that's played out in the market. So I think as we see a new competitor coming into the market, now payers are really thinking this through. There isn't any kind of sort of instinctive reactions. People have been very thoughtful, and we noticed because we have very close discussions with the managed care main players. And we're working with them as they think through this. And I think we feel pretty confident that we'll maintain a strong position as we enter 2016."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Matthew Harrison of Morgan Stanley.",11,"And our next question comes from Matthew Harrison of Morgan Stanley."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","And I want to extend my congratulations to both Johns. I thought if I could just ask 2 related specific questions. So first, Paul, maybe, I just want to make sure I understand what you're trying to say with respect to U.S. HCV volumes. If we look at the 2",177,"And I want to extend my congratulations to both Johns. I thought if I could just ask 2 related specific questions. So first, Paul, maybe, I just want to make sure I understand what you're trying to say with respect to U.S. HCV volumes. If we look at the 2 volumes, the numbers you've given up in the third and the fourth quarter, it's about 105,000 patients together, which is about 210,000 on a full-year basis, which is below the 236,000 you guys reported. And if I take the low end of the 47,000, which it sounds like you're saying is too low because of the VA from the fourth quarter, that's 188,000 annualized. So I just -- if you can just give us some direction on -- I'm sure you're not going to tell us a number, around those numbers, just so we're clear on exactly what you're trying to say. And then maybe related to that, can you just specifically address where you think Access is going to go for Medicaid in prisons this year?"
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Sure. So if you've got your pencil ready, these are the numbers that, I think, happened last year. In fact, I'll take you back even into quarter 4, 2014 where we think 46,000 HCV starts were in the market. These are total starts, by the way. In quarter 1,",286,"Sure. So if you've got your pencil ready, these are the numbers that, I think, happened last year. In fact, I'll take you back even into quarter 4, 2014 where we think 46,000 HCV starts were in the market. These are total starts, by the way. In quarter 1, 2015, there were 72,000. And that really was the peak of this warehoused patient part of the curve, then dropped down into quarter 2 of 65,000. There were still some of those warehoused patients coming through. And in quarter 3 was 62,000, and quarter 4 was 50,000. We know that in quarter 3, a lot of patients were treated by the VA who, by the way, seems to be incredibly efficient at getting patients into treatment. And we know that in quarter 4, very few patients were initiated by the VA. So I think if you do the basic math on that, you would get up to about 230-something-thousand forecasting that forward into 2016 if you assume that VA picks up. Then I think this sort of merges into the second part of your question, which is what happens with Medicaid and other public payers who, to date, have really treated very, very few people. So our assumption is they're still not going to treat that many more patients this year, is the way we're thinking forward. But we are hopeful that, that will be a trend that improves over time as people start to see how effective these drugs are and, particularly, 8-week usage of Harvoni which, as I mentioned, in the real world, it seems to be incredibly effective and offers very good value. So that's how we're thinking about it. I hope that's clear."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Cory Kasimov of JPMorgan.",10,"And our next question comes from Cory Kasimov of JPMorgan."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Also my congrats to both John and John on a great run and a great opportunity. So I wanted to ask about longer-term trends, the evolution of the HCV market. I know it's hard for everyone to get their hands around, but you indicated again there are about 3",166,"Also my congrats to both John and John on a great run and a great opportunity. So I wanted to ask about longer-term trends, the evolution of the HCV market. I know it's hard for everyone to get their hands around, but you indicated again there are about 3 million HCV patients in the U.S. that have yet to be treated. About half of those are diagnosed. In terms of new patients that are entering the system, how similar or different are they from the existing patients or those that have already been cured in terms of, I guess, the overall motivation to be treated, fibrosis score insurance coverage. We get a lot of questions on are these future patients actually legitimate candidates in terms of being under the care of a doc, not IV drug users, et cetera. So can you just comment, try to give us a little bit more comfort in how we can be thinking about this longer-term evolution in the U.S.?"
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","So, Cory, I've mentioned before that we have some proprietary research that we do to try and monitor the flow of patients into treated care, and that means people who are diagnosed with hepatitis C and are registered with a hepatitis C prescriber. And tha",241,"So, Cory, I've mentioned before that we have some proprietary research that we do to try and monitor the flow of patients into treated care, and that means people who are diagnosed with hepatitis C and are registered with a hepatitis C prescriber. And that number has been remarkably consistent at around -- we have actually 3 different sources of data, and it's around high 20,000s to 30,000 patients a month have been falling into that category. So they're diagnosed with HCV, and they're registered with a treater. So if you do the math on that, clearly, that's 360,000 patients coming into treatment a year, and we're seeing treatment levels are lower than that. And what that speaks to is the types of patients are different amongst that 360,000 group, and their sort of pathway to actual treatment varies considerably. But it does appear, again, doing the math and assuming the research is correct, that there is a line at the door of patients that still need to be treated and are accessible. I don't think those are the people that are, let's say, out of society or -- these are people that are accessible and for one reason or another reason, they haven't started treatment yet. But there's a strong flow of patients still out there, and I don't think we're anywhere near getting to the point where we're dealing with patients that are extremely difficult, let's say, to manage."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Phil Nadeau of Cowen & Company.",11,"And our next question comes from Phil Nadeau of Cowen & Company."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Let me add my congratulations to John Martin and John Milligan. John Milligan, a question for you. I found it interesting that in your prepared remarks, right after you were introduced, you mentioned that you wanted to take Gilead into therapeutic areas o",99,"Let me add my congratulations to John Martin and John Milligan. John Milligan, a question for you. I found it interesting that in your prepared remarks, right after you were introduced, you mentioned that you wanted to take Gilead into therapeutic areas outside of antivirals. And I know, in an answer to a prior question, you went through the assets you have in other areas. And I'm curious whether you're signaling a need for even more assets in those areas and, in particular, if you had a shopping list, which areas will be on the top of your list?"
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","So I mean, it's pretty clear we've done some great things in HIV and HCV. But for the company to grow, we have to work in other areas. That doesn't mean that we're not going to continue to work at hepatitis B, which is important to us, and there is the po",439,"So I mean, it's pretty clear we've done some great things in HIV and HCV. But for the company to grow, we have to work in other areas. That doesn't mean that we're not going to continue to work at hepatitis B, which is important to us, and there is the potential to cure that disease. We all recognize that as a hard thing to do as well as curing HIV, which is an equally or harder thing to do, perhaps. So that does imply that we have to go outside of antivirals for continued growth, and we're interested in doing that as we've been hiring and growing with new things in our portfolio over a number of years. I think we have some good core teams that can help us grow into those areas. And so the answer is yes, we're very interested in acquiring assets through partnerships or potentially acquisitions that could help us grow in those areas. And with the tripling of our revenue over the last few years, the need to do so sooner rather than later is hyped. That being said, we want to get the right assets at the right price. And so we have the flexibilities certainly with our balance sheet in that current business to be patient to get things to not be forced into doing something before we want to. And so we are looking in the area of oncology. We are looking at additional things in inflammatory diseases, things that are adjacent to there, to see what opportunities might fit within our portfolio so that we could create a really strong franchise like we have in HIV and HCV with multiple options for success in those areas. Some of it will depend on what happens in our portfolio this year as we make progress with our MMP-9 antibody or not. Obviously, we're looking heavily at NASH with the FXR agonists. We're very interested in liver diseases, so that's a very important area for us. And we'll continue to try to bolster those to make sure that the company has the assets necessary to have the progress for the future. Is there a shopping list? There's always a list that you have in your mind or sometimes on paper. That's probably dangerous. So mine's in my mind with which I think about things that would be important for us or things that could have the right opportunity at the right price. Whether or not those things ever come to fruition depends on a lot of factors. But clearly, we're going to be very interested in taking a look this year."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","And with the assets having sold off pretty aggressively in the public markets over the last several months, does that make things more attractive to you? Or is it really about getting the right assets that's derisked and price is secondary?",41,"And with the assets having sold off pretty aggressively in the public markets over the last several months, does that make things more attractive to you? Or is it really about getting the right assets that's derisked and price is secondary?"
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Well, it makes it more attractive. There's no question.",9,"Well, it makes it more attractive. There's no question."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Ying Huang of Bank of America Merrill Lynch.",14,"And our next question comes from Ying Huang of Bank of America Merrill Lynch."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","First one on maybe pricing trend. If my math is right, if you take about $5.5[ph] billion you booked in the second half, divided by about 112,000 patients starting patients, you're looking at roughly 50,000 per patient revenue in the U.S. in the second ha",103,"First one on maybe pricing trend. If my math is right, if you take about $5.5[ph] billion you booked in the second half, divided by about 112,000 patients starting patients, you're looking at roughly 50,000 per patient revenue in the U.S. in the second half of 2015. So now with Merck's new drug launch in HCV, how should we think about pricing trend in the market in 2016? And then, I also have a question about diagnosis rate. Based on experience you have in the field, can you provide a little bit more color on the rate of newly diagnosed patients in HCV?"
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Well, maybe I'll talk about pricing, first of all. I mean, I think everyone knows this, but it's really net price is the important number here for payers in the U.S. and, indeed, in Europe. So there seems to be over the last few days a somewhat of misinfo",145,"Well, maybe I'll talk about pricing, first of all. I mean, I think everyone knows this, but it's really net price is the important number here for payers in the U.S. and, indeed, in Europe. So there seems to be over the last few days a somewhat of misinformational confusion around the WACC price and discounts. So we feel that our pricing is extremely competitive and offers very, very good value, given the competitive set. And as I said earlier, payers in the U.S., this time around, are taking a very much more thoughtful look at the labels and trying to make sure they do the right thing for their clients. And so we feel pretty strong and pretty confident in the solid bases, let's say, of our price in the U.S. market. And the second question was about HCV presented to newly diagnosed patients."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","I think that's a hard thing to get at. We still see about 30,000 patients coming into care every month so that's been an interesting metric for us, because more patients are coming into care than are being treated. We don't know how many are newly diagnos",227,"I think that's a hard thing to get at. We still see about 30,000 patients coming into care every month so that's been an interesting metric for us, because more patients are coming into care than are being treated. We don't know how many are newly diagnosed and how many are coming out of a bucket of diagnosed patients. But it is interesting to note that our most recent data still suggests there's about 1.5 million patients diagnosed in America, which means that -- and that was about 1.6 million when we launched Sovaldi. So that implies that there has been a refilling of that bucket, a replenishment, if you will. I don't know if buckets are the right term [ph] here. But it is category of patient as more patients are being diagnosed and working their way through the system. So we don't have a firm handle on exact numbers, so that's the closest approximation I can give you. But it does suggest that there's a pretty good flow of patients who are now becoming aware and coming in to at least be diagnosed. We don't know the characterization of those patients. There was an earlier question about whether those are patients eligible for treatment since many of the Medicaids are not treating many patients. And that's something we're trying to figure out right now."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","And Ying, I may want to add that there is the CDC recommendation about general diagnosis. We have a number of projects in a number of American cities to look at, subpopulations that we test and we demonstrate that you can actually have fairly high diagnos",74,"And Ying, I may want to add that there is the CDC recommendation about general diagnosis. We have a number of projects in a number of American cities to look at, subpopulations that we test and we demonstrate that you can actually have fairly high diagnosis rates up to 20% in some of these populations. And I think as people become aware of these things, I think the diagnosis will increase. That's our belief."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Alethia Young of Credit Suisse.",11,"And our next question comes from Alethia Young of Credit Suisse."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","To both Johns, congrats on a great history and a great future. Two questions, the shorter one's quick. In Japan, can you just help us understand like kind of how to think about this whether it's a 12% or maybe perhaps the larger kind of 50% range of disco",128,"To both Johns, congrats on a great history and a great future. Two questions, the shorter one's quick. In Japan, can you just help us understand like kind of how to think about this whether it's a 12% or maybe perhaps the larger kind of 50% range of discounts, I mean, when it comes to what kind of the pricing discount will happen? And then also just on Genvoya. I was just -- I saw Stribild was down a little bit in new start and total share. So I just wanted to understand if you think the total lion's share is coming from Stribild or do you think there's like some maybe a triple of kind of new starts or maybe switches coming in with the Genvoya launch?"
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Okay, maybe I'll comment on Japan. We are fully aware of the new pricing regulation that's just been introduced in Japan. We are, let's say, highly confident that, that will affect Harvoni and Sovaldi in Japan. We are not totally certain yet on the number",69,"Okay, maybe I'll comment on Japan. We are fully aware of the new pricing regulation that's just been introduced in Japan. We are, let's say, highly confident that, that will affect Harvoni and Sovaldi in Japan. We are not totally certain yet on the number or the timing of that likely price cut. But we have factored that in to our guidance. And the second question was on Stribild."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","And switches on Genvoya.",4,"And switches on Genvoya."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","And Genvoya.",2,"And Genvoya."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","And switches, yes, yes. Well, Genvoya has gone off to a really good start. We think that about 80% of the Genvoya business today is from switches. And we think that the majority of those switches are actually from Stribild so far. So that probably account",88,"And switches, yes, yes. Well, Genvoya has gone off to a really good start. We think that about 80% of the Genvoya business today is from switches. And we think that the majority of those switches are actually from Stribild so far. So that probably accounts for the Stribild share number. We think, of the switches to Genvoya, about 10% of those switches so far have come from non-Gilead products. So we're pleased with the pace of switching, and we're pleased that we're also getting some incremental growth."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Brian Abrahams of Jefferies.",10,"And our next question comes from Brian Abrahams of Jefferies."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","My congratulations to John Martin on all your accomplishments as CEO and to John Milligan on your well-deserved new role. So a question related to the inflammatory franchise. Historically, you guys have had a lot of success developing and commercializing",133,"My congratulations to John Martin on all your accomplishments as CEO and to John Milligan on your well-deserved new role. So a question related to the inflammatory franchise. Historically, you guys have had a lot of success developing and commercializing products with best-in-class features along efficacy, safety and dosing that enable you to really dominate a space such as in HIV and hep C. RA and inflammatory valve diseases are a little bit different, they're a lot more crowded. Wonder if you could talk a little bit about some of the ways you're thinking about conducting the development paths for drugs like filgotinib and 5745 to maximize differentiation? Perhaps, you could talk about combination opportunities there and how this ties into your long-term commercial strategy as you enter these new therapeutic areas."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes so, Brian, as I've said before, we believe filgotinib, by itself, if you compare it with other JAK inhibitors, is a very valuable franchise. It has good efficacy and it could have safety advantages. And I'm saying it could have because I'm making cros",196,"Yes so, Brian, as I've said before, we believe filgotinib, by itself, if you compare it with other JAK inhibitors, is a very valuable franchise. It has good efficacy and it could have safety advantages. And I'm saying it could have because I'm making cross-study comparisons. So until we do a large Phase III program, we don't really know that for certain. But then as you pointed out where we afterwards fairly quickly want to go with filgotinib is in combination therapy. We believe that in inflammatory valve disease and also RA, there is a huge unmet need still. If you look at some of the ACR20 responses, they are up to 80%, but ACR70s are only in the teens or 20% at most. So that means there's a huge improvement left to be done, and that, we believe, could be done with combination therapies. We're going to go ahead and combine our JAK inhibitor with our MMP-9. That's going to be the first thing. And afterwards, also [indiscernible] the zinc compounds and the BTK inhibitor. So that's where we think we could have a big impact on the future of the treatment of inflammatory conditions."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Brian Skorney of Robert W. Baird.",12,"And our next question comes from Brian Skorney of Robert W. Baird."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","My congratulations to John and John. Just 2, I guess. I guess the first question is in terms of Japanese sales, I understand there's a government-mandated price cut given the revenue that Sovaldi and Harvoni are generating. Can you just walk us through ho",159,"My congratulations to John and John. Just 2, I guess. I guess the first question is in terms of Japanese sales, I understand there's a government-mandated price cut given the revenue that Sovaldi and Harvoni are generating. Can you just walk us through how that flows as of January 1? And can you give us a scale of what we should expect further price cut? And then just to dig down a little more on Merck's pricing and how it impacts you guys. I think we're all surprised by the quickness in the gross to net discount that AbbVie and you had applied for the initial launches. I guess, the question is Merck clearly is going to take a pretty substantial discount versus what you guys have out. Or are you at a point where you're comfortable enough in the profile that you're drawing a line in the sand to say you're essentially not going to be discounting anymore?"
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Let me start by talking about Japan. We're not going to say what our assumption is around the tax outcome. I mean, I think I already said before. We understand the rules. It's pretty clear what the range is, and we're going to be somewhere in that range.",188,"Let me start by talking about Japan. We're not going to say what our assumption is around the tax outcome. I mean, I think I already said before. We understand the rules. It's pretty clear what the range is, and we're going to be somewhere in that range. And we're also not sure exactly the timing of that. So but we have -- we built an assumption into our guidance that we've given, and I can't really comment further on that at this point. Then on the gross to net, I mean, I think your question is are we confident enough to walk away. And I think the answer is yes, we are. But we're hopeful that our close discussions with payers and the strength of our label and the strength of the -- the relative strength of our labels compared to the competitors and, of course, this enormous wealth of real-world data that we've got gives us a position where we sincerely hope the right thing is done for patients and patients get access to our medicines. So I think that's the way we think about it."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","And Brian, other than the cost of drug, you should also consider, of course, the cost of treatment. There is a genotype required for genotype 1a. The resistance test will cost about $700 and incurs some time delay. There is a test for ALTs at 8 weeks and",114,"And Brian, other than the cost of drug, you should also consider, of course, the cost of treatment. There is a genotype required for genotype 1a. The resistance test will cost about $700 and incurs some time delay. There is a test for ALTs at 8 weeks and at 12 weeks so you have to dose for 16 weeks. And also, it's possible that, well, a fairly significant number of the genotype 1a patients, and those are 50% in U.S., they will require 16 weeks with ribavirin. So that's not -- it's more than 12 -- it increases the treatment cost proportionately compared to 12 weeks or 8 weeks, in our case, with Harvoni."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","But I think the good news, just to reemphasize, is that the payers across the United States have been very cognizant of this and thinking carefully the full implications and not being dazzled by the headlines of a low back price.",41,"But I think the good news, just to reemphasize, is that the payers across the United States have been very cognizant of this and thinking carefully the full implications and not being dazzled by the headlines of a low back price."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","And we have time for one more question. Our final question comes from the line of Terence Flynn of Goldman Sachs.",21,"And we have time for one more question. Our final question comes from the line of Terence Flynn of Goldman Sachs."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I have 2 because I'm guessing now you might not want to answer the first one. But just for Robin on capital allocation, you mentioned 77% of free cash flow return from 2010 through 2015. As you look forward, do you guys have a target payout ratio in mind?",96,"I have 2 because I'm guessing now you might not want to answer the first one. But just for Robin on capital allocation, you mentioned 77% of free cash flow return from 2010 through 2015. As you look forward, do you guys have a target payout ratio in mind? And then, the second one was just on EU hep C patient volumes in '16. Paul, you gave us a lot of context for U.S., but maybe just if you could be a little bit more specific in terms of actually thinking about volumes in Europe."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Sure, Terence. I'll take the first one. You're right. I'm not going to give a specific number. And as I mentioned on the call, I think it varies based on the other investments we're making. And the numbers we gave you were on average. There have been peri",87,"Sure, Terence. I'll take the first one. You're right. I'm not going to give a specific number. And as I mentioned on the call, I think it varies based on the other investments we're making. And the numbers we gave you were on average. There have been periods where we've been higher and periods we've been lower. But by using the word substantial, I think you can assume it to remain significant, but could vary period from period -- or year-to-year. That's how I'd look at it."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","And on the EU volumes, we estimated that in the EU, I should say, so the 28 countries in the EU where the product's been launched so far in 2015, around about 140 patients in total were treated. We have a slightly lower market share in Europe than we do i",278,"And on the EU volumes, we estimated that in the EU, I should say, so the 28 countries in the EU where the product's been launched so far in 2015, around about 140 patients in total were treated. We have a slightly lower market share in Europe than we do in the U.S., and that's because of payer type arrangements that our competitors got in place. The range of market share ranges from 70% to 90%. But I would say on the average would be about 80% of that 140. All of the main countries, the big countries in Europe have now gone through their sort of warehoused points of the launch trajectory with the patient flow and are getting into more stable patient flows, but are growing. So I think that's my main point. We anticipate higher numbers of patients in 2016 over '15. And countries like the U.K. really didn't treat very many patients at all so far, but they are now beginning to ramp up. And then, some of the smaller countries, Netherlands, Austria, are beginning to grow patient numbers. Having said that, I also mentioned earlier price volume agreements. These are set up to try and encourage more patients being treated. But obviously, the flipside to those arrangements is that the price per patient comes down, and there's better value to treat more patients. The other thing, I think, it's the real-world data with 8 weeks of Harvoni treatment. It looks stronger and stronger and is more convincing to European payers. And therefore, they will also use that opportunity to try and treat more patients, but of course, at a lower revenue per patient."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Candice, and thank you all for joining us today. We appreciate your continued interest in Gilead. And the team here looks forward to providing you with updates on our future progress.",33,"Thank you, Candice, and thank you all for joining us today. We appreciate your continued interest in Gilead. And the team here looks forward to providing you with updates on our future progress."
29002,322206567,925071,"Gilead Sciences Inc., Q4 2015 Earnings Call, Feb 02, 2016",2016-02-02,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This concludes the program, and you may all disconnect. Have a great day, everyone.",24,"Ladies and gentlemen, thank you for participating in today's conference. This concludes the program, and you may all disconnect. Have a great day, everyone."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences First Quarter 2016 Earnings Conference Call. My name is Candace, and I will be your conference operator today. [Operator Instructions]And as a reminder, this conference",64,"Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences First Quarter 2016 Earnings Conference Call. My name is Candace, and I will be your conference operator today. [Operator Instructions]
And as a reminder, this conference call is being recorded. I would now like to turn the call over to Patrick O'Brien, Vice President of Investor Relations. Please go ahead."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Candace, and good afternoon, everyone. Just after market closed today, a press release was issued with earnings results for the first quarter of 2016. The press release and detailed slides are available on the Investor Relations section of the",220,"Thank you, Candace, and good afternoon, everyone. Just after market closed today, a press release was issued with earnings results for the first quarter of 2016. The press release and detailed slides are available on the Investor Relations section of the Gilead website. 
Joining today's call will be John Madidan, President and Chief Executive Officer; Robin Washington, Executive Vice President and Chief Financial Officer; Paul Carter, Executive Vice President of Commercial Operations; and Norbert Bischofberger, Executive Vice President of Research and Development and Chief Scientific Officer. 
Before we begin formal remarks, let me remind you that we will be making forward-looking statements, including plans and expectations with respect to products, product candidates, financial projections and use of capital, all of which involve certain assumptions, risk and uncertainties that are beyond our control and could cause actual results to differ materially from these statements. A description of these risks can be found in the latest SEC disclosure documents and recent press releases. 
In addition, Gilead does not undertake any obligation to update any forward-looking statements made during this call. 
Non-GAAP financial measures will be used to help you understand the company's underlying business performance. The GAAP to non-GAAP reconciliations are provided in the earnings press release as well as on the Gilead website. 
I'll now turn the call over to John."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Patrick, and thank you, everyone, for joining us today. While we want to keep our remarks relatively brief to allow plenty of time for your questions, I do want to make a few comments about the first 2 months of 2016 and what I see as the outlo",1032,"Thank you, Patrick, and thank you, everyone, for joining us today. While we want to keep our remarks relatively brief to allow plenty of time for your questions, I do want to make a few comments about the first 2 months of 2016 and what I see as the outlook for the rest of the year. 
Gilead's HIV franchise is off to a great start with the recent U.S. FDA approvals of [indiscernible], which followed the approval of Genvoya late last year. Over the last 6 months, I've had the opportunity talk with physicians and patients about the importance of having highly effective and safer options, especially for patients facing a lifetime of therapy. 
With the approval of our 3 new regimens, we are now able to offer a range of options to address the diverse medical requirements of people with HIV, including those new to treatment, those who have been on therapy for a long time and have run short of options and those who desire to switch medications for a variety of reasons. 
Since 2001, Gilead therapies have played a transformative role in changing HIV infection from a fatal and debilitating disease into a chronic and manageable condition. That's true around the world, as broader access to HIV treatment has helped divert millions of AIDS deaths. 
Innovation remains important in the continuing fighting of HIV, and we're proud that [indiscernible] is the first new backbone approved by the FDA in more than a decade. 
Gilead continues the commitment to helping HIV patients around the globe with our research and development activities, including novel agents for daily treatment, long-acting regimens and HIV cure. 
In liver disease, we just wrapped up an exciting week in Barcelona at the International Liver Conference, or ISL, as it's known. It was a remarkable meeting, especially considering the significant change in the HCV treatment landscape since the conference was held last in Spain 4 years ago. The outlook for patients has completely changed, with dramatic improvements in cure rates for a wider range of patients. 
Presentations at ISL included results from several Phase II and Phase III studies evaluating sofosbuvir plus GS-9857. These are 2 investigational paginated fixed-dose combination therapies for the treatment of HCV. 
The data presented continues to underscore the high cure rates and safety of our sofosbuvir-based therapies and support their utility across all HCV patients genotypes in a wide range of disease stages. 
Data were also presented on the use of TAF for patients with chronic hepatitis B infection. 48-week results from 2 Phase III studies demonstrated potential to advance the treatment of HCV, operating a similar efficacy profile to Viread improved bone and renal safety parameters. 
Based on these results, we submitted a new drug application for TAF, and FDA has set a PDUFA date of November 11. 
We also submitted a regulatory applications for TAF in the European Union and Japan last quarter. 
I'm particularly encouraged by the work that's going on in NASH, which we've augmented with our agreement to acquire the Nimbus [indiscernible], or ACC program, as was announced last month. NASH expect 15 million people in the U.S. as expected to become the leading indication for liver transplantation by 2020. Including the ACC program, Gilead has 4 investigational compounds that target unique disease pathways, including production of lipids, inflammation and fibrosis from each of which are thought to contribute to or cause NASH. Data in ISL were percent at supporting the development of Gilead's investigational agents for the treatment of NASH, including simtuzumab, a monoclonal antibody that is selected for [indiscernible] 2, which is also being evaluated primarily sclerosing cholangitis, GS-4997 and S1 inhibitor and GS-9674 and FXR agonist. Members also presented positive Phase I data for the programs lead candidate, NDI-010976, which targets ACC, the key step in the bread biosynthesis pathway. 
Overall, I'm enthusiastic about the future of Gilead and excited to have the opportunity to help building the company's long history of success. Over the past few months, I've had conversations with external stakeholders and employees across all parts of our organization. It's gratifying to see the extent to which Gilead products and commitment to access have uniquely changed the course of diseases for so many people throughout the world. We now have the opportunity to do so again in many new areas. 
A few things to [indiscernible] in those conversations. First, positions in patients share the excitement that our medical and commercial teams have regarding Gilead's new treatment options for HCV and HIV, particularly the new TAF-based therapies. Access continues to improve for people with HCV around the world, and in fact, we have treated close to 1 million patients with sofosbuvir-based regimens Sovaldi was first approved in late 2013. That's a remarkable achievement in just over 2 years. 
With regards to HIV, as many of you are aware, TAF was added to the Medicines Patent Pool and to our various Access Program. The clinical data just TAF-based regimens may be the best option in both the developed and developing world. We will build on success we've had with the TDF-regimens, now used by nearly 10 million people every single day, to make TAF regimens accessible around the world, providing much-needed new options. 
Secondly, I believe we have a rich pipeline, creating opportunities that may allow the transformation of the treatment of many diseases like NASH, HPV and defamatory diseases, certain cancers and cardiovascular conditions, for which few, if any options exist. 
We are committed to building on our company's long history of success, and I'm confident that our innovation and hard work will deliver on our shared goal of delivering new treatments and providing broad access to Gilead's medicines for patients in need. 
Finally, we continue to look for business development opportunities that add to our court year. Areas in our fitted with Gilead's expertise and capabilities. We are actively assessing options and will make most when the right opportunities present themselves. 
I will now turn the call over to Robin, who will provide an overview of our financial results for the quarter. Robin will be followed by Paul, who will provide additional color on the company's performance across product and geographies."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, John, and good afternoon, everyone. We are pleased to report on first quarter results, with non-GAAP diluted earnings per share of $3.03 per share compared to $2.94 for the same period last year. Total revenues for the quarter were $7.8 billion,",926,"Thanks, John, and good afternoon, everyone. We are pleased to report on first quarter results, with non-GAAP diluted earnings per share of $3.03 per share compared to $2.94 for the same period last year. 
Total revenues for the quarter were $7.8 billion, up 3% year-over-year and down 8% sequentially. Product sales for the quarter were $7.7 billion, up 4% year-over-year and down 9% sequentially. 
Starting with HIV and other antivirals. Product sales for the first quarter increased to $2.9 billion, up 19% year-over-year, primarily driven by increased sales in the U.S. 
We continue to see strong uptake of our newer single-tablet regimens, including Genvoya, which was launched in November 2015. Additionally, year-over-year, Stribild and Complera grew 34% and 19%, respectively. 
Sequentially, T-cells decreased 4%, primarily driven by sub-wholesaler inventory decreases in the U.S., reflective of the seasonal inventory pattern from quarter 4 to quarter 1. HCV product sales for the first quarter decreased 6% year-over-year to $4.3 billion, primarily driven by a decrease in Harvoni sales in the U.S., which was partially offset by the launch of our HCV products in Japan and other international markets. 
In the U.S., the year-over-year Harvoni sales decline was driven by lower patient starts and the full-quarter impact of higher commercial rebates, which were entered into during the first quarter of 2015. 
Sequentially, HCV product sales decreased 12%, primarily driven by revenue declines in the U.S. and Japan. In the U.S., the decline was due to the increase in discounts required to open up access to patients with lower fibrosis scores and a modest shift in payer mix toward more deeply discounted government payer segments. 
In addition, revenue was further impacted by higher-than-expected prior quarter rebate claims. Rebate claims come in 1 to 2 quarters in arrears and were updated in Q1 to reflect the higher claims received. 
In Japan, SOVALDI volumes declined from high early-launch levels, similar to other markets, and channel inventory pricing for Sovaldi and Harvoni was adjusted during March for the mandatory price reduction effective as of April 1. 
Turning to our other therapeutic areas. Product sales of cardiovascular, respiratory and other were $498 million, up 19% year-over-year and down 5% sequentially. 
Moving to gross margin. Non-GAAP product gross margin was 87.2% for the first quarter of 2016 compared to 90.9% for the same period last year. The decrease reflects a $200 million charge or $0.12 earnings per share related to the jury verdict in the Merck trial in March. Although the proceedings in the Merck trial are not complete and the losing party will appeal once the court enters judgment, we booked the charge to comply with accounting rules related to contingencies. 
Now turning to expenses. Non-GAAP R&D expenses was $769 million for the first quarter, up 18% compared to the same period last year, due to the continued progression of clinical studies, particularly in liver disease and HIV. Non-GAAP SG&A expenses were $638 million for the first quarter, up 6% compared to the same period last year. These expenses increased primarily due to higher costs to support the growth of Gilead's business and were offset by favorable adjustments related to the Branded Prescription Drug beat of $191 million, following the receipt of the preliminary 2016 IRS invoice. 
From a balance sheet perspective, during the first quarter, we generated cash flows from operations of $3.9 billion and ended the quarter with $21.3 billion in cash and investments. 
We continue to return capital to our shareholders through dividends and opportunistic share repurchases. Earlier this afternoon, we announced that our Board of Directors declared a dividend of $0.47 per share for the second quarter of 2016, an increase of 10% from the prior quarter. 
$8 billion in cash was utilized to repurchase shares of our common stock during the quarter, consisting of $3 billion of open-market repurchases or 33.4 million shares, and $5 billion under the accelerated share repurchase program, ASR, that we announced in February. 46.1 million shares were repurchased under this program during the quarter. 
The final settlement of the ASR program was completed earlier this month, and we received an additional 8.1 million shares. 
In total, 54.3 million shares were retired under the ASR program at an average price of $92.09 per share. 
As of March 31, the amount of capital returned to shareholders, consisting of dividends and share repurchases, exceeded the total amount of capital returned during the first 3 quarters of 2015 combined. 
During the quarter, we completed a $15 billion share repurchase program approved byour board in January 2015 and, as of April 1, have begun repurchasing shares under our $12 billion 2016 share repurchase program approved in January of this year. 
Since 2012, we've repurchased over 260 million shares or 17% of shares outstanding. 
Finally, we are reiterating our full year 2016 guidance provided to you on February 2 and summarized on Slide 25 in the earnings results presentation available on our corporate website. 
As a reminder, guidance for product sales is subject to a number of uncertainties, including an uncertain global macroeconomic environment, adoption of additional pricing measures to reduce HCV spending; volatility in foreign currency exchange rates; inaccuracy in HCV patients start estimates; additional competitive launches in HCV; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; and a larger-than-anticipated shift in payer mix to more highly discounted payer segments such as PHS, FFS, Medicaid and the VA. 
I will now turn the call over to Paul to provide more details in our commercial results for the quarter."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, Robin, and good afternoon, everyone. Our commercial performance remained strong through the first quarter. I'd like to start with HIV and Genvoya, the first of our TAF-based single-tablet regimens. We're pleased with the launch of Genvoya, both",1498,"Thanks, Robin, and good afternoon, everyone. Our commercial performance remained strong through the first quarter. 
I'd like to start with HIV and Genvoya, the first of our TAF-based single-tablet regimens. We're pleased with the launch of Genvoya, both in the U.S. and in the European markets, where we've achieved reimbursement. 
Starting with the U.S. Through 5 months post the launch of Genvoya, cumulative prescriptions were twofold more than any HIV product from any company since ATRIPLA, which was the first single-tablet regimen to come to market back in 2006. As expected, most of Genvoya's initial perceptions came from switches. Qualitative feedback from HIV prescribers is very encouraging indicating a clear intent to switch patients at the earliest opportunity. 
Stribild and Complera showed strong year-over-year prescription growth at 18% and 5%, respectively, and in quarter 4 2015, Stribild was the leading product in the U.S. for patients nave to treatment. With the launches of Genvoya and now, just very recently, [indiscernible], we expect switches out of TDF-based single-tablet regimens into the TAF regimens to grow significantly. 
In fact, 82% of Genvoya's prescriptions have been switches. 49% of the switches have come from Stribild. 
We are seeing an improvement in our ability to retain switch patients, meaning fewer patients who switch from Gilead TDF-containing regimens move to non-Gilead products. Of all the patients who switched to Genvoya, 91% came from a Gilead regimen, and 9% came from a non-Gilead product. 
In addition to such as, preliminary quarter 1 2016 data indicate to us that Genvoya may soon be among the most prescribed products of patients new to treatment. 
Historically, in quarter 1, we've seen a decrease in sub-wholesaler inventories following a buildup in the prior quarter. We observed that's a fact again this year, leading to a sequential decrease in HIV product sales. 
Finally, in the U.S., I'd like to highlight the growing use of Truvada [indiscernible], which was more than 20% of Truvada demand last quarter and drove a 17% year-on-year growth in prescriptions. 
Turning to Europe. We're also pleased with the way that our HIV business is performing, with successful reimbursement and launches of Genvoya in several countries, including Germany and the Nordics. In other countries, Stribild and Eviplera continue to replace ATRIPLA. Stribild remains the most prescribed regimen for patients nave to treatment in the EU, with Eviplera in third place. 
Genvoya was launched in Germany during quarter 1, and at the end of the quarter, preliminary data indicated it had the leading market share for both nave and switch patients. 
The product was launched and fully reimbursed and Spain just 2 weeks ago. And we're very excited about the opportunities to offer providers another important option to address the needs of their patients. 
It's also been recognized as a preferred regimen in numerous country guidelines, including Germany, Spain and Italy, even before reimbursement has been agreed. This is testament to the favorable clinical profile of Genvoya, a single-tablet regimen that best addresses the needs of patients who require long-term chronic therapy. We're working hard to negotiate timely reimbursement across the rest of the European markets. 
Finally, in HIV, we launched [indiscernible] this month in the U.S. and the EU. We see this launch as a milestone in HIV treatment, as [indiscernible] is the first new NRTI backbone since Truvada 10 years ago. Given the very high use of Truvada as a preferred back bone third multiple third agents, including TVK, we're confident that [indiscernible] will quickly replaced Truvada and become the leading HIV regimen backbone in all our markets. 
Now moving to hepatitis C. We continue to see revenue dynamics around the world, which vary by country. As Robin noted, our overall HCV product revenue decreased 6% year-over-year and 12% sequentially. 
I'll now describe the different dynamics by geographic region. Starting with the U.S. market. We've seen an increase of new patients in the first quarter, offset by lower revenue per patient due to several factors that include an increase in our gross-to-net adjustments as well as the shortening average duration of therapy. 
Total market patient starts increased around 10% over Q4 to an estimated 55,000 in Q1. This was primarily driven by the continued opening of access across payer segments to allow for the treatment of patients with low fibrosis scores as well as an increase in treatment by the VA during the second half of the quarter, as funding made its way to the various VA site. The revenue associated with this increase in patient starts was partially offset by an increase in discounts associated with our contract agreements entered into during the first quarter of 2015, which provides for additional discounts the practices provide to a broader patient population. We also saw a gradual shift to more deeply discounted payer segments such as VA, PHS and Medicaid compared to the prior quarter. 
In addition, revenue was further impacted by higher-than-expected prior quarter rebate claim, which come in 1 to 2 quarters in arrears and were updated in quarter 1 to reflect the higher claims received. The average duration of therapy has shortened, as fewer patients require 24 weeks of treatment, and a higher proportion of genotype 1 patients are treated for 8 weeks, resulting in slightly lower revenues for patients. 
The ability to treat for 8 weeks notably has a strong competitive differentiation. In fact, our market share remains strong, with more than 90% of all patients treated in the quarter being prescribed by the Harvoni or Sovaldi. Qualitative feedback suggests that prescribing HCV physicians are encouraged by the fact that real-world outcomes mimic the experience in clinical trials. 
Several presentations of real-world data at easel reinforce what has been seen in clinical practice. 
As we think about the rest of the year in the U.S., patient slow peaked in quarter 1 2015 then declined in quarter 2 and stabilized in quarter 3 and quarter 4 of 2015. In quarter 1 of 2016, there was an uptick in new patient starts. Our data show that 25,000 to 30,000 patients a month are entering treated care, which exceeds the number of patients starting therapy on a monthly basis. That means there are many more people who could benefit from treatment who are already linked to care. We expect new patient starts to remain consistent through the rest of 2016. 
Despite the number of patients treated today, they are still over 3,000 -- 3 million, I'm sorry, patients in the U.S. who have yet to be treated. About half of these patients are undiagnosed. Education and awareness efforts to increase rates of diagnosis are important. And as we well know from public health efforts in the HIV area, these efforts playout over many years. We're encouraged to see data that screening and diagnosis rates have increased at least twofold over the last 5 years. 
Now turning to Europe. Total HCV revenue in Europe was down 13% year-over-year and down 1% sequentially, while overall Gilead patient starts increased 5% sequentially to around 31,000 in the quarter. Average revenue per patient declined due to a shift in geographic mix and shorter average treatment durations. We also saw a negative foreign exchange movement, which affected HCV revenues by about 8% year-on-year and 3% sequentially. 
The mix of sales in the EU is such that more patients and are now being treated in countries who have lowered at prices for patients. European countries continue to vary significantly in terms of patient access, with many still limiting treatment to patients with high fibrosis scores. We anticipate that as sicker patients are treated, these restrictions will start to loosen, as healthier patients can be cared for within existing budgets. Again, as in the U.S., we treat just a small fraction of patients diagnosed. We're encouraged by ongoing efforts and commitments by governments to increase diagnosis and treatments across Europe. 
Now moving to Japan. Revenue was over $1 billion during the quarter. We're pleased with the successful launches of Sovaldi and Harvoni, where a strong patient flow and higher market shares continued through quarter 1. More than 30,000 patients were treated with Gilead products during the quarter, representing a market share greater than 90%. 
Other markets, where we recently launched our HCV products, include Australia, where nearly 5,000 patients started treatment in Q1. This reflects a commitment by the Australian government to address their HCV burden and the usual warehousing of patients prior to the launch of sofosbuvir-based regimens. 
In closing, our underlying HCV business is strong and sustainable. We've treated around 700,000 patients in the U.S., Europe and Japan. And despite strong competition, Gilead has maintained high market shares in all regions. 
The Gilead commercial organization is focused on executing our numerous HIV and HCV product launches across multiple geographies during the remainder of the year. 
In addition to our 3 TAF-based HIV products, we're preparing to launch our pan-genotypic HCV product as early as next quarter in the U.S. 
Thank you, and now let's open the call for questions. Operator?"
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Geoffrey Meacham with workplace.",15,"[Operator Instructions] And our first question comes from the line of Geoffrey Meacham with workplace."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","It seems like lower revenue per patient is -- was one of the bigger contributors to the sequential trends. So a couple of questions. What was the initial outlook for higher volumes coming from commercial patients just with respect to broader access for F0",72,"It seems like lower revenue per patient is -- was one of the bigger contributors to the sequential trends. So a couple of questions. What was the initial outlook for higher volumes coming from commercial patients just with respect to broader access for F0 in F1? And then was the volume contribution this quarter pretty meaningful from the VA system? Just want to get a sense of the sequential trends there, too."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","So, yes. So several things happened in the quarter with -- in relation to volume and revenue per patient. So maybe I'll try and deal with all of them. So the first thing, as you've said, we had -- and we expected this and hoped for it, that several of the",430,"So, yes. So several things happened in the quarter with -- in relation to volume and revenue per patient. So maybe I'll try and deal with all of them. So the first thing, as you've said, we had -- and we expected this and hoped for it, that several of the large commercial payers opened up access to patients regardless of their fibrosis scores during quarter 1. The consequence of that was that they triggered a discount that had been previously negotiated in order to incentivize that opening up of restrictions. So that was the first thing. And then the VA, as you know, treated very few patients in quarter 4 last year because of lack of funding. That funding was agreed for a 2-year period and focused on HCV medicines and was clarified late December. Than the VA went through a process of evaluating the clinical valuation of products available from not just us but, obviously, new entrants to the market. And that process took through till mid to late January. And we have to negotiate with the VA, and we did give the VA some extra discount, which resulted them in putting our products on their formulary and also opening up, again, access to all patients within the VA. So there are no restrictions on patients. And again, we see this as a large positive. And as those funding got distributed around the VA centers, we started seeing a very large uptick in VA treatment from about the middle of the quarter. And we anticipate that, that will continue through the year. The second kind of area [indiscernible] of course, we have the entrance of Merck into the market. And so we judiciously exercised our contractual right to preserve access. And in a few cases, we did increase a little bit of discount to some payer to ensure that Harvoni, in particular, remained on formularies and with full access. The third thing, I think, we've seen, as I indicated in the comments, was a slight and gradual shift of payer mix away from the commercial and Medicare Part D payers towards the more government payers. And that was probably about a 10% shift from quarter 4 to quarter 1. And then the final piece, as we indicated, we did have a catch-up, a true-up of some rebate claims that came in respect of quarter 3 and quarter 4, that were able bit higher than the estimated last quarter and which we put right during quarter 1. So that really is the dynamic between volumes and revenue per patient."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Mark Schoenebaum of Evercore ISI.",11,"And our next question comes from Mark Schoenebaum of Evercore ISI."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Everyone's very focused on what you're going to do with your cash, PD, M&A. So I have actually one simple question, probably for John. Would you be willing to go hostile? And if not, why not? How do you feel about that? Because clearly overhearing is that",67,"Everyone's very focused on what you're going to do with your cash, PD, M&A. So I have actually one simple question, probably for John. Would you be willing to go hostile? And if not, why not? How do you feel about that? Because clearly overhearing is that the small companies won't engage right now because they don't like evaluations, but the larger companies are very interested."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Mark, it's John. Mergers and acquisitions are always a process. And so the ability to go hostile is limited by how much data or how much cooperation you need. And so in each situation, you'd have to kind of think about what do I need to know about the pip",101,"Mark, it's John. Mergers and acquisitions are always a process. And so the ability to go hostile is limited by how much data or how much cooperation you need. And so in each situation, you'd have to kind of think about what do I need to know about the pipeline or about things that are not public about a company in order to be comfortable making sort of a public offer for the company. But that being said, we've never declared ourselves unwilling to go hostile. I do prefer a friendly process, but it would just depend on the situation itself."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Geoffrey Porges of Leerink Partners.",11,"And our next question comes from Geoffrey Porges of Leerink Partners."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I guess, a follow-up on that question. You've invested, looks like about $19 billion or $20 billion over the last year, reducing your share count. The share count has come down by about 10%. But your EPS is pretty much flat, maybe up low single digits ver",96,"I guess, a follow-up on that question. You've invested, looks like about $19 billion or $20 billion over the last year, reducing your share count. The share count has come down by about 10%. But your EPS is pretty much flat, maybe up low single digits versus last year. Are you convinced that, that's the best use of your capital? You've got $21 billion in cash and about the same amount of debt. So are you going to revisit that? Or is that more or less the path that you believe generates the best returns here?"
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Jeff, it's Robert Dickerson. I'm going to let Robin address the first part of the question.",16,"Jeff, it's Robert Dickerson. I'm going to let Robin address the first part of the question."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Geoff, it's Robin. I think, as we've said all along, we'd look at how we leverage our cash as not only being share repurchases and dividends, but also, we consistently look at investing in our core pipeline as well as M&A, where appropriate. And similar t",167,"Geoff, it's Robin. I think, as we've said all along, we'd look at how we leverage our cash as not only being share repurchases and dividends, but also, we consistently look at investing in our core pipeline as well as M&A, where appropriate. And similar to the amounts that you called out relative to cash, it's actually about 17% [ph] reduction in share count, as I mentioned on the call. We have done a lot of M&A as well, and I think we'll continue to do that, as John said, when the right opportunities present themselves. So I think we've always been fairly clear that we're balancing doing all of those things and purposely focused on share repurchases because in the accident M&A. It allows us to be flexible and more opportunistic. But when the right M&A opportunities present themselves, it allows us to reduce our share repurchases in order to make those necessary acquisitions and leverage our cash and debt and borrowing if we need to."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. It's Just, for us, it's very simple. The other flexibility to do both things, that is returning shareholder value through stock repurchases and dividends and, of course, continue to be opportunistic in M&A. How we're deploying it is sort of a reflect",105,"Yes. It's Just, for us, it's very simple. The other flexibility to do both things, that is returning shareholder value through stock repurchases and dividends and, of course, continue to be opportunistic in M&A. How we're deploying it is sort of a reflection of the things we're interested in. I think for example, the Nimbus acquisition, while relatively small, could bring a very, very unique product to us and something that we had focused on during the quarter. We're continuing to look for opportunities like that, and we will continue to aggressively look for opportunities to deployour cash and investing in things other than Gilead."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","Our next question comes from Michael Yee of RBC Capital Markets.",11,"Our next question comes from Michael Yee of RBC Capital Markets."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I wanted to revisit some questions that was talking about related to price and volume. You did mention on the positive that net new patient starts were up about 10%, which is great. But then the total revenues in U.S. declined by 11%. So somewhat could do",97,"I wanted to revisit some questions that was talking about related to price and volume. You did mention on the positive that net new patient starts were up about 10%, which is great. But then the total revenues in U.S. declined by 11%. So somewhat could do the math and imply that price was down 10% to 20%. And can you comment on that are maybe just describe where you think the price volume equation was in the quarter and how we should think about net price changing quarter-over-quarter and how that should change over the year?"
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. I think we are in a much more stable place than we were 1 year ago at this time. I think I described it. Just now, we've made some contractual moves, which have opened up access. We're very happy about that. We're happy that some of the government pa",167,"Yes. I think we are in a much more stable place than we were 1 year ago at this time. I think I described it. Just now, we've made some contractual moves, which have opened up access. We're very happy about that. We're happy that some of the government payers are beginning to treat a few people. We're very happy about the VA, in particular, ramping up its treatment levels. I said that we'd had to compete in the VA, and we did that. But we're enjoying very high market shares wherever physicians have the choice of prescribing. And that's always been our aim, to make sure that physicians and patients can choose what drug they think's appropriate. And wherever that's the case, Gilead seems to do pretty well. So I would say, looking forward, we're in a fairly stable place now. I mean, clearly, over time, as competition increases, prices are likely to incrementally move in one direction, I would think. But I think we're stable."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","On one side, we're getting lots of access, but on the other side, [indiscernible] just to be fair?",18,"On one side, we're getting lots of access, but on the other side, [indiscernible] just to be fair?"
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Correct.",1,"Correct."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from the line of Cory Kasimov with JPMorgan.",13,"And our next question comes from the line of Cory Kasimov with JPMorgan."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Going back to the strategic theme. You've talked in the past about wanting to be leader in oncology. But given the issues you've had with Zydelig and the leadership changes you've also had, are you as committed to that space as you once were? And if so, w",63,"Going back to the strategic theme. You've talked in the past about wanting to be leader in oncology. But given the issues you've had with Zydelig and the leadership changes you've also had, are you as committed to that space as you once were? And if so, what's your thought on the potential opportunities you see out there between solid tumors and hemog?"
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Cory, it's John. It's a good question. If you think about where we are in our oncology portfolio, we haven't focused heavily on a number of activities around these kinase inhibitors and have actually behind Zydelig a number of opportunities are moving to",186,"Cory, it's John. It's a good question. If you think about where we are in our oncology portfolio, we haven't focused heavily on a number of activities around these kinase inhibitors and have actually behind Zydelig a number of opportunities are moving to clinic, including our Syk inhibitor, our BTK inhibitor, probably Norbert about this, but I would say, we have numerous opportunities that we're continuing to pursue. You had mentioned we want to be a leader in oncology. We think of oncology as one leg of a future company that could be important to us, along with our investment in NASH and inflammatory diseases. We do see some good opportunities out there, and we see some gooder opportunities internally. So I don't just as eidetic setback hasn't changed our appetite for trying to do more transformative things in oncology. It was never going to be a franchise product like sofosbuvir, a very good beginning for us to cover just my thought process around it as a result of the setback because of the toxicities we've seen. Norbert, do you want to add anything to that?"
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","No. As John said, Zydelig has not decreased our appetite, increased our appetite to do more in oncology. We're now at a point where a number of programs are coming to fruition. For instance, something, we need to file early next year the Phase III studies",127,"No. As John said, Zydelig has not decreased our appetite, increased our appetite to do more in oncology. We're now at a point where a number of programs are coming to fruition. For instance, something, we need to file early next year the Phase III studies are fully enrolled we should get a result of the end of this year. And antibodies and Phase III for gastric cancer. We're at the end of those ranging with combinations of PA 3 kinase BTK, and that will move into front-line treatment. So we have a number of interesting things ongoing internally, and of course, as Johnson said, we're continuously looking certainly and finding suitable opportunities. And if the right opportunity comes, along, then we will take advantage of it."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Brian Abrahams with Jefferies.",10,"And our next question comes from Brian Abrahams with Jefferies."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I was wondering if you could talk a little bit about hep C diagnostic initiatives and maybe some of the pull-throughs was that you're seeing or might expect to see an patient identification? And I'm particularly curious if you have a sense among the growi",82,"I was wondering if you could talk a little bit about hep C diagnostic initiatives and maybe some of the pull-throughs was that you're seeing or might expect to see an patient identification? And I'm particularly curious if you have a sense among the growing number of new patient starts, who may have been identified last year and are now getting access with the fewer restrictions versus patients who are getting identified this year and coming on to treated care currently?"
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","John? So it's actually very hard to tell when people are being diagnosed and who's been treated when. Anecdotally, I can tell I was out visiting some doctors in California just last week. Patients are -- there are plenty of patients there that many people",295,"John? So it's actually very hard to tell when people are being diagnosed and who's been treated when. Anecdotally, I can tell I was out visiting some doctors in California just last week. Patients are -- there are plenty of patients there that many people who are linked of care now. And with the fibrosis restrictions being dropped now, most physicians can treat certainly in the commercial area and Medicare area, can treat whoever they want. One thing's clear, though, that there are still prior authorizations in place, and there's still a fair amount of office paperwork and bureaucracy that have to be put in place for each patient. Then as the patients themselves, many of whom just simply are quite mentally ready or psychologically ready to commit to their disciplined 8-week or 12-week treatment. And with these products, of course, if insurance comes on, do it twice, they want to try to get it right first time. The doctors want to get it right first [ph] time. The patients were negated right first. So we're seeing some of the sort of delays in patient starting have to do with the patient just being ready to commit to sort of disciplined 8 or 12, 12 weeks of patients. On the diagnosis side, I mean, again, anecdotally, we just know that there's a lot of activities going on. A lot of people telling us what's going on around the countryside, and we do see diagnosis rates increasing significantly. So I think there are that's of patients being diagnosed, and there are plenty of patients coming in to treatment. And there's a waiting list of patients at most offices. By the way, our estimate on diagnosis is about 200,000 new diagnoses happened in the U.S. last year."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Brian, I think I might add that we have a number of demonstration projects ongoing in the United States to look for places, institutions, populations and figure out what the diagnosis positivity would be. And it's surprising, we have identified some place",79,"Brian, I think I might add that we have a number of demonstration projects ongoing in the United States to look for places, institutions, populations and figure out what the diagnosis positivity would be. And it's surprising, we have identified some places like ER rooms that have 0 positivity rates or greater than 10%. We hope that those the demonstration projects will then lead to a broader recognition of the value of diagnosis and identification of hepatitis C individuals."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from the line of Brian Skorney of Robert Baird.",14,"And our next question comes from the line of Brian Skorney of Robert Baird."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I guess, 2 quick ones. I know we talked a little bit about at easel, jumped refresh on a timeline in terms of when you think you can that a thoughts sofosbuvir-based regimens approved in China. How do you think about pricing there to kind of capture share",97,"I guess, 2 quick ones. I know we talked a little bit about at easel, jumped refresh on a timeline in terms of when you think you can that a thoughts sofosbuvir-based regimens approved in China. How do you think about pricing there to kind of capture share patients who are looking at a branded drug versus potentially penetrating further in. And then just on the U.S. Have you guys heard anything in terms of a warehouse build in genotype 3 ahead of a soft launch? Should we expect a SOF/VEL launch of patients upon that approval?"
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","So Brian, I'll start with the China question. So in terms of timing for China, there is a fairly fixed process. And according to the recent processes, we could possibly have sofosbuvir in the market in 2017. As you may have seen, there are new  -- the Chi",271,"So Brian, I'll start with the China question. So in terms of timing for China, there is a fairly fixed process. And according to the recent processes, we could possibly have sofosbuvir in the market in 2017. As you may have seen, there are new  -- the Chinese government is working hard to try to accelerate review and approval of HCV drugs because currently, none are on the market or direct acting antivirals, and that could help us accelerate the timelines in China. We are working on that. Particularly of interest to be accelerating a timeline for SOF/VEL rilpivirine, genotypes in China. Genotyping is not common in China, this could provide a very good option for the people of China. So that's what -- there's hope, but we can't guarantee of course, that we can accelerate that approval, to be honest, current timeline, which is 2019. The, Chinese market is fairly large. Between 10 million and 20 million people got to have HCV. I do want to get into public discussions of pricing, but I do think there's a price volume relationship that would work for us and for the Chinese system that could be very, very good for us both. And so that's what we're working towards as access in China. Your second question was on warehousing for genotype 3 patients. Currently, a lot of genotype 3 patients are being treated with soft in combination with [indiscernible]. And that seems -- there seems to be fairly decent access for that. So looking at Paul, don't think there's any real warehousing going on. But maybe you're more aware than I am."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Well, there's about 7% or 8% of the U.S. HCV epidemiology is genotype 3. I mean, we don't have any data on it, but certainly, we get -- I'm getting the impression for my team anecdotally, there is a little bit of warehousing, but not least because sofosbu",93,"Well, there's about 7% or 8% of the U.S. HCV epidemiology is genotype 3. I mean, we don't have any data on it, but certainly, we get -- I'm getting the impression for my team anecdotally, there is a little bit of warehousing, but not least because sofosbuvir ledipasvir very expensive regimens. And the hope is that the cost of the genotype 3 treatment will come down somewhat after SOF/VEL comes on to the market, which is the PDUFA date is 28th of June. So people are thinking about that. So we're optimistic."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Phil Nadeau of Cowen and Company.",12,"And our next question comes from Phil Nadeau of Cowen and Company."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","2 questions on Japan. I know you said that there was some change in pricing because of the April 1 price declines during the quarter. What other dynamics are going on in Japan during this quarter? Where do you think you are entering the bolus [ph] in Japa",97,"2 questions on Japan. I know you said that there was some change in pricing because of the April 1 price declines during the quarter. What other dynamics are going on in Japan during this quarter? Where do you think you are entering the bolus [ph] in Japan? How much longer could that go? And then I believe there are price discounts that come in with a certain volume being reached. We would like to assume that does could be get in July. And what kind of dynamics the expect to see the Japanese market going forward?"
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","So we're very, very pleased with the addition of our launches in Japan. In terms of patient flow, the genotype 2 patients, which represent about 20% of the Japanese epidemiology and HCV, are beginning to stabilize now. So those are the patients being trea",246,"So we're very, very pleased with the addition of our launches in Japan. In terms of patient flow, the genotype 2 patients, which represent about 20% of the Japanese epidemiology and HCV, are beginning to stabilize now. So those are the patients being treated with Sovaldi. Those numbers we launched on May 25 last year. We initially had a bolus, and then those numbers came down through quarter 4. And quarter 1 at the lower level in quarter 4. But we're seeing a stable flow of patients now in genotype 2, and we would anticipate that to be stable through the rest of the year. Genotype 1's treated by Harvoni. We've had an enormous number of patients initially. We're not quite sure if the curve in Japan is identical to the sort of curves we've seen in the U.S. or other major markets. And that's because there was a DAA in the market for Harvoni to treat quite a few people. So there might not have been quite such large amount of warehousing. In any case, we're seeing the Harvoni patient numbers coming down gradually, not quite as steep as some other markets. And yet, that's yet to stabilize. But I'm pretty sure I know it will stabilize at some time in the next quarter or 2. So that's how we're seeing, trick about 30,000 patients during the quarter. So that number will be there or thereabouts, I think, for the rest of the year."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","And what about the volume discounts? Are those going to come later in the year? And what kind of dynamics...",20,"And what about the volume discounts? Are those going to come later in the year? And what kind of dynamics..."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","I'm sorry, we're not anticipating any further price movements in this year in Japan.",15,"I'm sorry, we're not anticipating any further price movements in this year in Japan."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Matthew Harrison of Morgan Stanley.",11,"And our next question comes from Matthew Harrison of Morgan Stanley."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Sorry, can you hear me?",5,"Sorry, can you hear me?"
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes, I can.",3,"Yes, I can."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","One follow-up on Phil's question on Japan. Can you just be clear with us the pricing that you talked about in March, was that the fullest end of the 30% price cut? Or will there be more in April? Just so we can understand how much was reflected in this qu",101,"One follow-up on Phil's question on Japan. Can you just be clear with us the pricing that you talked about in March, was that the fullest end of the 30% price cut? Or will there be more in April? Just so we can understand how much was reflected in this quarter. And then on the rebates that you talk about, the true-up that happened, would you expect that to swing again through the rest of this year? Or do you think that, that is now at a level that is what you're forward-looking expectations are for the level of rebates?"
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","I'll do the first part, and Robin will talk about the second part. So the pricing in Japan, official prize reduction was just under 32% and officially from the 1st of April. We actually reduced our prices into wholesalers early in March. And the reason fo",133,"I'll do the first part, and Robin will talk about the second part. So the pricing in Japan, official prize reduction was just under 32% and officially from the 1st of April. We actually reduced our prices into wholesalers early in March. And the reason for that was because the price cut was announced much earlier. And therefore, we wanted to just kind of smooth out the inventory situation. So that's why we reduced our price into wholesalers a little bit earlier. And by the end of the quarter, inventory levels were up to, I would say, reasonable levels relative to demand. And actually, a little bit -- those inventory levels a little bit down on where we ended the quarter 4 because overall demand was slightly down because of Harvoni. Robin?"
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Sure. And to answer the second part of your question relative to the rebate accruals that both Paul and I have mentioned, we regularly have to adjust our cruel to reflect the trends and timing of rebates. And I would say still the trends and the dynamics",120,"Sure. And to answer the second part of your question relative to the rebate accruals that both Paul and I have mentioned, we regularly have to adjust our cruel to reflect the trends and timing of rebates. And I would say still the trends and the dynamics and the complexity around the reimbursement in these markets still make them somewhat difficult to predict. So I wouldn't say they were all one-time in nature. There may be a small component that you can say when we were trying to look at the level of inventory that maybe was one-time in nature. But these dynamics, I think, we may see continue into the future. The honest answer is we don't necessarily know."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from the line of Ying Huang of Bank of America Merrill Lynch.",17,"And our next question comes from the line of Ying Huang of Bank of America Merrill Lynch."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","First of all, I want to probe able bit about the rebates. Can you clarify whether it was actually access based for volume-based? Because we can see from the script apparently the volume is not really picking up after those big insurance open the access re",106,"First of all, I want to probe able bit about the rebates. Can you clarify whether it was actually access based for volume-based? Because we can see from the script apparently the volume is not really picking up after those big insurance open the access regardless of course. So I wonder what happens there? And then secondly, I think, Paul, you mentioned that the payer mix is getting a little bit worst this quarter but can you talk about your thoughts on payer mix going forward? Is it going to be continuing shift to the public payers or, I guess, the lower price environment or not?"
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Hi, Ying. So the first question was about patient volumes coming in and relative to the opening up of the fibrosis scores. So I'm not sure whether you looked at data or not, but we get new to brand base, which is really the leading indicator of new starts",218,"Hi, Ying. So the first question was about patient volumes coming in and relative to the opening up of the fibrosis scores. So I'm not sure whether you looked at data or not, but we get new to brand base, which is really the leading indicator of new starts in the quarter. So we've seen, and this is just retail scripts, by the way, so that doesn't include the VA. It doesn't include scripts that go through ESI and various other groups. So it's partly representative. And what we've seen amongst those scripts is new starts in the quarter have gone up, and and that's going to be exactly in line with our expectations with the fibrosis scores being relieved. Total scripts are relatively flat, and part of that is because in quarter 4, of course, the patient numbers, throughout really 2015 quarter-on-quarter, the new starts were coming down. And therefore, the refills associated with those new starts falling into quarter 1 was somewhat down. So aggregate of the next the numbers total prescriptions in the quarter look relatively flat and slightly disengaged from the fibrosis piece. So I think that hopefully covers that. And then, of course, the VA, isn't included in that group, and that was a large number of patients coming in to the system."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","And then the payer mix?",5,"And then the payer mix?"
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","The payer mix, I think, directionally, I mean, this is not a dramatic move. I think, directionally, we anticipate that Medicaid will start. There's a lot of pressure on Medicaid to treat patients. And we anticipate the public payer sector will start propo",104,"The payer mix, I think, directionally, I mean, this is not a dramatic move. I think, directionally, we anticipate that Medicaid will start. There's a lot of pressure on Medicaid to treat patients. And we anticipate the public payer sector will start proportionately, getting a little bit bigger in our mix. I mean, just as an example, around 77% of our payer mix at the end of quarter 4, during quarter 4, was really commercial and Medicaid Part D. That number's dropped down now to about 64% as a proportion. So we're seeing a shift. And I would imagine that, that will continue gradually."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","And then would you guys ever talk about the relative magnitude compared to 46% you flagged last year?",18,"And then would you guys ever talk about the relative magnitude compared to 46% you flagged last year?"
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","No. I mean, we're going to give guidance and our guidance. We gave the gross net number once. We have built that into our guidance for the rest of the year, so we're not planning on breaking that out at all.",41,"No. I mean, we're going to give guidance and our guidance. We gave the gross net number once. We have built that into our guidance for the rest of the year, so we're not planning on breaking that out at all."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Robyn Karnauskas of Citi.",10,"And our next question comes from Robyn Karnauskas of Citi."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","So just thinking about the moving parts of the course of the year and the color you gave on the fibrosis scores. With so many people getting rejected early on based on fibrosis score, how might they flow into the system during the year? Because  there's a",141,"So just thinking about the moving parts of the course of the year and the color you gave on the fibrosis scores. With so many people getting rejected early on based on fibrosis score, how might they flow into the system during the year? Because  there's a lot of patients. Do you see them coming on even the work of them come in a bolus? We see some choppiness in the quarter? And then the second question I had was how comfortable are you that you can -- that the pricing negotiations will have been done and we won't see further pricing negotiations coming with the new [indiscernible]-based regimens coming next year? Do you think there's going to be a number around of surprises in 2017 for discounting? Or do you think we've reached a little bit of lower of steady-state?"
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","I think it's hard to tell on the flow of patients, first of all. What we do know, there's plenty of plenty of patients out there. As I said, odd days, we work 3 different sources of data, which shows that 25,000 to 30,000 patients are coming at the treatm",300,"I think it's hard to tell on the flow of patients, first of all. What we do know, there's plenty of plenty of patients out there. As I said, odd days, we work 3 different sources of data, which shows that 25,000 to 30,000 patients are coming at the treatment. Obviously, a lot less than that are actually being treated. And anecdotally, as I said, I think it's because there's bureaucracy still in the physicians' offices, which give kind of I guess, sort of giving us as a number of patients and can be treated. And also, from the patient side and people actually ready to be treated. I think they want to be teed up, they like the treatment, but they might not want to actually starve some more in the morning. So I think we should expect patient flow to be fairly stable through this year. And then on the negotiations side, I mean, I think, with real-world data, payers are tending now to really take a lot more time and put a lot more thought into evaluating the clinical profiles of the products. And until we see the clinical profiles of the new products, it's very hard to predict how competitive they are. I mean, if they're competitive, I think we have to anticipate prices will come down or negotiate because we certainly don't want to lose any access to patients around products. And we'll defend our market share vigorously. So it's hard to predict. I think, directionally, competition equals lower prices. But we're going to be focusing on looking at differentiating our products. We've got great products out there now, and our pipeline looks really exciting. So I think we're in good shape for a long and sustainable and healthy HCV business in the U.S."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Alethia Young of Credit Suisse.",11,"And our next question comes from Alethia Young of Credit Suisse."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Just one, Mike, if we go back to the beginning of this year and think about like a $30 billion to $31 billion put out there, has the mix between hep C and HIV changed? It seems like HIV is that are already launch in hep C has more pricing pressure. And th",79,"Just one, Mike, if we go back to the beginning of this year and think about like a $30 billion to $31 billion put out there, has the mix between hep C and HIV changed? It seems like HIV is that are already launch in hep C has more pricing pressure. And that is also can you confirm maybe if we're seeing a competition in the Big 5 from like kind of new competitors like Merck coming to market?"
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Maybe I can take the first part of your question. This is Robin. We gave guidance for the full you. I would say, yes, this quarter, we had a slightly uptick relative to our HIV expectations and slightly down relative to HCV. But I think we still have reco",75,"Maybe I can take the first part of your question. This is Robin. We gave guidance for the full you. I would say, yes, this quarter, we had a slightly uptick relative to our HIV expectations and slightly down relative to HCV. But I think we still have recorded [indiscernible] Paul said, we continue to be opportunistic relative to patient starts and more stable, predictable environment going forward. But it's still very early to tell."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. And in Europe, I mean, I've got to say the payers are treating the products generally with less consideration to the clinical differences than we're seeing in the U.S. And there are some payers who are treating products a bit more like commodities. A",211,"Yes. And in Europe, I mean, I've got to say the payers are treating the products generally with less consideration to the clinical differences than we're seeing in the U.S. And there are some payers who are treating products a bit more like commodities. And we're working hard to make sure that we educate them as best as possible. And I think the real-world data, much of which originates from Europe, is much supporting us in that. But we have seen some instances of for example, tenders in the Nordics, which have a very binaryoutcome. And there's certain times that we have decided that both tenders' prices were the value of our products. So our marketers been able bit less than Europe. And specifically, to answer a question, I think all 3 players are out there in Europe trying to get business. But at the end of the day, we hope that people will recognize that the Gilead products are highly effective, very simple, very tolerable. And the real-world data, which is now the vast amounts of it, really does support us when physicians make their choices. As I said earlier, where physicians have the freedom of prescription, we tended to have very, very strong market shares in the 90% plus."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Ian Somaiya of BMO Capital.",11,"And our next question comes from Ian Somaiya of BMO Capital."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Maybe just changing topic a little bit, that question for Norbert. I was hoping you just could speak to the 3 oral candidates you have for NASH just how they would that's how you plan to develop them, how they might go underplay potential combination stra",93,"Maybe just changing topic a little bit, that question for Norbert. I was hoping you just could speak to the 3 oral candidates you have for NASH just how they would that's how you plan to develop them, how they might go underplay potential combination strategies. And as you kind of think about the larger sort of BD question that keeps being asked, do you have enough data on your internal programs to make decisions in terms of what additional product that might benefit your internal efforts in NASH also in hep B?"
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","So Ian, actually, it's 4 product that we have currently in early clinical studies, if you include the Nimbus compound. That deal, by the way, has not closed yet, but it should close in the next week. So we have the [indiscernible] inhibitor, the ACC 1 2 i",218,"So Ian, actually, it's 4 product that we have currently in early clinical studies, if you include the Nimbus compound. That deal, by the way, has not closed yet, but it should close in the next week. So we have the [indiscernible] inhibitor, the ACC 1 2 inhibitor, the simtuzumab and the FXR agonist. And we could, by the end of this year, be in 4 Phase II studies really in NASH to look at the effect of any one of these agents by themselves. And then we would also, at the same time, going to start combination studies to see that we always have said we believe in the 3 points of disease [indiscernible] there's fibrosis inflammation and metabolic. We now have agents that address all of them. And we're absolutely -- our hypothesis is that ultimately, it's a complex biological disease, and probably more than one agent will be needed. And we're looking forward maybe sometime next year, we will then go into Phase III. With regards to BD, we're, of course, looking. At the moment, there is nothing out there that, I would say, we have to get. As I said, we have 4 components. We're going to look at those individually and then, as results come in, make decisions about else we would need."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","And then what about hep B? Just similar question. Just with the assets you do have, I know you provided very little information or shared very little information with us. But just as you think about your internal portfolio, do you feel like you have the a",59,"And then what about hep B? Just similar question. Just with the assets you do have, I know you provided very little information or shared very little information with us. But just as you think about your internal portfolio, do you feel like you have the assets you need to move forward with it and, obviously, capture the market?"
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","I would say, Ian, so we have, as you know, 4774, 477 is the -- 4779, that's the [indiscernible] immune vaccine. We presented data at that left AASLD showing that, at least, in suppressed patients it did not need to reduction in ""s"" antigen. We have curren",147,"I would say, Ian, so we have, as you know, 4774, 477 is the -- 4779, that's the [indiscernible] immune vaccine. We presented data at that left AASLD showing that, at least, in suppressed patients it did not need to reduction in ""s"" antigen. We have currently going to study in treatment-nave patients. We can have 96, 20 [indiscernible] tailor 7 [ph] agonist in Phase II as well or Phase IIa. And then we have 2 other internal programs that we haven't disclosed yet. They are pre-IND, but we have identified with 2 different mechanisms, molecules that we want to develop or evaluate in human clinical studies. But having that said, it's early, I mean, as a general statement, in hepatitis B cure. And we are really having a very open-minded and looking out the much outside what else is there potentially that would fit our portfolio."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Terence Flynn of Goldman Sachs.",11,"And our next question comes from Terence Flynn of Goldman Sachs."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I was just wondering, you mentioned this 25,000 to 30,000 per month number of patients coming into treatment. And then you gave us the new diagnosis last year in the U.S. And so that equates to about 17,000 per month. So is it safe to assume that of the n",100,"I was just wondering, you mentioned this 25,000 to 30,000 per month number of patients coming into treatment. And then you gave us the new diagnosis last year in the U.S. And so that equates to about 17,000 per month. So is it safe to assume that of the new patients coming on in treatment, half are newly diagnosed and half are coming from the currently diagnosed pool? Am I thinking about that the right way? And then the second question was just can you tell us a percentage of patients that are getting 8 weeks of therapy this quarter?"
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Terrence, yes, I think, broadly speaking, your math is correct on that. I mean, it's hard to tell exactly where the patients are coming from. But I think, mathematically, that sounds about right. Sorry, what was the second question?",39,"Terrence, yes, I think, broadly speaking, your math is correct on that. I mean, it's hard to tell exactly where the patients are coming from. But I think, mathematically, that sounds about right. Sorry, what was the second question?"
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","[indiscernible] 8 weeks.",3,"[indiscernible] 8 weeks."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes, sorry, 8 weeks. We've drifted slowly but surely a part of 8 weeks. I think we're about 43% now. I've got emphasize the data we have is called intend to treat rather than actual prescriptions. So the intent to treat in the U.S. is about 43%. The epide",71,"Yes, sorry, 8 weeks. We've drifted slowly but surely a part of 8 weeks. I think we're about 43% now. I've got emphasize the data we have is called intend to treat rather than actual prescriptions. So the intent to treat in the U.S. is about 43%. The epidemiology, as we've previously said, propositions and about half genotype 1 patients would fall into the criteria that would trigger an 8-week treatment."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Jim Birchenough of Wells Fargo.",11,"And our next question comes from Jim Birchenough of Wells Fargo."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","[indiscernible] maintenance question and then a more meaningful question. On the maintenance side, you referred to kind of shift from 24 weeks to 8 weeks. And the breakdown the 8-, 12- and 24-week treatment numbers? HCV and where they see that heading? An",97,"[indiscernible] maintenance question and then a more meaningful question. On the maintenance side, you referred to kind of shift from 24 weeks to 8 weeks. And the breakdown the 8-, 12- and 24-week treatment numbers? HCV and where they see that heading? And a more meaningful question is NASH is obviously an important part of your future growth strategy. FXR is in that category. How confident are you that you can separate out the metabolic effects of FXR agonism in versus just beneficial effects once the basis for that [indiscernible] and when will you see that data?"
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. We're not going to break down the weeks of therapy. I mean, I just said what do we think the 8-week amount is. But there is some real have to just model yourself. I'll now hand over to Norbert for the second question.",44,"Yes. We're not going to break down the weeks of therapy. I mean, I just said what do we think the 8-week amount is. But there is some real have to just model yourself. I'll now hand over to Norbert for the second question."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","So Tim, as you know, steroid FXR agonist do many, many things, not only in the liver, but also in other target organs. So our philosophy is that we have an FXR agonist that purely acts at the level of the G.I. So he does not get totally absorbed to any me",167,"So Tim, as you know, steroid FXR agonist do many, many things, not only in the liver, but also in other target organs. So our philosophy is that we have an FXR agonist that purely acts at the level of the G.I. So he does not get totally absorbed to any meaningful degree. And what it does, at the level of the G.I. releases FGF 19. And we believe that FGF 19 does everything that it needs to do in order to impact on NASH. That's our hypothesis, and we're testing that. And we should have data available in the fourth quarter of this year. So that's a fairly easy experiment to do. You simply look at availability, which is below the increase in FGF-19 levels with some of the [indiscernible] metabolic effect. That way, we also think we can prevent [indiscernible]. We can prevent the cholesterol effects. We can prevent ankylosing spondylitis. If that's all is true, it should be a much safer and cleaner FXR."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","And Norbert, what is the form for that beta release? And I guess, what are the next steps for that program? How far behind are you from things that are in Phase III right now of FXR agonist?",38,"And Norbert, what is the form for that beta release? And I guess, what are the next steps for that program? How far behind are you from things that are in Phase III right now of FXR agonist?"
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","We could probably have some of the preliminary data at AASLD. And we will then move into Phase III soon after that. So we're not that far behind other companies.",30,"We could probably have some of the preliminary data at AASLD. And we will then move into Phase III soon after that. So we're not that far behind other companies."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from the line of Alan Carr of Needham & Company.",14,"And our next question comes from the line of Alan Carr of Needham & Company."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Wondering if you can talk a bit more about the new diagnoses in 2015 that you mentioned. So there was around 200,000. Do you have any other details around that about where they were found or, I guess, trend over the course of the year? Is it increasing?",48,"Wondering if you can talk a bit more about the new diagnoses in 2015 that you mentioned. So there was around 200,000. Do you have any other details around that about where they were found or, I guess, trend over the course of the year? Is it increasing?"
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","I don't have a lot of details at my fingertips, Alan. I would say, just to build on what Norbert was saying earlier, the interactions we're having with many people working on diagnosis projects around the country are that there's a lot of -- surprisingly",147,"I don't have a lot of details at my fingertips, Alan. I would say, just to build on what Norbert was saying earlier, the interactions we're having with many people working on diagnosis projects around the country are that there's a lot of -- surprisingly high level of positive diagnosis in some of the urban centers and in ER rooms, in particular, in those urban centers, where diagnosis rates have been double, at least, worth evenly local investigators have anticipated. Why that is, I'm not sure. But this has been consistent throughout the country. So I would say that diagnosis rates, the 200,000, would grow rather than shrink certainly for the next few years. And this great effort, of course, now to encourage diagnosis because people know that, at the end of it, they're going to be treated and have a higher probability of being cured."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And we have time for one final question. Our last question comes from the line of Tony Butler with Guggenheim.",20,"And we have time for one final question. Our last question comes from the line of Tony Butler with Guggenheim."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Norbert, very quickly, if you could. Recognizing the Nimbus closes next week, has there not been any other ACC inhibitors, which have actually failed the? And if that's true, what might be unique about the Nimbus program? I understand it may attack a diff",62,"Norbert, very quickly, if you could. Recognizing the Nimbus closes next week, has there not been any other ACC inhibitors, which have actually failed the? And if that's true, what might be unique about the Nimbus program? I understand it may attack a different part of the molecule, which would be interesting for you to elaborate on, if that isn't the case."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. So Tony, you're exactly right. We have been previous ACC programs at Merck and Pfizer. They have not been successful. And the reason had to do with the specificity. This compound is really unique. It's a low animal inhibitor for both ACC 1 and ACC 2.",205,"Yes. So Tony, you're exactly right. We have been previous ACC programs at Merck and Pfizer. They have not been successful. And the reason had to do with the specificity. This compound is really unique. It's a low animal inhibitor for both ACC 1 and ACC 2. And it inhibits not only the pathway that goes to [indiscernible] production, but it also inhibits the level of the mitochondrial. It stimulates, I might say, lipid asset beta oxidation. So it does really 2 things. It inhibits the formation of lipids, [indiscernible] mostly, and at the same time, it stimulates the beta oxidation of lipids. There has been some anecdotal reports from the Pfizer compound that inhibition of ACC 1 and 2 results in a decrease in liver fat. That's, by the way, something we would do as one of the next experiments. We would look by MRI on reduction of -- we've already shown at the presentation that lipid liver genesis. Now we have to show also that inhibits fat content of the liver. So fairly straightforward [indiscernible] we are easy to do. And I think once we have shown that we are pretty high confidence that there would be meaningful clinical benefit of the compound."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, and thank you all for joining us today. We appreciate your continued interest in Gilead. And the team here look forward to providing you with updates on our future progress.",32,"Thank you, and thank you all for joining us today. We appreciate your continued interest in Gilead. And the team here look forward to providing you with updates on our future progress."
29002,330109201,966504,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for per dissipating in today's conference. This does conclude the program and you may all disconnect. Have a great day, everyone.",26,"Ladies and gentlemen, thank you for per dissipating in today's conference. This does conclude the program and you may all disconnect. Have a great day, everyone."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences First Quarter 2016 Earnings Conference Call. My name is Candace, and I will be your conference operator today. [Operator Instructions] And as a reminder, this conference c",64,"Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences First Quarter 2016 Earnings Conference Call. My name is Candace, and I will be your conference operator today. [Operator Instructions] And as a reminder, this conference call is being recorded.
I would now like to turn the call over to Patrick O'Brien, Vice President of Investor Relations. Please go ahead."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Candace, and good afternoon, everyone. Just after market closed today, a press release was issued with earnings results for the first quarter of 2016. The press release and detailed slides are available on the Investor Relations section of the",221,"Thank you, Candace, and good afternoon, everyone. Just after market closed today, a press release was issued with earnings results for the first quarter of 2016. The press release and detailed slides are available on the Investor Relations section of the Gilead website.
Joining today's call will be John Milligan, President and Chief Executive Officer; Robin Washington, Executive Vice President and Chief Financial Officer; Paul Carter, Executive Vice President of Commercial Operations; and Norbert Bischofberger, Executive Vice President of Research and Development and Chief Scientific Officer.
Before we begin formal remarks, let me remind you that we will be making forward-looking statements, including plans and expectations with respect to products, product candidates, financial projections and the use of capital, all of which involve certain assumptions, risks and uncertainties that are beyond our control and could cause actual results to differ materially from these statements. A description of these risks can be found in the latest SEC disclosure documents and recent press releases. In addition, Gilead does not undertake any obligation to update any forward-looking statements made during this call.
Non-GAAP financial measures will be used to help you understand the company's underlying business performance. The GAAP to non-GAAP reconciliations are provided in the earnings press release as well as on the Gilead website.
I'll now turn the call over to John."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Patrick, and thank you, everyone, for joining us today. While we want to keep our remarks relatively brief to allow plenty of time for your questions, I do want to make a few comments about the first few months of 2016 and what I see as the out",1043,"Thank you, Patrick, and thank you, everyone, for joining us today. While we want to keep our remarks relatively brief to allow plenty of time for your questions, I do want to make a few comments about the first few months of 2016 and what I see as the outlook for the rest of the year.
Gilead's HIV franchise is off to a great start with the recent U.S. FDA approvals of Odefsey and Descovy, which followed the approval of Genvoya late last year. Over the last 6 months, I've had the opportunity talk with physicians and patients about the importance of having highly effective and safer options, especially for patients facing a lifetime of therapy.
With the approval of our 3 new regimens, we are now able to offer a range of options to address the diverse medical requirements of people with HIV, including those new to treatment, those who've been on therapy for a long time and have run short of options and those who desire to switch medications for a variety of reasons.
Since 2001, Gilead therapies have played a transformative role in changing HIV infection from a fatal and debilitating disease into a chronic and manageable condition. That's true around the world, as broader access to HIV treatment has helped divert millions of AIDS deaths.
Innovation remains important in the continuing fighting of HIV, and we're proud that Descovy is the first new backbone approved by the FDA in more than a decade.
Gilead continues the commitment to helping HIV patients around the globe with our research and development activities, including novel agents for daily treatment, long-acting regimens and HIV cure.
In liver disease, we just wrapped up an exciting week in Barcelona at the International Liver Conference (sic) [ International Liver Congress
], or EASL, as it's known. It was a remarkable meeting, especially considering the significant change in the HCV treatment landscape since the conference was held last in Spain 4 years ago. The outlook for patients has completely changed with dramatic improvements in cure rates for a wider range of patients.
Presentations at EASL included results from several Phase II and Phase III studies evaluating sofosbuvir/ledipasvir and sofosbuvir/ledipasvir plus GS-9857. These are 2 investigational pan-genotypic fixed-dose combination therapies for the treatment of HCV.
The data presented continues to underscore the high cure rates and safety of our sofosbuvir-based therapies and support their utility across all HCV patient genotypes in a wide range of disease stages.
Data were also presented on the use of TAF for patients with chronic hepatitis B infection. 48-week results from 2 Phase III studies demonstrated potential to advance the treatment of HCV, offering a similar efficacy profile to Viread with improved bone and renal safety parameters. Based on these results, we submitted a new drug application for TAF, and FDA has set a PDUFA date of November 11.
We also submitted regulatory applications for TAF in the European Union and Japan last quarter.
I'm particularly encouraged by the work that's going on in NASH, which we've augmented with our agreement to acquire the Nimbus Acetyl-CoA Carboxylase, or ACC, program, as was announced last month. NASH affects up to 15 million people in the U.S. and is expected to become the leading indication for liver transplantation by 2020.
Including the ACC program, Gilead has 4 investigational compounds that target unique disease pathways, including production of lipids, inflammation and fibrosis, each of which are thought to contribute to or cause NASH. Data in EASL represented support in the development of Gilead's investigational agents for the treatment of NASH, including simtuzumab, a monoclonal antibody that is selected for LOXL2, which is also being evaluated to primary sclerosing cholangitis; GS-4997, an ASK1 inhibitor; and GS-9674, an FXR agonist. Nimbus also presented positive Phase I data for the program's lead candidate, NDI-010976, which targets ACC, the key step in the lipid biosynthesis pathway.
Overall, I'm enthusiastic about the future of Gilead and excited to have the opportunity to help build in the company's long history of success. Over the past few months, I've had conversations with external stakeholders and employees across all parts of our organization. It's gratifying to see the extent to which Gilead's products and commitment to access have uniquely changed the course of diseases for so many people throughout the world. We now have the opportunity to do so again in many new areas.
A few things to note in those conversation. First, physicians and patients share the excitement that our medical and commercial teams have regarding Gilead's new treatment options for HCV and HIV, particularly the new TAF-based therapies. Access continues to improve for people with HCV around the world, and in fact, we have treated close to 1 million patients with sofosbuvir-based regimens since Sovaldi was first approved in late 2013. That's a remarkable achievement in just over 2 years.
With regards to HIV, as many of you are aware, TAF was added to the Medicines Patent Pool and to our various Access Programs. The clinical data suggest TAF-based regimens may be the best option in both the developed and developing world. We will build on success we've had with the TDF-regimens, now used by nearly 10 million people every single day, to make TAF regimens accessible around the world, providing much-needed new options.
Secondly, I believe we have a rich pipeline, creating opportunities that may allow the transformation of the treatment of many diseases like NASH, HPV inflammatory diseases, certain cancers and cardiovascular conditions, for which few, if any, options exist.
We are committed to building on our company's long history of success, and I'm confident that our innovation and hard work will deliver on our shared goal of delivering new treatments and providing broad access to Gilead's medicines for patients in need.
Finally, we continue to look for business development opportunities that add to our core therapeutic areas and are a fit with Gilead's expertise and capabilities. We are actively assessing options and we'll make moves when the right opportunities present themselves.
I will now turn the call over to Robin who'll provide an overview of our financial results for the quarter. Robin will be followed by Paul who'll provide additional color on the company's performance across products and geographies."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, John, and good afternoon, everyone. We are pleased to report our first quarter results with non-GAAP diluted earnings per share of $3.03 per share compared to $2.94 for the same period last year. Total revenues for the quarter were $7.8 billion, u",930,"Thanks, John, and good afternoon, everyone. We are pleased to report our first quarter results with non-GAAP diluted earnings per share of $3.03 per share compared to $2.94 for the same period last year. Total revenues for the quarter were $7.8 billion, up 3% year-over-year and down 8% sequentially. Product sales for the quarter were $7.7 billion, up 4% year-over-year and down 9% sequentially.
Starting with HIV and other antivirals. Product sales for the first quarter increased to $2.9 billion, up 19% year-over-year, primarily driven by increased sales in the U.S.
We continue to see strong uptake of our newer single-tablet regimens, including Genvoya, which was launched in November 2015. Additionally, year-over-year, Stribild and Complera grew 34% and 19%, respectively.
Sequentially, these sales decreased 4% primarily driven by sub-wholesaler inventory decreases in the U.S., reflective of the seasonal inventory pattern from quarter 4 to quarter 1.
HCV product sales for the first quarter decreased 6% year-over-year to $4.3 billion primarily driven by a decrease in Harvoni sales in the U.S., which was partially offset by the launch of our HCV products in Japan and other international markets.
In the U.S., the year-over-year Harvoni sales decline was driven by lower patient starts and a full-quarter impact of higher commercial rebates, which were entered into during the first quarter of 2015.
Sequentially, HCV product sales decreased 12% primarily driven by revenue declines in the U.S. and Japan. In the U.S., the decline was due to the increase in discounts required to open up access to patients with lower fibrosis scores and a modest shift in payer mix towards more deeply discounted government payer segments.
In addition, revenue was further impacted by higher-than-expected prior quarter rebate claims. Rebate claims come in 1 to 2 quarters in arrears and were updated in Q1 to reflect the higher claims received.
In Japan, Sovaldi volumes declined from high early-launch levels, similar to other markets, and channel inventory pricing for Sovaldi and Harvoni was adjusted during March for the mandatory price reduction effective as of April 1.
Turning to our other therapeutic areas. Product sales of cardiovascular, respiratory and other were $498 million, up 19% year-over-year and down 5% sequentially.
Moving to gross margin. Non-GAAP product gross margin was 87.2% for the first quarter of 2016 compared to 90.9% for the same period last year. The decrease reflects a $200 million charge or $0.12 earnings per share related to the jury verdict in the Merck trial in March. Although the proceedings in the Merck trial are not complete and the losing party will appeal once the court enters judgment, we booked the charge to comply with accounting rules related to contingencies.
Now turning to expenses. Non-GAAP R&D expense -- expenses were $769 million for the first quarter, up 18% compared to the same period last year, due to the continued progression of clinical studies, particularly in liver disease and HIV. Non-GAAP SG&A expenses were $638 million for the first quarter, up 6% compared to the same period last year. These expenses increased primarily due to higher costs to support the growth of Gilead's business and were offset by favorable adjustments related to the Branded Prescription Drug fee of $191 million, following the receipt of the preliminary 2016 IRS invoice.
From a balance sheet perspective, during the first quarter, we generated cash flows from operations of $3.9 billion and ended the quarter with $21.3 billion in cash and investments.
We continue to return capital to our shareholders through dividends and opportunistic share repurchases. Earlier this afternoon, we announced that our Board of Directors declared a dividend of $0.47 per share for the second quarter of 2016, an increase of 10% from the prior quarter. $8 billion in cash was utilized to repurchase shares of our common stock during the quarter, consisting of $3 billion of open-market repurchases or 33.4 million shares, and $5 billion under the accelerated share repurchase program, ASR, that we announced in February. 46.1 million shares were repurchased under this program during the quarter. The final settlement of the ASR program was completed earlier this month, and we received an additional 8.1 million shares. In total, 54.3 million shares were retired under the ASR program at an average price of $92.09 per share.
As of March 31, the amount of capital returned to shareholders, consisting of dividends and share repurchases, exceeded the total amount of capital returned during the first 3 quarters of 2015 combined.
During the quarter, we completed a $15 billion share repurchase program approved by our board in January 2015 and, as of April 1, have begun repurchasing shares under our $12 billion 2016 share repurchase program approved in January of this year.
Since 2012, we've repurchased over 260 million shares or 17% of shares outstanding.
Finally, we are reiterating our full year 2016 guidance provided to you on February 2 and summarized on Slide 25 in the earnings results presentation available on our corporate website.
As a reminder, guidance for product sales is subject to a number of uncertainties, including an uncertain global macroeconomic environment; adoption of additional pricing measures to reduce HCV spending; volatility in foreign currency exchange rates; inaccuracy in HCV patients start estimates; additional competitive launches in HCV; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; and a larger-than-anticipated shift in payer mix to more highly discounted payer segments such as PHS, FFS, Medicaid and the VA.
I will now turn the call over to Paul to provide more details on our commercial results for the quarter."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, Robin, and good afternoon, everyone. Our commercial performance remained strong through the first quarter. I'd like to start with HIV and Genvoya, the first of our TAF-based single-tablet regimens. We're pleased with the launch of Genvoya, both in",1506,"Thanks, Robin, and good afternoon, everyone. Our commercial performance remained strong through the first quarter. I'd like to start with HIV and Genvoya, the first of our TAF-based single-tablet regimens. We're pleased with the launch of Genvoya, both in the U.S. and in the European markets where we've achieved reimbursement.
Starting with the U.S. Through 5 months post the launch of Genvoya, cumulative prescriptions were twofold more than any HIV product from any company since Atripla, which was the first single-tablet regimen to come to market back in 2006. As expected, most of Genvoya's initial prescriptions came from switches. Qualitative feedback from HIV prescribers is very encouraging in indicating a clear intent to switch patients at the earliest opportunity.
Stribild and Complera showed strong year-over-year prescription growth at 18% and 5%, respectively. And in quarter 4 2015, Stribild was the leading product in the U.S. for patients nave to treatment. With the launches of Genvoya and now, just very recently, Odefsey, we expect switches out of TDF-based single-tablet regimens into the TAF regimens to grow significantly. In fact, 82% of Genvoya's prescriptions have been switches. 49% of the switches have come from Stribild.
We are seeing an improvement in our ability to retain switch patients, meaning, fewer patients who switch from Gilead TDF-containing regimens move to non-Gilead products. Of all the patients who switched to Genvoya, 91% came from a Gilead regimen, and 9% came from a non-Gilead product.
In addition to switches, preliminary quarter 1 2016 data indicate to us that Genvoya may soon be among the most prescribed products of patients new to treatment.
Historically, in quarter 1, we've seen a decrease in sub-wholesaler inventories following a buildup in the prior quarter. We observed this effect again this year, leading to a sequential decrease in HIV product sales.
Finally, in the U.S., I'd like to highlight the growing use of Truvada for PrEP, which was more than 20% of Truvada demand last quarter and drove a 17% year-on-year growth in prescriptions.
Turning to Europe. We're also pleased with the way that our HIV business is performing with successful reimbursement and launches of Genvoya in several countries, including Germany and the Nordics. In other countries, Stribild and Eviplera continued to replace Atripla. Stribild remains the most prescribed regimen for patients nave to treatment in the EU, with Eviplera in the third place.
Genvoya was launched in Germany during quarter 1, and at the end of the quarter, preliminary data indicate it had the leading market share for both nave and switch patients. The product was launched and fully reimbursed in Spain just 2 weeks ago. And we're very excited about the opportunities to offer providers another important option to address the needs of their patients. It's also been recognized as a preferred regimen in numerous country guidelines, including Germany, Spain and Italy, even before reimbursement has been agreed. This is testament to the favorable clinical profile of Genvoya, a single-tablet regimen that better addresses the needs of patients who require long-term chronic therapy. We're working hard to negotiate timely reimbursement across the rest of the European markets.
Finally, in HIV, we launched Descovy this month in the U.S. and the EU. We see this launch as a milestone in HIV treatment, as Descovy is the first new NRTI backbone since Truvada 10 years ago. Given the very high use of Truvada as a preferred backbone with third -- multiple third agents, including Tivicay, we're confident that Descovy will quickly replace Truvada and become the leading HIV regimen backbone in all our markets.
Now moving to hepatitis C. We continue to see revenue dynamics around the world, which vary by country. As Robin noted, our overall HCV product revenue decreased 6% year-over-year and 12% sequentially.
I'll now describe the different dynamics by geographic region, starting with the U.S. market. We've seen an increase of new patients in the first quarter, offset by lower revenue per patient due to several factors that include an increase in our gross-to-net adjustments as well as a shortening average duration of therapy.
Total market patient starts increased around 10% over Q4 to an estimated 55,000 in Q1. This was primarily driven by the continued opening of access across payer segments to allow for the treatment of patients with low fibrosis scores as well as an increase in treatment by the VA during the second half of the quarter as funding made its way to the various VA sites. The revenue associated with this increase in patient starts was partially offset by an increase in discounts associated with our contracted -- contract agreements entered into during the first quarter of 2015, which provide for additional discounts if access is provided to a broader patient population. We also saw a gradual shift to more deeply discounted payer segments, such as VA, PHS and Medicaid, compared to the prior quarter.
In addition, revenue was further impacted by higher-than-expected prior quarter rebate claim, which come in 1 to 2 quarters in arrears and were updated in quarter 1 to reflect the higher claims received. The average duration of therapy has shortened as fewer patients require 24 weeks of treatment and a higher proportion of genotype 1 patients are treated for 8 weeks, resulting in slightly lower revenues for patients.
The ability to treat for 8 weeks, notably, has a strong competitive differentiation. In fact, our market share remained strong with more than 90% of all patients treated in the quarter being prescribed by the Harvoni or Sovaldi. Qualitative feedback suggests that prescribing HCV physicians are encouraged by the fact that real-world outcomes mimic the experience in clinical trials.
Several presentations of real-world data at EASL reinforce what has been seen in clinical practice.
As we think about the rest of the year in the U.S., patient flow peaked in quarter 1 2015 then declined in quarter 2 and stabilized in quarter 3 and quarter 4 of 2015. In quarter 1 of 2016, there was an uptick in new patient starts. Our data show that 25,000 to 30,000 patients a month are entering treated care, which exceeds the number of patients starting therapy on a monthly basis. That means there are many more people who could benefit from treatment who are already linked to care. We expect new patient starts to remain consistent through the rest of 2016.
Despite the number of patients treated today, there are still over 3,000 -- 3 million, I'm sorry, patients in the U.S. who have yet to be treated. About half of these patients are undiagnosed. Education and awareness efforts to increase rates of diagnosis are important. And as we well know from public health efforts in the HIV area, these efforts play out over many years. We're encouraged to see data that screening and diagnosis rates have increased at least twofold over the last 5 years.
Now turning to Europe. Total HCV revenue in Europe was down 13% year-over-year and down 1% sequentially. While overall Gilead patient starts increased 5% sequentially to around 31,000 in the quarter, average revenue per patient declined due to a shift in geographic mix and shorter average treatment duration. We also saw a negative foreign exchange movement, which affected HCV revenues by about 8% year-on-year and 3% sequentially.
The mix of sales in the EU is such that more patients and are now being treated in countries, which have lower net prices per patient. European countries continue to vary significantly in terms of patient access with many still limiting treatment to patients with high fibrosis scores. We anticipate that as sicker patients are treated, these restrictions will start to loosen as healthier patients can be cared for within existing budgets.
Again, as in the U.S., we treat just a small fraction of patients diagnosed. We are encouraged by ongoing efforts and commitments by governments to increase diagnosis and treatments across Europe.
Now moving to Japan. Revenue was over $1 billion during the quarter. We're pleased with the successful launches of Sovaldi and Harvoni where a strong patient flow and high market shares continued through quarter 1. More than 30,000 patients were treated with Gilead products during the quarter, representing a market share greater than 90%.
Other markets where we recently launched our HCV products include Australia where nearly 5,000 patients started treatment in Q1. This reflects a strong commitment by the Australian government to address their HCV burden and the usual warehousing of patients prior to the launch of sofosbuvir-based regimens.
In closing, our underlying HCV business is strong and sustainable. We've treated around 700,000 patients in the U.S., Europe and Japan. And despite strong competition, Gilead has maintained high market shares in all regions.
The Gilead commercial organization is focused on executing our numerous HIV and HCV product launches across multiple geographies during the remainder of the year. In addition to our 3 TAF-based HIV products, we're preparing to launch our pan-genotypic HCV product as early as next quarter in the U.S.
Thank you, and now let's open the call for questions. Operator?"
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Geoff Meacham of Barclays.",15,"[Operator Instructions] And our first question comes from the line of Geoff Meacham of Barclays."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Seems like lower revenue per patient is -- was one of the bigger contributors to the sequential trends, so a couple of questions. Was the -- what was the initial outlook for higher volumes coming from commercial patients just with respect to broader acces",74,"Seems like lower revenue per patient is -- was one of the bigger contributors to the sequential trends, so a couple of questions. Was the -- what was the initial outlook for higher volumes coming from commercial patients just with respect to broader access for F0 in F1? And then, was the volume contribution this quarter pretty meaningful from the VA system? Just want to get a sense for the sequential trends there, too."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Geoff, so yes. So several things happened in the quarter with -- in relation to volume and revenue per patient. So maybe I'll try and deal with all of them. So the first thing, as you've said, we had -- and we expected this and hoped for it, that several",437,"Geoff, so yes. So several things happened in the quarter with -- in relation to volume and revenue per patient. So maybe I'll try and deal with all of them. So the first thing, as you've said, we had -- and we expected this and hoped for it, that several of the large commercial payers opens up access to patients regardless of their fibrosis scores during quarter 1. The consequence of that was that they triggered a discount that had been previously negotiated in order to incentivize that opening up of restrictions. So that was the first thing. And then the VA, as you know, treated very few patients in quarter 4 last year because of lack of funding. That funding was agreed for a 2-year period and focused on HCV medicines and was clarified late December. Than the VA went through a process of evaluating the clinical evaluation of products available from not just us but, obviously, new entrants to the market, and that process took through until mid to late January. And we have to negotiate with the VA, and we did give the VA some extra discounts, which resulted in them putting our products on their formulary and also opening up, again, access to all patients within the VA. So there are no restrictions on patients. And again, we see this as a large positive. And as those funding got distributed around the VA centers, we start to see a very large uptick in VA treatment from about the middle of the quarter, and we anticipate that, that will continue through the year. The second kind of area that have [ph] on course is we have the entrance of Merck into the market. And so we judiciously exercised our contractual right to preserve access. And in a few cases, we did increase a little bit of discount to some payer to ensure that Harvoni, in particular, remained on formularies and with full access. The third thing, I think, we've seen, as I indicated in the comments, was a slight and gradual shift of payer mix away from the commercial and Medicare Part D payers towards the more government payers. And that was probably about a 10% shift from quarter 4 to quarter 1. And then the final piece, as we indicate, is we did have a catch-up, a true-up of some rebate claims that came, in respect of quarter 3 and quarter 4, that were a little bit higher than we estimated last quarter and which we put right during quarter 1. So that really is the dynamic between volumes and revenue per patient."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Mark Schoenebaum of Evercore ISI.",11,"And our next question comes from Mark Schoenebaum of Evercore ISI."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Everyone's very focused on what you're going to do with your cash, PD, M&A. So I have actually one simple question, probably for John. Would you be willing to go hostile? And if not, why not? How do you feel about that? Because clearly, overhearing is tha",67,"Everyone's very focused on what you're going to do with your cash, PD, M&A. So I have actually one simple question, probably for John. Would you be willing to go hostile? And if not, why not? How do you feel about that? Because clearly, overhearing is that the small companies won't engage right now because they don't like evaluations, but the larger companies are very interested."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Mark, it's John. Mergers and acquisitions are always a process, and so the ability to go hostile is limited by how much data or how much cooperation you need. And so in each situation, you'd have to kind of think about what do I need to know about the pip",101,"Mark, it's John. Mergers and acquisitions are always a process, and so the ability to go hostile is limited by how much data or how much cooperation you need. And so in each situation, you'd have to kind of think about what do I need to know about the pipeline or about things that are not public about a company in order to be comfortable making sort of a public offer for the company. But that being said, we've never declared ourselves unwilling to go hostile. I do prefer a friendly process, but it would just depend on the situation itself."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Geoffrey Porges of Leerink Partners.",11,"And our next question comes from Geoffrey Porges of Leerink Partners."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I guess a follow-up on that question. You've invested, looks like, about $19 billion or $20 billion over the last year, reducing your share count. And the share count has come down by about 10%. But your EPS is pretty much flat, maybe up low single digits",98,"I guess a follow-up on that question. You've invested, looks like, about $19 billion or $20 billion over the last year, reducing your share count. And the share count has come down by about 10%. But your EPS is pretty much flat, maybe up low single digits versus last year. Are you convinced that, that's the best use of your capital? You've got $21 billion in cash and about the same amount of debt. So are you going to revisit that? Or is that more or less the path that you believe generates the best returns here?"
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Geoff, I think that was directed to me, but I'm going to let Robin answer the first part of the question.",21,"Geoff, I think that was directed to me, but I'm going to let Robin answer the first part of the question."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Geoff, it's Robin. I think, as we've said all along, we've looked at how we leverage our cash as not only being share repurchases and dividends, but also, we consistently look at investing in our core pipeline as well as M&A where appropriate. And similar",167,"Geoff, it's Robin. I think, as we've said all along, we've looked at how we leverage our cash as not only being share repurchases and dividends, but also, we consistently look at investing in our core pipeline as well as M&A where appropriate. And similar to the amounts that you called out relative to cash, it's actually about 17% reduction in share count, as I mentioned on the call. We have done a lot of M&A as well, and I think we'll continue to do that, as John said, when the right opportunities present theirselves. So I think we've always been fairly clear that we're balancing, doing all of those things and purposely focused on share repurchases because, in the absent of M&A, it allows us to be flexible and more opportunistic. But when the right M&A opportunities present theirselves, it allows us to reduce our share repurchases in order to make those necessary acquisitions and leverage our cash and debt and borrowing if we need to."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. It's just, for us, it's fairly simple. We have the flexibility to do both things, that is returning shareholder value through stock repurchases and dividends and, of course, continue to be opportunistic in M&A. How we're deploying it is sort of a ref",107,"Yes. It's just, for us, it's fairly simple. We have the flexibility to do both things, that is returning shareholder value through stock repurchases and dividends and, of course, continue to be opportunistic in M&A. How we're deploying it is sort of a reflection of the things we're interested in. I think, for example, the Nimbus acquisition, while relatively small, could bring a very, very unique product to us and something that we had focused on during the quarter. We're continuing to look for opportunities like that, and we will continue to aggressively look for opportunities to deploy our cash and investing in things other than Gilead."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Michael Yee of RBC Capital Markets.",12,"And our next question comes from Michael Yee of RBC Capital Markets."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Wanted to revisit some questions that was talking about relating to price and volume. You did mention on a positive that net new patient starts were up about 10%, which is great, but then the total revenues in U.S. declined by 11%. So someone could do the",98,"Wanted to revisit some questions that was talking about relating to price and volume. You did mention on a positive that net new patient starts were up about 10%, which is great, but then the total revenues in U.S. declined by 11%. So someone could do the math and imply that price was down 10% to 20%. And I -- can you comment on that or maybe just describe where you think the price volume equation was in the quarter? And how we should think about net price changing quarter-over-quarter, and how that should change over the year?"
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes, Michael. I mean, I think we are in a much more stable place than we were 1 year ago at this time. I think I described it. Just now, we've made some contractual moves, which have opened up access. We're very happy about that. We're happy that some of",171,"Yes, Michael. I mean, I think we are in a much more stable place than we were 1 year ago at this time. I think I described it. Just now, we've made some contractual moves, which have opened up access. We're very happy about that. We're happy that some of the government payers are beginning to treat a few people. We were very happy about the VA, in particular, ramping up its treatment levels. I said that we'd had to compete in the VA, and we did that. But we're enjoying very high market shares wherever physicians have the choice of prescribing. And that's always been our aim, to make sure that physicians and patients can choose what drug they think's appropriate. And wherever that's the case, Gilead seems to do pretty well. So I would say, looking forward, we're in a fairly stable place now. I mean, clearly, over time, as competition increases, prices are likely to incrementally move in one direction, I would think. But I think we're stable."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","So on one side, we're getting lots of access, but on the other side, my math is not totally off, just to be fair?",24,"So on one side, we're getting lots of access, but on the other side, my math is not totally off, just to be fair?"
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Correct.",1,"Correct."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from the line of Cory Kasimov of JPMorgan.",13,"And our next question comes from the line of Cory Kasimov of JPMorgan."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Going back to the strategic theme, you've talked in the past about wanting to be a leader in oncology. But given the issues you've had with Zydelig and the leadership changes you've also had, are you as committed to that space as you once were? And if so,",64,"Going back to the strategic theme, you've talked in the past about wanting to be a leader in oncology. But given the issues you've had with Zydelig and the leadership changes you've also had, are you as committed to that space as you once were? And if so, what's your thought on the potential opportunities you see out there between solid tumors and hemog?"
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Cory, it's John. That's quite a big question. So if you think about where we are in our oncology portfolio, we haven't focused heavily on a number of activities around these kinase inhibitors and have actually behind Zydelig a number of opportunities are",198,"Cory, it's John. That's quite a big question. So if you think about where we are in our oncology portfolio, we haven't focused heavily on a number of activities around these kinase inhibitors and have actually behind Zydelig a number of opportunities are moving into clinic, including our Syk inhibitor, our BTK inhibitor. I should probably let Norbert go on about this, but I would say we have numerous opportunities that we're continuing to pursue. You have mentioned we want to be a leader in oncology. We think of oncology as one leg of a future company that could be important to us, along with our investments in NASH and inflammatory diseases. We do see some good opportunities out there, and we see some good opportunities internally. So I don't -- the Zydelig setback hasn't changed our appetite for trying to do more transformative things in oncology. It was never going to be a franchise product like Viread or sofosbuvir but was a good beginning for us. And I really haven't changed my thought process around it as a result of the setback because of the toxicities we've seen.
Norbert, do you want to add anything to that?"
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","No. As John said, Zydelig has not only -- not decreased our appetite, it has increased our appetite to do more in oncology. And we're now at a point where a number of programs are coming to fruition. For instance, momelotinib, we're intending to file earl",134,"No. As John said, Zydelig has not only -- not decreased our appetite, it has increased our appetite to do more in oncology. And we're now at a point where a number of programs are coming to fruition. For instance, momelotinib, we're intending to file early next year. The Phase III studies are fully enrolled. We should get results at the end of this year. The anti-MMP-9 antibodies in Phase III for gastric cancer were at the end of dose ranging with combinations of PI3K Syk and Syk BTK, and that will move into frontline treatment. So we have a number of interesting things ongoing internally, and of course, as John said, we're continuously looking externally at finding suitable opportunities. And if the right opportunity comes along, then we will take advantage of it."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Brian Abrahams of Jefferies.",10,"And our next question comes from Brian Abrahams of Jefferies."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I was wondering if you could talk a little bit about hep C diagnostic initiatives and maybe some of the pull-throughs that you're seeing or might expect to see on patient identification. And I'm particularly curious if you have a sense, among the growing",81,"I was wondering if you could talk a little bit about hep C diagnostic initiatives and maybe some of the pull-throughs that you're seeing or might expect to see on patient identification. And I'm particularly curious if you have a sense, among the growing number of new patient starts, who may have been identified last year and are now getting access with the fewer restrictions versus patients who are getting identified this year and coming on to treated care currently."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Shall I go ahead, John, maybe -- so it's actually very hard to tell when people are being diagnosed and who's been treated when. Anecdotally, I can tell you, and I was out visiting some doctors in California just last week, patients are -- there are plent",312,"Shall I go ahead, John, maybe -- so it's actually very hard to tell when people are being diagnosed and who's been treated when. Anecdotally, I can tell you, and I was out visiting some doctors in California just last week, patients are -- there are plenty of patients there that many people who are linked to care now. And with the fibrosis restrictions being dropped now, most physicians can treat, starting in the commercial area and Medicare area, can treat whoever they want. One thing's clear, though, that there are still prior authorizations in place, and there's still a fair amount of office paperwork and bureaucracy that have to be put in place for each patient. Then as the patients themselves, many of whom just simply aren't quite mentally ready or psychologically ready to commit to their disciplined 8-week or 12-week treatment. And with these products, of course, if insurance comes on, came to do it twice, they want to try to get it right first time. The doctors want to get it right first time, and the patients want to get it right first time. So we're seeing that some of the sort of delays in patient starting had to do with the patient just being ready to commit to sort of disciplined 8 or 12 weeks of patients (sic) [ treatment ]. On the diagnosis side, I mean, again, anecdotally, we just know that there's a lot of activities going on. A lot of people are telling us what's going on around the countryside, and we do see diagnosis rates increasing significantly. So I think that plenty of patients are being diagnosed, and there are plenty of patients coming into treatment. And there's a waiting list of patients at most offices. By the way, our estimate on diagnosis is about 200,000 new diagnoses happened in the U.S. last year."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes, Brian, I think I might want to add that we have a number of demonstration projects ongoing in the United States to look for places, institutions, populations and figure out what the diagnosis positivity would be. And it's surprising, we've identified",81,"Yes, Brian, I think I might want to add that we have a number of demonstration projects ongoing in the United States to look for places, institutions, populations and figure out what the diagnosis positivity would be. And it's surprising, we've identified some places like ER rooms that have 0 positivity rates or greater than 10%. We hope that those demonstration projects will then lead to a broader recognition of the value of diagnosis and identification of hepatitis C infected individuals."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from the line of Brian Skorney of Robert Baird.",14,"And our next question comes from the line of Brian Skorney of Robert Baird."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I guess, 2 quick ones. I know we talked a little bit about this at EASL, John, but just to refresh us the timeline in terms of when you think you can get a sofosbuvir-based regimens approved in China? How do you think about pricing that there to kind of c",105,"I guess, 2 quick ones. I know we talked a little bit about this at EASL, John, but just to refresh us the timeline in terms of when you think you can get a sofosbuvir-based regimens approved in China? How do you think about pricing that there to kind of capture a share of patients who are looking at a branded drug versus potentially penetrating further in. And then, just on the U.S. Have you guys heard anything in terms of a warehouse build in genotype 3 ahead of a soft value launch? Should we be expecting a small bolus of patients upon that approval?"
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","So Brian, I'll start with the China question. So in terms of timing for China, there is a fairly fixed process. And according to the recent processes, we could possibly have sofosbuvir in the market in 2017. As you may have seen, there are new  -- the Chi",288,"So Brian, I'll start with the China question. So in terms of timing for China, there is a fairly fixed process. And according to the recent processes, we could possibly have sofosbuvir in the market in 2017. As you may have seen, there are new  -- the Chinese government is working hard to try to accelerate review and approval of HCV drugs because currently, none are on the market of the direct acting antivirals, and that could help us accelerate the timelines into China. We are working on that. Particularly of interest to us would be accelerating the timeline for sofo/ledipasvir, because there are so many different genotypes in China. Genotyping is not common in China, and this could provide a very good option for the people of China. So that's what -- there's hope, but we can't guarantee, of course, that we could accelerate that approval, to be honest in the current timeline, which is 2019. The Chinese market is fairly large. Between 10 million and 20 million people are thought to have HCV. I don't want to get into public discussions of pricing, but I do think there's a price volume relationship that would work for us and for the Chinese health system that could be very, very good for us both. And so that's what we're working towards, is access in China. Your second question was on warehousing for genotype 3 patients. Currently, a lot of genotype 3 patients are being treated with SOF in combination with Daclatasvir. And so that seems -- there seems to be fairly decent access for that. So looking at Paul, I don't think there's any real warehousing going on. But maybe you're more aware of it than I am."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Well, there's about 7% or 8% of the U.S. HCV epidemiology is genotype 3. I mean, we don't have any data on it, but certainly, we get -- I'm getting the impression from my team anecdotally, there is a little bit of warehousing, but not least because of sof",101,"Well, there's about 7% or 8% of the U.S. HCV epidemiology is genotype 3. I mean, we don't have any data on it, but certainly, we get -- I'm getting the impression from my team anecdotally, there is a little bit of warehousing, but not least because of sofosbuvir Daclatasvir is obviously a very expensive regimen. And, you know the hope is that the cost of the genotype 3 treatment will come down somewhat after SOF/VEL comes on to the market, which it is -- the PDUFA date is 28 of June. So people are thinking about that. So we're optimistic."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Phil Nadeau of Cowen and Company.",12,"And our next question comes from Phil Nadeau of Cowen and Company."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","2 questions on Japan. I know you said that there was some change in pricing because of the April 1 price decline this -- during the quarter. What other dynamics were going on in Japan during this quarter? Where do you think you are entering the bolus in J",102,"2 questions on Japan. I know you said that there was some change in pricing because of the April 1 price decline this -- during the quarter. What other dynamics were going on in Japan during this quarter? Where do you think you are entering the bolus in Japan? How much longer could that go? And then certainly I believe that there are price discounts that come in with a certain volume being reached. Would you like to assume that those could be hit in July, and what kind of dynamics do you expect to see in the Japanese market going forward?"
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","So we're very, very pleased with the execution of our launches in Japan. In terms of patient flow, the genotype 2 patients, which represent about 20% of the Japanese epidemiology in HCV, are beginning to stabilize now. So those are the patients being trea",256,"So we're very, very pleased with the execution of our launches in Japan. In terms of patient flow, the genotype 2 patients, which represent about 20% of the Japanese epidemiology in HCV, are beginning to stabilize now. So those are the patients being treated with Sovaldi. Those numbers -- we launched on May 25 of last year. We initially had a bolus, and then those numbers came down through quarter 4. And quarter 1 is at a lower level than quarter 4. But we're seeing a stable flow of patients now in genotype 2, and we would anticipate that to be stable through the rest of the year. Genotype 1's treated by Harvoni. We've had an enormous number of patients initially. We're not quite sure if the curve in Japan is identical to the sort of curves we've seen in the U.S. or other major markets. And that's because there was a DAA in the market for Harvoni, that was to treat quite a few people. So there might not have been quite such large amount of warehousing. In any case, we're seeing the Harvoni patient numbers coming down gradually, not quite as steep as some other markets. And yet, that's yet to stabilize. But I'm pretty sure, in fact I know it will stabilize at some time in the next quarter or 2. So that's how we're seeing. We treated about 30,000 patients during the quarter. So that number will -- it'll be there or thereabouts, I think, for the rest of the year."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","And what about the volume discounts? Are those going to come later in the year? And what kind of dynamics...",20,"And what about the volume discounts? Are those going to come later in the year? And what kind of dynamics..."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","I'm sorry, we're not anticipating any further price movements in this year in Japan.",15,"I'm sorry, we're not anticipating any further price movements in this year in Japan."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Matthew Harrison of Morgan Stanley.",11,"And our next question comes from Matthew Harrison of Morgan Stanley."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I had just 1 follow-up on Phil's question on Japan. Can you just be clear with us. The pricing that you talked about in March, was that the fullest end of the 30% price cut? Or will there be more in April? Just so we can understand how much was reflected",104,"I had just 1 follow-up on Phil's question on Japan. Can you just be clear with us. The pricing that you talked about in March, was that the fullest end of the 30% price cut? Or will there be more in April? Just so we can understand how much was reflected in this quarter. And then on the rebates that you talked about, the true-up that happened, would you expect that to swing again through the rest of this year? Or do you think that, that is now at a level that expresses what you're forward-looking expectations are for the level of rebates?"
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","I'll do the first part, and Robin will talk about the second part. So the pricing in Japan, the official price reduction was just under 32% and officially from the 1st of April. We actually reduced our prices into wholesalers early in March. And the reaso",135,"I'll do the first part, and Robin will talk about the second part. So the pricing in Japan, the official price reduction was just under 32% and officially from the 1st of April. We actually reduced our prices into wholesalers early in March. And the reason for that was because the price cut was announced much earlier. And therefore, we wanted to just kind of smooth out the inventory situation. So that's why we reduced our price into wholesalers a little bit earlier. And by the end of the quarter, inventory levels were up to, I would say, reasonable levels relative to demand. And actually, a little bit -- those inventory levels are a little bit down on where we ended quarter 4, because the overall demand was slightly down because of Harvoni. Robin?"
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Sure. So I'm actually to answer the second part of your question that's relative to the rebate accruals that both Paul and I have mentioned. We regularly have to adjust our accruals to reflect the trends and timing of rebates. And I would say still the tr",125,"Sure. So I'm actually to answer the second part of your question that's relative to the rebate accruals that both Paul and I have mentioned. We regularly have to adjust our accruals to reflect the trends and timing of rebates. And I would say still the trends and the dynamics that were [indiscernible] the complexity around reimbursement in these markets still make them somewhat difficult to predict. So I wouldn't say they were all one-time in nature. There may be a small component that you could say -- when we were trying to look at the level of inventory that maybe was one-time in nature. But these dynamics, I think, we may see continue into the future. The honest answer is we don't necessarily know."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from the line of Ying Huang of Bank of America Merrill Lynch.",17,"And our next question comes from the line of Ying Huang of Bank of America Merrill Lynch."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","First of all, I want to probe a little bit about the rebates. Can you clarify whether it was actually access-based or volume-based? Because, we can see from the script apparently the volume is not really picking up after those big insurance opened up the",107,"First of all, I want to probe a little bit about the rebates. Can you clarify whether it was actually access-based or volume-based? Because, we can see from the script apparently the volume is not really picking up after those big insurance opened up the access, regardless of [indiscernible]. So I wonder what happens there? And then secondly, I think, Paul, you mentioned that the payer mix is getting a little bit worse this quarter, but can you talk about your thoughts on payer mix going forward? Is it going to be continuing shift to the public payers or, I guess, the lower price environment or not?"
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Ying, so the first question was about patient volumes coming in and relative to the opening up of the fibrosis scores. So I'm not sure whether you looked at the data or not, but we get new to brand base, which is really the leading indicator of new starts",224,"Ying, so the first question was about patient volumes coming in and relative to the opening up of the fibrosis scores. So I'm not sure whether you looked at the data or not, but we get new to brand base, which is really the leading indicator of new starts in the quarter. So we've seen, and this is just retail scripts, by the way, so that doesn't include the VA, it doesn't include scripts that go through ESI and various other groups. So it's partly representative. And what we've seen amongst those scripts is new starts in the quarter have gone up, and that's gone up exactly in line with our expectations with the fibrosis scores being relieved. Total scripts there remained relatively flat and part of that is because in quarter 4, of course, the patient numbers, throughout, really 2015 quarter-on-quarter, the new starts were coming down. And therefore, the refills associated with those new starts falling into quarter 1 was somewhat down. So the aggregate of that makes the numbers of total prescriptions in the quarter look relatively flat and is slightly disengaged from the fibrosis piece. So I think that hopefully covers that part. And then, of course, the VA, as I said, isn't included in that group, and that was a large number of patients coming in to the system."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","And then the payer mix?",5,"And then the payer mix?"
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","The payer mix, I think, directionally -- I mean, this is not a dramatic move. I think, directionally, we anticipate that Medicaid will start. There's a lot of pressure on Medicaid to treat patients. And we anticipate the public payer sector will start pro",106,"The payer mix, I think, directionally -- I mean, this is not a dramatic move. I think, directionally, we anticipate that Medicaid will start. There's a lot of pressure on Medicaid to treat patients. And we anticipate the public payer sector will start proportionately, getting a little bit bigger in our mix. I mean, just as an example, around 77% of our payer mix at the end of quarter 4 or during quarter 4, was really commercial and Medicaid Part D. That number's dropped down now to about 64% as a proportion. So we're seeing a shift. And I would imagine that, that will continue gradually."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","And then would you guys ever talk about the relative magnitude compared to 46% you flagged last year?",18,"And then would you guys ever talk about the relative magnitude compared to 46% you flagged last year?"
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","No. I mean, we're not going to give guidance on our guidance. We gave the gross net number once. We've built that into our guidance for the rest of the year, so we're not planning on breaking that out at all.",41,"No. I mean, we're not going to give guidance on our guidance. We gave the gross net number once. We've built that into our guidance for the rest of the year, so we're not planning on breaking that out at all."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Robyn Karnauskas of Citi.",10,"And our next question comes from Robyn Karnauskas of Citi."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","So just thinking about the moving parts over the course of the year and the color you gave on the fibrosis scores. So, with so many people getting rejected early on based on fibrosis score, how might they flow into the system during the year? Because  the",143,"So just thinking about the moving parts over the course of the year and the color you gave on the fibrosis scores. So, with so many people getting rejected early on based on fibrosis score, how might they flow into the system during the year? Because  there's a lot of patients. Do you see them coming on evenly or could they come in a bolus? And we could see some choppiness in the quarters? And then the second question I had was, how comfortable are you that you can -- that some of the pricing negotiations will have been done and we won't see further pricing negotiations coming with the new nuc-based regimens coming next year? You think there's going to be another round of surprises in 2017 for discounting? Or do you think we've reached a little bit lower of a steady-state?"
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","I think it's hard to tell on the flow of patients, first of all. What we do know, there's plenty, plenty of patients out there. As I said, odd days, we got 3 different sources of data which shows that 25,000 to 30,000 patients are coming into treatment. O",304,"I think it's hard to tell on the flow of patients, first of all. What we do know, there's plenty, plenty of patients out there. As I said, odd days, we got 3 different sources of data which shows that 25,000 to 30,000 patients are coming into treatment. Obviously, a lot less than that are actually being treated. And anecdotally, as I've said, I think it's because there's bureaucracy still in the physicians' offices, which give a kind of, I guess, I've to sort of guessing in a sense of number of patients that can be treated. And also, there's, from the patient side, people are actually ready to be treated. I think they want to be teed up, if you like, for treatment, but they might not want to actually starve tomorrow morning. So I think we should expect patient flow to be fairly stable through this year. And then on the negotiation side, I mean -- I think, with real-world data, payers are tending now to really take a lot more time and put a lot more thought into evaluating the clinical profiles of the products. And until we see the clinical profiles of the new products, it's very hard to predict how competitive they are. I mean, if they're competitive, I think we have to anticipate prices will come down and we'll negotiate, because we certainly don't want to lose any access to patients for our products. And we'll defend our market share vigorously. So it's hard to predict. I think, directionally, competition equals lower prices. But we're going to be focusing on looking at differentiating our products. We've got great products out there now and our pipeline looks really exciting. So I think we're in good shape for a long and sustainable and healthy HCV business in the U.S."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Alethia Young of Credit Suisse.",11,"And our next question comes from Alethia Young of Credit Suisse."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Just 1. Mike, if we go back to the beginning of this year and think about like the $30 billion to $31 billion you've put out there, has the mix between hep C and HIV changed? It seems like HIV is little bit better on the new launches and hep C, has more p",84,"Just 1. Mike, if we go back to the beginning of this year and think about like the $30 billion to $31 billion you've put out there, has the mix between hep C and HIV changed? It seems like HIV is little bit better on the new launches and hep C, has more pricing pressure. And then just also, can you confirm, maybe, if we're seeing a competition in the Big 5 from like, kind of new competitors like Merck coming to the market?"
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Maybe Alethia, I can take the first part of your question. This is Robin. I mean, we gave guidance for the full year. I would say, yes, this quarter, we had a slightly uptick relative to our HIV expectations and slightly down relative to HCV. But I think",82,"Maybe Alethia, I can take the first part of your question. This is Robin. I mean, we gave guidance for the full year. I would say, yes, this quarter, we had a slightly uptick relative to our HIV expectations and slightly down relative to HCV. But I think we still have recorded the placings out and as Paul said, we continue to be opportunistic relative to patient starts, or more stable, predictable environment going forward. But it's still very early to tell."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. And in Europe, I mean that -- I've got to say the payers are treating the products, generally, with less consideration to the clinical differences than we're seeing in the U.S. And there are some payers who are treating the products a bit more like c",223,"Yes. And in Europe, I mean that -- I've got to say the payers are treating the products, generally, with less consideration to the clinical differences than we're seeing in the U.S. And there are some payers who are treating the products a bit more like commodities. And we're working hard to make sure that we educate them as best as possible. And I think the real-world data, much of which originates from Europe, is really supporting us in that. But we have seen some instances of -- for example, tenders in the Nordics, which have a very binary outcome. And there's certain times that we've decided that those tenders' prices don't warrant the value of our products. So our market share has been a little bit less than Europe. And specifically, to answer your question, I think all 3 players are out there in Europe trying to get business. But at the end of the day, we hope that people will recognize that the Gilead products are highly effective, very simple, very tolerable. And the real-world data, which is now -- you know there's vast amounts of it, really does support us when physicians make their choices. And as I said earlier, where physicians have the freedom of prescription, we've tended to have very, very strong market shares and they're 90% plus."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Ian Somaiya of BMO Capital.",11,"And our next question comes from Ian Somaiya of BMO Capital."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Maybe just changing the topic a little bit. That question for Norbert. I was hoping you just speak to the 3 oral candidates you have for NASH now, and just how they would -- how you plan to develop them, how they might underplay potential combination stra",95,"Maybe just changing the topic a little bit. That question for Norbert. I was hoping you just speak to the 3 oral candidates you have for NASH now, and just how they would -- how you plan to develop them, how they might underplay potential combination strategies? And as you kind of think about the larger sort of BD question that keeps being asked, do you have enough data on your internal programs to make decisions in terms of what additional products that might benefit your internal efforts in NASH and also in hep B?"
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","So Ian, actually, its 4 products that we have currently in early clinical studies, if you include the Nimbus compound. That deal, by the way, has not closed yet, but it should close in the next week. So we have the ASK inhibitor, the ACC 1 2 inhibitor, th",226,"So Ian, actually, its 4 products that we have currently in early clinical studies, if you include the Nimbus compound. That deal, by the way, has not closed yet, but it should close in the next week. So we have the ASK inhibitor, the ACC 1 2 inhibitor, the simtuzumab and then the FXR agonist. And we could, by the end of this year, be in 4 Phase II studies, really, in NASH to look at the effects of any one of these agents by themselves. And then we would also, at the same time, we are going to start combination studies to see, do we always have to say it, we believe in the 3 points of that disease pathogenisis. There is fibrosis inflammation and metabolic. We now have agents that address all of them. And we're absolutely -- our hypothesis is that ultimately, it's a complex biological disease, and probably more than one agent will be needed. And we're looking forward, maybe, sometime next year, we will then go into Phase III. With regards to BD, we're, of course, looking. At the moment, there is nothing out there that, I would say, we have to get. As I said, we have 4 components. We're going to look at those individually, and then, as the results come in, make decisions what else we would need."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","And then, what about hep B? There's a similar question. Just with the assets that you do have, I know that you've provided very little information or shared very little information with us. But just as you think about your internal portfolio, do you feel",61,"And then, what about hep B? There's a similar question. Just with the assets that you do have, I know that you've provided very little information or shared very little information with us. But just as you think about your internal portfolio, do you feel like you have the assets you need to move forward within and, obviously, capture the market?"
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","I would say, Ian, so we have, as you know, 4774, that's the 4774 would be a --  4779 that's the GlobeImmune vaccine. We've presented the data at the last AASLD showing that, at least, in biologically-suppressed patients it did not lead to a reduction in """,146,"I would say, Ian, so we have, as you know, 4774, that's the 4774 would be a --  4779 that's the GlobeImmune vaccine. We've presented the data at the last AASLD showing that, at least, in biologically-suppressed patients it did not lead to a reduction in ""s"" antigen. We have currently going to study in treatment-nave patients. We can have 9620 to TLR7 agonist in Phase II as well or Phase IIa. And then we have 2 other internal programs that we haven't disclosed yet. They are pre-IND, but we have identified with 2 different mechanisms, molecules that we want to develop or evaluate in human clinical studies. But having that said, it's early, I mean, as a general statement, in hepatitis B cure. And we are really having a very open mind and looking outside what else is there potentially that would fit our portfolio."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Terence Flynn of Goldman Sachs.",11,"And our next question comes from Terence Flynn of Goldman Sachs."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I was just wondering, you mentioned this 25,000 to 30,000 per month number of patients coming into treatment. And then you gave us the new diagnosis last year in the U.S. And so that equates to about 17,000 per month. So is it safe to assume that of the n",100,"I was just wondering, you mentioned this 25,000 to 30,000 per month number of patients coming into treatment. And then you gave us the new diagnosis last year in the U.S. And so that equates to about 17,000 per month. So is it safe to assume that of the new patients coming out of treatment, half are newly diagnosed and half are coming from the currently diagnosed pool? Am I thinking about that the right way? And then the second question was, just can you tell us the percentage of patients that are getting 8 weeks of therapy this quarter?"
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Terence, yes, I think, broadly speaking, your maths sum is correct on that. I mean, it's hard to tell exactly where the patients are coming from. But I think, mathematically, that sounds about right. Sorry, what was the second question?",40,"Terence, yes, I think, broadly speaking, your maths sum is correct on that. I mean, it's hard to tell exactly where the patients are coming from. But I think, mathematically, that sounds about right. Sorry, what was the second question?"
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","[indiscernible]",1,"[indiscernible]"
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Yes, Sorry, 8 weeks.",4,"Yes, Sorry, 8 weeks."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes, sorry, 8 weeks. We've drifted slowly but surely upwards on the 8 weeks. I think we're about 43%. Now I've got to emphasize the data we have is called intent to treat rather than actual prescriptions. So the intent to treat in the U.S. is about 43%. T",74,"Yes, sorry, 8 weeks. We've drifted slowly but surely upwards on the 8 weeks. I think we're about 43%. Now I've got to emphasize the data we have is called intent to treat rather than actual prescriptions. So the intent to treat in the U.S. is about 43%. The epidemiology, as we've previously said, would probably suggest that about half genotype 1 patients would fall into the criteria that would trigger off 8-week treatment."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Jim Birchenough of Wells Fargo.",11,"And our next question comes from Jim Birchenough of Wells Fargo."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Bit of a maintenance question and then a more meaningful question. On the maintenance side, you referred to a, kind of shift from 24 weeks to 8 weeks. Could you breakdown the 8-, 12- and 24-week treatment numbers in HCV, and where you see that heading? An",101,"Bit of a maintenance question and then a more meaningful question. On the maintenance side, you referred to a, kind of shift from 24 weeks to 8 weeks. Could you breakdown the 8-, 12- and 24-week treatment numbers in HCV, and where you see that heading? And a more meaningful question is NASH is obviously an important part of your future growth strategy. FXR is in that category. How confident are you that you can separate out the metabolic effects of excess FXR agonism versus just beneficial effects plus the basis for that [indiscernible] and when will you see that data?"
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. We're not going to break down the weeks of therapy. I mean, I just said, what do we think the 8-week amount is. But the rest you'll have to just model yourself. I'll now hand over to Norbert for the second question.",43,"Yes. We're not going to break down the weeks of therapy. I mean, I just said, what do we think the 8-week amount is. But the rest you'll have to just model yourself. I'll now hand over to Norbert for the second question."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","So Jim, as you know, steroid FXR agonist do many, many things. Not only in the liver, but also in other target organs. So our philosophy is that we have an FXR agonist that purely acts at the level of the G.I. So it does not get totally absorbed to any me",179,"So Jim, as you know, steroid FXR agonist do many, many things. Not only in the liver, but also in other target organs. So our philosophy is that we have an FXR agonist that purely acts at the level of the G.I. So it does not get totally absorbed to any meaningful degree. And then what it does, at the level of the G.I., it releases FGF 19. And we believe that FGF 19 does everything that it needs to do in order to impact on NASH. That's our hypothesis, and we're testing that. And we should have data available in the fourth quarter of this year. So that's a fairly easy experiment to do. You simply look at bioavailability, which is below but the FGF-19 might be increased to FGF-19 levels with some of the consequent metabolic effects. That way, we also think we can prevent pruritus. We can prevent the cholesterol effects. We can prevent alkaline phosphor decelerations et cetera. And so, if this all is true, it should be a much safer and cleaner FXR agonist."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","And Norbert, when is the forum for that data release? And I guess, what are the next steps for that program? How far behind are you from things that are in Phase III right now of the FXR agonist?",39,"And Norbert, when is the forum for that data release? And I guess, what are the next steps for that program? How far behind are you from things that are in Phase III right now of the FXR agonist?"
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","We could probably have some of the preliminary data at AASLD. And we will then move into Phase III soon after that. So we're not that far behind other companies.",30,"We could probably have some of the preliminary data at AASLD. And we will then move into Phase III soon after that. So we're not that far behind other companies."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from the line of Alan Carr of Needham & Company.",14,"And our next question comes from the line of Alan Carr of Needham & Company."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Wondering if you can talk a bit more about the new diagnoses in 2015 that you mentioned. So there was around 200,000. Do you have any other details around that, about where they were found or, I guess, trend over the course of the year? Is it increasing?",48,"Wondering if you can talk a bit more about the new diagnoses in 2015 that you mentioned. So there was around 200,000. Do you have any other details around that, about where they were found or, I guess, trend over the course of the year? Is it increasing?"
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","I don't have a lot of details at my fingertips actually, Alan. I would say, just to build on what Norbert was saying earlier, the interactions we're having with many people working on diagnosis projects around the country are that there's a lot of -- surp",151,"I don't have a lot of details at my fingertips actually, Alan. I would say, just to build on what Norbert was saying earlier, the interactions we're having with many people working on diagnosis projects around the country are that there's a lot of -- surprisingly high level of positive diagnosis in some of the urban centers and in ER rooms, in particular, in those urban centers, where diagnosis rates have been double, at least, what evenly, you know, local investigators have anticipated. Why that is, I'm not sure. But this has been consistent throughout the country. So I would say that diagnosis rates, the 200,000, would grow rather than shrink, certainly for the next few years. And this is great effort, of course, now to encourage diagnosis because people know that, at the end of it, they're going to be treated and have a higher probability of being cured."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And we have time for one final question. Our last question comes from the line of Tony Butler with Guggenheim.",20,"And we have time for one final question. Our last question comes from the line of Tony Butler with Guggenheim."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Norbert, very quickly, if you could. Recognizing that Nimbus closes next week, has there not been other ACC inhibitors, which have actually failed? And if that's true, what might be unique about the Nimbus program? I understand it may attack a different p",61,"Norbert, very quickly, if you could. Recognizing that Nimbus closes next week, has there not been other ACC inhibitors, which have actually failed? And if that's true, what might be unique about the Nimbus program? I understand it may attack a different part of the molecule, which would be interesting for you to elaborate on, if that is indeed the case."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. So Tony, you're exactly right. There have been previous ACC programs at Merck and Pfizer. They have not been successful. And the reason had to do with the specificity. This compound is really unique. It's a known animal or inhibitor for both ACC 1 an",222,"Yes. So Tony, you're exactly right. There have been previous ACC programs at Merck and Pfizer. They have not been successful. And the reason had to do with the specificity. This compound is really unique. It's a known animal or inhibitor for both ACC 1 and ACC 2. And it inhibits not only the pathway that goes to de novo lipogenesis, so you know, [indiscernible] coenzymate production, but it also inhibits the level of the mitochondrium. It stimulates, I might say, a lipid asset beta oxidation. So it does really 2 things. It inhibits the formation of lipids, palmitate mostly, and at the same time, it stimulates the beta oxidation of lipids. And so we are -- there has been some anecdotal reports from the Pfizer compound that inhibition of ACC 1 and 2 results in a decrease in liver fat. That's, by the way, something we would do as one of the next experiments. We would look by MRI, on reduction of -- we've already shown at AASLD presentation that it inhibits lipogenesis. Now we have to show, also, that it inhibits lipid -- fat content of the liver. So fairly straightforward and an easy experiment to do. And I think once we've shown that, we have pretty high confidence that there would be a meaningful clinical benefit of the compound."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you [indiscernible], and thank you all for joining us today. We appreciate your continued interest in Gilead. And the team here looks forward to providing you with updates on our future progress.",33,"Thank you [indiscernible], and thank you all for joining us today. We appreciate your continued interest in Gilead. And the team here looks forward to providing you with updates on our future progress."
29002,330109201,966828,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program and you may all disconnect. Have a great day, everyone.",25,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program and you may all disconnect. Have a great day, everyone."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences First Quarter 2016 Earnings Conference Call. My name is Candace, and I will be your conference operator today. [Operator Instructions] And as a reminder, this conference c",64,"Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences First Quarter 2016 Earnings Conference Call. My name is Candace, and I will be your conference operator today. [Operator Instructions] And as a reminder, this conference call is being recorded.
I would now like to turn the call over to Patrick O'Brien, Vice President of Investor Relations. Please go ahead."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Candace, and good afternoon, everyone. Just after market closed today, a press release was issued with earnings results for the first quarter of 2016. The press release and detailed slides are available on the Investor Relations section of the",221,"Thank you, Candace, and good afternoon, everyone. Just after market closed today, a press release was issued with earnings results for the first quarter of 2016. The press release and detailed slides are available on the Investor Relations section of the Gilead website.
Joining today's call will be John Milligan, President and Chief Executive Officer; Robin Washington, Executive Vice President and Chief Financial Officer; Paul Carter, Executive Vice President of Commercial Operations; and Norbert Bischofberger, Executive Vice President of Research and Development and Chief Scientific Officer.
Before we begin formal remarks, let me remind you that we will be making forward-looking statements, including plans and expectations with respect to products, product candidates, financial projections and the use of capital, all of which involve certain assumptions, risks and uncertainties that are beyond our control and could cause actual results to differ materially from these statements. A description of these risks can be found in the latest SEC disclosure documents and recent press releases. In addition, Gilead does not undertake any obligation to update any forward-looking statements made during this call.
Non-GAAP financial measures will be used to help you understand the company's underlying business performance. The GAAP to non-GAAP reconciliations are provided in the earnings press release as well as on the Gilead website.
I'll now turn the call over to John."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Patrick, and thank you, everyone, for joining us today. While we want to keep our remarks relatively brief to allow plenty of time for your questions, I do want to make a few comments about the first few months of 2016 and what I see as the out",1044,"Thank you, Patrick, and thank you, everyone, for joining us today. While we want to keep our remarks relatively brief to allow plenty of time for your questions, I do want to make a few comments about the first few months of 2016 and what I see as the outlook for the rest of the year.
Gilead's HIV franchise is off to a great start with the recent U.S. FDA approvals of Odefsey and Descovy, which followed the approval of Genvoya late last year. Over the last 6 months, I've had the opportunity talk with physicians and patients about the importance of having highly effective and safer options, especially for patients facing a lifetime of therapy.
With the approval of our 3 new regimens, we are now able to offer a range of options to address the diverse medical requirements of people with HIV, including those new to treatment, those who've been on therapy for a long time and have run short of options and those who desire to switch medications for a variety of reasons.
Since 2001, Gilead therapies have played a transformative role in changing HIV infection from a fatal and debilitating disease into a chronic and manageable condition. That's true around the world, as broader access to HIV treatment has helped divert millions of AIDS deaths.
Innovation remains important in the continuing fighting of HIV, and we're proud that Descovy is the first new backbone approved by the FDA in more than a decade.
Gilead continues the commitment to helping HIV patients around the globe with our research and development activities, including novel agents for daily treatment, long-acting regimens and HIV cure.
In liver disease, we just wrapped up an exciting week in Barcelona at the International Liver Conference (sic) [ International Liver Congress
], or EASL, as it's known. It was a remarkable meeting, especially considering the significant change in the HCV treatment landscape since the conference was held last in Spain 4 years ago. The outlook for patients has completely changed with dramatic improvements in cure rates for a wider range of patients.
Presentations at EASL included results from several Phase II and Phase III studies evaluating sofosbuvir/ledipasvir and sofosbuvir/ledipasvir plus GS-9857. These are 2 investigational pan-genotypic fixed-dose combination therapies for the treatment of HCV.
The data presented continues to underscore the high cure rates and safety of our sofosbuvir-based therapies and support their utility across all HCV patient genotypes in a wide range of disease stages.
Data were also presented on the use of TAF for patients with chronic hepatitis B infection. 48-week results from 2 Phase III studies demonstrate its potential to advance the treatment of HPV, offering a similar efficacy profile to Viread with improved bone and renal safety parameters. Based on these results, we submitted a new drug application for TAF, and FDA has set a PDUFA date of November 11.
We also submitted regulatory applications for TAF in the European Union and Japan last quarter.
I'm particularly encouraged by the work that's going on in NASH, which we've augmented with our agreement to acquire the Nimbus Acetyl-CoA Carboxylase, or ACC, program, as was announced last month. NASH affects up to 15 million people in the U.S. and is expected to become the leading indication for liver transplantation by 2020.
Including the ACC program, Gilead has 4 investigational compounds that target unique disease pathways, including production of lipids, inflammation and fibrosis, each of which are thought to contribute to or cause NASH. Data in EASL represented support in the development of Gilead's investigational agents for the treatment of NASH, including simtuzumab, a monoclonal antibody that is selected for LOXL2, which is also being evaluated in primary sclerosing cholangitis; GS-4997, an ASK1 inhibitor; and GS-9674, an FXR agonist. Nimbus also presented positive Phase I data for the program's lead candidate, NDI-010976, which targets ACC, the key step in lipid biosynthesis pathway.
Overall, I'm enthusiastic about the future of Gilead and excited to have the opportunity to help build on the company's long history of success. Over the past few months, I've had conversations with external stakeholders and employees across all parts of our organization. It's gratifying to see the extent to which Gilead's products and commitment to access have uniquely changed the course of diseases for so many people throughout the world. We now have the opportunity to do so again in many new areas.
A few things stood out during the conversation. First, physicians and patients share the excitement that our medical and commercial teams have regarding Gilead's new treatment options for HCV and HIV, particularly the new TAF-based therapies. Access continues to improve for people with HCV around the world, and in fact, we have treated close to 1 million patients with sofosbuvir-based regimens since Sovaldi was first approved in late 2013. That's a remarkable achievement in just over 2 years.
With regards to HIV, as many of you are aware, TAF was added to the Medicines Patent Pool and to our various Access Programs. The clinical data suggest TAF-based regimens may be the best option in both the developed and developing world. We will build on success we've had with the TDF-based regimens, now used by nearly 10 million people every single day, to make TAF regimens accessible around the world, providing much-needed new options.
Secondly, I believe we have a rich pipeline, creating opportunities that may allow the transformation of the treatment of many diseases like NASH, HPV, inflammatory diseases, certain cancers and cardiovascular conditions, for which few, if any, options exist.
We are committed to building on our company's long history of success, and I'm confident that our innovation and hard work will deliver on our shared goal of delivering new treatments and providing broad access to Gilead's medicines for patients in need.
Finally, we continue to look for business development opportunities that add to our core therapeutic areas and are a fit with Gilead's expertise and capabilities. We are actively assessing options and we'll make moves when the right opportunities present themselves.
I will now turn the call over to Robin, who'll provide an overview of our financial results for the quarter. Robin will be followed by Paul, who'll provide additional color on the company's performance across products and geographies."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, John, and good afternoon, everyone. We are pleased to report our first quarter results with non-GAAP diluted earnings per share of $3.03 per share compared to $2.94 for the same period last year. Total revenues for the quarter were $7.8 billion, u",930,"Thanks, John, and good afternoon, everyone. We are pleased to report our first quarter results with non-GAAP diluted earnings per share of $3.03 per share compared to $2.94 for the same period last year. Total revenues for the quarter were $7.8 billion, up 3% year-over-year and down 8% sequentially. Product sales for the quarter were $7.7 billion, up 4% year-over-year and down 9% sequentially.
Starting with HIV and other antivirals. Product sales for the first quarter increased to $2.9 billion, up 19% year-over-year, primarily driven by increased sales in the U.S.
We continue to see strong uptake of our newer single-tablet regimens, including Genvoya, which was launched in November 2015. Additionally, year-over-year, Stribild and Complera grew 34% and 19%, respectively.
Sequentially, these sales decreased 4% primarily driven by sub-wholesaler inventory decreases in the U.S., reflective of the seasonal inventory pattern from quarter 4 to quarter 1.
HCV product sales for the first quarter decreased 6% year-over-year to $4.3 billion primarily driven by a decrease in Harvoni sales in the U.S., which was partially offset by the launch of our HCV products in Japan and other international markets.
In the U.S., the year-over-year Harvoni sales decline was driven by lower patient starts and the full-quarter impact of higher commercial rebates, which were entered into during the first quarter of 2015.
Sequentially, HCV product sales decreased 12%, primarily driven by revenue declines in the U.S. and Japan. In the U.S., the decline was due to the increase in discounts required to open up access to patients with lower fibrosis scores and a modest shift in payer mix towards more deeply discounted government payer segments.
In addition, revenue was further impacted by higher-than-expected prior quarter rebate claims. Rebate claims come in 1 to 2 quarters in arrears and were updated in Q1 to reflect the higher claims received.
In Japan, Sovaldi volumes declined from high early-launch levels, similar to other markets, and channel inventory pricing for Sovaldi and Harvoni was adjusted during March for the mandatory price reduction effective as of April 1.
Turning to our other therapeutic areas. Product sales of cardiovascular, respiratory and other were $498 million, up 19% year-over-year and down 5% sequentially.
Moving to gross margin. Non-GAAP product gross margin was 87.2% for the first quarter of 2016 compared to 90.9% for the same period last year. The decrease reflects a $200 million charge or $0.12 earnings per share related to the jury verdict in the Merck trial in March. Although the proceedings in the Merck trial are not complete and the losing party will appeal once the court enters judgment, we booked the charge to comply with accounting rules related to contingencies.
Now turning to expenses. Non-GAAP R&D expense -- expenses were $769 million for the first quarter, up 18% compared to the same period last year, due to the continued progression of clinical studies, particularly in liver disease and HIV. Non-GAAP SG&A expenses were $638 million for the first quarter, up 6% compared to the same period last year. These expenses increased primarily due to higher costs to support the growth of Gilead's business and were offset by favorable adjustments related to the Branded Prescription Drug fee of $191 million, following the receipt of the preliminary 2016 IRS invoice.
From a balance sheet perspective, during the first quarter, we generated cash flows from operations of $3.9 billion and ended the quarter with $21.3 billion in cash and investments.
We continue to return capital to our shareholders through dividends and opportunistic share repurchases. Earlier this afternoon, we announced that our Board of Directors declared a dividend of $0.47 per share for the second quarter of 2016, an increase of 10% from the prior quarter. $8 billion in cash was utilized to repurchase shares of our common stock during the quarter, consisting of $3 billion of open-market repurchases or 33.4 million shares, and $5 billion under the accelerated share repurchase program, ASR, that we announced in February. 46.1 million shares were repurchased under this program during the quarter. The final settlement of the ASR program was completed earlier this month, and we received an additional 8.1 million shares. In total, 54.3 million shares were retired under the ASR program at an average price of $92.09 per share.
As of March 31, the amount of capital returned to shareholders, consisting of dividends and share repurchases, exceeded the total amount of capital returned during the first 3 quarters of 2015 combined.
During the quarter, we completed a $15 billion share repurchase program approved by our board in January 2015 and, as of April 1, have begun repurchasing shares under our $12 billion 2016 share repurchase program approved in January of this year.
Since 2012, we've repurchased over 260 million shares or 17% of shares outstanding.
Finally, we are reiterating our full year 2016 guidance provided to you on February 2 and summarized on Slide 25 in the earnings results presentation available on our corporate website.
As a reminder, guidance for product sales is subject to a number of uncertainties, including an uncertain global macroeconomic environment; adoption of additional pricing measures to reduce HCV spending; volatility in foreign currency exchange rates; inaccuracy in HCV patients start estimates; additional competitive launches in HCV; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; and a larger-than-anticipated shift in payer mix to more highly discounted payer segments such as PHS, FFS, Medicaid and the VA.
I will now turn the call over to Paul to provide more details on our commercial results for the quarter."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, Robin, and good afternoon, everyone. Our commercial performance remained strong through the first quarter. I'd like to start with HIV and Genvoya, the first of our TAF-based single-tablet regimens. We're pleased with the launch of Genvoya, both in",1504,"Thanks, Robin, and good afternoon, everyone. Our commercial performance remained strong through the first quarter. I'd like to start with HIV and Genvoya, the first of our TAF-based single-tablet regimens. We're pleased with the launch of Genvoya, both in the U.S. and in the European markets where we've achieved reimbursement.
Starting with the U.S. Through 5 months post the launch of Genvoya, cumulative prescriptions were twofold more than any HIV product from any company since Atripla, which was the first single-tablet regimen to come to market back in 2006. As expected, most of Genvoya's initial prescriptions came from switches. Qualitative feedback from HIV prescribers is very encouraging in indicating a clear intent to switch patients at the earliest opportunity.
Stribild and Complera showed strong year-over-year prescription growth at 18% and 5%, respectively. And in quarter 4 2015, Stribild was the leading product in the U.S. for patients nave to treatment. With the launches of Genvoya and now, just very recently, Odefsey, we expect switches out of TDF-based single-tablet regimens into the TAF regimens to grow significantly. In fact, 82% of Genvoya's prescriptions have been switches. 49% of the switches have come from Stribild.
We are seeing an improvement in our ability to retain switch patients, meaning, fewer patients who switch from Gilead TDF-containing regimens move to non-Gilead products. Of all the patients who switched to Genvoya, 91% came from a Gilead regimen, and 9% came from a non-Gilead product.
In addition to switches, preliminary quarter 1 2016 data indicate to us that Genvoya may soon be among the most prescribed products of patients new to treatment.
Historically, in quarter 1, we've seen a decrease in sub-wholesaler inventories following a buildup in the prior quarter. We observed this effect again this year, leading to a sequential decrease in HIV product sales.
Finally, in the U.S., I'd like to highlight the growing use of Truvada for PrEP, which was more than 20% of Truvada demand last quarter and drove a 17% year-on-year growth in prescriptions.
Turning to Europe. We're also pleased with the way that our HIV business is performing with successful reimbursement and launches of Genvoya in several countries, including Germany and the Nordics. In other countries, Stribild and Eviplera continue to replace Atripla. Stribild remains the most prescribed regimen for patients nave to treatment in the EU, with Eviplera in third place.
Genvoya was launched in Germany during quarter 1, and at the end of the quarter, preliminary data indicate it had the leading market share for both nave and switch patients. The product was launched and fully reimbursed in Spain just 2 weeks ago. And we're very excited about the opportunities to offer providers another important option to address the needs of their patients. It's also been recognized as a preferred regimen in numerous country guidelines, including Germany, Spain and Italy, even before reimbursement has been agreed. This is testament to the favorable clinical profile of Genvoya, a single-tablet regimen that better addresses the needs of patients who require long-term chronic therapy. We're working hard to negotiate timely reimbursement across the rest of the European markets.
Finally, in HIV, we launched Descovy this month in the U.S. and the EU. We see this launch as a milestone in HIV treatment, as Descovy is the first new NRTI backbone since Truvada 10 years ago. Given the very high use of Truvada as a preferred backbone with third -- multiple third agents, including Tivicay, we're confident that Descovy will quickly replace Truvada and become the leading HIV regimen backbone in all our markets.
Now moving to hepatitis C. We continue to see revenue dynamics around the world, which vary by country. As Robin noted, our overall HCV product revenue decreased 6% year-over-year and 12% sequentially.
I'll now describe the different dynamics by geographic region, starting with the U.S. market. We've seen an increase of new patients in the first quarter, offset by lower revenue per patient due to several factors that include an increase in our gross-to-net adjustments as well as a shortening average duration of therapy.
Total market patient starts increased around 10% over Q4 to an estimated 55,000 in Q1. This was primarily driven by the continued opening of access across payer segments to allow for the treatment of patients with low fibrosis scores as well as an increase in treatment by the VA during the second half of the quarter as funding made its way to the various VA sites. The revenue associated with this increase in patient starts was partially offset by an increase in discounts associated with our contracted -- contract agreements entered into during the first quarter of 2015, which provide for additional discounts if access is provided to a broader patient population. We also saw a gradual shift to more deeply discounted payer segments, such as VA, PHS and Medicaid, compared to the prior quarter.
In addition, revenue was further impacted by higher-than-expected prior quarter rebate claim, which come in 1 to 2 quarters in arrears and were updated in quarter 1 to reflect the higher claims received. The average duration of therapy has shortened as fewer patients require 24 weeks of treatment and a higher proportion of genotype 1 patients are treated for 8 weeks, resulting in slightly lower revenues for patients.
The ability to treat for 8 weeks, notably, has a strong competitive differentiation. In fact, our market share remained strong with more than 90% of all patients treated in the quarter being prescribed by the Harvoni or Sovaldi. Qualitative feedback suggests that prescribing HCV physicians are encouraged by the fact that real-world outcomes mimic the experience in clinical trials.
Several presentations of real-world data at EASL reinforce what has been seen in clinical practice.
As we think about the rest of the year in the U.S., patient flow peaked in quarter 1 2015 then declined in quarter 2 and stabilized in quarter 3 and quarter 4 of 2015. In quarter 1 of 2016, there was an uptick in new patient starts. Our data showed that 25,000 to 30,000 patients a month are entering treated care, which exceeds the number of patients starting therapy on a monthly basis. That means there are many more people who could benefit from treatment who are already linked to care. We expect new patient starts to remain consistent through the rest of 2016.
Despite the number of patients treated today, there are still over 3,000 -- 3 million, I'm sorry, patients in the U.S. who have yet to be treated. About half of these patients are undiagnosed. Education and awareness efforts to increase rates of diagnosis are important. And as we well know from public health efforts in the HIV area, these efforts play out over many years. We're encouraged to see data that screening and diagnosis rates have increased at least twofold over the last 5 years.
Now turning to Europe. Total HCV revenue in Europe was down 13% year-over-year and down 1% sequentially. While overall Gilead patient starts increased 5% sequentially to around 31,000 in the quarter, average revenue per patient declined due to a shift in geographic mix and shorter average treatment duration. We also saw a negative foreign exchange movement, which affected HCV revenues by about 8% year-on-year and 3% sequentially.
The mix of sales in the EU is such that more patients are now being treated in countries which have lower net prices per patient. European countries continue to vary significantly in terms of patient access with many still limiting treatment to patients with high fibrosis scores. We anticipate that as sicker patients are treated, these restrictions will start to loosen as healthier patients can be cared for within existing budgets.
Again, as in the U.S., we treat just a small fraction of patients diagnosed. We are encouraged by ongoing efforts and commitments by governments to increase diagnosis and treatments across Europe.
Now moving to Japan. Revenue was over $1 billion during the quarter. We're pleased with the successful launches of Sovaldi and Harvoni where a strong patient flow and high market shares continued through quarter 1. More than 30,000 patients were treated with Gilead products during the quarter, representing a market share greater than 90%.
Other markets where we recently launched our HCV products include Australia where nearly 5,000 patients started treatment in Q1. This reflects a strong commitment by the Australian government to address their HCV burden and the usual warehousing of patients prior to the launch of sofosbuvir-based regimens.
In closing, our underlying HCV business is strong and sustainable. We've treated around 700,000 patients in the U.S., Europe and Japan. And despite strong competition, Gilead has maintained high market shares in all regions.
The Gilead commercial organization is focused on executing our numerous HIV and HCV product launches across multiple geographies during the remainder of the year. In addition to our 3 TAF-based HIV products, we're preparing to launch our pan-genotypic HCV product as early as next quarter in the U.S.
Thank you, and now let's open the call for questions. Operator?"
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Geoff Meacham of Barclays.",15,"[Operator Instructions] And our first question comes from the line of Geoff Meacham of Barclays."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Seems like lower revenue per patient is -- was one of the bigger contributors to the sequential trends, so a couple of questions. Was the -- what was the initial outlook for higher volumes coming from commercial patients just with respect to broader acces",74,"Seems like lower revenue per patient is -- was one of the bigger contributors to the sequential trends, so a couple of questions. Was the -- what was the initial outlook for higher volumes coming from commercial patients just with respect to broader access for F0 in F1? And then, was the volume contribution this quarter pretty meaningful from the VA system? Just want to get a sense for the sequential trends there, too."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Geoff, so yes. So several things happened in the quarter with -- in relation to volume and revenue per patient. So maybe I'll try and deal with all of them. So the first thing, as you've said, we had -- and we expected this and hoped for it, that several",436,"Geoff, so yes. So several things happened in the quarter with -- in relation to volume and revenue per patient. So maybe I'll try and deal with all of them. So the first thing, as you've said, we had -- and we expected this and hoped for it, that several of the large commercial payers opens up access to patients regardless of their fibrosis scores during quarter 1. The consequence of that was that they triggered a discount that had been previously negotiated in order to incentivize that opening up of restrictions. So that was the first thing. And then the VA, as you know, treated very few patients in quarter 4 last year because of lack of funding. That funding was agreed for a 2-year period and focused on HCV medicines and was clarified late December. Than the VA went through a process of evaluating the clinical evaluation of products available from not just us but, obviously, new entrants to the market, and that process took through until mid to late January. And we have to negotiate with the VA, and we did give the VA some extra discounts, which resulted in them putting our products on their formulary and also opening up, again, access to all patients within the VA. So there are no restrictions on patients. And again, we see this as a large positive. And as those funding got distributed around the VA centers, we start to see a very large uptick in VA treatment from about the middle of the quarter, and we anticipate that, that will continue through the year. The second kind of area that happened, of course, was we have the entrance of Merck into the market. And so we judiciously exercise our contractual right to preserve access. And in a few cases, we did increase a little bit of discount to some payer to ensure that Harvoni, in particular, remains on formularies and with full access. The third thing I think we've seen, as I indicated in the comments, was a slight and gradual shift of payer mix away from the commercial and Medicare Part D payers towards the more government payers. And that was probably about a 10% shift from quarter 4 to quarter 1. And then the final piece, as we indicate, is we did have a catch-up, a true-up of some rebate claims that came, in respect to quarter 3 and quarter 4, that were a little bit higher than we estimated last quarter and which we put right during quarter 1. So that really is the dynamic between volumes and revenue per patient."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Mark Schoenebaum of Evercore ISI.",11,"And our next question comes from Mark Schoenebaum of Evercore ISI."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Everyone's very focused on what you're going to do with your cash, PD, M&A. So I have actually one simple question, probably for John. Would you be willing to go hostile? And if not, why not? How do you feel about that? Because clearly, overhearing is tha",67,"Everyone's very focused on what you're going to do with your cash, PD, M&A. So I have actually one simple question, probably for John. Would you be willing to go hostile? And if not, why not? How do you feel about that? Because clearly, overhearing is that the small companies won't engage right now because they don't like evaluations, but the larger companies are very interested."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Mark, it's John. Mergers and acquisitions are always a process, and so the ability to go hostile is limited by how much data or how much cooperation you need. And so in each situation, you'd have to kind of think about what do I need to know about the pip",101,"Mark, it's John. Mergers and acquisitions are always a process, and so the ability to go hostile is limited by how much data or how much cooperation you need. And so in each situation, you'd have to kind of think about what do I need to know about the pipeline or about things that are not public about a company in order to be comfortable making sort of a public offer for the company. But that being said, we've never declared ourselves unwilling to go hostile. I do prefer a friendly process, but it would just depend on the situation itself."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Geoffrey Porges of Leerink Partners.",11,"And our next question comes from Geoffrey Porges of Leerink Partners."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I guess a follow-up on that question. You've invested, looks like, about $19 billion or $20 billion over the last year, reducing your share count. And the share count has come down by about 10%. But your EPS is pretty much flat, maybe up low single digits",98,"I guess a follow-up on that question. You've invested, looks like, about $19 billion or $20 billion over the last year, reducing your share count. And the share count has come down by about 10%. But your EPS is pretty much flat, maybe up low single digits versus last year. Are you convinced that, that's the best use of your capital? You've got $21 billion in cash and about the same amount of debt. So are you going to revisit that? Or is that more or less the path that you believe generates the best returns here?"
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Geoff, I think that was directed to me, but I'm going to let Robin answer the first part of the question.",21,"Geoff, I think that was directed to me, but I'm going to let Robin answer the first part of the question."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Geoff, it's Robin. I think, as we've said all along, we've looked at how we leverage our cash as not only being share repurchases and dividends, but also, we consistently look at investing in our core pipeline as well as M&A where appropriate. And similar",167,"Geoff, it's Robin. I think, as we've said all along, we've looked at how we leverage our cash as not only being share repurchases and dividends, but also, we consistently look at investing in our core pipeline as well as M&A where appropriate. And similar to the amounts that you called out relative to cash, it's actually about 17% reduction in share count, as I mentioned on the call. We have done a lot of M&A as well, and I think we'll continue to do that, as John said, when the right opportunities present theirselves. So I think we've always been fairly clear that we're balancing, doing all of those things and purposely focused on share repurchases because, in the absent of M&A, it allows us to be flexible and more opportunistic. But when the right M&A opportunities present theirselves, it allows us to reduce our share repurchases in order to make those necessary acquisitions and leverage our cash and debt and borrowing if we need to."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. It's just, for us, it's fairly simple. We have the flexibility to do both things, that is returning shareholder value through stock repurchases and dividends and, of course, continue to be opportunistic in M&A. How we're deploying it is sort of a ref",107,"Yes. It's just, for us, it's fairly simple. We have the flexibility to do both things, that is returning shareholder value through stock repurchases and dividends and, of course, continue to be opportunistic in M&A. How we're deploying it is sort of a reflection of the things we're interested in. I think, for example, the Nimbus acquisition, while relatively small, could bring a very, very unique product to us and something that we had focused on during the quarter. We're continuing to look for opportunities like that, and we will continue to aggressively look for opportunities to deploy our cash and investing in things other than Gilead."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Michael Yee of RBC Capital Markets.",12,"And our next question comes from Michael Yee of RBC Capital Markets."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Wanted to revisit some questions that was talking about related to price and volume. You did mention on a positive that net new patient starts were up about 10%, which is great, but then the total revenues in U.S. declined by 11%. So someone could do the",98,"Wanted to revisit some questions that was talking about related to price and volume. You did mention on a positive that net new patient starts were up about 10%, which is great, but then the total revenues in U.S. declined by 11%. So someone could do the math and imply that price was down 10% to 20%. And I -- can you comment on that or maybe just describe where you think the price volume equation was in the quarter? And how we should think about net price changing quarter-over-quarter, and how that should change over the year?"
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes, Michael. I mean, I think we are in a much more stable place than we were 1 year ago at this time. I think I described it just now. We've made some contractual moves, which have opened up access. We're very happy about that. We're happy that some of t",171,"Yes, Michael. I mean, I think we are in a much more stable place than we were 1 year ago at this time. I think I described it just now. We've made some contractual moves, which have opened up access. We're very happy about that. We're happy that some of the government payers are beginning to treat a few people. We were very happy about the VA, in particular, ramping up its treatment levels. I said that we'd had to compete in the VA, and we did that. But we're enjoying very high market shares wherever physicians have the choice of prescribing. And that's always been our aim, to make sure that physicians and patients can choose what drug they think's appropriate. And wherever that's the case, Gilead seems to do pretty well. So I would say, looking forward, we're in a fairly stable place now. I mean, clearly, over time, as competition increases, prices are likely to incrementally move in one direction, I would think. But I think we're stable."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","So on one side, we're getting lots of access, but on the other side, my math is not totally off, just to be fair?",24,"So on one side, we're getting lots of access, but on the other side, my math is not totally off, just to be fair?"
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Correct.",1,"Correct."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from the line of Cory Kasimov of JPMorgan.",13,"And our next question comes from the line of Cory Kasimov of JPMorgan."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Going back to the strategic theme, you've talked in the past about wanting to be a leader in oncology. But given the issues you've had with Zydelig and the leadership changes you've also had, are you as committed to that space as you once were? And if so,",64,"Going back to the strategic theme, you've talked in the past about wanting to be a leader in oncology. But given the issues you've had with Zydelig and the leadership changes you've also had, are you as committed to that space as you once were? And if so, what's your thought on the potential opportunities you see out there between solid tumors and hemog?"
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Cory, it's John. That's, of course, a big question. So if you think about where we are in our oncology portfolio, we haven't focused heavily on a number of activities around these kinase inhibitors and have actually behind Zydelig a number of opportunitie",199,"Cory, it's John. That's, of course, a big question. So if you think about where we are in our oncology portfolio, we haven't focused heavily on a number of activities around these kinase inhibitors and have actually behind Zydelig a number of opportunities are moving into clinic, including our Syk inhibitor, our BTK inhibitor. I should probably let Norbert go on about this, but I would say we have numerous opportunities that we're continuing to pursue. You have mentioned we want to be a leader in oncology. We think of oncology as one leg of a future company that could be important to us, along with our investments in NASH and inflammatory diseases. We do see some good opportunities out there, and we see some good opportunities internally. So I don't -- the Zydelig setback hasn't changed our appetite for trying to do more transformative things in oncology. It was never going to be a franchise product like Viread or sofosbuvir but was a good beginning for us. And I really haven't changed my thought process around it as a result of the setback because of the toxicities we've seen.
Norbert, do you want to add anything to that?"
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","No. As John said, Zydelig has not only -- not decreased our appetite, it has increased our appetite to do more in oncology. And we're now at a point where a number of programs are coming to fruition. For instance, momelotinib, we're intending to file earl",134,"No. As John said, Zydelig has not only -- not decreased our appetite, it has increased our appetite to do more in oncology. And we're now at a point where a number of programs are coming to fruition. For instance, momelotinib, we're intending to file early next year. The Phase III studies are fully enrolled. We should get results at the end of this year. The anti-MMP-9 antibodies in Phase III for gastric cancer were at the end of dose ranging with combinations of PI3K Syk and Syk BTK, and that will move into frontline treatment. So we have a number of interesting things ongoing internally, and of course, as John said, we're continuously looking externally at finding suitable opportunities. And if the right opportunity comes along, then we will take advantage of it."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Brian Abrahams of Jefferies.",10,"And our next question comes from Brian Abrahams of Jefferies."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I was wondering if you could talk a little bit about hep C diagnostic initiatives and maybe some of the pull-throughs that you're seeing or might expect to see on patient identification. And I'm particularly curious if you have a sense, among the growing",80,"I was wondering if you could talk a little bit about hep C diagnostic initiatives and maybe some of the pull-throughs that you're seeing or might expect to see on patient identification. And I'm particularly curious if you have a sense, among the growing number of new patient starts, who may have been identified last year and are now getting access with fewer restrictions versus patients who are getting identified this year and coming on to treated care concurrently."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Shall I go ahead, John, maybe -- so it's actually very hard to tell when people are being diagnosed and who's been treated when. Anecdotally, I can tell you, and I was out visiting some doctors in California just last week, patients are -- there are plent",312,"Shall I go ahead, John, maybe -- so it's actually very hard to tell when people are being diagnosed and who's been treated when. Anecdotally, I can tell you, and I was out visiting some doctors in California just last week, patients are -- there are plenty of patients there that many people who are linked to care now. And with the fibrosis restrictions being dropped now, most physicians can treat, certainly in the commercial area and Medicare area, can treat whoever they want. One thing's clear, though, that there are still prior authorizations in place, and there's still a fair amount of office paperwork and bureaucracy that have to be put in place for each patient. Then as the patients themselves, many of whom just simply aren't quite mentally ready or psychologically ready to commit to their disciplined 8-week or 12-week treatment. And with these products, of course, if insurance comes on, keen to do it twice, they want to try to get it right first time. The doctors want to get it right first time, and the patients want to get it right first time. So we're seeing that some of the sort of delays in patient starting had to do with the patient just being ready to commit to sort of disciplined 8 or 12 weeks of patients (sic) [ treatment ]. On the diagnosis side, I mean, again, anecdotally, we just know that there's a lot of activities going on. A lot of people are telling us what's going on around the countryside, and we do see diagnosis rates increasing significantly. So I think that plenty of patients are being diagnosed, and there are plenty of patients coming into treatment. And there's a waiting list of patients at most offices. By the way, our estimate on diagnosis is about 200,000 new diagnoses happened in the U.S. last year."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes, Brian, I think I might want to add that we have a number of demonstration projects ongoing in the United States to look for places, institutions, populations and figure out what the diagnosis positivity would be. And it's surprising, we've identified",81,"Yes, Brian, I think I might want to add that we have a number of demonstration projects ongoing in the United States to look for places, institutions, populations and figure out what the diagnosis positivity would be. And it's surprising, we've identified some places like ER rooms that have 0 positivity rates or greater than 10%. We hope that those demonstration projects will then lead to a broader recognition of the value of diagnosis and identification of hepatitis C infected individuals."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from the line of Brian Skorney of Robert Baird.",14,"And our next question comes from the line of Brian Skorney of Robert Baird."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I guess, 2 quick ones. I know we talked a little bit about this at EASL, John, but just to refresh us the timeline in terms of when you think you can get a sofosbuvir-based regimens approved in China? How do you think about pricing that there to kind of c",105,"I guess, 2 quick ones. I know we talked a little bit about this at EASL, John, but just to refresh us the timeline in terms of when you think you can get a sofosbuvir-based regimens approved in China? How do you think about pricing that there to kind of capture a share of patients who are looking at a branded drug versus potentially penetrating further in. And then, just on the U.S. Have you guys heard anything in terms of a warehouse build in genotype 3 ahead of a soft value launch? Should we be expecting a small bolus of patients upon that approval?"
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","So Brian, I'll start with the China question. So in terms of timing for China, there is a fairly fixed process. And according to the recent processes, we could possibly have sofosbuvir in the market in 2017. As you may have seen, there are new -- the Chin",288,"So Brian, I'll start with the China question. So in terms of timing for China, there is a fairly fixed process. And according to the recent processes, we could possibly have sofosbuvir in the market in 2017. As you may have seen, there are new -- the Chinese government is working hard to try to accelerate review and approval of HCV drugs because currently, none are on the market of the direct acting antivirals, and that could help us accelerate the timelines into China. We are working on that. Particularly of interest to us would be accelerating the timeline for sofo/ledipasvir, because there are so many different genotypes in China. Genotyping is not common in China, and this could provide a very good option for the people of China. So that would -- there's hope, but we can't guarantee, of course, that we could accelerate that approval, to be honest in the current timeline, which is 2019. The Chinese market is fairly large. Between 10 million and 20 million people are thought to have HCV. I don't want to get into public discussions of pricing, but I do think there's a price volume relationship that would work for us and for the Chinese health system that could be very, very good for us both. And so that's what we're working towards, is access in China. Your second question was on warehousing for genotype 3 patients. Currently, a lot of genotype 3 patients are being treated with SOF in combination with Daclatasvir. And so that seems -- there seems to be fairly decent access for that. So looking at Paul, I don't think there's any real warehousing going on. But maybe you're more aware of it than I am."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Well, there's about 7% or 8% of the U.S. HCV epidemiology is genotype 3. I mean, we don't have any data on it, but certainly, we get -- I'm getting the impression from my team anecdotally, there is a little bit of warehousing, but not least because sofosb",100,"Well, there's about 7% or 8% of the U.S. HCV epidemiology is genotype 3. I mean, we don't have any data on it, but certainly, we get -- I'm getting the impression from my team anecdotally, there is a little bit of warehousing, but not least because sofosbuvir Daclatasvir is obviously a very expensive regimen. And, you know the hope is that the cost of the genotype 3 treatment will come down somewhat after SOF/VEL comes on to the market, which it is -- the PDUFA date is 28 of June. So people are thinking about that. So we're optimistic."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Phil Nadeau of Cowen and Company.",12,"And our next question comes from Phil Nadeau of Cowen and Company."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","A few questions on Japan. I know you said that there was some change in pricing because of the April 1 price decline this -- during the quarter. What other dynamics were going on in Japan during this quarter? Where do you think you are entering the bolus",103,"A few questions on Japan. I know you said that there was some change in pricing because of the April 1 price decline this -- during the quarter. What other dynamics were going on in Japan during this quarter? Where do you think you are entering the bolus in Japan? How much longer could that go? And then certainly I believe that there are price discounts that come in with a certain volume being reached. Would you like to assume that those could be hit in July, and what kind of dynamics do you expect to see in the Japanese market going forward?"
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","So we're very, very pleased with the execution of our launches in Japan. In terms of patient flow, the genotype 2 patients, which represent about 20% of the Japanese epidemiology in HCV, are beginning to stabilize now. So those are the patients being trea",255,"So we're very, very pleased with the execution of our launches in Japan. In terms of patient flow, the genotype 2 patients, which represent about 20% of the Japanese epidemiology in HCV, are beginning to stabilize now. So those are the patients being treated with Sovaldi. Those numbers -- we launched on May 25 last year. We initially had a bolus, and then those numbers came down through quarter 4. And quarter 1 is at a lower level than quarter 4. But we're seeing a stable flow of patients now in genotype 2, and we would anticipate that to be stable through the rest of the year. Genotype 1's treated by Harvoni. We've treated an enormous number of patients initially. We're not quite sure if the curve in Japan is identical to the sort of curves we've seen in the U.S. or other major markets. And that's because there was a DAA in the market for Harvoni, which did treat quite a few people. So there might not have been quite such a large amount of warehousing. In any case, we're seeing the Harvoni patient numbers coming down gradually, not quite as steep as some other markets. And yet, that's yet to stabilize. But I'm pretty sure, in fact I know it will stabilize at some time in the next quarter or 2. So that's how we're seeing. We treated about 30,000 patients during the quarter. So that number will -- it'll be there or thereabouts, I think, for the rest of the year."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","And what about the volume discounts? Are those going to come later in the year? And what kind of dynamics...",20,"And what about the volume discounts? Are those going to come later in the year? And what kind of dynamics..."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","I'm sorry, we're not anticipating any further price movements in this year in Japan.",15,"I'm sorry, we're not anticipating any further price movements in this year in Japan."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Matthew Harrison of Morgan Stanley.",11,"And our next question comes from Matthew Harrison of Morgan Stanley."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I had just 1 follow-up on Phil's question on Japan. Can you just be clear with us? The pricing that you talked about in March, was that the fullest end of the 30% price cut? Or will there be more in April? Just so we can understand how much was reflected",104,"I had just 1 follow-up on Phil's question on Japan. Can you just be clear with us? The pricing that you talked about in March, was that the fullest end of the 30% price cut? Or will there be more in April? Just so we can understand how much was reflected in this quarter. And then on the rebates that you talked about, the true-up that happened, would you expect that to swing again through the rest of this year? Or do you think that, that is now at a level that expresses what you're forward-looking expectations are for the level of rebates?"
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","I'll do the first part, and Robin will talk about the second part. So the pricing in Japan, the official price reduction was just under 32% and officially from the 1st of April. We actually reduced our prices into wholesalers early in March. And the reaso",135,"I'll do the first part, and Robin will talk about the second part. So the pricing in Japan, the official price reduction was just under 32% and officially from the 1st of April. We actually reduced our prices into wholesalers early in March. And the reason for that was because the price cut was announced much earlier. And therefore, we wanted to just kind of smooth out the inventory situation. So that's why we reduced our price into wholesalers a little bit earlier. And by the end of the quarter, inventory levels were up to, I would say, reasonable levels relative to demand. And actually, a little bit -- those inventory levels are a little bit down on where we ended quarter 4, because the overall demand was slightly down because of Harvoni. Robin?"
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Sure. So Matthew, to answer the second part of your question relative to the rebate accruals that both Paul and I have mentioned. We regularly have to adjust our accruals to reflect the trends and timing of rebates. And I would say still the trends and th",124,"Sure. So Matthew, to answer the second part of your question relative to the rebate accruals that both Paul and I have mentioned. We regularly have to adjust our accruals to reflect the trends and timing of rebates. And I would say still the trends and the dynamics that were -- and the complexity around reimbursement in these markets still make them somewhat difficult to predict. So I wouldn't say they were all one-time in nature. There may be a small component that you could say -- when we were trying to look at the level of inventory that maybe was one-time in nature. But these dynamics, I think, we may see continue into the future. The honest answer is we don't necessarily know."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from the line of Ying Huang of Bank of America Merrill Lynch.",17,"And our next question comes from the line of Ying Huang of Bank of America Merrill Lynch."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","First of all, I want to probe a little bit about the rebates. Can you clarify whether it's actually access-based or volume-based? Because, we can see from the script apparently the volume is not really picking up after those big insurance opened up the ac",107,"First of all, I want to probe a little bit about the rebates. Can you clarify whether it's actually access-based or volume-based? Because, we can see from the script apparently the volume is not really picking up after those big insurance opened up the access, regardless of F scores. So I wonder what happens there? And then secondly, I think, Paul, you mentioned that the payer mix is getting a little bit worse this quarter, but can you talk about your thoughts on payer mix going forward? Is it going to be continuing shift to the public payers or, I guess, the lower price environment or not?"
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Ying, so the first question was about patient volumes coming in and relative to the opening up of the fibrosis scores. So I'm not sure whether you looked at this data or not, but we get new to brand base, which is really the leading indicator of new start",224,"Ying, so the first question was about patient volumes coming in and relative to the opening up of the fibrosis scores. So I'm not sure whether you looked at this data or not, but we get new to brand base, which is really the leading indicator of new starts in the quarter. So we've seen, and this is just retail scripts, by the way, so that doesn't include the VA, it doesn't include scripts that go through ESI and various other groups. So it's partly representative. And what we've seen amongst those scripts is new starts in the quarter have gone up, and that's gone up exactly in line with our expectations with the fibrosis scores being relieved. Total scripts there remained relatively flat and part of that is because in quarter 4, of course, the patient numbers, throughout, really 2015 quarter-on-quarter, the new starts were coming down. And therefore, the refills associated with those new starts falling into quarter 1 was somewhat down. So the aggregate of that makes the numbers of total prescriptions in the quarter look relatively flat and is slightly disengaged from the fibrosis piece. So I think that hopefully covers that part. And then, of course, the VA, as I said, isn't included in that group, and that was a large number of patients coming in to the system."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","And then the payer mix?",5,"And then the payer mix?"
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","The payer mix, I think, directionally -- I mean, this is not a dramatic move. I think, directionally, we anticipate that Medicaid will start. There's a lot of pressure on Medicaid to treat patients. And we anticipate the public payer sector will start pro",106,"The payer mix, I think, directionally -- I mean, this is not a dramatic move. I think, directionally, we anticipate that Medicaid will start. There's a lot of pressure on Medicaid to treat patients. And we anticipate the public payer sector will start proportionately, getting a little bit bigger in our mix. I mean, just as an example, around 77% of our payer mix at the end of quarter 4 or during quarter 4 was really commercial and Medicaid Part D. That number's dropped down now to about 64% as a proportion. So we're seeing a shift. And I would imagine that, that will continue gradually."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","And then would you guys ever talk about the relative magnitude compared to 46% you flagged last year?",18,"And then would you guys ever talk about the relative magnitude compared to 46% you flagged last year?"
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","No. I mean, we're not going to give guidance on our guidance. We gave the gross net number once. We've built that into our guidance for the rest of the year, so we're not planning on breaking that out at all.",41,"No. I mean, we're not going to give guidance on our guidance. We gave the gross net number once. We've built that into our guidance for the rest of the year, so we're not planning on breaking that out at all."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Robyn Karnauskas of Citi.",10,"And our next question comes from Robyn Karnauskas of Citi."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","So just thinking about the moving parts over the course of the year and the color you gave on fibrosis scores. So, with so many people getting rejected early on based on fibrosis score, how might they flow into the system during the year? Because there",142,"So just thinking about the moving parts over the course of the year and the color you gave on fibrosis scores. So, with so many people getting rejected early on based on fibrosis score, how might they flow into the system during the year? Because theres a lot of patients. Do you see them coming on evenly or could they come in a bolus? And we could see some choppiness in the quarters? And then the second question I had was, how comfortable are you that you can -- that some of the pricing negotiations will have been done and we won't see further pricing negotiations coming with the new nuc-based regimens coming next year? You think there's going to be another round of surprises in 2017 for discounting? Or do you think we've reached a little bit lower of a steady-state?"
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","I think it's hard to tell on the flow of patients, first of all. What we do know, there's plenty, plenty of patients out there. As I said, odd days, we got 3 different sources of data which shows that 25,000 to 30,000 patients are coming into treatment. O",305,"I think it's hard to tell on the flow of patients, first of all. What we do know, there's plenty, plenty of patients out there. As I said, odd days, we got 3 different sources of data which shows that 25,000 to 30,000 patients are coming into treatment. Obviously, a lot less than that are actually being treated. And anecdotally, as I've said, I think it's because there's bureaucracy still in the physicians' offices, which give a kind of, I guess, I have to sort of guessing in a sense of number of patients that can be treated. And also, there's, from the patient side, people are actually ready to be treated. I think they want to be teed up, if you like, for treatment, but they might not want to actually starve tomorrow morning. So I think we should expect patient flow to be fairly stable through this year. And then on the negotiation side, I mean -- I think, with real-world data, payers are tending now to really take a lot more time and put a lot more thought into evaluating the clinical profiles of the products. And until we see the clinical profiles of the new products, it's very hard to predict how competitive they are. I mean, if they're competitive, I think we have to anticipate prices will come down and we'll negotiate, because we certainly don't want to lose any access to patients for our products. And we'll defend our market share vigorously. So it's hard to predict. I think, directionally, competition equals lower prices. But we're going to be focusing on looking at differentiating our products. We've got great products out there now and our pipeline looks really exciting. So I think we're in good shape for a long and sustainable and healthy HCV business in the U.S."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Alethia Young of Credit Suisse.",11,"And our next question comes from Alethia Young of Credit Suisse."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Just 1. Mike, if we go back to the beginning of this year and think about like the $30 billion to $31 billion you've put out there, has the mix between hep C and HIV changed? It seems like HIV is going little better on the new launches and hep C, has more",84,"Just 1. Mike, if we go back to the beginning of this year and think about like the $30 billion to $31 billion you've put out there, has the mix between hep C and HIV changed? It seems like HIV is going little better on the new launches and hep C, has more pricing pressure. And then just also, can you confirm, maybe, if we're seeing a competition in the Big 5 from like, kind of new competitors like Merck coming to the market?"
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Maybe Alethia, I can take the first part of your question. This is Robin. I mean, we gave guidance for the full year. I would say, yes, this quarter, we had a slightly uptick relative to our HIV expectations and slightly down relative to HCV. But I think",83,"Maybe Alethia, I can take the first part of your question. This is Robin. I mean, we gave guidance for the full year. I would say, yes, this quarter, we had a slightly uptick relative to our HIV expectations and slightly down relative to HCV. But I think we still got -- recorded the placings out and as Paul said, we continue to be opportunistic relative to patient starts, or more stable, predictable environment going forward. But it's still very early to tell."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. And in Europe, I mean that -- I've got to say the payers are treating the products, generally, with less consideration to the clinical differences than we're seeing in the U.S. And there are some payers who are treating the products a bit more like c",223,"Yes. And in Europe, I mean that -- I've got to say the payers are treating the products, generally, with less consideration to the clinical differences than we're seeing in the U.S. And there are some payers who are treating the products a bit more like commodities. And we're working hard to make sure that we educate them as best as possible. And I think the real-world data, much of which originates from Europe, is really supporting us in that. But we have seen some instances of -- for example, tenders in the Nordics, which have a very binary outcome. And there's certain times that we've decided that those tenders' prices don't warrant the value of our products. So our market share has been a little bit less in Europe. And specifically, to answer your question, I think all 3 players are out there in Europe trying to get business. But at the end of the day, we hope that people will recognize that the Gilead products are highly effective, very simple, very tolerable. And the real-world data, which is now -- you know there's vast amounts of it, really does support us when physicians make their choices. And as I said earlier, where physicians have the freedom of prescription, we've tended to have very, very strong market shares and they're 90% plus."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Ian Somaiya of BMO Capital.",11,"And our next question comes from Ian Somaiya of BMO Capital."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Maybe just changing the topic a little bit. That question for Norbert. I was hoping you could just speak to the 3 oral candidates you have for NASH now, just how they would -- how you plan to develop them, how they might sort of underplay potential combin",97,"Maybe just changing the topic a little bit. That question for Norbert. I was hoping you could just speak to the 3 oral candidates you have for NASH now, just how they would -- how you plan to develop them, how they might sort of underplay potential combination strategies? And as you kind of think about the larger sort of BD question that keeps being asked, do you have enough data on your internal programs to make decisions in terms of what additional products that might benefit your internal efforts in NASH and also in hep B?"
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","So Ian, actually, it's 4 products that we have currently in early clinical studies, if you include the Nimbus compound. That deal, by the way, has not closed yet, but it should close in the next week. So we have the ASK inhibitor, the ACC 1 2 inhibitor, t",227,"So Ian, actually, it's 4 products that we have currently in early clinical studies, if you include the Nimbus compound. That deal, by the way, has not closed yet, but it should close in the next week. So we have the ASK inhibitor, the ACC 1 2 inhibitor, the simtuzumab and then the FXR agonist. And we could, by the end of this year, be in 4 Phase II studies, really, in NASH to look at the effects of any one of these agents by themselves. And then we would also, at the same time, we are going to start combination studies to see, do we always have to say it, we believe in the 3 points of pet [ph] disease pathogenesis. There is fibrosis, inflammation, and metabolic. We now have agents that address all of them. And we're absolutely -- our hypothesis is that ultimately, it's a complex biological disease, and probably more than one agent would be needed. And we're looking forward, maybe, sometime next year, we will then go into Phase III. With regards to BD, we're, of course, looking. At the moment, there is nothing out there that, I would say, we have to get. As I said, we have 4 components. We're going to look at those individually, and then, as the results come in, make decisions what else we would need."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","And then, what about hep B? There's a similar question. Just with the assets you do have, I know that you've provided very little information or shared very little information with us. But just as you think about your internal portfolio, do you feel like",61,"And then, what about hep B? There's a similar question. Just with the assets you do have, I know that you've provided very little information or shared very little information with us. But just as you think about your internal portfolio, do you feel like you have the assets you need to move forward with it and, obviously, capture the market?"
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","I would say, Ian, so we have, as you know, 4774, that's a 4774 would be a -- 4779, that's the GlobeImmune vaccine. We've presented the data at the last AASLD showing that, at least, in virally suppressed patients it did not lead to a reduction in ""s"" anti",147,"I would say, Ian, so we have, as you know, 4774, that's a 4774 would be a -- 4779, that's the GlobeImmune vaccine. We've presented the data at the last AASLD showing that, at least, in virally suppressed patients it did not lead to a reduction in ""s"" antigen. We have currently going to study in treatment-nave patients. We then have 9620 to TLR7 agonist in Phase II as well or Phase IIa. And then we have 2 other internal programs that we haven't disclosed yet. They are pre-IND, but we have identified with 2 different mechanisms, molecules that we want to develop or evaluate in human clinical studies. But having that said, it's early, I mean, as a general statement, in hepatitis B cure. And we are really having a very open mind and looking outside what else is there potentially that would fit our portfolio."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Terence Flynn of Goldman Sachs.",11,"And our next question comes from Terence Flynn of Goldman Sachs."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I was just wondering, you mentioned this 25,000 to 30,000 per month number of patients coming into treatment. And then you gave us the new diagnosis last year in the U.S. And so that equates to about 17,000 per month. So is it safe to assume that of the n",100,"I was just wondering, you mentioned this 25,000 to 30,000 per month number of patients coming into treatment. And then you gave us the new diagnosis last year in the U.S. And so that equates to about 17,000 per month. So is it safe to assume that of the new patients coming out of treatment, half are newly diagnosed and half are coming from the currently diagnosed pool? Am I thinking about that the right way? And then the second question was, just can you tell us the percentage of patients that are getting 8 weeks of therapy this quarter?"
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Terence, yes, I think, broadly speaking, your maths sum is correct on that. I mean, it's hard to tell exactly where the patients are coming from. But I think, mathematically, that sounds about right. Sorry, what was the second question?",40,"Terence, yes, I think, broadly speaking, your maths sum is correct on that. I mean, it's hard to tell exactly where the patients are coming from. But I think, mathematically, that sounds about right. Sorry, what was the second question?"
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","[indiscernible]",1,"[indiscernible]"
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","8 weeks.",2,"8 weeks."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes, sorry, 8 weeks. We've drifted slowly but surely upwards on the 8 weeks. I think we're about 43%. Now I've got to emphasize the data we have is called intent to treat rather than actual prescriptions. So the intent to treat in the U.S. is about 43%. T",74,"Yes, sorry, 8 weeks. We've drifted slowly but surely upwards on the 8 weeks. I think we're about 43%. Now I've got to emphasize the data we have is called intent to treat rather than actual prescriptions. So the intent to treat in the U.S. is about 43%. The epidemiology, as we've previously said, would probably suggest that about half genotype 1 patients would fall into the criteria that would trigger off 8-week treatment."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Jim Birchenough of Wells Fargo.",11,"And our next question comes from Jim Birchenough of Wells Fargo."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Bit of a maintenance question and then a more meaningful question. On the maintenance side, you referred to a, kind of shift from 24 weeks to 8 weeks. Could you break down the 8-, 12- and 24-week treatment numbers in HCV, and where you see that heading? A",102,"Bit of a maintenance question and then a more meaningful question. On the maintenance side, you referred to a, kind of shift from 24 weeks to 8 weeks. Could you break down the 8-, 12- and 24-week treatment numbers in HCV, and where you see that heading? And a more meaningful question is NASH is obviously an important part of your future growth strategy. FXR is in that category. How confident are you that you can separate out the metabolic effects of excess FXR agonism versus just beneficial effects? What's the basis for that [indiscernible] and when will we see that data?"
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. We're not going to break down the weeks of therapy. I mean, I just said, what do we think the 8-week amount is. But the rest you'll have to just model yourself. And I'll hand over to Norbert for the second question.",43,"Yes. We're not going to break down the weeks of therapy. I mean, I just said, what do we think the 8-week amount is. But the rest you'll have to just model yourself. And I'll hand over to Norbert for the second question."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","So Jim, as you know, steroid FXR agonist do many, many things. Not only in the liver, but also in other target organs. So our philosophy is that we have an FXR agonist that purely acts at the level of the G.I. So it does not get totally absorbed to any me",177,"So Jim, as you know, steroid FXR agonist do many, many things. Not only in the liver, but also in other target organs. So our philosophy is that we have an FXR agonist that purely acts at the level of the G.I. So it does not get totally absorbed to any meaningful degree. And then what it does, at the level of the G.I., it releases FGF19. And we believe that FGF19 does everything that it needs to do in order to impact on NASH. That's our hypothesis, and we're testing that. And we should have data available in the fourth quarter of this year. So that's a fairly easy experiment to do. You simply look at bioavailability, which is below but the FGF19 might be increased to FGF19 levels with some of the consequent metabolic effects. That way, we also think we can prevent pruritus. We can prevent the cholesterol effects. We can prevent alkaline phosphor decelerations, et cetera. And so, if this all is true, it should be a much safer and cleaner FXR agonist."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","And Norbert, when is the forum for that data release? And I guess, what are the next steps for that program? How far behind are you from things that are in Phase III right now of that FXR agonist?",39,"And Norbert, when is the forum for that data release? And I guess, what are the next steps for that program? How far behind are you from things that are in Phase III right now of that FXR agonist?"
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","We could probably have some of the preliminary data at AASLD. And we will then move into Phase III soon after that. So we're not that far behind other companies.",30,"We could probably have some of the preliminary data at AASLD. And we will then move into Phase III soon after that. So we're not that far behind other companies."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from the line of Alan Carr of Needham & Company.",14,"And our next question comes from the line of Alan Carr of Needham & Company."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Wondering if you can talk a bit more about the new diagnoses in 2015 that you mentioned. So there was around 200,000. Do you have any other details around that, about where they were found or, I guess, trend over the course of the year? Is it increasing?",48,"Wondering if you can talk a bit more about the new diagnoses in 2015 that you mentioned. So there was around 200,000. Do you have any other details around that, about where they were found or, I guess, trend over the course of the year? Is it increasing?"
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","I don't have a lot of details at my fingertips actually, Alan. I would say, just to build on what Norbert was saying earlier, the interactions we're having with many people working on diagnosis projects around the country are that there's a lot of -- surp",148,"I don't have a lot of details at my fingertips actually, Alan. I would say, just to build on what Norbert was saying earlier, the interactions we're having with many people working on diagnosis projects around the country are that there's a lot of -- surprisingly high level of positive diagnosis in some of the urban centers and in ER rooms, in particular, in those urban centers, where diagnosis rates have been double, at least, what evenly local investigators have anticipated. Why that is, I'm not sure. But this has been consistent throughout the country. So I would say that diagnosis rates, the 200,000, would grow rather than shrink, certainly for the next few years. And there's great efforts, of course, now to encourage diagnosis because people know that, at the end of it, they're going to be treated and have a high probability of being cured."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","And we have time for one final question. Our last question comes from the line of Tony Butler with Guggenheim.",20,"And we have time for one final question. Our last question comes from the line of Tony Butler with Guggenheim."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Norbert, very quickly, if you could. Recognizing that Nimbus closes next week, have there not been other ACC inhibitors which have actually failed? And if that's true, what might be unique about the Nimbus program? I understand it may attack a different p",61,"Norbert, very quickly, if you could. Recognizing that Nimbus closes next week, have there not been other ACC inhibitors which have actually failed? And if that's true, what might be unique about the Nimbus program? I understand it may attack a different part of the molecule, which would be interesting for you to elaborate on, if that is indeed the case."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. So Tony, you're exactly right. There have been previous ACC programs at Merck and Pfizer. They have not been successful. And the reason had to do with the specificity. This compound is really unique. It's a low-nanaimo inhibitor for both ACC 1 and AC",218,"Yes. So Tony, you're exactly right. There have been previous ACC programs at Merck and Pfizer. They have not been successful. And the reason had to do with the specificity. This compound is really unique. It's a low-nanaimo inhibitor for both ACC 1 and ACC 2. And it inhibits not only the pathway that goes to de novo lipogenesis, so [indiscernible] coenzymate production, but it also inhibits the level of the mitochondrium. It stimulates, I might say, lipid asset beta oxidation. So it does really 2 things. It inhibits the formation of lipids, palmitate mostly, and at the same time, it stimulates the beta oxidation of lipids. And so we are -- there has been some anecdotal reports from the Pfizer compound that inhibition of ACC 1 and 2 results in a decrease in liver fat. That's, by the way, something we would do as one of the next experiments. We would look by MRI, on reduction of -- we've already shown at the EASL presentation that it inhibits lipogenesis. Now we have to show, also, that it inhibits lipid -- fat content of the liver. So fairly straightforward and an easy experiment to do. And I think once we've shown that, we have pretty high confidence that there would be a meaningful clinical benefit of the compound."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Candace, and thank you all for joining us today. We appreciate your continued interest in Gilead. And the team here looks forward to providing you with updates on our future progress.",33,"Thank you, Candace, and thank you all for joining us today. We appreciate your continued interest in Gilead. And the team here looks forward to providing you with updates on our future progress."
29002,330109201,966885,"Gilead Sciences Inc., Q1 2016 Earnings Call, Apr 28, 2016",2016-04-28,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program and you may all disconnect. Have a great day, everyone.",25,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program and you may all disconnect. Have a great day, everyone."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Second Quarter 2016 Earnings Conference Call. My name is Candace, and I will be your conference operator. [Operator Instructions] And as a reminder, this conference call i",62,"Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Second Quarter 2016 Earnings Conference Call. My name is Candace, and I will be your conference operator. [Operator Instructions] And as a reminder, this conference call is being recorded. 
I would now like to turn the call over to Sung Lee, Vice President, Investor Relations. Please go ahead."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Candace, and good afternoon, everyone. Just after market closed today, a press release was issued with earnings results for the second quarter of 2016. The press release and detailed slides are available on the Investor Relations section of the",219,"Thank you, Candace, and good afternoon, everyone. Just after market closed today, a press release was issued with earnings results for the second quarter of 2016. The press release and detailed slides are available on the Investor Relations section of the Gilead website. 
Joining today's call will be John Milligan, President and Chief Executive Officer; Robyn Washington, Executive Vice President and Chief Financial Officer; Kevin Young, Chief Operating Officer; and Norbert Bischofberger, Executive Vice President of Research and Development and Chief Scientific Officer. 
Before we begin formal remarks, let me remind you that we will be making forward-looking statements, including plans and expectations with respect to products, product candidates, financial projections and the use of capital, all of which involve certain assumptions, risks and uncertainties that are beyond our control and could cause actual results to differ materially from these statements. A description of these risks can be found in the latest SEC disclosures documents and recent press releases. In addition, Gilead does not undertake any obligation to update any forward-looking statements made during this call.
Non-GAAP financial measures will be used to help you understand the company's underlying business performance. The GAAP to non-GAAP reconciliations are provided in the earnings press release as well as on the Gilead website. 
I will now turn the call over to Robyn."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, Sung, and good afternoon, everyone. We are pleased to share results for the second quarter of 2016. I'll first review our financials, and Kevin and John will then make a few comments. Total revenues for the second quarter was $7.8 billion, wit",1044,"Thanks, Sung, and good afternoon, everyone. 
We are pleased to share results for the second quarter of 2016. I'll first review our financials, and Kevin and John will then make a few comments. 
Total revenues for the second quarter was $7.8 billion, with non-GAAP diluted earnings per share of $3.08. This compares to revenues of $8.2 billion and non-GAAP earnings per share of $3.15 for the same period last year. Product sales for the second quarter was $7.7 billion, down 6% year-over-year and flat sequentially. The year-over-year decline was driven by lower HCV sales, partially offset by increased sales in HIV and other therapeutic areas. Sequentially, we saw an increase in HIV, U.S. HCV and other product sales that were offset by a decline in HCV sales in Japan and Europe. 
Turning to the U.S. Product sales for the second quarter was $4.9 billion, down 12% year-over-year. HCV product sales were $2.3 billion, down 33% year-over-year, driven by lower revenues per patient as a result of increased rebates and discounts due primarily to payer mix and lower patient starts for Harvoni, as the initial group of warehoused patients was treated in 2015. Sequentially, our HCV product sales were up 13%, driven by a $270 million adjustment to our HCV sales returns reserve rate and the initial inventory build for Epclusa. Strong uptake of our TAF-based regimens drove 23% year-over-year and 11% sequential growth of our HIV product sales. The quarterly revenues of $2.2 billion were also positively impacted by the upward trajectory of Truvada used for PrEP.
Turning to Europe. Product sales for the second quarter were $1.6 billion, down 18% year-over-year, primarily driven by lower HCV patient starts and a higher proportion of patient starts from countries that have a lower net average price. Sequentially, sales in Europe were flat, excluding the impact of currency movements, with HIV sales growth offset by lower HCV sales. 
In Japan, product sales for the second quarter were $619 million, down 43% sequentially as a result of lower patient starts from Harvoni and the full quarter effect of the mandatory price reductions for both Sovaldi and Harvoni, which were discussed during our last call. 
Moving to gross margin. Our non-GAAP product gross margin for the second quarter of 2016 was 92% and benefited from the reversal of a $200 million litigation charge recorded in the first quarter of 2016, following the favorable decision in the Merck case. 
Now turning to expenses. Non-GAAP R&D expenses were $1 billion for the second quarter, up 48% compared to the same period last year, primarily due to the purchase of a U.S. Food and Drug Administration priority review voucher and the progression of clinical studies. Non-GAAP SG&A expenses for the second quarter were up 10% compared to the same period last year, primarily due to higher costs to support new product launches and our geographic expansion. From a balance sheet perspective, during the second quarter, we generated cash flow from operations of $4.9 billion and ended the quarter with $24.6 billion in cash and investments. While our cash flows will remain strong in the second half of the year, we anticipate a sequential decrease in Q3 2016 due to required cash payments related to our current government rebates in the U.S. and abroad as well as milestone payments associated with our R&D pipeline progression. 
We continue to return capital to our shareholders through dividends and share repurchases. During the second quarter, we repurchased 10.5 million shares for $1 billion under the $12 billion 2016 share repurchase program, and we received an additional 8.1 million shares in April 2016 from the final settlement of the accelerated share repurchase program announced in February 2016. The total share repurchases in the first half of the year were $98.2 million at a cost of $90 billion. As previously communicated, we anticipate share repurchases in second half of 2016 to be lower than the first half of 2016 as we focus our capital allocation on advancing our R&D opportunities. 
Finally, we are updating full year 2016 guidance, which is outlined on Slide 21. The changes are as follows: we are lowering net product sales guidance to a range of $29.5 billion to $30.5 billion. While we are seeing continued strength in non-HCV product sales, given the current trends in payer and patient flow dynamics for HCV, our updated models for just net product sales will range from being slightly above to slightly below $30 billion for the year. As such, we believe it is prudent to update our full year 2016 guidance. The factors contributing to this conclusion include: lower HCV revenue per patient as a result of a mix shift towards more heavily discounted payer segments in the U.S. and [indiscernible] with a lower net average price in Europe; a trend towards slowing patient starts in the U.S. Commercial segment and some earlier launch markets of Europe; the continued gradual trend towards shorter duration; and loss of some market share to competition. This guidance is subject to a number of uncertainties, including potential changes in the global macroeconomic environment, adoption of additional pricing measures to reduce HCV spending; volatility in foreign currency exchange rates; inaccuracy in our HCV patient start estimates; additional competitive launches in HCV; an increase in discounts, chargebacks and rebates due to ongoing commercial payer contract negotiations; and a larger-than-anticipated shift in payer mix to more highly discounted payer segments such as PHS, FFS, Medicaid and the VA. 
We are increasing our R&D expense guidance to a range of $3.6 billion to $3.8 billion, driven by acquisition-related expenses for Nimbus Apollo, Inc. and the purchase of a U.S. Food and Drug Administration priority review voucher, slightly offset by lower-than-anticipated clinical trial expenses. 
We are lowering SG&A expense guidance to a range of $3.1 billion to $3.3 billion, primarily driven by the favorable onetime adjustment to the expected invoice from the IRS for the Branded Prescription Drug fee, which lowered Q1 2016 SG&A expense. 
Diluted EPS impact of acquisition-related upfront collaboration, stock-based compensation and other expenses increases to a new range of $1.47 to $1.53 as a result of our recent M&A activity. All other components of our 2016 guidance remain unchanged. 
I would like to now turn the call over to Kevin."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Robin, and good afternoon, everyone. Let me say immediately how terrific it is to be back at Gilead in a full-time capacity. Working with exceptional executive colleagues around the table here in [indiscernible] City, interacting with my seni",1699,"Thank you, Robin, and good afternoon, everyone. 
Let me say immediately how terrific it is to be back at Gilead in a full-time capacity. Working with exceptional executive colleagues around the table here in [indiscernible] City, interacting with my senior operating management team and seeing the dedication of thousands of Gilead employees around the world leaves me in no doubt as to the long-term prospects for this outstanding company. 
While still early days, over the last 2 months in my new role, I've had the opportunity to reflect on Gilead's recent product introductions, the evolving health care landscape and the operating challenges on our near-term horizon. I'd like to share 3 general observations with you today. 
First, I am struck by the commitment that you shared, by physicians, payers and governments around the world, to reduce the prevalence of hepatitis C. Even countries with challenging economic circumstances are finding ways to prioritize the treatment of HCV patients. In the 2.5 years since the launch of Sovaldi, more than 1 million patients have been treated on a sofosbuvir-based regimen. Beneath this aggregated number are several landmark statistics. The United States has already treated nearly 0.5 million patients to date with Sovaldi and Harvoni. Equally, over 200,000 patients in Europe have been treated with Gilead regimens. Japan has treated approximately 100,000 patients in a little over a year. And just this year, Australia has treated an estimated 17,000 patients in a matter of months. Health care systems have demonstrably mobilized to reach those patients most in need. These are remarkable facts that clearly underscore the profile of the products we have introduced. Equally, they have implications to longer-term treatment dynamics and portfolio life cycles. Secondly, in the area of HIV, I'm impressed by how the clinical data for TAF-based regimens are resonating with the many constituents who tirelessly drive for better patient care. The understanding that these regimens can help address a growing need for highly effective and safer treatment options for lifelong HIV therapy is evidenced by the early success of Genvoya. I will highlight some impressive data points later.
Thirdly, I'll remind you just how complex the delivery of health care continues to be. Gilead's focus on flawless execution, on controlling the variables that we can control with the highest levels of competence and compliance is critical and is my top priority. 
Now let me take you through the details of the commercial performance for the second quarter. Starting with HCV. In the U.S., total HCV revenue is $2.3 billion, up 13% sequentially and down 33% year-over-year. Since the beginning of the year, access has improved and almost all major commercial payers have been moved by [indiscernible] criteria, joining Medicare and the VA in this regard. Medicaid remains the only payer segment where use is still generally restricted to the sicker patients. There are other significant barriers to access, but we are encouraged that some states have recently moved away from fibrosis restrictions towards more open access.
In terms of patient starts, approximately 69,000 [ph] people began HCV therapy in the second quarter, and an estimated 90% of these patients started on a sofosbuvir-based regimen. Importantly, third-party databases suggest that new patients are being identified through increased screening efforts. As evidenced, approximately 14 million people were screened for HCV for the period of 2014 through 2015, and approximately 280,000 were confirmed RNA positive in that 2-year period. These figures represent a significant increase from the years prior to the launch of Sovaldi. We estimate that 3 million individuals remain infected with HCV in the U.S., approximately half of whom are diagnosed.
Although patient starts increased for the second consecutive quarter and patient inflows into care remain recently steady at around 30,000 patients a month, the dynamics vary by patient segments. 
Within the commercial and Medicare segments, some larger payers have recently opened up access. We now estimate that up to 90% of all commercial covered lives have access without regard to fibrosis score. While the payers that recently opened up access are bringing in more patients, we are seeing a modest downward trend in patient starts among payers that have had full access in place for longer periods of time. The sickest patients have largely been treated, and the movement we are seeing is towards treating genotype 1 patients with low fibrosis scores and thus greater use of the 8-week treatment regimen for Harvoni. 
In terms of all new HCV treatment starts in the second quarter, approximately 45% came from within the public payer systems. We anticipate this percentage will remain largely the same through the remainder of the year. The VA is one example of a payer within this segment, and their commitment to treating and curing [indiscernible] who have HCV using budget allocated by Congress to do so is truly groundbreaking. We are aware that in some cities, extra clinics have been scheduled to help shoulder the workload. However, we also expect that in the longer term, disadvantaged patients within the VA system will be harder to reach and bring into care and that the rate of treatment will decline.
Turning to Europe. Total HCV revenue in the second quarter was $775 million, down 32% year-over-year and down 7% sequentially. Overall, Gilead patient starts decreased to around 28,000 for the quarter. We observed steady treatment rates in Italy and Spain but lower numbers in early launch markets like Germany and France. Patient starts in the U.K. continue to be limited by NHS England budget restrictions. Additionally, we saw a slight decline in average treatment duration, as countries like Germany are treating more patients with low fibrosis scores, who qualify for an 8-week treatment duration.
In several European markets, locally documented cure rates are equal to, if not better than, what was demonstrated in Sovaldi and Harvoni clinical studies. This has resonated with governments and payer bodies, and some countries such as France are considering removing all fibrosis score criteria. We will watch this picture closely and share evolving news with you in the future. 
Moving to Japan. As Robin mentioned, revenue was $619 million, down 43% sequentially. We believe this was related to 2 factors: first, the decline in genotype 1 new patient starts following the Q1 2016 peak when a very large number of individuals with advanced disease initiated therapy; and second, the full treatment effect of a mandatory price reduction previously described on last quarter's call.
Finally, for HCV, a [indiscernible] was recently approved in the U.S., the EU and Canada. These approvals are true milestones in patient care since Epclusa is the first pan-genotypic, once-daily, single-tablet option. Epclusa will be an important treatment option in the U.S. as an estimated 20% to 25% of HCV patients have genotypes 2 and 3. And equally, across Europe, there are some countries that have up to 30% of patients with genotype 3 alone. 
In concluding my remarks on hepatitis C, I will return to my earlier comments. Gilead is proud to be part of a fundamental disease paradigm shift, delivering disease cures to virtually all patients treated. That's why we developed Sovaldi, Harvoni and Epclusa and have a third single-tablet regimen in clinical testing. 
Whilst the pace of new patient treatments may slow in coming years and quantifying that pace is incredibly hard, there is still an opportunity to identify and cure many HCV infected people around the globe. 
Moving to HIV. We are pleased with the launch of our top-based [ph] products in the U.S. and in the European markets where we have already achieved reimbursement. In the U.S., total HIV and other antiviral revenue was $2.2 billion, up 11% sequentially, and Genvoya revenue nearly doubled in Q2 versus Q1. The product represents the most successful HIV launch since the introduction of Atripla, the first single-tablet regimen, a decade ago. After its first 6 months of availability, Genvoya is already the most prescribed regimen for both treatment-nave and switch patients. 
78% of all Genvoya prescriptions have come from switches. Half of the switches have come from Stribild, and importantly, 10% of switches have come from non-Gilead therapies. Among all patients who switched, we have seen an increase in our ability to retain patients on a Gilead product. 
Whilst still in the early stages of the [indiscernible] and Descovy launches, we are seeing similar patient dynamic to Genvoya. Over 90% of all [indiscernible] and Descovy prescriptions have come from switches. And 6% and 11% of switches, respectively, have come from non-Gilead therapies. 
Finally, in the U.S., I would like to highlight the growing use of Truvada for PrEP. We estimate somewhere in the order of 60,000 to 70,000 patients were using Truvada for PrEP in the second quarter. This number accounts for approximately 1/3 of Truvada demand. This is encouraging, as we know Truvada has an important role to play as part of comprehensive HIV prevention for many at-risk individuals.
Turning to Europe. Total HIV and other antiviral revenue was $755 million, up 5% sequentially, driven by the launches of Genvoya and Descovy. Genvoya has gained pricing approval in 11 countries and is now the market leader in Germany for both treatment-nave and switch patients after only 6 month of availability. We anticipate additional launches in France, Italy and the U.K. in the second half of the year. 
Genvoya is a preferred regimen in several HIV treatment guidelines, including Italy, where it was added before pricing and reimbursement. Preferred listings are anticipated in other EU guidelines later this year and into 2017. EACS guidelines are expected to be updated, following the HIV Glasgow 2016 Conference in October.
Finally, I would like to briefly update you on the outstanding performance of the Gilead U.S. cardiovascular team. Letairis and Ranexa together generated $356 million in revenue during the quarter, representing a 12% year-over-year increase. Today, over 0.25 million people in the United States regularly receive Ranexa. And Letairis remains the overall ERA market leader in PAH. 
In closing, Gilead achieved a great deal of across our operations during the quarter, and I am confident that we will continue to make significant progress in the second half of 2016. 
I would now like to turn the call over to John."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, Kevin. Before I get started, I just want to say it's great to have you back on the Gilead full team -- full time as our new Chief Operating Officer. Today, in addition to the remarks of Robin and Kevin regarding the quarter, I'd like to make a f",1154,"Thanks, Kevin. Before I get started, I just want to say it's great to have you back on the Gilead full team -- full time as our new Chief Operating Officer. 
Today, in addition to the remarks of Robin and Kevin regarding the quarter, I'd like to make a few comments of my own. Over the last 2.5 years, we've made great progress in helping provide access to Sovaldi and Harvoni for HCV patients. Throughout the world, more than 1 million HCV sufferers have not been treated, with nearly half of those coming from the U.S. A lot of these drugs were unprecedented in our industry, and patients are treated at a much faster initial rate than we or anyone else possible. Looking back, we can now say that in every country, the peak number of patients treated was achieved within 2 or 3 quarters of the launch of Harvoni. And that peak number is far higher than what we had -- what had ever been achieved before, about 3x that seen with the launch of the HCV in 2011.
As we've reached the mid-point of this year, we now see the market maturing to a slower rate of treatment for HCV-infected individuals. And as we think about this one more normal patient starts, there are a few things to keep in mind. As Kevin mentioned, there are about 3 million people who are infected in the U.S., and slightly more than half of those have been diagnosed. Many of these diagnosed patients have less advanced liver disease upon reentering care. For example, in the United States in the second quarter this year, we estimate that only 13% of patients starting treatment had F4 fibrosis scores compared with more than 21% the year prior to that. With less severely ill patients, there is less urgency to immediately treat patients. This may explain the slower rate of treatment versus last year. However, we do believe these patients will eventually benefit from treatment, and this means the flow of patients will continue for many years to come.
There's also an opportunity to diagnose patients [indiscernible] into care. As Kevin mentioned, we estimate that about 280,000 HCV patients are diagnosed in the U.S. in the last 2 years. So the value and importance of the U.S. GDP recommendations for HCV testing. So while there has been a slowing of treatment compared to the rush of patients when Sovaldi and Harvoni where first approved, the HCV market is attractive over the longer term providing the revenues, strong cash flow and earnings per share on top of our base business and chronic therapies. 
Because of this, our focus on improving care for HCV and affected individuals has not wavered. Beyond the recent approvals of Epclusa, we are actively working on a third single-tablet regimen that combines the 2 active ingredients in Epclusa with the third investigational compound, [indiscernible]. This combination, known as SOF/VEL box, is being evaluated at 4 Phase III clinical trials among patients who have previously failed direct and develop treatments. It's also being studied for its potential to offer an 8-week treatment duration for treatment-nave patients of all genotypes. We expect to have top line data available for SOF/VEL box by the end of the year. 
We're making tremendous minus headway in HIV as well, both of our portfolio of newer products and our pipeline. We've had several key approvals with Descovy approved in U.S. and Europe last quarter and Odefsey approved an earlier this month. It's clear these medications offer a significant advance for patients, and that advance has been recognized now by multiple professionals and public health groups, including the International Antiviral Society of the U.S.A. and the Department of Health and Human Services, both of which were released updated guidance of use TAF-based regimens for initial HIV therapy. 
We continue to generate clinical data that support the favorable time to fix and medical performance of our TAF-based products. Last week, we announced the results of 2 Phase IIIb switch studies evaluating Odefsey and Biologics suppressed, switching from comp there or Atripla. Of this he achieved similar rates of urological suppression as the TDF-based regimen. These studies reinforce efficacy of Odefsey as with the renal and bones of the advantages, and we plan to present data cents later this year. 
Last month, we presented the first human data on [indiscernible], our investigational, integration inhibitor at the American Society for Microbiology. Data from 4 preclinical and Phase I studies examined the antiviral processes, resistance profile, pharmacokinetics and safety of tenofovir providing the rationale to further evaluate the compound. Dolutegravir is part of a single-tablet regimen and combination with TAF and [indiscernible], is currently in Phase III trial. Enrollment of more than 2,300 patients across 4 registrational studies was completed earlier this month. The 48-weak endpoints for this study will be reached in the second quarter of next year, and the data play out as we all, NDA and MAA filings could occur in the third quarter of 2017.
With the approval and rapid adoption of our TAF-based regimens, an exciting new STR and Phase III development and an active HIV research pipeline, I'm confident that we will be able to extend our leadership position in the HIV market and broaden our ability to help even more patients around the world. 
Outside of working antivirals, Gilead is focused on some of the biggest health challenges today. Several important data sets that are anticipated in the second half of this year may help us to find a strategy of pathway forward for tackling these challenges. And our Nass program, where we have 4 active clinical programs, we'll have data from the Phase II studies of GS-4997, our S-1 inhibitor and simtuzumab, our monoclonal antibody and [indiscernible]. 2 The Phase II study of simtuzumab for primary sclerosing will also conclude. We will also have data from the Phase II studies of GS-4997 in diabetic and pulmonary arterial hypertension or PAH. And finally, we expect data from 2 Phase III studies of myelofibrosis before the end of the year. If these data are positive, these studies will form the basis for an MDA filing in the first quarter of 2017. 
These are important milestones and represent a great deal of work across the organization to enroll and advance these studies and analyze complex data sets as they become available. Gilead continues to innovate in every level and every part of the organization. Next month, we will publish our first corporate social responsibility report that looks at access sustainability, graph making and other positive contributions to the communities we serve, and I urge you to read it. I'm proud of the work that's been that way our employees and extend my many thanks to the for all the ways they are making a difference of around the world. 
Thank you, and let's now open up the call for sessions. Operator?"
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Geoff Meacham with Barclays.",15,"[Operator Instructions] 
And our first question comes from the line of Geoff Meacham with Barclays."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Kevin, good to have you back on the call. So I wanted to dig into your comments and also John's comments on the hep C new starts. And I guess, I'm curious because you have better F0, F1 Access. You have positive impact theoretically from the CDC guideline",110,"Kevin, good to have you back on the call. So I wanted to dig into your comments and also John's comments on the hep C new starts. And I guess, I'm curious because you have better F0, F1 Access. You have positive impact theoretically from the CDC guidelines and very low penetration in markets such as the prison population, I'm just curious why, could you put your finger on maybe 1 or 2 things that you feel like could ultimately become a growth driver to give us back to better sequential growth? I'm just trying to figure out what the tipping point is of some of these different volume drivers."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Jeff, nice to hear your voice as well. Thank you for your comments. I am not at all pessimistic about the long-term prospects for hepatitis C. In fact, I'm rather optimistic. I think what we have seen 2014, 2015 is an enormous group of the less well patie",335,"Jeff, nice to hear your voice as well. Thank you for your comments. I am not at all pessimistic about the long-term prospects for hepatitis C. In fact, I'm rather optimistic. I think what we have seen 2014, 2015 is an enormous group of the less well patients treated, particularly by specialists, hepatitis C treaters. It's really quite amazing. I think this quarter, we've highlighted perhaps going forward is really sort of a payer mix situation that we've got. The VA has definitely increased in terms of its contribution to the 69,000 [ph] total HCV starts, which, of course, was an increase on quarter 1. So a lot of VA patients are coming through, and the VA is very, very motivated to try to essentially eradicate the drivers from that population. I think, yes, we did see pickup in 2 of the large players that came onstream with open fibrosis scores from the beginning of the year, but we did see some downtick in other commercial payers. So net-net, it was slightly a decrease in overall commercial patients. What I feel about the long term and as we go into years further forward and we kind of hit an equilibrium of patients is all around what I mentioned and John mentioned, around diagnoses. There's been a considerable pickup in the number of HCV tests, 2014, 2015, about a 65% increase in the number of HCV tests. 280,000 in that 2-year period were HCV net positive. So as John said, they will eventually work their way through treatment. But still over  1/4 of the population being diagnosed is at 4. So there's still a lot of sickness out there in patients. So whilst the health care system here and some of the European markets have done heroic things in treating patients in the last 2 years, I still think, with 1.5 million diagnosed patients in the United States, that we are going to see a continued healthy flow of patients that can benefit from our products."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Geoffrey Porges of Leerink.",10,"And our next question comes from Geoffrey Porges of Leerink."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Kevin, welcome back, and good to hear you. So following up on this issue of HCV outlook, historically, in this category, after each market has peaked, it's begun a steady slow, sometimes slow anyway, decline. We certainly saw a rapid decline after the pro",143,"Kevin, welcome back, and good to hear you. So following up on this issue of HCV outlook, historically, in this category, after each market has peaked, it's begun a steady slow, sometimes slow anyway, decline. We certainly saw a rapid decline after the protease inhibitor. More slow decline after we went to ribavirin and interferon. Are you suggesting to us that you think that there is a stable outlook for the HCV revenue on a market-by-market basis from these levels? Or are you suggesting that we should see more like an orderly and steady decline? And could you particularly comment about Europe, where I think it was surprising to see patient numbers in the big early markets roll over so quickly, particularly Germany and Japan? Is that a onetime step-down? Or are we going to continue at or below this level going forward?"
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes, thanks for the question, Jeff. I think it is encouraging that patient starts in the U.S. and Europe have been recently steady over the past 3 quarters. Japan's a good story. I can certainly, at some point, comment on that this afternoon. I think, fro",292,"Yes, thanks for the question, Jeff. I think it is encouraging that patient starts in the U.S. and Europe have been recently steady over the past 3 quarters. Japan's a good story. I can certainly, at some point, comment on that this afternoon. I think, from my perspective and Robin, John around the table year, I think it's more of the latter comment that there will continue to be a gradual decline in new patient starts. But an equilibrium will be eventually hit. Quite the timing of that, Jeff, it's really, really, really hard to take. I've just got to believe that with the amount of testing, with the amount of diagnoses with the CDC guidelines, Gilead itself in Q3, Q4 this year going do some more educational programs around the need to test and treat that, we will eventually hit an equilibrium. In terms of Europe, Italy and Spain are very steady. I should tell you that in Italy, there are still 200,000 quite sick individuals, people to be treated and they're in treated care. And the Italian government do want to go ahead and try and mobilize providers to do that treating. So there's still an enormous number initially. I think the more -- the markets are more akin to the U.S. like, first and foremost, Germany and, to a slightly lesser extent, France, starting to see that sort of turnover of patients. We've got full access in terms of fibrosis score in Germany. And we're hoping, as I said, that we get broad access in France. The U.K. is a different situation, and that's largely due to payer restrictions. But again, still an enthusiasm to treat, but 1 or 2 of those markets, there is some maturing going on."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Mark Schoenebaum of Evercore ISI.",11,"And our next question comes from Mark Schoenebaum of Evercore ISI."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","This is Regina Grubman for Mark. I actually want to change topics and shift to hepatitis B. On your Q1 call, you mentioned your hep B program included a vaccine, the TLR-7 and 2 internal preclinical candidates. When will we see an update on the internal c",71,"This is Regina Grubman for Mark. I actually want to change topics and shift to hepatitis B. On your Q1 call, you mentioned your hep B program included a vaccine, the TLR-7 and 2 internal preclinical candidates. When will we see an update on the internal candidates? And also you mentioned taking a look at external opportunities for hepatitis B. Is hep B still a potential area of interest for acquisition?"
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Regina, you asked a question about what our pipeline is for hepatitis B. So we have, as you know, 2 compounds [indiscernible] clinical development. One is an active vaccine, 477 90 [ph], the collaboration with GlobeImmune. That's currently in the later st",303,"Regina, you asked a question about what our pipeline is for hepatitis B. So we have, as you know, 2 compounds [indiscernible] clinical development. One is an active vaccine, 477 90 [ph], the collaboration with GlobeImmune. That's currently in the later stages of being evaluated in [indiscernible] patients. The [indiscernible] data has been released maybe a year ago. That data does not show any activity. So we don't have high hopes that this compound will work. Then the TLR-7 agonist is not just finishing the first cohort, which is in suppressed patients. And we are currently initiating the second quarter [ph] that's ongoing. We hope that will add the presentation in the first quarter rated by ASL the hopefully, the abstract deadline. Then you asked a question about we have 2 other compounds in development. Well, you know what we're pursuing, maybe I should answer this more generally, so we're pursuing 3 approaches to hepatitis B cure. So one is adding another different mechanism to the nucleotides because there's observation that despite being under hepatitis B therapies like Gilead or TAF, there was always a little bit of virus left, HCV maybe takes about, if you look at their your sensitive methods. So by adding another mechanism to a weaker completely suppressed there was down to 0, would that lead to an eventual cure or hepatitis [indiscernible] conversion? The second thing we're pursuing is immunotherapy, so that belongs to vaccine and the TLR-7 that I talked about already. And we have a TLR 8 agonist currently that is working its way towards an IND. And then the third possibility, that's the most hopeful but also the one that's least scientifically proven that's going directly after cccDNA. And that's really told early to talk about at this point. It's still in the research status."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Michael Yee of RBC Capital Markets.",12,"And our next question comes from Michael Yee of RBC Capital Markets."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","You talked a lot about volume and demand in the different buckets. But can you talk about the payer mix shift? Specifically, I wanted to ask on Medicaid. Can you just help us out with what percent of sales Medicaid is? And what is going on in that bucket?",98,"You talked a lot about volume and demand in the different buckets. But can you talk about the payer mix shift? Specifically, I wanted to ask on Medicaid. Can you just help us out with what percent of sales Medicaid is? And what is going on in that bucket? I presume it is state-by-state negotiation. Can you talk about what's going on there? Is there a step-by-step negotiation you have to go through? Is it pretty much done? Walk us through that bucket. And what percent of hep C that is in U.S. so I can understand them."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Michael, it's Kevin. Thank you for the question. I prefer not to break out specifically the percentage of the public payers in terms of Medicaid. As I said, all our public payers lumped together for the quarter were about 45%. That's an increase from the",171,"Michael, it's Kevin. Thank you for the question. I prefer not to break out specifically the percentage of the public payers in terms of Medicaid. As I said, all our public payers lumped together for the quarter were about 45%. That's an increase from the previous quarter. But as I said, that's all driven by VA. We've seen very little change, really, in the scale and size of our Medicaid business. I think it would be true to say that Medicaid's the states are slowly progressively opening up. 40% of Medicaid patients come from the 5 largest states. 2 of those, New York and Florida, now have no fibrosis score. So as states do progressively consider opening up, they typically come to us for a contract. We think about those contracts very carefully. Depending on the size of Medicaid, we obviously put out our submission in. Realistically, I think we may win. We hold the majority of those, but there may be occasions when occasionally, Medicaid stake goes to the competition."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Matthew Harrison of Morgan Stanley.",11,"And our next question comes from Matthew Harrison of Morgan Stanley."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Robin, if you could just address the $279 million onetime swing. We obviously saw a swing in the first quarter and then a swing this quarter again. Can you give us some insight into what's going on with those changes and chargebacks and if you should cont",71,"Robin, if you could just address the $279 million onetime swing. We obviously saw a swing in the first quarter and then a swing this quarter again. Can you give us some insight into what's going on with those changes and chargebacks and if you should continue to expect to see some of those numbers? And then just separately on PrEP, any plans to get a TAF-based regimen approved for PrEP?"
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Sure. I'll take the first part, and then Norbert will take the second. First of all, there's 2 separate things that we're talking about here, Q2 versus Q1. The first one is Q2. We did have a sales recon reserve adjustment really related to the fact that a",348,"Sure. I'll take the first part, and then Norbert will take the second. First of all, there's 2 separate things that we're talking about here, Q2 versus Q1. The first one is Q2. We did have a sales recon reserve adjustment really related to the fact that as we introduce our new hep C product, we're required to go out and do an external proxy related to sales return reserve. And just recently, just this past quarter, we closed several of a lot related to our products return is accepted. That gives us a triggering event by which we can look at returns versus how we [indiscernible]. The other keeping about the timing of this related to that [indiscernible] a lot. So they bring on a new product, they want to kind of rebased their level of return that we are expecting to see. So that's really the adjustment period. For the most part, you can see it's onetime in nature. You may have small adjustments going forward, but as long as we turn continue where they are found in that 2 79 [ph] kind of a onetime event. Last quarter, we had a different issue and that related to rebate claims for hepatitis C. As I said on the call last time, we always have a situation where we're constantly training up claims around HCV rebate because we get those claims 1 to 2 quarters in arrear. This quarter was a bit different than the last quarters that we saw model remains [indiscernible] modernization of the level of those claims relative to the prior quarter. So it wasn't -- it did reverse the other way. That was just a slowing of what we saw in Q1. So we're, for lack of a better word, still a bit more caught up relative to return this quarter than we were at the end of Q1. So 2 different items, but you caught up at 2 79 [ph] because that was the onetime event and we want to ensure that we understood relative to the future projection of HCV sale."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","F/TAF [indiscernible] so we and also the outside medical community believe that obviously, F/TAF will have advantages in terms of use for PrEP versus TRUVADA for all the obvious data that were published already. And also we have data now in human and anim",130,"F/TAF [indiscernible] so we and also the outside medical community believe that obviously, F/TAF will have advantages in terms of use for PrEP versus TRUVADA for all the obvious data that were published already. And also we have data now in human and animal models that show that I presume efficacy. The thing we're debating internally and not only have further discussions with the FDA is what clinical study that needs to be done that leads to approval. It would have to be a normal with a comparative study and tend to see [indiscernible] what will be the primary. And that's currently a discussion we're having with the FDA. We hope we can come to some conclusion within the next months or so and then I'll let you know."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Brian Abraham of Jefferies.",10,"And our next question comes from Brian Abraham of Jefferies."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Kevin, with the list pricing and label established for Epclusa, just wondering what's the right way to think about Epclusa's potential impact on the genotype 2, 3 franchise, particularly with respect to the net price per patient treatment duration relativ",69,"Kevin, with the list pricing and label established for Epclusa, just wondering what's the right way to think about Epclusa's potential impact on the genotype 2, 3 franchise, particularly with respect to the net price per patient treatment duration relative to Sovaldi and just how we should be thinking about the overall market dynamics there. I'm just wondering if you could also quantify the inventory build this quarter there."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes, great question, Brian. Nice to hear your voice as well. Brian, the majority of the revenues in the second quarter, which is right to the end, the majority of that was inventory that Robin called out. So we've really only just begun the introduction,",304,"Yes, great question, Brian. Nice to hear your voice as well. Brian, the majority of the revenues in the second quarter, which is right to the end, the majority of that was inventory that Robin called out. So we've really only just begun the introduction, both the promotion and the education around Epclusa. Now I'm really pleased that the responses been excellent, and our advisory boards and our speaker programs have been good acceptance. Whilst we have obviously a pan-genotypic label, I think the reality is that physicians are very, very comfortable, as our payers, with Harvoni for genotype 1. Obviously, that's a mix of 12-week treatments and 8-week. Just for your information, the 8-week cost of Harvoni is now 45% of patients treated in the United States. So I think people are just really comfortable with the clinical effect and the value proposition of Harvoni in GT1, which that all means that the slot that people see come Epclusa, is in the 2 and 3 patients. As I highlighted, it's something like an order of 20% to 25% of patients in the United States. I think the obvious advantage, both clinically and from a payer point of view, is you really do have a 12-week single-tablet regimen. You don't have to extend the treatment duration. You don't have to use ribavirin. There's quite a number of patients treated with Sovaldi, certainly, in the United States. So really, when somebody takes away that regimen, and it's an excellent slot looks. So we've had very good reception to Epclusa. It's extremely early days. It will take us 3 to 6 months to get payer approval. Physicians can apply based on medical need, and we know they're doing that. So just very early days and weeks. It seems to have found a very nice entry point."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from the line of Cory Kasimov of JPMorgan.",13,"And our next question comes from the line of Cory Kasimov of JPMorgan."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I have a bigger picture question for you. Really just following the latest management shuffle back in 2Q, I'm wondering if these changes portend any material shift or consideration of a shift in, I guess, your commercial or pricing strategy really the ove",75,"I have a bigger picture question for you. Really just following the latest management shuffle back in 2Q, I'm wondering if these changes portend any material shift or consideration of a shift in, I guess, your commercial or pricing strategy really the overall strategy for the business or any of the key businesses. And is this plain into the bump in anticipated R&D with the associated downtick in SG&A, as illustrated by your updated guidance?"
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","I think there were a couple of questions there. So It's John Milligan. So In terms of let me get to the last, but you said there was a bump in R&D. That is true, relating somewhat to our acquisition of Nimbus. So there were charges associated with that, t",238,"I think there were a couple of questions there. So It's John Milligan. So In terms of let me get to the last, but you said there was a bump in R&D. That is true, relating somewhat to our acquisition of Nimbus. So there were charges associated with that, there were also charges associated -- I should say expenses associated with the purchase of FDA priority or review voucher. So we're very pleased to get that onboard, and we look forward to explaining when we're going to use that. Above and beyond that, actually, R&D expenses were slightly down what we need to have forecasted because we continue to hold the cost centers to our accountable and continue to drive good value through our clinical teams and getting studies done at a very cost-effective way. So in terms of that, there's no difference. The SG&A line came down a little bit because there's onetime charges that were lower than the sword IRS charges were lower than we anticipated. So kind of what we would expect. In terms of signaling of our pricing or changes in management about structures, I don't really think there's anything to signal there in terms of our pricing strategy. We're highly competitive. We think we have a very good differentiated product, and we'll continue to do the best for the company and for patients by coming to the right level of price and access."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes, and I would just add, Cory, that the Gilead way is always to lead with the science around our product. Nothing's changed. In my eyes, as I've come back into the company, we lead with science. That's what you in specialist markets. It is reality that",111,"Yes, and I would just add, Cory, that the Gilead way is always to lead with the science around our product. Nothing's changed. In my eyes, as I've come back into the company, we lead with science. That's what you in specialist markets. It is reality that there is more contracting. I think we got a phenomenal team working on this. I met with them 2 weeks ago, and I think they are highly professional. And we also live with value. That's the key thing. We think we got tremendous products that either control disease or cure disease, and they have terrific value. And that's the cost we're going to state."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Phil Nadeau of Calvin.",10,"And our next question comes from Phil Nadeau of Calvin."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I have a question on capital allocation. In the prepared remarks, I think you mentioned in regards to cash flows being lower in the second half of the year and that part of that was investment in R&D, and as you just discussed, R&D expenses are really cha",99,"I have a question on capital allocation. In the prepared remarks, I think you mentioned in regards to cash flows being lower in the second half of the year and that part of that was investment in R&D, and as you just discussed, R&D expenses are really changing that much in the guidance. So kind of curious whether you have on your list of things to do in the second half of the year more deals, whether M&A or in licensing. And maybe you could give us some thoughts on how aggressive you're likely to be in those areas."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","So Phil, I'll start. I think relative to the cash flow, what I was messaging was really related to the dynamics of payments, right? So we have accrued rebates and other things that kind of caused volatility cash flows. So overall, our cash flows can be st",115,"So Phil, I'll start. I think relative to the cash flow, what I was messaging was really related to the dynamics of payments, right? So we have accrued rebates and other things that kind of caused volatility cash flows. So overall, our cash flows can be strong, but we definitely expect potential decrease in cash flows second half. Relative to our overall capital allocation, it's no different than what we've been messaging, again, more focused on our be in the opportunity, but I'll let John speak of a little bit more into this. Again, focus there and that, that additional focus was from what focused on share repurchases in the second half of the year."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","And as a follow up on what Robin said, so we were very aggressive about the first quarter of this year. That's what we backed off a the bit from where we were in the second half of the year, mostly you get the full year effect or greater effect of repurch",192,"And as a follow up on what Robin said, so we were very aggressive about the first quarter of this year. That's what we backed off a the bit from where we were in the second half of the year, mostly you get the full year effect or greater effect of repurchasing almost 100 million shares through [indiscernible] program. With regard to business development, obviously, we're a company that has been very open about being interested in doing more deals, especially deals of a certain size where we think we can get some leverage and we can use our organization to effectively accelerate or expand indications. We've done some good deals both with Galapagos and Nimbus recently. We are very interested in continuing that add more things to our pipeline, especially in the nonantiviral area where we continue to see growth in franchises. It's our hope that as we exit this year, we'll have a better, more complete story of programs internally and externally that we can use to talk about why the long-term prospects for growth are as good as we believe they are, and that's what we'll be focused on."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Robyn Karnauskas of Citi.",10,"And our next question comes from Robyn Karnauskas of Citi."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I guess, the question after hearing the comments about like thinking about volumes slowing or coming down and then thinking about growth and that changing over time, how do you -- how are you comfortable that you can provide guidance with these 2 variable",96,"I guess, the question after hearing the comments about like thinking about volumes slowing or coming down and then thinking about growth and that changing over time, how do you -- how are you comfortable that you can provide guidance with these 2 variables? Do you have any bookends for how low we can go that give you the comfort? And then the question is, you affirmed guidance last quarter and lowered it this quarter. What was the one thing you think that really changed your view over the last 3 months that led to that?"
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","I'll start and then hand the phone to Robin. Robyn, it's really hard. We've got markets in different stages of development, whether it be U.S., parts of the U.S, different countries in Europe and, obviously, interesting profound dynamics in Japan. So that",128,"I'll start and then hand the phone to Robin. Robyn, it's really hard. We've got markets in different stages of development, whether it be U.S., parts of the U.S, different countries in Europe and, obviously, interesting profound dynamics in Japan. So that's partly made up of patient flows and partly made up of sort of payer flows. I think the big thing this quarter, from the point of view of the U.S., was very much of payer kind of mix with the large addition of patients from the VA. So I think the last 3 months, that was probably the biggest thing. We have not changed our prices in the U.S., Q2 versus Q1. It was largely, we're seeing this dramatic but incredibly successful program from VA."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Robyn, I'll add to that. I agree with Kevin. I think the heavier percentage of more discounted payers, along with the fact that on the commercial side, right, we're seeing slight decreases [ph] in the U.S. And Kevin mentioned earlier about what we're also",168,"Robyn, I'll add to that. I agree with Kevin. I think the heavier percentage of more discounted payers, along with the fact that on the commercial side, right, we're seeing slight decreases [ph] in the U.S. And Kevin mentioned earlier about what we're also seeing relative to the mix shift in countries in Europe, less of Northern Europe, Germany, France and more of Italy and Spain. So the other part of your question is reflecting what we told you earlier about the call is that really difficult area. It's unlike any other. It's security market and it's very large relative to Gilead's total revenue. And so it's the first and we have [indiscernible] outer year how can we continue can we really guide allowing to see revenue. So we guided this year but it's definitely something [indiscernible] is the kind of think about the trends of HCV going forward in all the dynamics that we're tried to do with it's pretty complex. So more to follow on that."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Ian Somaiya of Bank of America Merrill Lynch.",14,"And our next question comes from Ian Somaiya of Bank of America Merrill Lynch."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","A quick one on pricing environment. So if you look at VA sector and also the commercial sector, what kind of impacts are you seeing from competition, particularly Merck, from a pricing perspective? And then quickly on R&D side. Do you plan to develop a do",69,"A quick one on pricing environment. So if you look at VA sector and also the commercial sector, what kind of impacts are you seeing from competition, particularly Merck, from a pricing perspective? And then quickly on R&D side. Do you plan to develop a double [ph] maintenance regimen for example recently Tivicay plus it during accommodation should actually good results in family of protruding patients in the conference."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","So I'll take the first part in terms of kind of pricing and the competitive impacts. Very little in terms of our commercial payer areas because the contracts are essentially you we are set up the end of last year for the full year. So very little change i",148,"So I'll take the first part in terms of kind of pricing and the competitive impacts. Very little in terms of our commercial payer areas because the contracts are essentially you we are set up the end of last year for the full year. So very little change in market share within the commercial payer segments. We still have a very strong position in VA with Harvoni and Sovaldi, particularly Harvoni. I think, probably where we see increased competitive activity is in the Medicaid setting where, as I described have earlier, some of the smallest states are requesting contracts as they open up access. So I think that's probably where we see the competition and again, because of our very strong value proposition, we hope we can be successful in the majority of goals. But again, on occasions, we may find it very good to the competition."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","[indiscernible] So we're, of course, aware of the data that we're presenting IP. So they look clearly impressive, the number of genotypes with high SBR rates. However, what they're doing right now in Phase III is not looking at the 8-weak treatment durati",175,"[indiscernible] So we're, of course, aware of the data that we're presenting IP. So they look clearly impressive, the number of genotypes with high SBR rates. However, what they're doing right now in Phase III is not looking at the 8-weak treatment duration or genotypes in those patients. I would like to contrast this with our own Atripla combination, SOF/VEL walks that John Milligan mentioned. We are looking essentially at 2 patient populations. One patient population is experience, that have previously failed other DAAs, treatment duration for 12 weeks. And then we're looking at all genotypes, Sovaldi in patients for 8-week treatment duration. And we have one study in particular that only looks at 8 weeks of treatment duration, the most difficult to treat genotype 3 Sovaldi patients  because that's still a population where SBR rates are still in the low 90s and [indiscernible] to the high 90s type of forward. I think our Phase III program, the data supports our Phase II results, then we will be a step ahead of all new competition."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Ian Somaiya of BMO Capital Markets.",12,"And our next question comes from Ian Somaiya of BMO Capital Markets."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I just wanted to follow up on the Atripla opportunity within hep C. Specifically, Norbert, just I don't know if you could describe the proportion of patients that have maybe failed in the first sort of round of antivirals, whether it be, double therapy or",84,"I just wanted to follow up on the Atripla opportunity within hep C. Specifically, Norbert, just I don't know if you could describe the proportion of patients that have maybe failed in the first sort of round of antivirals, whether it be, double therapy or [indiscernible] alone. So I don't know if there's a pool that you can speak to. And then maybe, I guess, more question for Kevin. Just how do you think about the triplet and its impact on margin price share?"
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","So Ian, we -- as you know, we are doing essentially 4 studies with the triplets, what we call the triplets of [indiscernible]. 2 of them are in frequent experienced patients what we would aspire to is to have this compound universal tablet regimen. Now Ke",155,"So Ian, we -- as you know, we are doing essentially 4 studies with the triplets, what we call the triplets of [indiscernible]. 2 of them are in frequent experienced patients what we would aspire to is to have this compound universal tablet regimen. Now Kevin maybe you could comment on what the proportion of patients is that would qualify but I can tell you in Japan, there's a fairly large number of patients have been treated with the Bristol-Myers [indiscernible] regimen. I think, if I remember this correctly, they have SBR rates in the Phase III study, about 80% or there are about 9,000 patients now that we heard off that are treatment experienced in that field. Those 9,000 would immediately be candidates for our own studies. And as I said, I want to say it again, the other 2 studies is 8-week treatment duration for all patients, all genotypes, Sovaldi and [indiscernible]. Kevin?"
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. It's a good question, Ian. We're waiting to see some of the clinical -- obviously, emerging clinical data. Right now, I mean, we've got a situation something on the U.S. Japan, with its resistant situation, I think, is perhaps quite unique in terms o",187,"Yes. It's a good question, Ian. We're waiting to see some of the clinical -- obviously, emerging clinical data. Right now, I mean, we've got a situation something on the U.S. Japan, with its resistant situation, I think, is perhaps quite unique in terms of the original use of the Bristol-Myers regimen. But I think we've got patients being cured to an incredibly high level with Harvoni. And now we've got the right treatment, I think, and that gives us [indiscernible] 2s [ph] or 3s [ph]. I think in the U.S, perhaps in Europe, it will be far more modest, the opportunity. Having said that, depends where we are with those products, our products with where the competition is obviously, what we decide to do in terms of the pricing strategy. I think most importantly, from a company point of view, we think this is the right thing to do and probably the last step in the whole story around hepatitis C to help treatment experience for earlier patients. I think first and foremost, we think this is the right thing to do for patients in need."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Olivia of Credit Suisse.",10,"And our next question comes from Olivia of Credit Suisse."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Two kind of questions, same vein. Just one on oncology. Has this remained a focus for you guys as far as building assess their in building up that business as much as it was in the past when you talked about? And secondarily, just Norbert, with Nash. Can",65,"Two kind of questions, same vein. Just one on oncology. Has this remained a focus for you guys as far as building assess their in building up that business as much as it was in the past when you talked about? And secondarily, just Norbert, with Nash. Can you talk about some of data points, but what's going on with the FXR program as well?"
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Let me start off by -- and John Milligan will have to comment on it, too. We are in oncology. We have now [indiscernible] at the end of the Phase III program with the database here. If the data is partly [indiscernible] application next year we have that",282,"Let me start off by -- and John Milligan will have to comment on it, too. We are in oncology. We have now [indiscernible] at the end of the Phase III program with the database here. If the data is partly [indiscernible] application next year we have that MSP 9 and gastric cancer in Phase III. We're looking at other solid tumors. And we're now finally, after sorting out the dosing, starting the first, in combination of a K-3 inhibitor CLL. So with regard to Nash. Yes, we have now very interesting 4 modalities or 4 mechanisms that we are evaluating in Nash. And at least, with 3 of them, we know that they are doing what they're supposed to do pharmacologically. We have the data this year on the ask inhibitor that will include liver fat analyses, along with histology. The FXR agonist is currently in a Phase I, Phase IIa study. And by the way, we know about that compound already that it has minimal systemic absorption, but there are systemic levels of SGS 19. That was always our idea to have a compound after the G.I. that releases FGF 19. SGS 19 and efficacy. And by that, the rationale will be both that the side effects and other FXR agonist have. And then finally, we have [indiscernible ] ACC inhibitor, the Nimbus compound. And we know those data were presented IP so that it will reduce the noble pathogenesis. So what we're going to do, based on these data, is asking if we can both the Phase III next year and to better compound with Phase II with the FXR and the ACC inhibitor or even this year. John?"
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. Follow-up with Norbert's comments by saying is we're committed to oncology. We continue to be interested in assets, collaborations and partnerships where we can enhance our ability to continue to sell these products. Where we are seeing good progress",92,"Yes. Follow-up with Norbert's comments by saying is we're committed to oncology. We continue to be interested in assets, collaborations and partnerships where we can enhance our ability to continue to sell these products. Where we are seeing good progress, as Norbert mentioned, our BTK inhibitor, which is ultimate with our partner from ONO, it's now making its way to the clinic, and we've overcome some form elation challenges to allow us to go ahead. So that will be very, very, I think, an interesting avenue for us to continue to explore."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our final question comes from Terence Flynn of Goldman Sachs.",11,"And our final question comes from Terence Flynn of Goldman Sachs."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Just wondering, kind of 2 parts. First is just any opportunity to broaden your prescriber base on hep C. Kevin, would love your question -- your thoughts on that. And the second question relates to Genvoya. Can you just give us what percentage of the swit",49,"Just wondering, kind of 2 parts. First is just any opportunity to broaden your prescriber base on hep C. Kevin, would love your question -- your thoughts on that. And the second question relates to Genvoya. Can you just give us what percentage of the switches were from ATRIPLA?"
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Terence, first of all, in terms of sort of do you like feature where market, I did mention Australia earlier. That's an incredible story of treating and curing patients and amazing commitment by the government there. We are seeing more patients treated in",145,"Terence, first of all, in terms of sort of do you like feature where market, I did mention Australia earlier. That's an incredible story of treating and curing patients and amazing commitment by the government there. We are seeing more patients treated in Brazil. It's a lower price market, but we are seeing more. We are just the beginning our launch in Mexico. So yes, these are smaller markets. Typically, they are lower-priced. But those, if you like those, smaller waves, are starting to work. We are thinking carefully about China, how we launch there, probably in a very modest or very focused, very efficient way, should I say. So our expecting, as, I think, are very reasonable around China. So the second question, in terms of switch, about 18% of the switched patients is from Atripla. So I hope that gives you the number."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And that concludes our question-and-answer session for today. I'd like to turn the conference back over to Mr. Lee for closing remarks.",23,"And that concludes our question-and-answer session for today. I'd like to turn the conference back over to Mr. Lee for closing remarks."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Great. Thank you, Candace, and thank you all for joining us today. We appreciate your continued interest in Gilead, and the team here looks forward to providing you with updates on our future progress.",34,"Great. Thank you, Candace, and thank you all for joining us today. We appreciate your continued interest in Gilead, and the team here looks forward to providing you with updates on our future progress."
29002,369689622,1011501,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program and you may all disconnect. Have a great day, everyone.",25,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program and you may all disconnect. Have a great day, everyone."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Second Quarter 2016 Earnings Conference Call. My name is Candace, and I will be your conference operator today. [Operator Instructions] And as a reminder, this conference",63,"Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Second Quarter 2016 Earnings Conference Call. My name is Candace, and I will be your conference operator today. [Operator Instructions] And as a reminder, this conference call is being recorded. 
I would now like to turn the call over to Sung Lee, Vice President, Investor Relations. Please go ahead."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Great. Thank you, Candace, and good afternoon, everyone. Just after market closed today, a press release was issued with earnings results for the second quarter of 2016. The press release and detailed slides are available on the Investor Relations section",220,"Great. Thank you, Candace, and good afternoon, everyone. Just after market closed today, a press release was issued with earnings results for the second quarter of 2016. The press release and detailed slides are available on the Investor Relations section of the Gilead website. 
Joining today's call will be John Milligan, President and Chief Executive Officer; Robin Washington, Executive Vice President and Chief Financial Officer; Kevin Young, Chief Operating Officer; and Norbert Bischofberger, Executive Vice President of Research and Development and Chief Scientific Officer. 
Before we begin formal remarks, let me remind you that we will be making forward-looking statements, including plans and expectations with respect to products, product candidates, financial projections and the use of capital, all of which involve certain assumptions, risks and uncertainties that are beyond our control and could cause actual results to differ materially from these statements. A description of these risks can be found in the latest SEC disclosures documents and recent press releases. In addition, Gilead does not undertake any obligation to update any forward-looking statements made during this call.
Non-GAAP financial measures will be used to help you understand the company's underlying business performance. The GAAP to non-GAAP reconciliations are provided in the earnings press release as well as on the Gilead website. 
I will now turn the call over to Robin."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, Sung, and good afternoon, everyone. We are pleased to share results for the second quarter of 2016. I'll first review our financials, and Kevin and John will then make a few comments. Total revenues for the second quarter was $7.8 billion, wit",1045,"Thanks, Sung, and good afternoon, everyone. 
We are pleased to share results for the second quarter of 2016. I'll first review our financials, and Kevin and John will then make a few comments. 
Total revenues for the second quarter was $7.8 billion, with non-GAAP diluted earnings per share of $3.08. This compares to revenues of $8.2 billion and non-GAAP earnings per share of $3.15 for the same period last year. Product sales for the second quarter was $7.7 billion, down 6% year-over-year and flat sequentially. The year-over-year decline was driven by lower HCV sales, partially offset by increased sales in HIV and other therapeutic areas. Sequentially, we saw an increase in HIV, U.S. HCV and other product sales that were offset by a decline in HCV sales in Japan and Europe. 
Turning to the U.S. Product sales for the second quarter were $4.9 billion, down 12% year-over-year. HCV product sales were $2.3 billion, down 33% year-over-year, driven by lower revenues per patient as a result of increased rebates and discounts due primarily to payer mix and lower patient starts for Harvoni, as the initial group of warehouse patients was treated in 2015. Sequentially, our HCV product sales were up 13%, driven by a $270 million adjustment to our HCV sales returns reserve rate and the initial inventory build for Epclusa. Strong uptake of our TAF-based regimens drove 23% year-over-year and 11% sequential growth of our HIV product sales. The quarterly revenues of $2.2 billion were also positively impacted by the upward trajectory of Truvada used for PrEP.
Turning to Europe. Product sales for the second quarter were $1.6 billion, down 18% year-over-year, primarily driven by lower HCV patient starts and a higher proportion of patient starts from countries that have a lower net average price. Sequentially, sales in Europe were flat, excluding the impact of currency movements, with HIV sales growth offset by lower HCV sales. 
In Japan, product sales for the second quarter were $619 million, down 43% sequentially as a result of lower patient starts from Harvoni and the full quarter effect of the mandatory price reductions for both Sovaldi and Harvoni, which were discussed during our last call. 
Moving to gross margin. Our non-GAAP product gross margin for the second quarter of 2016 was 92%, and benefited from the reversal of a $200 million litigation charge recorded in the first quarter of 2016, following a favorable decision in the Merck case. 
Now turning to expenses. Non-GAAP R&D expenses were $1 billion for the second quarter, up 48% compared to the same period last year, primarily due to the purchase of a U.S. Food and Drug Administration priority review voucher and the progression of clinical studies. Non-GAAP SG&A expenses for the second quarter were up 10% compared to the same period last year, primarily due to higher costs to support new product launches and our geographic expansion. From a balance sheet perspective, during the second quarter, we generated cash flow from operations of $4.9 billion and ended the quarter with $24.6 billion in cash and investments. While our cash flows will remain strong in the second half of the year, we anticipate a sequential decrease in Q3 2016 due to required cash payments related to our current government rebates in the U.S. and abroad as well as milestone payments associated with our R&D pipeline progression. 
We continue to return capital to our shareholders through dividends and share repurchases. During the second quarter, we repurchased 10.5 million shares for $1 billion under the $12 billion 2016 share repurchase program, and we received an additional 8.1 million shares in April 2016 from the final settlement of the accelerated share repurchase program announced in February 2016. The total share repurchases in the first half of the year were $98.2 million at a cost of $90 billion. As previously communicated, we anticipate share repurchases in the second half of 2016 to be lower than the first half of 2016, as we focus our capital allocation on advancing our R&D opportunities. 
Finally, we are updating full year 2016 guidance, which is outlined on Slide 21. The changes are as follows: We are lowering net product sales guidance to a range of $29.5 billion to $30.5 billion. While we are seeing continued strength in non-HCV product sales, given the current trends in payer and patient flow dynamics for HCV, our updated models for just net product sales will range from being slightly above to slightly below $30 billion for the year. As such, we believe it is prudent to update our full year 2016 guidance. The factors contributing to this conclusion include: Lower HCV revenue per patient as a result of a mix shift towards more heavily discounted payer segments in the U.S. and continued with a lower net average price in Europe, a trend towards slowing patient starts in the U.S. Commercial segment and some earlier launch markets of Europe, the continued gradual trend towards shorter duration, and loss of some market share to competition. This guidance is subject to a number of uncertainties, including potential changes in the global macroeconomic environment; adoption of additional pricing measures to reduce HCV spending; volatility in foreign currency exchange rates; inaccuracy in our HCV patient start estimates; additional competitive launches in HCV; an increase in discounts, chargebacks and rebates due to ongoing commercial payer contract negotiations; and a larger-than-anticipated shift in payer mix to more highly discounted payer segments, such as PHS, FFS, Medicaid and the VA. 
We are increasing our R&D expense guidance to a range of $3.6 billion to $3.8 billion, driven by acquisition-related expenses for Nimbus Apollo, Inc. and the purchase of a U.S. Food and Drug Administration priority review voucher, slightly offset by lower-than-anticipated clinical trial expenses. 
We are lowering SG&A expense guidance to a range of $3.1 billion to $3.3 billion, primarily driven by the favorable onetime adjustment to the expected invoice from the IRS for the Branded Prescription Drug fee, which lowered Q1 2016 SG&A expense. 
Diluted EPS impact of acquisition-related upfront collaboration, stock-based compensation and other expenses increases to a new range of $1.47 to $1.53 as a result of our recent M&A activity. All other components of our 2016 guidance remain unchanged. 
I would like to now turn the call over to Kevin."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Robin, and good afternoon, everyone. Let me say immediately how terrific it is to be back at Gilead in a full-time capacity. Working with exceptional executive colleagues around the table here in Foster City, interacting with my senior operat",1697,"Thank you, Robin, and good afternoon, everyone. 
Let me say immediately how terrific it is to be back at Gilead in a full-time capacity. Working with exceptional executive colleagues around the table here in Foster City, interacting with my senior operating management team and seeing the dedication of the thousands of Gilead employees around the world leaves me in no doubt as to the long-term prospects for this outstanding company. 
Whilst early days, over the last 2 months in my new role, I've had the opportunity to reflect on Gilead's recent product introductions, the evolving health care landscape and the operating challenges on our near-term horizon. I'd like to share 3 general observations with you today. 
First, I am struck by the commitment that is shared by physicians, payers and governments around the world, to reduce the prevalence of hepatitis C. Even countries with challenging economic circumstances are finding ways to prioritize the treatment of HCV patients. In the 2.5 years since the launch of Sovaldi, more than 1 million patients have been treated on a sofosbuvir-based regimen. Beneath this aggregated number are several landmark statistics. The United States has already treated nearly 0.5 million patients to date with Sovaldi and Harvoni. Equally, over 200,000 patients in Europe have been treated with Gilead regimens. Japan has treated approximately 100,000 patients in a little over a year. And just this year, Australia has treated an estimated 17,000 patients in a matter of months. Health care systems have demonstrably mobilized to reach those patients most in need. These are remarkable facts that clearly underscore the profile of the products we have introduced. Equally, they have implications to longer-term treatment dynamics and portfolio life cycles. Secondly, in the area of HIV, I'm impressed by how the clinical data for TAF-based regimens are resonating with the many constituents who tirelessly drive for better patient care. The understanding that these regimens can help address a growing need for highly effective and safer treatment options for lifelong HIV therapy is evidenced by the early success of Genvoya. I will highlight some impressive data points later.
Thirdly, I'm reminded just how complex the delivery of health care continues to be. Gilead's focus on flawless execution, on controlling the variables that we can control with the highest levels of competent compliance is critical and is my top priority. 
Now let me take you through the details of the commercial performance for the second quarter. Starting with HCV. In the U.S., total HCV revenue is $2.3 billion, up 13% sequentially and down 33% year-over-year. Since the beginning of the year, access has improved and almost all major commercial payers have been moved by grocery store criteria, joining Medicare and the VA in this regard. Medicaid remains the only payer segment where I used to still generally restrict it to the sicker patients. There are other significant barriers to access, but we are encouraged that some states have recently moved away from fibrosis restrictions towards more open access.
In terms of patient starts, approximately 59,000 people began HCV therapy in the second quarter, and an estimated 90% of these patients started on a sofosbuvir-based regimen. Importantly, third-party databases suggest that new patients are being identified through increased screening efforts. As evidenced, approximately 14 million people were screened for HCV for the period of 2014 through 2015, and approximately 280,000 were confirmed RNA positive in that 2-year period. These figures represent a significant increase from the years prior to the launch of Sovaldi. We estimate that 3 million individuals remain infected with HCV in the U.S., approximately half of whom are diagnosed.
Although patient starts increased for the second consecutive quarter and patient inflows into care remained recently steady at around 30,000 patients a month, the dynamics vary by patient segments. 
Within the commercial and Medicare segments, some larger payers have recently opened up access. We now estimate that up to 90% of all commercial covered lives have access without regard to fibrosis score. While the payers that recently opened up access are bringing in more patients, we are seeing a modest downward trend in patient starts among payers that have had full access in place for longer periods of time. The sickest patients have largely been treated, and the movement we are seeing is towards treating genotype 1 patients with low fibrosis scores and thus greater use of the 8-week treatment regimen for Harvoni. 
In terms of all new HCV treatment starts in the second quarter, approximately 45% came from within the public payer systems. We anticipate this percentage will remain largely the same through the remainder of the year. The VA is one example of a payer within this segment, and their commitment to treating and curing veterans who have HCV using budget allocated by Congress to do so is truly groundbreaking. We are aware that in some cities, extra clinics have been scheduled to help shoulder the workload. However, we also expect that in the longer term, socially disadvantaged patients within the VA system will be harder to reach and bring into care and that the rate of treatment will decline.
Turning to Europe. Total HCV revenue in the second quarter was $775 million, down 32% year-over-year and down 7% sequentially. Overall, Gilead patient starts decreased to around 28,000 for the quarter. We observed steady treatment rates in Italy and Spain, but lower numbers in early launch markets like Germany and France. Patient starts in the U.K. continue to be limited by NHS England budget restrictions. Additionally, we saw a slight decline in average treatment duration, as countries like Germany are treating more patients with low fibrosis scores, who qualify for an 8-week treatment duration.
In several European markets, locally documented cure rates are equal to, if not better than, what was demonstrated in Sovaldi and Harvoni clinical studies. This has resonated with governments and payer bodies, and some countries such as France are considering removing all fibrosis score criteria. We will watch this picture closely and share evolving news with you in the future. 
Moving to Japan. As Robin mentioned, revenue was $619 million, down 43% sequentially. We believe this was related to 2 factors: First, the decline in genotype 1 new patient starts following the Q1 2016 peak when a very large number of individuals with advanced disease initiated therapy; and second, the full treatment effect of a mandatory price reduction previously described on last quarter's call.
Finally, for HCV, Epclusa was recently approved in the U.S., the EU and Canada. These approvals are true milestones in patient care since Epclusa is the first pan-genotypic, once-daily, single-tablet option. Epclusa will be an important treatment option in the U.S. as an estimated 20% to 25% of HCV patients have genotypes 2 and 3. And equally, across Europe, there are some countries that have up to 30% of patients with genotype 3 alone. 
In concluding my remarks on hepatitis C, I will return to my earlier comments. Gilead is proud to be part of a fundamental disease paradigm shift, delivering disease cures to virtually all patients treated. That's why we developed Sovaldi, Harvoni and Epclusa and have a third single-tablet regimen in clinical testing. 
Whilst the pace of new patient treatments may slow in coming years and quantifying that pace is incredibly hard, there is still an opportunity to identify and cure many HCV infected people around the globe. 
Moving to HIV. We are pleased with the launch of our TAF-based products in the U.S. and in the European markets where we have already achieved reimbursement. In the U.S., total HIV and other antiviral revenue was $2.2 billion, up 11% sequentially, and Genvoya revenue nearly doubled in Q2 versus Q1. The product represents the most successful HIV launch since the introduction of Atripla, the first single-tablet regimen, a decade ago. After its first 6 months of availability, Genvoya is already the most prescribed regimen for both treatment-nave and switch patients. 
78% of all Genvoya prescriptions have come from switches. Half of the switches have come from Stribild, and importantly, 10% of switches have come from non-Gilead therapies. Among all patients who switched, we have seen an increase in our ability to retain patients on a Gilead product. 
Whilst still in the early stages of the Odefsey and Descovy launches, we are seeing similar patient dynamic to Genvoya. Over 90% of all Odefsey and Descovy prescriptions have come from switches. And 6% and 11% of switches, respectively, have come from non-Gilead therapies. 
Finally, in the U.S., I would like to highlight the growing use of Truvada for PrEP. We estimate somewhere in the order of 60,000 to 70,000 patients were using Truvada for PrEP in the second quarter. This number accounts for approximately 1/3 of Truvada demand. This is encouraging, as we know Truvada has an important role to play as part of comprehensive HIV prevention for many at-risk individuals.
Turning to Europe. Total HIV and other antiviral revenue was $755 million, up 5% sequentially, driven by the launches of Genvoya and Descovy. Genvoya has gained pricing approval in 11 countries and is now the market leader in Germany for both treatment-nave and switch patients after only 6 months of availability. We anticipate additional launches in France, Italy and the U.K. in the second half of the year. 
Genvoya is a preferred regimen in several HIV treatment guidelines, including Italy, where it was added before pricing and reimbursement. Preferred listings are anticipated in other EU guidelines later this year and into 2017. EACS guidelines are expected to be updated following the HIV Glasgow 2016 Conference in October.
Finally, I would like to briefly update you on the outstanding performance of the Gilead U.S. cardiovascular team. Letairis and Ranexa together generated $356 million in revenue during the quarter, representing a 12% year-over-year increase. Today, over 0.25 million people in the United States regularly receive Ranexa. And Letairis remains the overall ERA market leader in PAH. 
In closing, Gilead achieved a great deal across our operations during the quarter, and I am confident that we will continue to make significant progress in the second half of 2016. 
I would now like to turn the call over to John."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, Kevin. Before I get started, I just wanted to say it's great to have you back on the Gilead full team -- full time as our new Chief Operating Officer. Today, in addition to the remarks of Robin and Kevin regarding the quarter, I'd like to make a",1165,"Thanks, Kevin. Before I get started, I just wanted to say it's great to have you back on the Gilead full team -- full time as our new Chief Operating Officer. 
Today, in addition to the remarks of Robin and Kevin regarding the quarter, I'd like to make a few comments of my own. Over the last 2.5 years, we've made great progress in helping provide access to Sovaldi and Harvoni for HCV patients. Throughout the world, more than 1 million HCV sufferers have now been treated with nearly half of those coming from the U.S. A lot of these drugs were unprecedented in our industry, and patients were treated at a much faster initial rate than we, or anyone else, thought possible. Looking back, we can now say that in every country, the peak number of patients treated was achieved within 2 or 3 quarters of the launch of Harvoni. And that peak number is far higher than what we had -- what had ever been achieved before, about 3x that seen with the launch of the HCV protease inhibitors in 2011.
As we'd reached the mid-point of this year, we now see the market maturing to a slower rate of treatment for HCV-infected individuals. And as we think about this more normal patient starts, there are a few things to keep in mind. As Kevin mentioned, there are about 3 million people who are infected in the U.S., and slightly more than half of those have been diagnosed. Many of these diagnosed patients have less advanced liver disease upon reentering care. For example, in the United States in the second quarter this year, we estimated that only 13% of patients starting treatment had F4 fibrosis scores compared with more than 21% the year prior to that. With less severely ill patients, there is less urgency to immediately treat patients. This may explain the slower rate of treatment versus last year. However, we do believe these patients will eventually benefit from treatment, and this means the flow of patients will continue for many years to come.
There's also an opportunity to diagnose patients and bring them into care. As Kevin mentioned, we estimated that about 280,000 HCV patients were diagnosed in the U.S. within the last 2 years, showing the value and importance of the U.S. CDC and CMS recommendations for HCV testing. So while there has been a slowing of treatment compared with the rush of patients when Sovaldi and Harvoni were first approved, the HCV market is attractive over the longer term, providing good revenues, strong cash flow and earnings per share, on top of our base business of chronic therapies. 
Because of this, our focus on approving care for HCV and the affected individuals has not wavered. Beyond the recent approvals of Epclusa, we are actively working on a third single-tablet regimen that combines the 2 active ingredients in Epclusa with a third investigational compound, [indiscernible] telaprevir. This combination, known as SOF/VEL/VOX, is being evaluated at 4 Phase III clinical trials among patients who have previously failed direct acting antiviral treatments. It's also being studied for its potential to offer an 8-week treatment duration for treatment-nave patients of all genotypes. We expect to have top line data available for SOF/VEL/VOX by the end of the year. 
We're making tremendous headway in HIV as well. Both of our portfolio of newer products and our pipeline. We've had several key approvals with Descovy approving the U.S. and Europe last quarter and Odefsey approved in Europe an earlier this month. It's clear these medications offer a significant advance for patients, and that advance has been recognized now by multiple professionals and public health groups, including the International Antiviral Society of the U.S.A. and the Department of Health and Human Services, both of which were released updated guidelines supporting the use of TAF-based regimens for initial HIV therapy. 
We continue to generate clinical data that support the favorable scientific and medical profile of our TAF-based products. Last week, we announced the results of 2 Phase IIIb switch studies, evaluating Odefsey in virologically suppressed adults switching from Complera or Atripla. Odefsey achieved similar rates of virological suppression as the TDF-based regimen. These studies reinforce the efficacy of Odefsey as well as the renal and bone safety advantages, and we plan to present full data sets later this year. 
Last month, we presented the first human data on bictegravir, our investigational, unlisted integration inhibitor, at the American Society for Microbiology. Data from 4 preclinical and Phase I studies examined the antiviral processes, resistance profile, pharmacokinetics and safety of bictegravir, providing the rationale to further evaluate the compound. Bictegravir as part of a single-tablet regimen, in combination with TAF and emtricitabine, is currently in Phase III trials. Enrollment of more than 2,300 patients across 4 registrational studies was completed earlier this month. The 48-week endpoints for this studies will be reached in the second quarter of next year, and if the data play out as we hope, NDA and MAA filings could occur in the third quarter of 2017.
With the approval and rapid adoption of our TAF-based regimens, an exciting new STR and Phase III development and an active HIV research pipeline, I'm confident that we will be able to extend our leadership position in the HIV market and broaden our ability to help even more patients around the world. 
Outside of our working antivirals, Gilead is focused on solving some of the biggest health challenges today. Several important data sets that are anticipated in the second half of this year may help us to find a strategy and pathway forward for tackling these challenges. In our NASH program, where we have 4 active clinical programs, we'll have data from the Phase II studies of GS-4997, our ASK-1 inhibitor, and simtuzumab, our monoclonal antibody and LOXL2. The Phase II study of simtuzumab for primary sclerosing cholangitis will also conclude. We will also have data from the Phase II studies of GS-4997 in diabetic nephropathy and pulmonary arterial hypertension, or PAH. And finally, we expect data from 2 Phase III studies for myelofibrosis before the end of the year. If these data are positive, these studies will form the basis for an MDA filing in the first quarter of 2017. 
These are important milestones and represent a great deal of work across the organization to enroll and advance these studies and analyze complex data sets as they become available. Gilead continues to innovate at every level and every part of the organization. Next month, we will publish our first corporate social responsibility report that looks at access sustainability, graph making and other positive contributions to the communities we serve, and I urge you to read it. 
I'm proud of the work that's been led by our employees and extend my many thanks to them for all the ways they are making a difference around the world. 
Thank you, and let's now open up the call for questions. Operator?"
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Geoff Meacham of Barclays.",15,"[Operator Instructions] And our first question comes from the line of Geoff Meacham of Barclays."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Kevin, good to have you back on the call, and on the seat, of course. So I wanted to dig into your comments and also John's comments on the hep C new starts. And just -- I guess, I'm curious because you have better F0, F1 Access. You have positive impact",121,"Kevin, good to have you back on the call, and on the seat, of course. So I wanted to dig into your comments and also John's comments on the hep C new starts. And just -- I guess, I'm curious because you have better F0, F1 Access. You have positive impact theoretically from the CDC guidelines and very low penetration in markets such as the prison population. I'm just curious why, could you put your finger on maybe 1 or 2 things that you feel like could ultimately be a -- become a growth driver to give us back to better sequential growth? I'm just trying to figure out what the tipping point is, on some of these different volume drivers."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Geoff, nice to hear your voice as well. Thank you for your comments. I'm not at all pessimistic about the long-term prospects for hepatitis C. In fact, I'm rather optimistic. I think what we have seen 2014, 2015 is an enormous group of the less well patie",335,"Geoff, nice to hear your voice as well. Thank you for your comments. I'm not at all pessimistic about the long-term prospects for hepatitis C. In fact, I'm rather optimistic. I think what we have seen 2014, 2015 is an enormous group of the less well patients treated, particularly by specialists, hepatitis C treaters. It's really quite amazing. I think this quarter, we've highlighted perhaps going forward is really sort of a payer mix situation that we've got. The VA has definitely increased in terms of its contribution to the 59,000 total HCV starts, which, of course, was an increase on quarter 1. So a lot of VA patients are coming through, and the VA is very, very motivated to try to essentially eradicate the virus from that population. I think, yes, we did see a pickup in 2 of the large players that came on stream with open fibrosis scores from the beginning of the year, but we did see some downtick in other commercial payers. So net-net, it was slightly a decrease in overall commercial patients. What I feel about the long term and as we go into years further forward and we kind of hit an equilibrium of patients is all around what I mentioned, and John mentioned, around diagnoses. There's been a considerable pickup in the number of HCV tests, 2014, 2015, about a 65% increase in the number of HCV tests. 280,000 in that 2-year period were HCV RNA positive. So as John said, they will eventually work their way through treatment. But still over 1/4 of the population being diagnosed is at 4. So there's still a lot of sickness out there in patients. So whilst the health care system here and some of the European markets have done heroic things in treating patients in the last 2 years, I still think, with 1.5 million diagnosed patients in the United States that we are going to see a continued healthy flow of patients that can benefit from our products."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Geoffrey Porges of Leerink.",10,"And our next question comes from Geoffrey Porges of Leerink."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","For Kevin, welcome back, and good to hear you. So following up on this -- some vexing issue of the HCV outlook. Historically, in this category after each market has peaked, it's begun a steady slow, sometimes slow, anyway, decline. We certainly saw a rapi",153,"For Kevin, welcome back, and good to hear you. So following up on this -- some vexing issue of the HCV outlook. Historically, in this category after each market has peaked, it's begun a steady slow, sometimes slow, anyway, decline. We certainly saw a rapid decline after the protease inhibitors, more slow decline after we went to ribavirin and with the interaction of pegylated interferon. Are you suggesting to us that you think that there is a stable outlook for the HCV revenue on a market-by-market basis from these levels? Or are you suggesting that we should see more like an orderly and steady decline? And could you particularly comment about Europe, where I think it was surprising to see patient numbers in the big early markets roll over so quickly, particularly Germany and Japan? Is that a onetime step-down? Or are we going to continue at or below this level going forward?"
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. Thanks for the question, Jeff. I think it is encouraging that patient starts in the U.S. and Europe have been recently steady over the past 3 quarters. Japan's a different story, and I can certainly, at some point, comment on that this afternoon. I t",298,"Yes. Thanks for the question, Jeff. I think it is encouraging that patient starts in the U.S. and Europe have been recently steady over the past 3 quarters. Japan's a different story, and I can certainly, at some point, comment on that this afternoon. I think, from my perspective and Robin, Norbert, John around the table here, I think it's more of the latter comment that there will continue to be a gradual decline in new patient starts, but an equilibrium will be eventually hit. Quite the timing of that, Geoff, it's really, really, really hard to peg. I've just got to believe that with the amount of testing, with the amount of diagnoses with the CDC guidelines, Gilead itself in Q3, Q4 this year are going do some more educational programs around the need to test and treat that. We will eventually hit an equilibrium. In terms of Europe, Italy and Spain are very steady. I should tell you that in Italy there are still 200,000 quite sick individuals, people to be treated, and they're in treated care. And the Italian government do want to go ahead and try and mobilize providers to do that treating. So it's still an enormous number in Italy. I think the more -- the markets that are more akin to the U.S. like, first and foremost, Germany and to a slight lesser extent, France, are starting to see that sort of turnover of patients. We've got full access in terms of fibrosis score in Germany, and we're hoping, as I said, that we get broader access in France. The U.K. is a different situation, and that's largely due to payer restrictions. But again, still an enthusiasm to treat, but 1 or 2 of those markets, there is some maturing going on."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Mark Schoenebaum of Evercore ISI.",11,"And our next question comes from Mark Schoenebaum of Evercore ISI."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","This is Regina Grebla in for Mark. I actually wanted to change topics and shift to hepatitis B. On your Q1 call, you mentioned your hep B program included a vaccine, the TLR7 agonist, and 2 other internal preclinical candidates. When will we see any data",73,"This is Regina Grebla in for Mark. I actually wanted to change topics and shift to hepatitis B. On your Q1 call, you mentioned your hep B program included a vaccine, the TLR7 agonist, and 2 other internal preclinical candidates. When will we see any data on the internal candidates? And also, you mentioned taking a look at external opportunities for hepatitis B. Is hep B still potential area of interest for acquisition?"
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. So Regina, you asked a question about what our pipeline is for hepatitis B. So we have, as you know, 2 compounds currently in clinical development. One is an active vaccine, 4779, the collaboration with GlobeImmune. That's currently in the later stag",325,"Yes. So Regina, you asked a question about what our pipeline is for hepatitis B. So we have, as you know, 2 compounds currently in clinical development. One is an active vaccine, 4779, the collaboration with GlobeImmune. That's currently in the later stages of being evaluated in non-suppressed state B patients. The suppressed state B patients, those data have been released, I think, maybe a year ago. That data did not show any activity, so we don't have high hopes that this compound will work. Then, the TLR7 agonist is that's just finishing the first cohort, which is in suppressed patients, and we are currently initiating -- the second cohort quarter is ongoing. We hope that we'll have the presentation of the first cohort ready by AASLD. Hopefully, we'll make that -- the abstract deadline. Then, you said that -- you asked the question about we had 2 other compounds in development. Well, you know what we're pursuing. Maybe I should answer this more generally. So we're pursuing 3 approaches to hepatitis B cure. So one is adding another different mechanism to the nucleosides because there's the observation that despite being undetectable with hepatitis B therapies like Viread or TAF, there was always a little bit of virus left, HBV there maybe takes about -- if you look at very sensitive PCR methods. So by adding another mechanism, so actually, we could completely suppress virus replication down to 0. Would that lead to an eventual cure or hepatitis S conversion? The second thing we're pursuing is immune therapy, so that belongs the vaccine and the TLR7 that I've talked about already. And we have a TLR8 agonist currently that is working its way towards an IND. And then the third possibility, that's the most hopeful but also the one that's least scientifically proven that's going directly after cccDNA, and that's really too early to talk about at this point. It's still in the research stages."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Michael Yee of RBC Capital Markets.",12,"And our next question comes from Michael Yee of RBC Capital Markets."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","You talked a lot about volume and demand in the different buckets. But can you talk about the payer mix shift? Specifically, I wanted to ask on Medicaid. Can you just help us out with what percent of sales Medicaid is? And what is going on in that bucket?",98,"You talked a lot about volume and demand in the different buckets. But can you talk about the payer mix shift? Specifically, I wanted to ask on Medicaid. Can you just help us out with what percent of sales Medicaid is? And what is going on in that bucket? I presume it's a state-by-state negotiation. Can you talk about what's going on there? Is there a state-by-state negotiation you have to go through? Is that pretty much done? Walk us through that bucket and what percent of hep C that is in U.S.A. so I can understand them."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Michael, it's Kevin. Thank you for the question. I prefer not to break out specifically the percentage of the public payers in terms of Medicaid. As I said, all our public payers lumped together for the quarter were about 45%. That's an increase from the",178,"Michael, it's Kevin. Thank you for the question. I prefer not to break out specifically the percentage of the public payers in terms of Medicaid. As I said, all our public payers lumped together for the quarter were about 45%. That's an increase from the previous quarter, but as I said, that's all driven by VA. We've seen very little change, really, in our -- in the scale and size of our Medicaid business. I think it would be true to say that Medicaid's -- the states are slowly progressively opening up. 40% of Medicaid patients come from the 5 largest states. Two of those, New York and Florida, now have no fibrosis score. So as states do progressively consider opening up, they typically come to us for a contract. We think about those contracts very carefully. Depending on the size of Medicaid, we obviously put out our submission in. Realistically, I think we may win, we hope, the majority of those, but there may be occasions when, occasionally, a Medicare -- Medicaid stake goes to the competition."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Matthew Harrison of Morgan Stanley.",11,"And our next question comes from Matthew Harrison of Morgan Stanley."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Robin, if you could just address the $279 million onetime swing. We obviously saw a swing in the first quarter and then a swing this quarter again. Can you just give us some insight into what's going on with those changes in chargebacks and if we should c",72,"Robin, if you could just address the $279 million onetime swing. We obviously saw a swing in the first quarter and then a swing this quarter again. Can you just give us some insight into what's going on with those changes in chargebacks and if we should continue to expect to see some of those numbers? And then just separately on PrEP, any plans to get a TAF-based regimen approved for PrEP?"
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Sure. I'll take the first part, and then Norbert will take the second. Matt, first of all, there are 2 separate things that we're talking about here Q2 versus Q1. The first one, the interrupt [ph] Q2. We did have a sales return reserve adjustment really r",362,"Sure. I'll take the first part, and then Norbert will take the second. Matt, first of all, there are 2 separate things that we're talking about here Q2 versus Q1. The first one, the interrupt [ph] Q2. We did have a sales return reserve adjustment really related to the fact that as we introduce our new hep C product, we're required to go out and get an external proxy related to sales return reserve. And just recently, just this past quarter, we closed several of the lots related to our products, which means that no further returns are accepted. So that gives us a triggering event by which we can look at returns versus how we had been accruing. The other key thing about the timing is just related to the Epclusa lot. So as we bring on a new product, we want to kind of want to rebase their level of returns that we expected to see. So that's really the adjustment there. For the most part, you could -- it's onetime in nature. We may have small adjustments going forward, but as long as returns continue where they are, then that $279 million is kind of a onetime event. Last quarter, we had a different issue, and that related to rebate claims for hepatitis C. And as I said on the call last time, we always have a situation where we're constantly truing up claims around HCV rebate because we get those claims 1 to 2 quarters in arrear. This quarter was a bit different than last quarters that we saw a modernization of the level of those claims relative to the prior quarter. So it wasn't -- it did reverse the other way. It was just a slowing of what we saw in Q1. So we're -- for lack of better word, so you're a little bit more caught up relative to returns this quarter than we were at the end of Q1. So 2 different items, but we caught up at $279 million because that was the onetime event. So we ensured -- we want to ensure that you understood relative to the future projection of HCV sale."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Matt, [indiscernible] your question about TAF [ph] , F/TAF or PrEP, so we and also the outside medical community believes that, obviously, discovery of F/TAF would have advantages in terms of use for PrEP versus TRUVADA for all the obvious data that we ha",149,"Matt, [indiscernible] your question about TAF [ph] , F/TAF or PrEP, so we and also the outside medical community believes that, obviously, discovery of F/TAF would have advantages in terms of use for PrEP versus TRUVADA for all the obvious data that we have published already. And also, we have data now in human -- in animal models that show that has the same efficacy. The thing we're debating internally and also we have had early discussions with FDA is what clinical study would need to be done that leads to approval. It would have to be an almost all likelihood and comparative study and tend to seek [indiscernible] what would be the sample size and what would be the powering. And that's currently a discussion we're having with FDA. We hope we can come to some conclusion within the next months or so and then let you know."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Brian Abrahams with Jefferies.",10,"And our next question comes from Brian Abrahams with Jefferies."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Kevin, good to hear your voice again. With the list pricing and label established for Epclusa, just wondering what's the right way to think about Epclusa's potential impact on the genotype 2/3 franchise, particularly with respect to the net price per pati",74,"Kevin, good to hear your voice again. With the list pricing and label established for Epclusa, just wondering what's the right way to think about Epclusa's potential impact on the genotype 2/3 franchise, particularly with respect to the net price per patient treatment duration relative to Sovaldi and just how we should be thinking about the overall market dynamics there. I'm just wondering if you could also quantify the inventory build this quarter there."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. Great question, Brian. Nice to hear your voice as well. Brian, the majority of the revenues in the second quarter, which is right to the end, the majority of that was inventory that Robin called out. So we've really only just begun the introduction,",303,"Yes. Great question, Brian. Nice to hear your voice as well. Brian, the majority of the revenues in the second quarter, which is right to the end, the majority of that was inventory that Robin called out. So we've really only just begun the introduction, both the promotion and the education around Epclusa. I'm really pleased that the response has been excellent, and our advisory boards and our speaker programs have been good acceptance. Whilst we have obviously a pan-genotypic label, I think the reality is that physicians are very, very comfortable, as our payers with Harvoni for genotype 1. Obviously, that's a mix of 12-week treatments and 8-week. Just for your information, the 8-week cost of Harvoni is now 45% of patients treated in the United States. So I think people are just really comfortable with the clinical effect and the value proposition of Harvoni in GT1, which that all means that the slot that people see Epclusa is in the 2 and 3 patient. As I highlighted, it's something like in the order of 20% to 25% of patients in the United States. I think the obvious advantage, both clinically and from a payer point of view, is you really do have a 12-week single-tablet regimen. You don't have to extend the treatment duration. You don't have to use ribavirin. There's quite a number of patients treated with Sovaldi, Daclatasvir, certainly, in United States. So really, somewhat, it takes away that regimen, and it's an excellent slot. So we've had very good reception to Epclusa. It's extremely early days. It will take us 3 to 6 months to get payer approval. Physicians can apply based on medical need, and we know they're doing that, so just very early days and weeks. It seems to have found a very nice entry point."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from the line of Cory Kasimov of JPMorgan.",13,"And our next question comes from the line of Cory Kasimov of JPMorgan."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I have a bigger picture question for you. Really, just following the latest management shuffle back in 2Q, I'm wondering if these changes portend any material shift or consideration of a shift in, I guess, your commercial or pricing strategy, really, the",75,"I have a bigger picture question for you. Really, just following the latest management shuffle back in 2Q, I'm wondering if these changes portend any material shift or consideration of a shift in, I guess, your commercial or pricing strategy, really, the overall strategy for the business or any of the key businesses. And is this playing into the bump in anticipated R&D with the associated downtick in SG&A as illustrated by your updated guidance?"
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","I think there were a couple of questions there. So it's John Milligan. So in terms of -- let me get to the last bit. You said there was a bump in R&D. That is true, relating somewhat to our acquisition of Nimbus. So there were charges associated with that",243,"I think there were a couple of questions there. So it's John Milligan. So in terms of -- let me get to the last bit. You said there was a bump in R&D. That is true, relating somewhat to our acquisition of Nimbus. So there were charges associated with that. There were also charges associated -- I should say expenses associated with the purchase of an FDA priority review voucher. So we're very pleased to get that onboard, and we look forward to explaining when we're going to use that. Above and beyond that, actually, R&D expenses were slightly down what we -- beneath what we have forecasted because we continue to hold the cost centers to -- accountable and continue to drive good value through our clinical teams in getting studies done at a very cost-effective way. So in terms of that, there's no difference. The SG&A line came down a little bit because of some onetime charges that were lower than we -- sorry, the IRS charges was lower than we anticipated, so kind of what we would expect. In terms of signaling about pricing or changes in management about structures, I don't really think there's anything to signal there in terms of our pricing strategy. We're highly competitive. We think we have a very good differentiated product, and we'll continue to do the best for the company and for patients by coming to the right level of price and access."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. And I would just add, Cory, that the Gilead way is always to lead with the science around our product. Nothing's changed. In my eyes, as I have come back into the company, we lead with science. That's what you do in specialist markets. It is reality",111,"Yes. And I would just add, Cory, that the Gilead way is always to lead with the science around our product. Nothing's changed. In my eyes, as I have come back into the company, we lead with science. That's what you do in specialist markets. It is reality that there is more contracting. I think we got phenomenal team working on this. I met with them 2 weeks ago, and I think they're highly professional. And we also lead with value. That's the key thing. We think we got tremendous products that either control disease or cure disease, and they are terrific value. And that's the cause we're going to state."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Phil Nadeau of Cowen.",10,"And our next question comes from Phil Nadeau of Cowen."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Kevin, it's good to have you back. I have a question on capital allocation. In prepared remarks, I think you mentioned in regards to cash flows being lower in the second half of the year that part of that was investment in R&D, and as you just discussed,",104,"Kevin, it's good to have you back. I have a question on capital allocation. In prepared remarks, I think you mentioned in regards to cash flows being lower in the second half of the year that part of that was investment in R&D, and as you just discussed, the R&D expenses aren't really changing that much in the guidance. So kind of curious whether you have on your list of things to do in the second half of the year more deals, whether M&A or in-licensing. And maybe you could give us some thoughts on how aggressive you're likely to be in those areas."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","So Phil, I'll start. I think relative to the cash flow, what I was messaging was really just related to the dynamics of payments, right? So we have accrued rebates and other things that kind of caused volatility to quarter-end cash flows. So overall, our",115,"So Phil, I'll start. I think relative to the cash flow, what I was messaging was really just related to the dynamics of payments, right? So we have accrued rebates and other things that kind of caused volatility to quarter-end cash flows. So overall, our cash flows remain strong, but we definitely expect a sequential decrease in cash flows second half. Relative to overall capital allocation, it's no different than what we've been messaging, again, more focused on our BMD opportunities, but I'll let John speak of a little bit more and just, again, focus there. And that additional focus has meant we're somewhat less focused on share repurchases the second half of the year."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","And as a follow-up on what Robin said, Phil, we were very aggressive in the first quarter of this year. That's why we back off a bit from where we were in the second half of the year. Mostly, you get the full year effect or a greater effect of repurchasin",194,"And as a follow-up on what Robin said, Phil, we were very aggressive in the first quarter of this year. That's why we back off a bit from where we were in the second half of the year. Mostly, you get the full year effect or a greater effect of repurchasing the almost 100 million shares through Robin's program. With regard to business development, obviously, we're a company that has been very open about being interested in doing more deals, especially deals of a certain size where we think we can get some leverage and we can use our organization to effectively accelerate or expand indications. We've done some good deals both with Galapagos and Nimbus recently. We are very interested in continuing that to add more things to our pipeline, especially in the non-antiviral area where we continue to see growth in franchises. It's our hope that as we exit this year, we'll have a better, more complete story of programs internally and externally that we can use to talk about why the long-term prospects for growth are as good as we believe they are, and that's what we'll be focused on."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Robyn Karnauskas of Citi.",10,"And our next question comes from Robyn Karnauskas of Citi."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I guess, the question for me after hearing some of the comments about like thinking about volumes slowing or coming down and then thinking about growth and that changing over time is how do you -- how are you comfortable that you can provide guidance with",101,"I guess, the question for me after hearing some of the comments about like thinking about volumes slowing or coming down and then thinking about growth and that changing over time is how do you -- how are you comfortable that you can provide guidance with these 2 variables? Do you have any bookends for how low we can go that give you the comfort? And then the question is you affirmed guidance last quarter and lowered it this quarter. What was the one thing you think that really changed your view over the last 3 months that led to that?"
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Sure. You want to start, Kevin?",6,"Sure. You want to start, Kevin?"
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","I'll start and then hand the question to Robin. Robyn, it's really hard. We've got markets in different stages of development, whether it be U.S., parts of the U.S., different countries in Europe and obviously, interesting and profound dynamics in Japan.",130,"I'll start and then hand the question to Robin. Robyn, it's really hard. We've got markets in different stages of development, whether it be U.S., parts of the U.S., different countries in Europe and obviously, interesting and profound dynamics in Japan. So they're partly made up of patient flows and partly made up of sort of payer flows. I think the big thing this quarter, from the point of view of the U.S., was very much the payer kind of mix with the large addition of patients from the VA. So I think in the last 3 months, that was probably the biggest thing. We have not changed our prices in the U.S. Q2 versus Q1. It was largely we're seeing this dramatic but incredibly successful program from VA."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. Robyn, if I'll add to that, I agree with Kevin. I think the heavier percentage of more discounted payers, along with the fact that on the commercial side, right, we're seeing slight increases in the U.S. And Kevin mentioned earlier about what we're a",183,"Yes. Robyn, if I'll add to that, I agree with Kevin. I think the heavier percentage of more discounted payers, along with the fact that on the commercial side, right, we're seeing slight increases in the U.S. And Kevin mentioned earlier about what we're also seeing relative to the mix shift in countries in Europe, less of Northern Europe, Germany, France and more of Italy and Spain. So the other part of your question is what you were [ph] earlier throughout the call, this is a really difficult area to predict. It's unlike any other. It's a curative market, and it's very large relative to Gilead's total revenue. And so it's the first thing we ask ourselves as we think in the outer years how can we continue or can we really guide around HCV revenues. So we've guided this year, but it's definitely something we're giving a lot of thought as we kind of think about the trends of HCV going forward and all the dynamics that we're trying to deal with it. It's very complex, so more to follow on that."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Ying Huang of Bank of America Merrill Lynch.",14,"And our next question comes from Ying Huang of Bank of America Merrill Lynch."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I have a quick one on also the pricing environment. So if you look at VA sector and also the commercial sector, what kind of impacts are you seeing from competition, particularly Merck's Zepatier, from the pricing perspective? And then quickly on R&D side",74,"I have a quick one on also the pricing environment. So if you look at VA sector and also the commercial sector, what kind of impacts are you seeing from competition, particularly Merck's Zepatier, from the pricing perspective? And then quickly on R&D side. Do you plan to develop a doublet maintenance regimen? For example, recently, Tivicay plus EDURANT, the combination showed actually good results in heavily protruded [ph] patients in the near conference."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","So I'll take the first part in terms of kind of pricing and the competitive impacts. Very little in terms of our commercial payer areas because the contracts essentially were set up at the end of last year for the full year, so very little change in marke",145,"So I'll take the first part in terms of kind of pricing and the competitive impacts. Very little in terms of our commercial payer areas because the contracts essentially were set up at the end of last year for the full year, so very little change in market share within the commercial payer segment. We still have a very strong position in VA with Harvoni and Sovaldi, particularly Harvoni. I think, probably where we're seeing increased competitive activity is in the Medicaid setting where, as I described earlier, some of the smallest states are requesting contracts as they open up access. So I think that's probably where we see the competition. And again, because of our very strong value proposition, we hope we can be successful in the majority of those. But again, on occasions, we may find that they go to the competition."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. Ying, you asked the question about the ViiV, the entering [indiscernible] . So we're, of course, aware of the data that we'll present at ID. So they look clearly impressive, the number of genotypes with high SVR rates. However, what they're doing rig",200,"Yes. Ying, you asked the question about the ViiV, the entering [indiscernible] . So we're, of course, aware of the data that we'll present at ID. So they look clearly impressive, the number of genotypes with high SVR rates. However, what they're doing right now in Phase III is not looking at the 8-weak treatment duration or genotypes enrolled patients. I would like to contrast this with our own triple combination, SOF/VEL/VOX, that John Milligan mentioned. We are looking essentially at 2-patient population or 1-patient population's experience that had previously failed other DAAs. That treatment duration is for 12 weeks. And then we're looking at all genotypes, cirrhotic and non-cirrhotic patients for 8-week treatment duration. And we had 1 study, in particular, that only looks at 8 weeks of treatment duration in the most difficult to treat genotype 3 cirrhotic patients because that's still a population where SVR rates are still in the low 90s. And if we could push that up into the high 90s, that would be a step forward. So I think our -- if our Phase III program, the data, support our Phase II results, then we will be a step ahead of all the competition."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Ian Somaiya of BMO Capital Markets.",12,"And our next question comes from Ian Somaiya of BMO Capital Markets."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I just wanted to follow up on the triplet opportunity within hep C. Specifically, Norbert, just I don't know if you could describe the proportion of patients that have maybe failed the -- in the first round -- sort of round of antivirals, whether it be do",89,"I just wanted to follow up on the triplet opportunity within hep C. Specifically, Norbert, just I don't know if you could describe the proportion of patients that have maybe failed the -- in the first round -- sort of round of antivirals, whether it be doublet therapy or SOF alone. So I don't know if there's a prevalent pool that you can speak to. And then maybe, I guess, more question for Kevin. Just how do you think about the triplet and its impact on margin price share?"
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","So Ian, we -- as you know, we are doing essentially 4 studies with the triplets, what -- we call it the triplets, SOF/VEL/VOX. Two of them are in treatment-experienced patients, and what we would aspire to is to have this compound BD [ph] universal salvag",168,"So Ian, we -- as you know, we are doing essentially 4 studies with the triplets, what -- we call it the triplets, SOF/VEL/VOX. Two of them are in treatment-experienced patients, and what we would aspire to is to have this compound BD [ph] universal salvage regimen. Now Kevin, maybe you could comment on what the proportion of patients is that would qualify for this. But something I can tell you, in Japan, there's a fairly large number of patients that had been treated with the Bristol-Myers GI NS5A regimen. I think, if I remember this correctly, they have SVR rates in the Phase III study of about 80% or thereabouts, and there are about 9,000 patients now that we heard of that are treatment experienced at that field. And those 9,000 would immediately be candidates for our own studies. And as I said, I want to say it again, the other 2 studies is 8 weeks treatment duration for all patients, all genotypes, cirrhotics and noncirrhotics. Kevin?"
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. It's a good question, Ian. We're waiting to see some of the clinical -- obviously, emerging clinical data. Right now we -- I think we got a situation certainly in the U.S. Japan is -- Japan, with this resistant situation, I think, is perhaps quite un",192,"Yes. It's a good question, Ian. We're waiting to see some of the clinical -- obviously, emerging clinical data. Right now we -- I think we got a situation certainly in the U.S. Japan is -- Japan, with this resistant situation, I think, is perhaps quite unique in terms of the original use of the Bristol-Myers regimen. But I think we got patients being cured to an incredibly high level with Harvoni, and now we've got the right treatment, I think, and that goes with the 2s and 3s. So I think in the U.S., perhaps in Europe, it will be far more modest, the opportunity. Having said that, depends where we are with those products, our products with where the competition is obviously, what we decide to do in terms of the pricing strategy. I think most importantly, from a company point of view, we think this is the right thing to do and probably the last step in the whole story around hepatitis C to help treatment experience of earlier patients. So I think, first and foremost, we think this is the right thing to do for patients in need."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Alethia Young of Crdit Suisse.",11,"And our next question comes from Alethia Young of Crdit Suisse."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Let me be the thousandth person, Kevin, to say welcome back. It's great to have you here. Two kind of questions in kind of the same vein. Just one on oncology. Has this remained a focus for you guys as far as building assets there and building out that bu",92,"Let me be the thousandth person, Kevin, to say welcome back. It's great to have you here. Two kind of questions in kind of the same vein. Just one on oncology. Has this remained a focus for you guys as far as building assets there and building out that business as much as it was in the past when you talked about it? And secondarily, just, Norbert, with NASH, can you just talk about some of the data points coming up and like, what's going on with the FXR program as well?"
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. So Alethia, let me start off by -- firstly and John Milligan will have towards -- comment on it, too. We are in oncology. We have now -- momelotinib is at the end of the Phase III program. We should have data this year. If the data is partly [indisce",233,"Yes. So Alethia, let me start off by -- firstly and John Milligan will have towards -- comment on it, too. We are in oncology. We have now -- momelotinib is at the end of the Phase III program. We should have data this year. If the data is partly [indiscernible] application next year. We have that MMP9 in gastric cancer in Phase III. We're looking at other solid tumors. And we're now finally, after sorting out the dosing, starting the first study in combination of a PI3K inhibitor with BTK in CLL. So with regards to NASH, yes, we have now very interesting 4 modalities or 4 mechanisms that we're evaluating in NASH, and at least with 3 of them, we know that they are doing what they're supposed to do pharmacologically. We will have data this year on the ASK inhibitor that will include liver fat analyses along with histology. The FXR agonist is currently in a Phase I, Phase IIa study. And by the way, we know about that compound already that it has minimal systemic absorption, but there are systemic levels of FGF19. That was always our idea to have a compound that acted the GI that releases FGF19. The FGF19 has the efficacy. And by that, the rationale we won't get the side effects that other FXR agonists have. And then finally, we have the [indiscernible] ASK inhibitor?"
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","ACC.",1,"ACC."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","ACC inhibitor, the Nimbus compound. And we know those data we'll present at ID so that it reduces the novel lipogenesis. So what we're going to do based on these data is you're asking whenever [ph] we could go into Phase III next year and to the other com",65,"ACC inhibitor, the Nimbus compound. And we know those data we'll present at ID so that it reduces the novel lipogenesis. So what we're going to do based on these data is you're asking whenever [ph] we could go into Phase III next year and to the other compound into with Phase II with the FXR and the ACC inhibitor or even this year. John?"
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. I just would follow up with Norbert's comments by saying, yes, we are committed to oncology, and we continue to be interested in assets, collaborations and partnerships where we could enhance our ability to continue to sell these products. But we are",98,"Yes. I just would follow up with Norbert's comments by saying, yes, we are committed to oncology, and we continue to be interested in assets, collaborations and partnerships where we could enhance our ability to continue to sell these products. But we are seeing good progress as Norbert mentioned. Our BTK inhibitor, which is we're developing with our partner from ONO, is now making its way to the clinic, and we've overcome some formulation challenges to allow us to go ahead. So that will be very, very, I think, an interesting avenue for us to continue to explore."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our final question comes from Terence Flynn of Goldman Sachs.",11,"And our final question comes from Terence Flynn of Goldman Sachs."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Just wondering -- kind of 2 parter. First is just any opportunity to broaden your prescriber base on hep C. Kevin, would love your thoughts on that. And the second question relates to Genvoya. Can you just give us what percentage of the switches were from",47,"Just wondering -- kind of 2 parter. First is just any opportunity to broaden your prescriber base on hep C. Kevin, would love your thoughts on that. And the second question relates to Genvoya. Can you just give us what percentage of the switches were from Atripla?"
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Terence, first of all, in terms of sort of do you like [ph] feature waves of market, I did mention Australia earlier. That's an incredible story of treating and curing patients and amazing commitment by the government there. We are seeing more patients tr",151,"Terence, first of all, in terms of sort of do you like [ph] feature waves of market, I did mention Australia earlier. That's an incredible story of treating and curing patients and amazing commitment by the government there. We are seeing more patients treated in Brazil. It's a lower-price market, but we are seeing more. We are just beginning our launch in Mexico. So yes, these are smaller markets. Typically, they are lower priced. But those -- if you like, those smaller waves are starting to work through. We are thinking carefully about China and how we launch there, probably in a very modest or very focused way, very efficient way should I say. So we -- our expectations, I think, are very reasonable around China. So the second question, in terms of switch, about 18% of the switched patients is from Atripla. So I hope that gives you the number."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And that concludes our question-and-answer session for today. I'd like to turn the conference back over to Mr. Lee for closing remarks.",23,"And that concludes our question-and-answer session for today. I'd like to turn the conference back over to Mr. Lee for closing remarks."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Great. Thank you, Candace, and thank you all for joining us today. We appreciate your continued interest in Gilead, and the team here looks forward to providing you with updates on our future progress.",34,"Great. Thank you, Candace, and thank you all for joining us today. We appreciate your continued interest in Gilead, and the team here looks forward to providing you with updates on our future progress."
29002,369689622,1011572,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Have a great day, everyone.",25,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Have a great day, everyone."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Second Quarter 2016 Earnings Conference Call. My name is Candace, and I'll be your conference operator today. [Operator Instructions] And as a reminder, this conference ca",63,"Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Second Quarter 2016 Earnings Conference Call. My name is Candace, and I'll be your conference operator today. [Operator Instructions] And as a reminder, this conference call is being recorded. 
I would now like to turn the call over to Sung Lee, Vice President of Investor Relations. Please go ahead."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Great. Thank you, Candace, and good afternoon, everyone. Just after market closed today, a press release was issued with earnings results for the second quarter of 2016. The press release and detailed slides are available on the Investor Relations section",221,"Great. Thank you, Candace, and good afternoon, everyone. Just after market closed today, a press release was issued with earnings results for the second quarter of 2016. The press release and detailed slides are available on the Investor Relations section of the Gilead website. 
Joining today's call will be John Milligan, President and Chief Executive Officer; Robin Washington, Executive Vice President and Chief Financial Officer; Kevin Young, Chief Operating Officer; and Norbert Bischofberger, Executive Vice President of Research and Development and Chief Scientific Officer. 
Before we begin formal remarks, let me remind you that we will be making forward-looking statements, including plans and expectations with respect to products, product candidates, financial projections and the use of capital, all of which involve certain assumptions, risks and uncertainties that are beyond our control and could cause the actual results to differ materially from these statements. A description of these risks can be found in the latest SEC disclosures documents and recent press releases. In addition, Gilead does not undertake any obligation to update any forward-looking statements made during this call.
Non-GAAP financial measures will be used to help you understand the company's underlying business performance. The GAAP to non-GAAP reconciliations are provided in the earnings press release, as well as on the Gilead website. 
I will now turn the call over to Robin."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, Sung, and good afternoon, everyone. We are pleased to share results for the second quarter of 2016. I'll first review our financials, and Kevin and John will then make a few comments. Total revenues for the second quarter were $7.8 billion, wi",1045,"Thanks, Sung, and good afternoon, everyone. 
We are pleased to share results for the second quarter of 2016. I'll first review our financials, and Kevin and John will then make a few comments. 
Total revenues for the second quarter were $7.8 billion, with non-GAAP diluted earnings per share of $3.08. This compares to revenues of $8.2 billion and non-GAAP earnings per share of $3.15 for the same period last year. Product sales for the second quarter were $7.7 billion, down 6% year-over-year and flat sequentially. The year-over-year decline was driven by lower HCV sales, partially offset by increased sales in HIV and other therapeutic areas. Sequentially, we saw an increase in HIV, U.S. HCV and other product sales that were offset by a decline in HCV sales in Japan and Europe. 
Turning to the U.S. Product sales for the second quarter were $4.9 billion, down 12% year-over-year. HCV product sales were $2.3 billion, down 33% year-over-year, driven by lower revenues per patient as a result of increased rebates and discounts due primarily to payer mix and lower patient starts for Harvoni, as the initial group of warehouse patients was treated in 2015. Sequentially, our HCV product sales were up 13%, driven by a $270 million adjustment to our HCV sales returns reserves rate and the initial inventory build for Epclusa. Strong uptake of our TAF-based regimens drove 23% year-over-year and 11% sequential growth of our HIV product sales. The quarterly revenues of $2.2 billion were also positively impacted by the upward trajectory of Truvada used for PrEP.
Turning to Europe. Product sales for the second quarter were $1.6 billion, down 18% year-over-year, primarily driven by lower HCV patient starts and a higher proportion of patient starts from countries that have a lower net average price. Sequentially, sales in Europe were flat, excluding the impact of currency movements, with HIV sales growth offset by lower HCV sales. 
In Japan, product sales for the second quarter were $619 million, down 43% sequentially as a result of lower patient starts on Harvoni and the full quarter effect of the mandatory price reductions for both Sovaldi and Harvoni, which were discussed during our last call. 
Moving to gross margin. Our non-GAAP product gross margin for the second quarter of 2016 was 92%, and benefited from the reversal of a $200 million litigation charge recorded in the first quarter of 2016, following a favorable decision in the Merck case. 
Now turning to expenses. Non-GAAP R&D expenses were $1 billion for the second quarter, up 48% compared to the same period last year, primarily due to the purchase of a U.S. Food and Drug Administration priority review voucher and the progression of clinical studies. Non-GAAP SG&A expenses for the second quarter were up 10% compared to the same period last year, primarily due to higher costs to support new product launches and our geographic expansion. 
From a balance sheet perspective, during the second quarter, we generated cash flow from operations of $4.9 billion and ended the quarter with $24.6 billion in cash and investments. While our cash flows will remain strong in the second half of the year, we anticipate a sequential decrease in Q3 2016 due to required cash payments related to our current government rebates in the U.S. and abroad, as well as milestone payments associated with our R&D pipeline progression. 
We continue to return capital to our shareholders through dividends and share repurchases. During the second quarter, we repurchased 10.5 million shares for $1 billion under the $12 billion 2016 share repurchase program, and we received an additional 8.1 million shares in April 2016 from the final settlement of the accelerated share repurchase program announced in February 2016. The total share repurchases in the first half of the year were 98.2 million at a cost of $9 billion. As previously communicated, we anticipate share repurchases in the second half of 2016 to be lower than the first half of 2016, as we focus our capital allocation on advancing our R&D opportunities. 
Finally, we are updating full year 2016 guidance, which is outlined on Slide 21. The changes are as follows: We are lowering net product sales guidance to a range of $29.5 billion to $30.5 billion. While we are seeing continued strength in non-HCV product sales, given the current trends in payer and patient flow dynamics for HCV, our updated models for just net product sales will range from being slightly above to slightly below $30 billion for the year. As such, we believe it is prudent to update our full year 2016 guidance. 
The factors contributing to this conclusion include: Lower HCV revenue per patient as a result of a mix shift towards more heavily discounted payer segments in the U.S. and companies with a lower net average price in Europe; a trend towards slowing patient starts in the U.S. Commercial segment and some earlier launch markets of Europe; the continued gradual trends towards shorter duration and loss of some market share to competition. 
This guidance is subject to a number of uncertainties, including: potential changes in the global macroeconomic environment; adoption of additional pricing measures to reduce HCV spending; volatility in foreign currency exchange rates; inaccuracy in our HCV patient start estimates; additional competitive launches in HCV; an increase in discounts, chargebacks and rebates due to ongoing commercial payer contract negotiations; and a larger-than-anticipated shift in payer mix to more highly discounted payer segments, such as PHS, FFS, Medicaid and the VA. 
We are increasing our R&D expense guidance to a range of $3.6 billion to $3.8 billion, driven by acquisition-related expenses for Nimbus Apollo, Inc. and the purchase of a U.S. Food and Drug Administration priority review voucher, slightly offset by lower-than-anticipated clinical trial expenses. 
We are lowering SG&A expense guidance to a range of $3.1 billion to $3.3 billion, primarily driven by the favorable onetime adjustment to the expected invoice from the IRS for the Branded Prescription Drug fee, which lowered Q1 2016 SG&A expense. 
Diluted EPS impact of acquisition-related upfront collaboration, stock-based compensation and other expenses increases to a new range of $1.47 to $1.53 as a result of our recent M&A activity. All other components of our 2016 guidance remain unchanged. 
I would like to now turn the call over to Kevin."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Robin, and good afternoon, everyone. Let me say immediately how terrific it is to be back at Gilead in a full-time capacity. Working with exceptional executive colleagues around the table here in Foster City, interacting with my senior operat",1693,"Thank you, Robin, and good afternoon, everyone. 
Let me say immediately how terrific it is to be back at Gilead in a full-time capacity. Working with exceptional executive colleagues around the table here in Foster City, interacting with my senior operating management team and seeing the dedication of the thousands of Gilead employees around the world leaves me in no doubt as to the long-term prospects for this outstanding company. 
Whilst early days, over the last 2 months in my new role, I've had the opportunity to reflect on Gilead's recent product introductions, the evolving health care landscape and the operating challenges on our near-term horizon. I'd like to share 3 general observations with you today. 
First, I am struck by the commitment that is shared by physicians, payers and governments around the world to reduce the prevalence of hepatitis C. Even countries with challenging economic circumstances are finding ways to prioritize the treatment of HCV patients. 
In the 2.5 years since the launch of Sovaldi, more than 1 million patients have been treated on a sofosbuvir-based regimen. Beneath this aggregated number are several landmark statistics. The United States has already treated nearly 0.5 million patients to date with Sovaldi and Harvoni. Equally, over 200,000 patients in Europe have been treated with Gilead regimens. Japan has treated approximately 100,000 patients in a little over a year. And just this year, Australia has treated an estimated 70,000 patients in a matter of months. Health care systems have demonstrably mobilized to reach those patients most in need. These are remarkable facts that clearly underscore the profile of the products we have introduced. Equally, they have implications to longer-term treatment dynamics and portfolio life cycles. 
Secondly, in the area of HIV, I'm impressed by how the clinical data for TAF-based regimens are resonating with the many constituents who tirelessly drive for better patient care. The understanding that these regimens can help address a growing need for highly effective and safer treatment options for lifelong HIV therapy is evidenced by the early success of Genvoya. I will highlight some impressive data points later.
Thirdly, I'm reminded just how complex the delivery of health care continues to be. Gilead's focus on flawless execution, on controlling the variables that we can control with the highest levels of conduct and compliance is critical and is my top priority. 
Now I'll get into the details of the commercial performance for the second quarter, starting with HCV. In the U.S., total HCV revenue was $2.3 billion, up 13% sequentially and down 33% year-over-year. Since the beginning of the year, access has improved and almost all major commercial payers have removed fibrosis score criteria, joining Medicare and the VA in this regard. Medicaid remains the only payer segment where use is still generally restrict it to the sicker patients. There are other significant barriers to access, but we are encouraged that some states have recently moved away from fibrosis restrictions towards more open access.
In terms of patient starts, approximately 59,000 people began HCV therapy in the second quarter, and an estimated 90% of these patients started on a sofosbuvir-based regimen. Importantly, third-party databases suggest that new patients are being identified through increased screening efforts. As evidenced, approximately 14 million people were screened for HCV for the period of 2014 through 2015, and approximately 280,000 were confirmed RNA positive in that 2-year period. These figures represent a significant increase from the years prior to the launch of Sovaldi. We estimate that 3 million individuals remain infected with HCV in the U.S., approximately half of whom are diagnosed.
Although patient starts increased for the second consecutive quarter and patient inflows into care remained recently steady at around 30,000 patients a month, the dynamics vary by patient segment. Within the commercial and Medicare segment, some larger payers have recently opened up access. We now estimate that up to 90% of all commercial covered lives have access without regard to fibrosis score. While the payers that recently opened up access are bringing in more patients, we are seeing a modest downward trend in patient starts among payers that have had full access in place for longer periods of time. The sickest patients have largely been treated, and the movement we are seeing is towards treating genotype 1 patients with lower fibrosis scores and thus greater use of the 8-week treatment regimen for Harvoni. 
In terms of all new HCV treatment starts in the second quarter, approximately 45% came from within the public payer systems. We anticipate this percentage will remain largely the same through the remainder of the year. The VA is one example of a payer within this segment, and their commitment to treating and curing veterans who have HCV using budget allocated by Congress to do so is truly groundbreaking. We are aware that in some cities, extra clinics have been scheduled to help shoulder the workload. However, we also expect that in the longer term, socially disadvantaged patients within the VA system will be harder to reach and bring into care and that the rate of treatment will decline.
Turning to Europe. Total HCV revenue in the second quarter was $775 million, down 32% year-over-year and down 7% sequentially. Overall, Gilead patient starts decreased to around 28,000 for the quarter. We observed steady treatment rates in Italy and Spain, but lower numbers in early launch markets like Germany and France. Patient starts in the U.K. continue to be limited by NHS England budget restrictions. Additionally, we saw a slight decline in average treatment duration, as countries like Germany are treating more patients with low fibrosis scores, who qualify for an 8-week treatment duration.
In several European markets, locally documented cure rates are equal to, if not better than, what was demonstrated in Sovaldi and Harvoni clinical studies. This has resonated with governments and payer bodies. And some countries such as France are considering removing all fibrosis score criteria. We will watch this picture closely and share evolving news with you in the future. 
Moving to Japan. As Robin mentioned, revenue was $619 million, down 43% sequentially. We believe this was related to 2 factors: First, the decline in genotype 1 new patient starts following the Q1 2016 peak when a very large number of individuals with advanced disease initiated therapy; and second, the full 3-month effect of a mandatory price reduction previously described on last quarter's call.
Finally, for HCV, Epclusa was recently approved in the U.S., the EU and Canada. These approvals are true milestones in patient care since Epclusa is the first pan-genotypic, once-daily, single-tablet option. Epclusa will be an important treatment option in the U.S. as an estimated 20% to 25% of HCV patients have genotypes 2 and 3. And equally, across Europe, there are some countries that have up to 30% of patients with genotype 3 alone. 
In concluding my remarks on hepatitis C, I will return to my earlier comments. Gilead is proud to be part of a fundamental disease paradigm shift, delivering disease cures to virtually all patients treated. That's why we developed Sovaldi, Harvoni and Epclusa and have a third single-tablet regimen in clinical testing. 
Whilst the pace of new patient treatment may slow in coming years and quantifying that pace is incredibly hard, there is still an opportunity to identify and cure many HCV infected people around the globe. 
Moving to HIV. We are pleased with the launch of our TAF-based products in the U.S. and in the European markets where we have already achieved reimbursement. In the U.S., total HIV and other antiviral revenue was $2.2 billion, up 11% sequentially, and Genvoya revenue nearly doubled in Q2 versus Q1. The product represents the most successful HIV launch since the introduction of Atripla, the first single-tablet regimen, a decade ago. After its first 6 months of availability, Genvoya is already the most prescribed regimen for both treatment-nave and switch patients. 
78% of all Genvoya prescriptions have come from switches. Half of the switches have come from Stribild, and importantly, 10% of switches have come from non-Gilead therapies. Among all patients who switched, we have seen an increase in our ability to retain patients on a Gilead product. 
Whilst still in the early stages of the Odefsey and Descovy launches, we are seeing similar patient dynamic to Genvoya. Over 90% of all Odefsey and Descovy prescriptions have come from switches. And 6% and 11% of switches, respectively, have come from non-Gilead therapies. 
Finally, in the U.S., I would like to highlight the growing use of Truvada for PrEP. We estimate somewhere in the order of 60,000 to 70,000 patients were using Truvada for PrEP in the second quarter. This number accounts for approximately 1/3 of Truvada demand. This is encouraging, as we know Truvada has an important role to play as part of comprehensive HIV prevention for many at-risk individuals.
Turning to Europe. Total HIV and other antiviral revenue was $755 million, up 5% sequentially, driven by the launches of Genvoya and Descovy. Genvoya has gained pricing approval in 11 countries and is now the market leader in Germany for both treatment-nave and switch patients after only 6 months of availability. We anticipate additional launches in France, Italy and the U.K. in the second half of the year. 
Genvoya is the preferred regimen in several HIV treatment guidelines, including Italy, where it was added before pricing and reimbursement. Preferred listings are anticipated in other EU guidelines later this year and into 2017. EACS guidelines are expected to be updated following the HIV Glasgow 2016 Conference in October.
Finally, I would like to briefly update you on the outstanding performance of the Gilead U.S. cardiovascular team. Letairis and Ranexa together generated $356 million in revenue during the quarter, representing a 12% year-over-year increase. Today, over 0.25 million people in the United States regularly receive Ranexa. And Letairis remains the overall ERA market leader in PAH. 
In closing, Gilead achieved a great deal across our operations during the quarter, and I am confident that we will continue to make significant progress in the second half of 2016. 
I would now like to turn the call over to John."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, Kevin. Before I get started, I just wanted to say it's great to have you back on the Gilead full team -- full time as our new Chief Operating Officer. Today, in addition to the remarks of Robin and Kevin regarding the quarter, I'd like to make a",1165,"Thanks, Kevin. Before I get started, I just wanted to say it's great to have you back on the Gilead full team -- full time as our new Chief Operating Officer. 
Today, in addition to the remarks of Robin and Kevin regarding the quarter, I'd like to make a few comments of my own. Over the last 2.5 years, we've made great progress in helping provide access to Sovaldi and Harvoni for HCV patients. Throughout the world, more than 1 million HCV sufferers have now been treated with nearly half of those coming from the U.S. While lots of these drugs were unprecedented in our industry, and patients were treated at a much faster initial rate than we, or anyone else, thought possible, looking back, we can now say that in every country, the peak number of patients treated was achieved within 2 or 3 quarters of the launch of Harvoni, but that peak number was far higher than what we had -- what had ever been achieved before; about 3x that seen with the launch of the HCV protease inhibitors in 2011.
As we've reached the mid-point of this year, we now see the market maturing to a slower rate of treatment for HCV-infected individuals. And as we think about this more normal patient starts, there are a few things to keep in mind. As Kevin mentioned, there are about 3 million people who are infected in the U.S., and slightly more than half of those have been diagnosed. Many of these diagnosed patients have less advanced liver disease upon reentering care. For example, in the United States in the second quarter this year, we estimated that only 13% of patients starting treatment had F4 fibrosis scores compared with more than 21% the year prior to that. With less severely ill patients, there is less urgency to immediately treat patients. And this may explain the slower rate of treatment versus last year. However, we do believe these patients will eventually benefit from treatment, and this means the flow of patients will continue for many years to come.
There's also an opportunity to diagnose patients and bring them into care. As Kevin mentioned, we estimated that about 280,000 HCV patients were diagnosed in the U.S. within the last 2 years, showing the value and importance of the U.S. CDC and CMS recommendations for HCV testing. So while there has been a slowing of treatment compared with the rush of patients when Sovaldi and Harvoni were first approved, the HCV market is attractive over the longer term, providing good revenues, strong cash flow and earnings per share, on top of our base business of chronic therapies. 
Because of this, our focus on improving care for HCV and infected individuals has not wavered. Beyond the recent approvals of Epclusa, we are actively working on a third single-tablet regimen that combines the 2 active ingredients in Epclusa with a third investigational compound, voxilaprevir. This combination, known as SOF/VEL/VOX, is being evaluated at 4 Phase III clinical trials among patients who have previously failed direct-acting antiviral treatments. It's also being studied for its potential to offer an 8-week treatment duration for treatment-nave patients of all genotypes. We expect to have top line data available for SOF/VEL/VOX by the end of the year. 
We're making tremendous headway in HIV as well; both of our portfolio of newer products and our pipeline. We've had several key approvals with Descovy approved in the U.S. and Europe last quarter and Odefsey approved in Europe earlier this month. It's clear these medications offer a significant advance for patients, and that advance has been recognized now by multiple professionals and public health groups, including the International Antiviral Society of the U.S.A. and the Department of Health and Human Services, both of which were released updated guidelines supporting the use of TAF-based regimens for initial HIV therapy. 
We continue to generate clinical data that support the favorable scientific and medical profile of our TAF-based products. Last week, we announced the results of 2 Phase IIIb switch studies, evaluating Odefsey in virologically suppressed adults switching from Complera or Atripla. Odefsey achieved similar rates of virological suppression as the TDF-based regimens. These studies reinforce the efficacy of Odefsey as well as the renal and bone safety advantages, and we plan to present full data sets later this year. 
Last month, we presented the first human data on bictegravir, our investigational, unboosted integrase inhibitor, at the American Society for Microbiology. Data from 4 preclinical and Phase I studies examined the antiviral potency, resistance profile, pharmacokinetics and safety of bictegravir, providing the rationale to further evaluate the compound. Bictegravir, as part of a single-tablet regimen, in combination with TAF and emtricitabine, is currently in Phase III trials. Enrollment of more than 2,300 patients across 4 registrational studies was completed earlier this month. The 48-week endpoints for these studies will be reached in the second quarter of next year, and if the data play out as we hope, NDA and MAA filings could occur in the third quarter of 2017.
With the approval and rapid adoption of our TAF-based regimens, an exciting new STR and Phase III development and an active HIV research pipeline, I'm confident that we will be able to extend our leadership position in the HIV market and broaden our ability to help even more patients around the world. 
Outside of our working antivirals, Gilead is focused on solving some of the biggest health challenges today. Several important data sets that are anticipated in the second half of this year may help us to find a strategy and pathway forward for tackling these challenges. 
In our NASH program, where we have 4 active clinical programs, we'll have data from the Phase II studies of GS-4997, our ASK-1 inhibitor, and simtuzumab, our monoclonal antibody against LOXL2. The Phase II study of simtuzumab for primary sclerosing cholangitis will also conclude. And we'll also have data from the Phase II studies of GS-4997 in diabetic nephropathy and pulmonary arterial hypertension, or PAH. And finally, we expect data from 2 Phase III studies for myelofibrosis before the end of the year. If these data are positive, these studies will form the basis for an MDA filing in the first quarter of 2017. 
These are important milestones and represent a great deal of work across the organization to enroll and advance these studies and analyze complex data sets as they become available. Gilead continues to innovate at every level and every part of the organization. Next month, we will publish our first corporate social responsibility report that looks at access, sustainability, grant making and other positive contributions to the communities we serve, and I urge each of you to read it. 
I'm proud of the work that's been led by our employees and extend my many thanks to them for all the ways they are making a difference around the world. 
Thank you, and let's now open up the call for questions. Operator?"
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Geoff Meacham of Barclays.",15,"[Operator Instructions] And our first question comes from the line of Geoff Meacham of Barclays."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Kevin, good to have you back on the call, and in the seat, of course. So I want to dig into your comments and also John's comments on the hep C new starts. And just, I guess I'm curious here because you have better F0, F1 Access. You have positive impact",121,"Kevin, good to have you back on the call, and in the seat, of course. So I want to dig into your comments and also John's comments on the hep C new starts. And just, I guess I'm curious here because you have better F0, F1 Access. You have positive impact theoretically from the CDC guidelines and very low penetration in markets such as the prison population. I'm just curious why, could you put your finger on maybe 1 or 2 things that you feel like could ultimately be a -- become a growth driver to get us back to better sequential growth? I'm just trying to figure out what the tipping point is, on some of these different volume drivers."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Geoff, nice to hear your voice as well. Thank you for your comments. I'm not at all pessimistic about the long-term prospects for hepatitis C. In fact, I'm rather optimistic. I think what we have seen 2014, 2015 is an enormous group of the less well patie",337,"Geoff, nice to hear your voice as well. Thank you for your comments. I'm not at all pessimistic about the long-term prospects for hepatitis C. In fact, I'm rather optimistic. I think what we have seen 2014, 2015 is an enormous group of the less well patients treated, particularly by specialist hepatitis C treaters. It's really quite amazing. I think this quarter and we've highlighted perhaps going forward is really sort of a payer mix situation that we've got. The VA has definitely increased in terms of its contribution to the 59,000 total HCV starts, which, of course, was an increase on quarter 1. So a lot of VA patients are coming through, and the VA is very, very motivated to try to essentially eradicate the virus from that population. I think, yes, we did see pickup in 2 of the large players that came on stream with open fibrosis scores from the beginning of the year, but we did see some downtick in other commercial payers. So net-net, it was slightly a decrease in overall commercial patients. What I feel about the long term and as we go into years further forward and we kind of hit an equilibrium of patients is all around what I mentioned, and John mentioned, around diagnoses. There's been a considerable pickup in the number of HCV tests; 2014, 2015, about a 65% increase in the number of HCV tests. 280,000 in that 2-year period were HCV RNA positive. So as John said, they will eventually work their way through to treatment. But still over 1/4 of the population being diagnosed is at 4. So there's still a lot of sickness out there in patients. So whilst the health care system here and in some of the European markets have done heroic things in treating patients in the last 2 years, I still think, with 1.5 million diagnosed patients in the United States that we are going to see a continued healthy flow of patients that can benefit from our products."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Geoffrey Porges of Leerink.",10,"And our next question comes from Geoffrey Porges of Leerink."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","For Kevin, welcome back, and good to hear you. So following up on this somewhat vexing issue of the HCV outlook. Historically, in this category after each market has peaked, it's begun a steady slow, sometimes slow, anyway, decline. We certainly saw a rap",152,"For Kevin, welcome back, and good to hear you. So following up on this somewhat vexing issue of the HCV outlook. Historically, in this category after each market has peaked, it's begun a steady slow, sometimes slow, anyway, decline. We certainly saw a rapid decline after the protease inhibitors, more slow decline after we went to ribavirin and with the introduction of pegylated interferon. Are you suggesting to us that you think that there is a stable outlook for the HCV revenue on a market-by-market basis from these levels? Or are you suggesting that we should see more like an orderly and steady decline? And could you particularly comment about Europe, where I think it was surprising to see patient numbers in the big early markets roll over so quickly, particularly Germany and Japan? Is that a onetime step-down? Or are we going to continue at or below this level going forward?"
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. Thanks for the question, Geoff. I think it is encouraging that patient starts in the U.S. and Europe have been reasonably steady over the past 3 quarters. Japan's a different story, I can certainly, at some point, comment on that this afternoon. I th",298,"Yes. Thanks for the question, Geoff. I think it is encouraging that patient starts in the U.S. and Europe have been reasonably steady over the past 3 quarters. Japan's a different story, I can certainly, at some point, comment on that this afternoon. I think, from my perspective and Robin, Norbert, John around the table here, I think it's more of the latter comment; that there will continue to be a gradual decline in new patient starts, but an equilibrium will be eventually hit. Quite the timing of that, Geoff, it's really, really, really hard to peg. I've just got to believe that with the amount of testing, with the amount of diagnoses with the CDC guidelines, Gilead itself in Q3, Q4 of this year are going do some more educational programs around the need to test and treat that. We will eventually hit an equilibrium. In terms of Europe, Italy and Spain are very steady. I should tell you that in Italy, there are still 200,000 quite sick individuals, people to be treated, and they're in treated care. And the Italian government do want to go ahead and try and mobilize providers to do that treating. So it's still an enormous number in Italy. I think the more -- the markets that are more akin to the U.S., like, first and foremost, Germany and to a slightly lesser extent, France, are starting to see that sort of turnover of patients. We've got full access in terms of fibrosis score in Germany, and we're hoping, as I said, that we get broader access in France. The U.K. is a different situation, and that's largely due to payer restrictions. But again, still an enthusiasm to treat, but 1 or 2 of those markets, there is some maturing going on."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Mark Schoenebaum of Evercore ISI.",11,"And our next question comes from Mark Schoenebaum of Evercore ISI."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","This is Regina Grebla in for Mark. I actually wanted to change topics and shift to hepatitis B. On your Q1 call, you mentioned your hep B program included a vaccine, the TLR7 agonist, and 2 other internal preclinical candidates. When will we see any data",73,"This is Regina Grebla in for Mark. I actually wanted to change topics and shift to hepatitis B. On your Q1 call, you mentioned your hep B program included a vaccine, the TLR7 agonist, and 2 other internal preclinical candidates. When will we see any data on the internal candidates? And also, you mentioned taking a look at external opportunities for hepatitis B. Is hep B still potential area of interest for acquisition?"
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. So Regina, you asked a question about what our pipeline is for hepatitis B. So we have, as you know, 2 compounds currently in clinical development. One is an active vaccine, 4779, the collaboration with GlobeImmune. That's currently in the later stag",323,"Yes. So Regina, you asked a question about what our pipeline is for hepatitis B. So we have, as you know, 2 compounds currently in clinical development. One is an active vaccine, 4779, the collaboration with GlobeImmune. That's currently in the later stages of being evaluated in non-suppressed hep B patients. The suppressed hep B patients, those data have been released, I think, maybe a year ago that they did not show any activity, so we don't have high hopes that the compound will work. Then, the TLR7 agonist is that's just finishing the first cohort, which is in suppressed patients, and we are currently initiating. The second cohort quarter is ongoing. We hope that we'll have the presentation of the first cohort ready by AASLD. Hopefully, we'll make that -- the abstract deadline. Then, you said that -- you asked the question about we had 2 other compounds in development. Well, you know what we're pursuing. Maybe I should answer this more generally. So we're pursuing 3 approaches to hepatitis B cure. The ne is adding another different mechanism to the nucleosides because there's the observation that despite being undetectable with hepatitis B therapies like Viread or TAF, there was always a little bit of virus left, HBV there may detectable if you look at very sensitive PCR methods. So by adding another mechanism, so actually, we could completely suppress virus replication down to 0, would that lead to an eventual cure or hepatitis S conversion? The second thing we're pursuing is immune therapy, so that belongs to the vaccine and the TLR7 that I've talked about already. And we have a TLR8 agonist currently that is working its way towards an IND. And then the third possibility, that's the most hopeful but also the one that's least scientifically proven that's going directly after cccDNA, and that's really too early to talk about at this point. It's still in the research stages."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Michael Yee of RBC Capital Markets.",12,"And our next question comes from Michael Yee of RBC Capital Markets."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","You talked a lot about volume and demand in the different buckets. But can you talk about the payer mix shift? Specifically, I wanted to ask on Medicaid. Can you just help us out with what percent of sales Medicaid is? And what is going on in that bucket?",98,"You talked a lot about volume and demand in the different buckets. But can you talk about the payer mix shift? Specifically, I wanted to ask on Medicaid. Can you just help us out with what percent of sales Medicaid is? And what is going on in that bucket? I presume it's a state-by-state negotiation. Can you talk about what's going on there? Is there a state-by-state negotiation you have to go through? Is that pretty much done? Walk us through that bucket and what percent of hep C that is in U.S.A. so I can understand them."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Michael, it's Kevin. Thank you for the question. I prefer not to break out specifically the percentage of the public payers in terms of Medicaid. As I said, all our public payers lumped together for the quarter were about 45%. That's an increase from the",177,"Michael, it's Kevin. Thank you for the question. I prefer not to break out specifically the percentage of the public payers in terms of Medicaid. As I said, all our public payers lumped together for the quarter were about 45%. That's an increase from the previous quarter, but as I said, that's all driven by VA. We've seen very little change, really, in our -- in the scale and size of our Medicaid business. I think it would be true to say that Medicaid's -- the states are slowly progressively opening up. 40% of Medicaid patients come from the 5 largest states. Two of those, New York and Florida, now have no fibrosis score. So as states do progressively consider opening up, they typically come to us for a contract. We think about those contracts very carefully. Depending on the size of Medicaid, we obviously put our submission in. Realistically, I think we may win, we hope, the majority of those, but there may be occasions when, occasionally, a Medicare -- Medicaid stake goes to the competition."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Matthew Harrison of Morgan Stanley.",11,"And our next question comes from Matthew Harrison of Morgan Stanley."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Robin, if you could just address the $279 million onetime swing. We obviously saw a swing in the first quarter and then a swing this quarter again. Can you just give us some insight into what's going on with those changes in chargebacks and if we should c",72,"Robin, if you could just address the $279 million onetime swing. We obviously saw a swing in the first quarter and then a swing this quarter again. Can you just give us some insight into what's going on with those changes in chargebacks and if we should continue to expect to see some of those numbers? And then just separately on PrEP, any plans to get a TAF-based regimen approved for PrEP?"
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Sure. I'll take the first part, and then Norbert will take the second. Matt, first of all, there are 2 separate things that we're talking about here Q2 versus Q1. First, let me address Q2. We did have a sales return reserve adjustment really related to th",360,"Sure. I'll take the first part, and then Norbert will take the second. Matt, first of all, there are 2 separate things that we're talking about here Q2 versus Q1. First, let me address Q2. We did have a sales return reserve adjustment really related to the fact that as we introduce our new hep C product, we're required to go out and get an external proxy related to sales return reserves. And just recently, just this past quarter, we closed several of the lots related to our products, which means that no further returns are accepted. So that gives us a triggering event by which we can look at returns versus how we had been accruing. The other key thing about the timing is just related to the Epclusa lot. So as we bring on a new product, we want to kind of want to rebase the level of returns that we are expecting to see. So that's really the adjustment there. For the most part, you could -- it's onetime in nature. We may have small adjustments going forward, but as long as returns continue where they are, then that $279 million is kind of a onetime event. Last quarter, we had a different issue, and that related to the rebate claims for hepatitis C. And as I said on the call last time, we always have a situation where we're constantly truing up claims around HCV rebate because we get those claims 1 to 2 quarters in arrears. This quarter was a bit different than last quarters that we saw a modernization of the level of those claims relative to the prior quarter. So it wasn't -- it didn't reverse the other way. It was just a slowing of what we saw in Q1. So we're, for lack of better words, maybe a little bit more caught up relative to returns this quarter than we were at the end of Q1. So 2 different items, but we caught up at $279 million because that was the onetime event. So we ensured -- we wanted to ensure that you understood relative to the future projection of HCV sales."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Matt, so to your question about F/TAF or PrEP, so we and also the outside medical community believes that, obviously, discovery of F/TAF would have advantages in terms of use for PrEP versus Truvada for all the obvious data that were published already. An",148,"Matt, so to your question about F/TAF or PrEP, so we and also the outside medical community believes that, obviously, discovery of F/TAF would have advantages in terms of use for PrEP versus Truvada for all the obvious data that were published already. And also, we have data now in human -- in animal models that show that that has the same efficacy. The thing we're debating internally and also we have had early discussions with FDA is what clinical study would need to be done that leads to approval. It would have to be, in almost all likelihood, a comparative study and tend to seek which is what would be the sample size and what would be the powering. And that's currently a discussion we're having with FDA. We hope we can come to some conclusion within the next months or so and then let you know."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Brian Abrahams with Jefferies.",10,"And our next question comes from Brian Abrahams with Jefferies."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Kevin, good to hear your voice again. With the list pricing and label established for Epclusa, I'm just wondering. What's the right way to think about Epclusa's potential impact on the genotype 2/3 franchise, particularly with respect to the net price per",75,"Kevin, good to hear your voice again. With the list pricing and label established for Epclusa, I'm just wondering. What's the right way to think about Epclusa's potential impact on the genotype 2/3 franchise, particularly with respect to the net price per patient treatment duration relative to Sovaldi and just how we should be thinking about the overall market dynamics there? I'm just wondering if you could also quantify the inventory build this quarter there."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. Great question, Brian. Nice to hear your voice as well. Brian, the majority of the revenues in the second quarter, which is right at the end, the majority of that was inventory that Robin called out. So we've really only just begun the introduction,",303,"Yes. Great question, Brian. Nice to hear your voice as well. Brian, the majority of the revenues in the second quarter, which is right at the end, the majority of that was inventory that Robin called out. So we've really only just begun the introduction, both the promotion and the education around Epclusa. I'm really pleased that the response has been excellent. In our advisory boards and our speaker programs there's been good acceptance. Whilst we have obviously a pan-genotypic label, I think the reality is that physicians are very, very comfortable, as are payers, with Harvoni for genotype 1. Obviously, there's a mix of 12-week treatments and 8-week. Just for your information, the 8-week course of Harvoni is now 45% of patients treated in the United States. So I think people are just really comfortable with the clinical effect and the value proposition of Harvoni in GT1, which therefore means that the slot that people see Epclusa is in the 2 and 3 patient. And as I highlighted, it's something like in the order of 20% to 25% of patients in the United States. I think the obvious advantage, both clinically and from a payer point of view, is you really do have a 12-week single-tablet regimen. You don't have to extend the treatment duration. You don't have to use ribavirin. There was quite a number of patients treated with Sovaldi, Daclatasvir, certainly, in United States. So really, in some ways, it takes away that regimen and is an excellent slot. So we've had very good reception to Epclusa. It's extremely early days. It'll take us 3 to 6 months to get payer approval. Physicians can apply based on medical need, and they're doing that. So just very early days and weeks. It seems to have found a very nice entry point."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from the line of Cory Kasimov of JPMorgan.",13,"And our next question comes from the line of Cory Kasimov of JPMorgan."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I have a bigger picture question for you. Really, just following the latest management shuffle back in 2Q, I'm wondering if these changes portend any material shift or consideration of a shift in, I guess, your commercial or pricing strategy, or really, t",76,"I have a bigger picture question for you. Really, just following the latest management shuffle back in 2Q, I'm wondering if these changes portend any material shift or consideration of a shift in, I guess, your commercial or pricing strategy, or really, the overall strategy for the business or any of the key businesses. And is this playing into the bump in anticipated R&D with the associated downtick in SG&A as illustrated by your updated guidance?"
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","I think there were a couple of questions there. So it's John Milligan. So in terms of -- let me get to the last bit. You said there was a bump in R&D. That is true, relating somewhat to our acquisition of Nimbus. So there were charges associated with that",246,"I think there were a couple of questions there. So it's John Milligan. So in terms of -- let me get to the last bit. You said there was a bump in R&D. That is true, relating somewhat to our acquisition of Nimbus. So there were charges associated with that and there are also charges associated -- I should say expenses associated with the purchase of an FDA priority review voucher. So we're very pleased to get that onboard, and we'll look forward to explaining when we're going to use that. Above and beyond that, actually, R&D expenses were slightly down what we -- beneath what we had forecasted because we continue to hold the cost of centers to -- accountable and continue to drive good value through our clinical teams in getting studies done at a very cost-effective way. So in terms of that, there's no difference. The SG&A line came down a little bit because of some onetime charges that were lower than we -- sorry, the IRS charge which was lower than we anticipated, so kind of what we would expect. In terms of signaling about pricing or changes in management about structures, I don't really think there's anything to signal there in terms of our pricing strategy. We're highly competitive. We think we have a very good differentiated product, and we'll continue to do the best for the company and for patients when coming to the right level of price and access."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. And I would just add, Cory, that the Gilead way is always to lead with the science around our product. Nothing's changed. In my eyes, as I have come back into the company, we lead with science. That's what you do in specialist markets. It is a realit",113,"Yes. And I would just add, Cory, that the Gilead way is always to lead with the science around our product. Nothing's changed. In my eyes, as I have come back into the company, we lead with science. That's what you do in specialist markets. It is a reality that there is more contracting. I think we've got a phenomenal team working on this. I met with them 2 weeks ago, and I think they're highly professional. And we always lead with value. That's the key thing. We think we've got tremendous products that either control disease or cure disease, and they are terrific value. And that's the course we're going to stay."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Phil Nadeau of Cowen.",10,"And our next question comes from Phil Nadeau of Cowen."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Kevin, it's great to have you back. I have a question on capital allocation. In the prepared remarks, I think you mentioned in regards to cash flows being lower in the second half of the year, that part of that was investment in R&D. And as you just discu",105,"Kevin, it's great to have you back. I have a question on capital allocation. In the prepared remarks, I think you mentioned in regards to cash flows being lower in the second half of the year, that part of that was investment in R&D. And as you just discussed, the R&D expenses aren't really changing that much in the guidance. So kind of curious whether you have on your list of things to do in the second half of the year more deals, whether M&A or in-licensing. And maybe you could give us some thoughts on how aggressive you're likely to be in those areas."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Well, Phil, I'll start. I think relative to the cash flow, what I was messaging was really just related to the dynamics of payments, right. So we have accrued rebates and other things that kind of caused volatility to quarterly cash flows. So overall, our",115,"Well, Phil, I'll start. I think relative to the cash flow, what I was messaging was really just related to the dynamics of payments, right. So we have accrued rebates and other things that kind of caused volatility to quarterly cash flows. So overall, our cash flows remain strong, but we definitely expect a sequential decrease in cash flows second half. Relative to overall capital allocation, it's no different than what we've been messaging, again, more focused on our BMD opportunities, but I'll let John speak of a little bit more and just, again, focus there. And that additional focus has meant we're somewhat less focused on share repurchases the second half of the year."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","And as a follow-up on what Robin said, Phil, we were very aggressive in the first quarter of this year. That's why we back off a little bit from where we are in the second half of the year. Mostly, you get the full year effect or a greater effect of repur",195,"And as a follow-up on what Robin said, Phil, we were very aggressive in the first quarter of this year. That's why we back off a little bit from where we are in the second half of the year. Mostly, you get the full year effect or a greater effect of repurchasing the almost 100 million shares through Robin's program. With regard to business development, obviously, we're a company that has been very open about being interested in doing more deals, especially deals of a certain size where we think we can get some leverage and we can use our organization to effectively accelerate or expand indications. We've done some good deals both with Galapagos and Nimbus recently. We are very interested in continuing that to add more things to our pipeline, especially in the non-antiviral area where we continue to see growth in franchises. It's our hope that as we exit this year, we'll have a better, more complete story of programs internally and externally that we can use to talk about why the long-term prospects for growth are as good as we believe they are, and that's what we'll be focused on."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Robyn Karnauskas of Citi.",10,"And our next question comes from Robyn Karnauskas of Citi."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I guess, the question for me after hearing some of the comments about like thinking about volumes slowing or coming down and then thinking about growth and that changing over time is how do you -- how are you comfortable that you can provide guidance with",102,"I guess, the question for me after hearing some of the comments about like thinking about volumes slowing or coming down and then thinking about growth and that changing over time is how do you -- how are you comfortable that you can provide guidance with these 2 variables? Or do you have any bookends for how low we can go that give you the comfort? And then the question is you affirmed guidance last quarter and lowered it this quarter. What was the one thing you think that really changed your view over the last 3 months that led to that?"
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Sure. You want to start, Kevin?",6,"Sure. You want to start, Kevin?"
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","I'll start and then hand the question to Robin. Robyn, it's really hard. We've got markets in different stages of development, whether it be U.S., parts of the U.S., different countries in Europe and obviously, interesting and profound dynamics in Japan.",130,"I'll start and then hand the question to Robin. Robyn, it's really hard. We've got markets in different stages of development, whether it be U.S., parts of the U.S., different countries in Europe and obviously, interesting and profound dynamics in Japan. So they're partly made up of patient flows and partly made up of sort of payer flows. I think the big thing this quarter, from the point of view of the U.S., was very much a payer kind of mix with the large addition of patients from the VA. So I think in the last 3 months, that was probably the biggest thing. We have not changed our prices in the U.S. Q2 versus Q1. It was largely we're seeing this dramatic but incredibly successful program from VA."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. Robyn, so I'll add to that. I agree with Kevin. I think the heavier percentage of more discounted payers, along with the fact that on the commercial side, right, we're seeing slight decreases in the U.S. And Kevin mentioned earlier about what we're a",184,"Yes. Robyn, so I'll add to that. I agree with Kevin. I think the heavier percentage of more discounted payers, along with the fact that on the commercial side, right, we're seeing slight decreases in the U.S. And Kevin mentioned earlier about what we're also seeing relative to the mix shift in countries in Europe; less of Northern Europe, Germany and France and more of Italy and Spain. To your other part of your question and to what you were [ph] earlier throughout the call, this is a really difficult area to predict. It's unlike any other. It's a curative market, and it's very large relative to Gilead's total revenues. And so it's a question we're asking ourselves as we think in the outer years how can we continue or can we really guide around HCV revenues. So we've guided this year, but it's definitely something we're giving a lot of thought to as we kind of think about the trends of HCV going forward and all the dynamics that we're trying to deal with. It's very complex, so more to follow on that."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Ying Huang of Bank of America Merrill Lynch.",14,"And our next question comes from Ying Huang of Bank of America Merrill Lynch."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I have a quick one on also the pricing environment. So if you look at VA sector and also the commercial sector, what kind of impacts are you seeing from competition, particularly Merck's Zepatier, from the pricing perspective? And then quickly on R&D side",74,"I have a quick one on also the pricing environment. So if you look at VA sector and also the commercial sector, what kind of impacts are you seeing from competition, particularly Merck's Zepatier, from the pricing perspective? And then quickly on R&D side. Do you plan to develop a doublet maintenance regimen? For example, recently, Tivicay plus EDURANT, the combination showed actually good results in heavily protruded [ph] patients in the near conference."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","So I'll take the first part in terms of kind of pricing and competitive impact. Very little in terms of our commercial payer areas because the contracts essentially were set up at the end of last year for the full year, so very little change in market sha",144,"So I'll take the first part in terms of kind of pricing and competitive impact. Very little in terms of our commercial payer areas because the contracts essentially were set up at the end of last year for the full year, so very little change in market share within the commercial payer segment. We still have a very strong position in VA with Harvoni and Sovaldi, particularly Harvoni. I think probably where we're seeing increased competitive activity is in the Medicaid setting where, as I described earlier, some of the smaller states are requesting contracts as they open up access. So I think that's probably where we see the competition. And again, because of our very strong value proposition, we hope we can be successful in the majority of those. But again, on occasions, we may find that they go to the competition."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. Ying, you asked a question about the ViiV, the expansion [ph] of the BCI in FIV. So we're, of course, aware of the data that were presented at EASL; they looked fairly impressive. They had a number of genotypes with high SVR rates. However, what they",205,"Yes. Ying, you asked a question about the ViiV, the expansion [ph] of the BCI in FIV. So we're, of course, aware of the data that were presented at EASL; they looked fairly impressive. They had a number of genotypes with high SVR rates. However, what they're doing right now in Phase III is not looking at the 8-weak treatment duration or genotypes enrolled patients. I would like to contrast this with our own triple combination, SOF/VEL/VOX, that John Milligan mentioned. We are looking essentially at 2-patient population of 1-patient population's experience that had previously failed other DAAs, that treatment duration is for 12 weeks; and then we're looking at all genotypes, cirrhotic and non-cirrhotic patients for 8-week treatment duration. And we had 1 study, in particular, that only looks at 8 weeks of treatment duration in the most difficult to treat genotype 3 cirrhotic patients because that's still a population where SVR rates are still in the low 90s. And if we could push that up into the high 90s, that would be a step forward. So I think our -- if our Phase III program, the data, support our Phase II results, then we will be a step ahead of all the competition."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Ian Somaiya of BMO Capital Markets.",12,"And our next question comes from Ian Somaiya of BMO Capital Markets."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I just wanted to follow up on the triplet opportunity within hep C. Specifically, Norbert, just I don't know if you could describe the proportion of patients that have maybe failed the -- in the first round -- sort of round of antivirals, whether it be do",91,"I just wanted to follow up on the triplet opportunity within hep C. Specifically, Norbert, just I don't know if you could describe the proportion of patients that have maybe failed the -- in the first round -- sort of round of antivirals, whether it be doublet therapy or SOF alone. So I don't know if there's a prevalent pool that you can speak to. And then maybe, I guess, it's more a question for Kevin. Just how do you think about the triplet and its impact on margin price share?"
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","So Ian, we -- as you know, we are doing essentially 4 studies with the triplets, what we call it the triplets, SOF/VEL/VOX. Two of them are in treatment-experienced patients, and what we would aspire to is to have this compound BD universal salvage regime",165,"So Ian, we -- as you know, we are doing essentially 4 studies with the triplets, what we call it the triplets, SOF/VEL/VOX. Two of them are in treatment-experienced patients, and what we would aspire to is to have this compound BD universal salvage regimen. Now, Kevin, maybe you could comment on what the proportion of patients is that would qualify for this. But something I can tell you, in Japan, there's a fairly large number of patients had been treated with the Bristol-Myers GI NS5A regimen. I think if I remember this correctly, they have SVR rates in the Phase III study of about 80% or thereabouts, and there are about 9,000 patients now that we heard of that are treatment experienced at that field. And those 9,000 would immediately be candidates for our own studies. And as I said, I want to say it again, the other 2 studies is 8 weeks treatment duration for all patients, all genotypes, cirrhotics and noncirrhotics. Kevin?"
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. It's a good question, Ian. We're waiting to see some of the clinical -- obviously, emerging clinical data. Right now, we've -- I think we've got a situation, certainly in the U.S. and Japan is -- Japan, with this resistant situation, I think is perha",193,"Yes. It's a good question, Ian. We're waiting to see some of the clinical -- obviously, emerging clinical data. Right now, we've -- I think we've got a situation, certainly in the U.S. and Japan is -- Japan, with this resistant situation, I think is perhaps quite unique in terms of the original use of the Bristol-Myers regimen. But I think we got patients being cured to an incredibly high level with Harvoni, and now we've got the right treatment, I think in Epclusa for the 2s and 3s. So I think in the U.S., perhaps in Europe, it will be far more modest, the opportunity. Having said that, it depends where we are with those products, our products with where the competition is obviously, what we decide to do in terms of the pricing strategy. I think most importantly, from a company point of view, we think this is the right thing to do and probably the last step in the whole story around hepatitis C to help treatment experience of failure patients. So I think, first and foremost, we think this is the right thing to do for patients in need."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Alethia Young of Crdit Suisse.",11,"And our next question comes from Alethia Young of Crdit Suisse."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Let me be the thousandth person, Kevin, to say welcome back and it's great to have you here. Two kind of questions in kind of the same vein. Just one on oncology. Has this remained a focus for you guys as far as building assets there and building out that",93,"Let me be the thousandth person, Kevin, to say welcome back and it's great to have you here. Two kind of questions in kind of the same vein. Just one on oncology. Has this remained a focus for you guys as far as building assets there and building out that business as much as it was in the past when you talk about it? And secondarily, just, Norbert, with NASH, can you just talk about some of the data points coming up and like, what's going on with the FXR program as well?"
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. So Alethia, let me start off by -- firstly and then John Milligan will afterwards comment on it, too. We are in oncology. We have now momelotinib is at the end of the Phase III program. We should have data this year. If the data is positive and going",246,"Yes. So Alethia, let me start off by -- firstly and then John Milligan will afterwards comment on it, too. We are in oncology. We have now momelotinib is at the end of the Phase III program. We should have data this year. If the data is positive and going fine, the NDA track, right application next year. We have that MMP9 in gastric cancer in Phase III. We're looking at other solid tumors. And we're now finally, after sorting out the dosing, starting the first study in combination of a PI3K inhibitor with BTK in CLL. So with regards to NASH, yes, we have now very interesting 4 modalities or 4 mechanisms that we're evaluating in NASH, and at least with 3 of them, we know that they are doing what they're supposed to do pharmacologically. We will have data this year on the ASK inhibitor that will include liver fat analyses along with histology. The FXR agonist is currently in a Phase I, Phase IIa study. And by the way, we know about that compound already that it has minimal systemic absorption, but there are systemic levels of FGF19. That was always our idea to have a compound that acts in the GI; that releases FGF19; the FGF19 has the efficacy. And by that, the rationale we won't get the side effect that other FXR agonists have. And then finally, we have -- oh the -- wait a moment -- ASK inhibitor, OC --"
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","ACC.",1,"ACC."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","ACC inhibitor, the Nimbus compound. And we know those data were presented at EASL, that it reduces the novel lipogenesis. So what we're going to do based on these data is [indiscernible] asking if we could go into Phase III next year and we have a compoun",63,"ACC inhibitor, the Nimbus compound. And we know those data were presented at EASL, that it reduces the novel lipogenesis. So what we're going to do based on these data is [indiscernible] asking if we could go into Phase III next year and we have a compound with the Phase II with the FXR and the ACC inhibitor or even this year. John?"
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. I just would follow up with Norbert's comment by saying, yes, we are committed to oncology. We continue to be interested in assets, collaborations and partnerships where we could enhance our ability to continue to sell these products, right. Where we",100,"Yes. I just would follow up with Norbert's comment by saying, yes, we are committed to oncology. We continue to be interested in assets, collaborations and partnerships where we could enhance our ability to continue to sell these products, right. Where we are seeing good progress, as Norbert mentioned, our BTK inhibitor, which is -- we're developing with our partner from ONO, is now making its way to the clinic, and we've overcome some formulation challenges to allow us to go ahead. So that will be very, very -- I think, an interesting avenue for us to continue to explore."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our final question comes from Terence Flynn of Goldman Sachs.",11,"And our final question comes from Terence Flynn of Goldman Sachs."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Just wondering a kind of 2-parter. The first is just any opportunity to broaden your prescriber base on hep C? Kevin, would love your thoughts on that. And the second question relates to Genvoya. Can you just give us what percentage of the switches were f",48,"Just wondering a kind of 2-parter. The first is just any opportunity to broaden your prescriber base on hep C? Kevin, would love your thoughts on that. And the second question relates to Genvoya. Can you just give us what percentage of the switches were from Atripla?"
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Terence, first of all, in terms of sort of like any future waves of market, I did mention Australia earlier. And that's an incredible story of treating and curing patients and amazing commitment by the government there. We are seeing more patients treated",152,"Terence, first of all, in terms of sort of like any future waves of market, I did mention Australia earlier. And that's an incredible story of treating and curing patients and amazing commitment by the government there. We are seeing more patients treated in Brazil. It's a lower-price market, but we are seeing more. We are just beginning our launch in Mexico. So yes, these are smaller markets. Typically, they are lower price. But those -- if you like, those smaller waves are starting to work through. We are thinking carefully about China and how we launch there, probably in a very modest or very focused way -- a very efficient way should I say. So we -- our expectations, I think, are very reasonable around China. So the second question, in terms of switch, about 18% of the switch patients is from Atripla. So I hope that gives you the number."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And that concludes our question-and-answer session for today. I'd like to turn the conference back over to Mr. Lee for closing remarks.",23,"And that concludes our question-and-answer session for today. I'd like to turn the conference back over to Mr. Lee for closing remarks."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Great. Thank you, Candace, and thank you all for joining us today. We appreciate your continued interest in Gilead, and the team here looks forward to providing you with updates on our future progress.",34,"Great. Thank you, Candace, and thank you all for joining us today. We appreciate your continued interest in Gilead, and the team here looks forward to providing you with updates on our future progress."
29002,369689622,1011623,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Have a great day, everyone.",25,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Have a great day, everyone."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Second Quarter 2016 Earnings Conference Call. My name is Candace, and I'll be your conference operator today. [Operator Instructions] And as a reminder, this conference ca",63,"Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Second Quarter 2016 Earnings Conference Call. My name is Candace, and I'll be your conference operator today. [Operator Instructions] And as a reminder, this conference call is being recorded. 
I would now like to turn the call over to Sung Lee, Vice President of Investor Relations. Please go ahead."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Great. Thank you, Candace, and good afternoon, everyone. Just after market closed today, a press release was issued with earnings results for the second quarter of 2016. The press release and detailed slides are available on the Investor Relations section",221,"Great. Thank you, Candace, and good afternoon, everyone. Just after market closed today, a press release was issued with earnings results for the second quarter of 2016. The press release and detailed slides are available on the Investor Relations section of the Gilead website. 
Joining today's call will be John Milligan, President and Chief Executive Officer; Robin Washington, Executive Vice President and Chief Financial Officer; Kevin Young, Chief Operating Officer; and Norbert Bischofberger, Executive Vice President of Research and Development and Chief Scientific Officer. 
Before we begin formal remarks, let me remind you that we will be making forward-looking statements, including plans and expectations with respect to products, product candidates, financial projections and the use of capital, all of which involve certain assumptions, risks and uncertainties that are beyond our control and could cause the actual results to differ materially from these statements. A description of these risks can be found in the latest SEC disclosures documents and recent press releases. In addition, Gilead does not undertake any obligation to update any forward-looking statements made during this call.
Non-GAAP financial measures will be used to help you understand the company's underlying business performance. The GAAP to non-GAAP reconciliations are provided in the earnings press release, as well as on the Gilead website. 
I will now turn the call over to Robin."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, Sung, and good afternoon, everyone. We are pleased to share results for the second quarter of 2016. I'll first review our financials, and Kevin and John will then make a few comments. Total revenues for the second quarter were $7.8 billion, wi",1045,"Thanks, Sung, and good afternoon, everyone. 
We are pleased to share results for the second quarter of 2016. I'll first review our financials, and Kevin and John will then make a few comments. 
Total revenues for the second quarter were $7.8 billion, with non-GAAP diluted earnings per share of $3.08. This compares to revenues of $8.2 billion and non-GAAP earnings per share of $3.15 for the same period last year. Product sales for the second quarter were $7.7 billion, down 6% year-over-year and flat sequentially. The year-over-year decline was driven by lower HCV sales, partially offset by increased sales in HIV and other therapeutic areas. Sequentially, we saw an increase in HIV, U.S. HCV and other product sales that were offset by a decline in HCV sales in Japan and Europe. 
Turning to the U.S. Product sales for the second quarter were $4.9 billion, down 12% year-over-year. HCV product sales were $2.3 billion, down 33% year-over-year, driven by lower revenues per patient as a result of increased rebates and discounts due primarily to payer mix and lower patient starts for Harvoni, as the initial group of warehouse patients was treated in 2015. Sequentially, our HCV product sales were up 13%, driven by a $270 million adjustment to our HCV sales returns reserves rate and the initial inventory build for Epclusa. Strong uptake of our TAF-based regimens drove 23% year-over-year and 11% sequential growth of our HIV product sales. The quarterly revenues of $2.2 billion were also positively impacted by the upward trajectory of Truvada used for PrEP.
Turning to Europe. Product sales for the second quarter were $1.6 billion, down 18% year-over-year, primarily driven by lower HCV patient starts and a higher proportion of patient starts from countries that have a lower net average price. Sequentially, sales in Europe were flat, excluding the impact of currency movements, with HIV sales growth offset by lower HCV sales. 
In Japan, product sales for the second quarter were $619 million, down 43% sequentially as a result of lower patient starts on Harvoni and the full quarter effect of the mandatory price reductions for both Sovaldi and Harvoni, which were discussed during our last call. 
Moving to gross margin. Our non-GAAP product gross margin for the second quarter of 2016 was 92%, and benefited from the reversal of a $200 million litigation charge recorded in the first quarter of 2016, following a favorable decision in the Merck case. 
Now turning to expenses. Non-GAAP R&D expenses were $1 billion for the second quarter, up 48% compared to the same period last year, primarily due to the purchase of a U.S. Food and Drug Administration priority review voucher and the progression of clinical studies. Non-GAAP SG&A expenses for the second quarter were up 10% compared to the same period last year, primarily due to higher costs to support new product launches and our geographic expansion. 
From a balance sheet perspective, during the second quarter, we generated cash flow from operations of $4.9 billion and ended the quarter with $24.6 billion in cash and investments. While our cash flows will remain strong in the second half of the year, we anticipate a sequential decrease in Q3 2016 due to required cash payments related to our current government rebates in the U.S. and abroad, as well as milestone payments associated with our R&D pipeline progression. 
We continue to return capital to our shareholders through dividends and share repurchases. During the second quarter, we repurchased 10.5 million shares for $1 billion under the $12 billion 2016 share repurchase program, and we received an additional 8.1 million shares in April 2016 from the final settlement of the accelerated share repurchase program announced in February 2016. The total share repurchases in the first half of the year were 98.2 million at a cost of $9 billion. As previously communicated, we anticipate share repurchases in the second half of 2016 to be lower than the first half of 2016, as we focus our capital allocation on advancing our R&D opportunities. 
Finally, we are updating full year 2016 guidance, which is outlined on Slide 21. The changes are as follows: We are lowering net product sales guidance to a range of $29.5 billion to $30.5 billion. While we are seeing continued strength in non-HCV product sales, given the current trends in payer and patient flow dynamics for HCV, our updated models for just net product sales will range from being slightly above to slightly below $30 billion for the year. As such, we believe it is prudent to update our full year 2016 guidance. 
The factors contributing to this conclusion include: Lower HCV revenue per patient as a result of a mix shift towards more heavily discounted payer segments in the U.S. and companies with a lower net average price in Europe; a trend towards slowing patient starts in the U.S. Commercial segment and some earlier launch markets of Europe; the continued gradual trends towards shorter duration and loss of some market share to competition. 
This guidance is subject to a number of uncertainties, including: potential changes in the global macroeconomic environment; adoption of additional pricing measures to reduce HCV spending; volatility in foreign currency exchange rates; inaccuracy in our HCV patient start estimates; additional competitive launches in HCV; an increase in discounts, chargebacks and rebates due to ongoing commercial payer contract negotiations; and a larger-than-anticipated shift in payer mix to more highly discounted payer segments, such as PHS, FFS, Medicaid and the VA. 
We are increasing our R&D expense guidance to a range of $3.6 billion to $3.8 billion, driven by acquisition-related expenses for Nimbus Apollo, Inc. and the purchase of a U.S. Food and Drug Administration priority review voucher, slightly offset by lower-than-anticipated clinical trial expenses. 
We are lowering SG&A expense guidance to a range of $3.1 billion to $3.3 billion, primarily driven by the favorable onetime adjustment to the expected invoice from the IRS for the Branded Prescription Drug fee, which lowered Q1 2016 SG&A expense. 
Diluted EPS impact of acquisition-related upfront collaboration, stock-based compensation and other expenses increases to a new range of $1.47 to $1.53 as a result of our recent M&A activity. All other components of our 2016 guidance remain unchanged. 
I would like to now turn the call over to Kevin."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Robin, and good afternoon, everyone. Let me say immediately how terrific it is to be back at Gilead in a full-time capacity. Working with exceptional executive colleagues around the table here in Foster City, interacting with my senior operat",1693,"Thank you, Robin, and good afternoon, everyone. 
Let me say immediately how terrific it is to be back at Gilead in a full-time capacity. Working with exceptional executive colleagues around the table here in Foster City, interacting with my senior operating management team and seeing the dedication of the thousands of Gilead employees around the world leaves me in no doubt as to the long-term prospects for this outstanding company. 
Whilst early days, over the last 2 months in my new role, I've had the opportunity to reflect on Gilead's recent product introductions, the evolving health care landscape and the operating challenges on our near-term horizon. I'd like to share 3 general observations with you today. 
First, I am struck by the commitment that is shared by physicians, payers and governments around the world to reduce the prevalence of hepatitis C. Even countries with challenging economic circumstances are finding ways to prioritize the treatment of HCV patients. 
In the 2.5 years since the launch of Sovaldi, more than 1 million patients have been treated on a sofosbuvir-based regimen. Beneath this aggregated number are several landmark statistics. The United States has already treated nearly 0.5 million patients to date with Sovaldi and Harvoni. Equally, over 200,000 patients in Europe have been treated with Gilead regimens. Japan has treated approximately 100,000 patients in a little over a year. And just this year, Australia has treated an estimated 70,000 patients in a matter of months. Health care systems have demonstrably mobilized to reach those patients most in need. These are remarkable facts that clearly underscore the profile of the products we have introduced. Equally, they have implications to longer-term treatment dynamics and portfolio life cycles. 
Secondly, in the area of HIV, I'm impressed by how the clinical data for TAF-based regimens are resonating with the many constituents who tirelessly drive for better patient care. The understanding that these regimens can help address a growing need for highly effective and safer treatment options for lifelong HIV therapy is evidenced by the early success of Genvoya. I will highlight some impressive data points later.
Thirdly, I'm reminded just how complex the delivery of health care continues to be. Gilead's focus on flawless execution, on controlling the variables that we can control with the highest levels of conduct and compliance is critical and is my top priority. 
Now I'll get into the details of the commercial performance for the second quarter, starting with HCV. In the U.S., total HCV revenue was $2.3 billion, up 13% sequentially and down 33% year-over-year. Since the beginning of the year, access has improved and almost all major commercial payers have removed fibrosis score criteria, joining Medicare and the VA in this regard. Medicaid remains the only payer segment where use is still generally restrict it to the sicker patients. There are other significant barriers to access, but we are encouraged that some states have recently moved away from fibrosis restrictions towards more open access.
In terms of patient starts, approximately 59,000 people began HCV therapy in the second quarter, and an estimated 90% of these patients started on a sofosbuvir-based regimen. Importantly, third-party databases suggest that new patients are being identified through increased screening efforts. As evidenced, approximately 14 million people were screened for HCV for the period of 2014 through 2015, and approximately 280,000 were confirmed RNA positive in that 2-year period. These figures represent a significant increase from the years prior to the launch of Sovaldi. We estimate that 3 million individuals remain infected with HCV in the U.S., approximately half of whom are diagnosed.
Although patient starts increased for the second consecutive quarter and patient inflows into care remained recently steady at around 30,000 patients a month, the dynamics vary by patient segment. Within the commercial and Medicare segment, some larger payers have recently opened up access. We now estimate that up to 90% of all commercial covered lives have access without regard to fibrosis score. While the payers that recently opened up access are bringing in more patients, we are seeing a modest downward trend in patient starts among payers that have had full access in place for longer periods of time. The sickest patients have largely been treated, and the movement we are seeing is towards treating genotype 1 patients with lower fibrosis scores and thus greater use of the 8-week treatment regimen for Harvoni. 
In terms of all new HCV treatment starts in the second quarter, approximately 45% came from within the public payer systems. We anticipate this percentage will remain largely the same through the remainder of the year. The VA is one example of a payer within this segment, and their commitment to treating and curing veterans who have HCV using budget allocated by Congress to do so is truly groundbreaking. We are aware that in some cities, extra clinics have been scheduled to help shoulder the workload. However, we also expect that in the longer term, socially disadvantaged patients within the VA system will be harder to reach and bring into care and that the rate of treatment will decline.
Turning to Europe. Total HCV revenue in the second quarter was $775 million, down 32% year-over-year and down 7% sequentially. Overall, Gilead patient starts decreased to around 28,000 for the quarter. We observed steady treatment rates in Italy and Spain, but lower numbers in early launch markets like Germany and France. Patient starts in the U.K. continue to be limited by NHS England budget restrictions. Additionally, we saw a slight decline in average treatment duration, as countries like Germany are treating more patients with low fibrosis scores, who qualify for an 8-week treatment duration.
In several European markets, locally documented cure rates are equal to, if not better than, what was demonstrated in Sovaldi and Harvoni clinical studies. This has resonated with governments and payer bodies. And some countries such as France are considering removing all fibrosis score criteria. We will watch this picture closely and share evolving news with you in the future. 
Moving to Japan. As Robin mentioned, revenue was $619 million, down 43% sequentially. We believe this was related to 2 factors: First, the decline in genotype 1 new patient starts following the Q1 2016 peak when a very large number of individuals with advanced disease initiated therapy; and second, the full 3-month effect of a mandatory price reduction previously described on last quarter's call.
Finally, for HCV, Epclusa was recently approved in the U.S., the EU and Canada. These approvals are true milestones in patient care since Epclusa is the first pan-genotypic, once-daily, single-tablet option. Epclusa will be an important treatment option in the U.S. as an estimated 20% to 25% of HCV patients have genotypes 2 and 3. And equally, across Europe, there are some countries that have up to 30% of patients with genotype 3 alone. 
In concluding my remarks on hepatitis C, I will return to my earlier comments. Gilead is proud to be part of a fundamental disease paradigm shift, delivering disease cures to virtually all patients treated. That's why we developed Sovaldi, Harvoni and Epclusa and have a third single-tablet regimen in clinical testing. 
Whilst the pace of new patient treatment may slow in coming years and quantifying that pace is incredibly hard, there is still an opportunity to identify and cure many HCV infected people around the globe. 
Moving to HIV. We are pleased with the launch of our TAF-based products in the U.S. and in the European markets where we have already achieved reimbursement. In the U.S., total HIV and other antiviral revenue was $2.2 billion, up 11% sequentially, and Genvoya revenue nearly doubled in Q2 versus Q1. The product represents the most successful HIV launch since the introduction of Atripla, the first single-tablet regimen, a decade ago. After its first 6 months of availability, Genvoya is already the most prescribed regimen for both treatment-nave and switch patients. 
78% of all Genvoya prescriptions have come from switches. Half of the switches have come from Stribild, and importantly, 10% of switches have come from non-Gilead therapies. Among all patients who switched, we have seen an increase in our ability to retain patients on a Gilead product. 
Whilst still in the early stages of the Odefsey and Descovy launches, we are seeing similar patient dynamic to Genvoya. Over 90% of all Odefsey and Descovy prescriptions have come from switches. And 6% and 11% of switches, respectively, have come from non-Gilead therapies. 
Finally, in the U.S., I would like to highlight the growing use of Truvada for PrEP. We estimate somewhere in the order of 60,000 to 70,000 patients were using Truvada for PrEP in the second quarter. This number accounts for approximately 1/3 of Truvada demand. This is encouraging, as we know Truvada has an important role to play as part of comprehensive HIV prevention for many at-risk individuals.
Turning to Europe. Total HIV and other antiviral revenue was $755 million, up 5% sequentially, driven by the launches of Genvoya and Descovy. Genvoya has gained pricing approval in 11 countries and is now the market leader in Germany for both treatment-nave and switch patients after only 6 months of availability. We anticipate additional launches in France, Italy and the U.K. in the second half of the year. 
Genvoya is the preferred regimen in several HIV treatment guidelines, including Italy, where it was added before pricing and reimbursement. Preferred listings are anticipated in other EU guidelines later this year and into 2017. EACS guidelines are expected to be updated following the HIV Glasgow 2016 Conference in October.
Finally, I would like to briefly update you on the outstanding performance of the Gilead U.S. cardiovascular team. Letairis and Ranexa together generated $356 million in revenue during the quarter, representing a 12% year-over-year increase. Today, over 0.25 million people in the United States regularly receive Ranexa. And Letairis remains the overall ERA market leader in PAH. 
In closing, Gilead achieved a great deal across our operations during the quarter, and I am confident that we will continue to make significant progress in the second half of 2016. 
I would now like to turn the call over to John."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, Kevin. Before I get started, I just wanted to say it's great to have you back on the Gilead full team -- full time as our new Chief Operating Officer. Today, in addition to the remarks of Robin and Kevin regarding the quarter, I'd like to make a",1165,"Thanks, Kevin. Before I get started, I just wanted to say it's great to have you back on the Gilead full team -- full time as our new Chief Operating Officer. 
Today, in addition to the remarks of Robin and Kevin regarding the quarter, I'd like to make a few comments of my own. Over the last 2.5 years, we've made great progress in helping provide access to Sovaldi and Harvoni for HCV patients. Throughout the world, more than 1 million HCV sufferers have now been treated with nearly half of those coming from the U.S. While lots of these drugs were unprecedented in our industry, and patients were treated at a much faster initial rate than we, or anyone else, thought possible, looking back, we can now say that in every country, the peak number of patients treated was achieved within 2 or 3 quarters of the launch of Harvoni, but that peak number was far higher than what we had -- what had ever been achieved before; about 3x that seen with the launch of the HCV protease inhibitors in 2011.
As we've reached the mid-point of this year, we now see the market maturing to a slower rate of treatment for HCV-infected individuals. And as we think about this more normal patient starts, there are a few things to keep in mind. As Kevin mentioned, there are about 3 million people who are infected in the U.S., and slightly more than half of those have been diagnosed. Many of these diagnosed patients have less advanced liver disease upon reentering care. For example, in the United States in the second quarter this year, we estimated that only 13% of patients starting treatment had F4 fibrosis scores compared with more than 21% the year prior to that. With less severely ill patients, there is less urgency to immediately treat patients. And this may explain the slower rate of treatment versus last year. However, we do believe these patients will eventually benefit from treatment, and this means the flow of patients will continue for many years to come.
There's also an opportunity to diagnose patients and bring them into care. As Kevin mentioned, we estimated that about 280,000 HCV patients were diagnosed in the U.S. within the last 2 years, showing the value and importance of the U.S. CDC and CMS recommendations for HCV testing. So while there has been a slowing of treatment compared with the rush of patients when Sovaldi and Harvoni were first approved, the HCV market is attractive over the longer term, providing good revenues, strong cash flow and earnings per share, on top of our base business of chronic therapies. 
Because of this, our focus on improving care for HCV and infected individuals has not wavered. Beyond the recent approvals of Epclusa, we are actively working on a third single-tablet regimen that combines the 2 active ingredients in Epclusa with a third investigational compound, voxilaprevir. This combination, known as SOF/VEL/VOX, is being evaluated at 4 Phase III clinical trials among patients who have previously failed direct-acting antiviral treatments. It's also being studied for its potential to offer an 8-week treatment duration for treatment-nave patients of all genotypes. We expect to have top line data available for SOF/VEL/VOX by the end of the year. 
We're making tremendous headway in HIV as well; both of our portfolio of newer products and our pipeline. We've had several key approvals with Descovy approved in the U.S. and Europe last quarter and Odefsey approved in Europe earlier this month. It's clear these medications offer a significant advance for patients, and that advance has been recognized now by multiple professionals and public health groups, including the International Antiviral Society of the U.S.A. and the Department of Health and Human Services, both of which were released updated guidelines supporting the use of TAF-based regimens for initial HIV therapy. 
We continue to generate clinical data that support the favorable scientific and medical profile of our TAF-based products. Last week, we announced the results of 2 Phase IIIb switch studies, evaluating Odefsey in virologically suppressed adults switching from Complera or Atripla. Odefsey achieved similar rates of virological suppression as the TDF-based regimens. These studies reinforce the efficacy of Odefsey as well as the renal and bone safety advantages, and we plan to present full data sets later this year. 
Last month, we presented the first human data on bictegravir, our investigational, unboosted integrase inhibitor, at the American Society for Microbiology. Data from 4 preclinical and Phase I studies examined the antiviral potency, resistance profile, pharmacokinetics and safety of bictegravir, providing the rationale to further evaluate the compound. Bictegravir, as part of a single-tablet regimen, in combination with TAF and emtricitabine, is currently in Phase III trials. Enrollment of more than 2,300 patients across 4 registrational studies was completed earlier this month. The 48-week endpoints for these studies will be reached in the second quarter of next year, and if the data play out as we hope, NDA and MAA filings could occur in the third quarter of 2017.
With the approval and rapid adoption of our TAF-based regimens, an exciting new STR and Phase III development and an active HIV research pipeline, I'm confident that we will be able to extend our leadership position in the HIV market and broaden our ability to help even more patients around the world. 
Outside of our working antivirals, Gilead is focused on solving some of the biggest health challenges today. Several important data sets that are anticipated in the second half of this year may help us to find a strategy and pathway forward for tackling these challenges. 
In our NASH program, where we have 4 active clinical programs, we'll have data from the Phase II studies of GS-4997, our ASK-1 inhibitor, and simtuzumab, our monoclonal antibody against LOXL2. The Phase II study of simtuzumab for primary sclerosing cholangitis will also conclude. And we'll also have data from the Phase II studies of GS-4997 in diabetic nephropathy and pulmonary arterial hypertension, or PAH. And finally, we expect data from 2 Phase III studies for myelofibrosis before the end of the year. If these data are positive, these studies will form the basis for an MDA filing in the first quarter of 2017. 
These are important milestones and represent a great deal of work across the organization to enroll and advance these studies and analyze complex data sets as they become available. Gilead continues to innovate at every level and every part of the organization. Next month, we will publish our first corporate social responsibility report that looks at access, sustainability, grant making and other positive contributions to the communities we serve, and I urge each of you to read it. 
I'm proud of the work that's been led by our employees and extend my many thanks to them for all the ways they are making a difference around the world. 
Thank you, and let's now open up the call for questions. Operator?"
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Geoff Meacham of Barclays.",15,"[Operator Instructions] And our first question comes from the line of Geoff Meacham of Barclays."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Kevin, good to have you back on the call, and in the seat, of course. So I want to dig into your comments and also John's comments on the hep C new starts. And just, I guess I'm curious here because you have better F0, F1 Access. You have positive impact",121,"Kevin, good to have you back on the call, and in the seat, of course. So I want to dig into your comments and also John's comments on the hep C new starts. And just, I guess I'm curious here because you have better F0, F1 Access. You have positive impact theoretically from the CDC guidelines and very low penetration in markets such as the prison population. I'm just curious why, could you put your finger on maybe 1 or 2 things that you feel like could ultimately be a -- become a growth driver to get us back to better sequential growth? I'm just trying to figure out what the tipping point is, on some of these different volume drivers."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Geoff, nice to hear your voice as well. Thank you for your comments. I'm not at all pessimistic about the long-term prospects for hepatitis C. In fact, I'm rather optimistic. I think what we have seen 2014, 2015 is an enormous group of the less well patie",337,"Geoff, nice to hear your voice as well. Thank you for your comments. I'm not at all pessimistic about the long-term prospects for hepatitis C. In fact, I'm rather optimistic. I think what we have seen 2014, 2015 is an enormous group of the less well patients treated, particularly by specialist hepatitis C treaters. It's really quite amazing. I think this quarter and we've highlighted perhaps going forward is really sort of a payer mix situation that we've got. The VA has definitely increased in terms of its contribution to the 59,000 total HCV starts, which, of course, was an increase on quarter 1. So a lot of VA patients are coming through, and the VA is very, very motivated to try to essentially eradicate the virus from that population. I think, yes, we did see pickup in 2 of the large players that came on stream with open fibrosis scores from the beginning of the year, but we did see some downtick in other commercial payers. So net-net, it was slightly a decrease in overall commercial patients. What I feel about the long term and as we go into years further forward and we kind of hit an equilibrium of patients is all around what I mentioned, and John mentioned, around diagnoses. There's been a considerable pickup in the number of HCV tests; 2014, 2015, about a 65% increase in the number of HCV tests. 280,000 in that 2-year period were HCV RNA positive. So as John said, they will eventually work their way through to treatment. But still over 1/4 of the population being diagnosed is at 4. So there's still a lot of sickness out there in patients. So whilst the health care system here and in some of the European markets have done heroic things in treating patients in the last 2 years, I still think, with 1.5 million diagnosed patients in the United States that we are going to see a continued healthy flow of patients that can benefit from our products."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Geoffrey Porges of Leerink.",10,"And our next question comes from Geoffrey Porges of Leerink."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","For Kevin, welcome back, and good to hear you. So following up on this somewhat vexing issue of the HCV outlook. Historically, in this category after each market has peaked, it's begun a steady slow, sometimes slow, anyway, decline. We certainly saw a rap",152,"For Kevin, welcome back, and good to hear you. So following up on this somewhat vexing issue of the HCV outlook. Historically, in this category after each market has peaked, it's begun a steady slow, sometimes slow, anyway, decline. We certainly saw a rapid decline after the protease inhibitors, more slow decline after we went to ribavirin and with the introduction of pegylated interferon. Are you suggesting to us that you think that there is a stable outlook for the HCV revenue on a market-by-market basis from these levels? Or are you suggesting that we should see more like an orderly and steady decline? And could you particularly comment about Europe, where I think it was surprising to see patient numbers in the big early markets roll over so quickly, particularly Germany and Japan? Is that a onetime step-down? Or are we going to continue at or below this level going forward?"
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. Thanks for the question, Geoff. I think it is encouraging that patient starts in the U.S. and Europe have been reasonably steady over the past 3 quarters. Japan's a different story, I can certainly, at some point, comment on that this afternoon. I th",298,"Yes. Thanks for the question, Geoff. I think it is encouraging that patient starts in the U.S. and Europe have been reasonably steady over the past 3 quarters. Japan's a different story, I can certainly, at some point, comment on that this afternoon. I think, from my perspective and Robin, Norbert, John around the table here, I think it's more of the latter comment; that there will continue to be a gradual decline in new patient starts, but an equilibrium will be eventually hit. Quite the timing of that, Geoff, it's really, really, really hard to peg. I've just got to believe that with the amount of testing, with the amount of diagnoses with the CDC guidelines, Gilead itself in Q3, Q4 of this year are going do some more educational programs around the need to test and treat that. We will eventually hit an equilibrium. In terms of Europe, Italy and Spain are very steady. I should tell you that in Italy, there are still 200,000 quite sick individuals, people to be treated, and they're in treated care. And the Italian government do want to go ahead and try and mobilize providers to do that treating. So it's still an enormous number in Italy. I think the more -- the markets that are more akin to the U.S., like, first and foremost, Germany and to a slightly lesser extent, France, are starting to see that sort of turnover of patients. We've got full access in terms of fibrosis score in Germany, and we're hoping, as I said, that we get broader access in France. The U.K. is a different situation, and that's largely due to payer restrictions. But again, still an enthusiasm to treat, but 1 or 2 of those markets, there is some maturing going on."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Mark Schoenebaum of Evercore ISI.",11,"And our next question comes from Mark Schoenebaum of Evercore ISI."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","This is Regina Grebla in for Mark. I actually wanted to change topics and shift to hepatitis B. On your Q1 call, you mentioned your hep B program included a vaccine, the TLR7 agonist, and 2 other internal preclinical candidates. When will we see any data",73,"This is Regina Grebla in for Mark. I actually wanted to change topics and shift to hepatitis B. On your Q1 call, you mentioned your hep B program included a vaccine, the TLR7 agonist, and 2 other internal preclinical candidates. When will we see any data on the internal candidates? And also, you mentioned taking a look at external opportunities for hepatitis B. Is hep B still potential area of interest for acquisition?"
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. So Regina, you asked a question about what our pipeline is for hepatitis B. So we have, as you know, 2 compounds currently in clinical development. One is an active vaccine, 4779, the collaboration with GlobeImmune. That's currently in the later stag",323,"Yes. So Regina, you asked a question about what our pipeline is for hepatitis B. So we have, as you know, 2 compounds currently in clinical development. One is an active vaccine, 4779, the collaboration with GlobeImmune. That's currently in the later stages of being evaluated in non-suppressed hep B patients. The suppressed hep B patients, those data have been released, I think, maybe a year ago that they did not show any activity, so we don't have high hopes that the compound will work. Then, the TLR7 agonist is that's just finishing the first cohort, which is in suppressed patients, and we are currently initiating. The second cohort quarter is ongoing. We hope that we'll have the presentation of the first cohort ready by AASLD. Hopefully, we'll make that -- the abstract deadline. Then, you said that -- you asked the question about we had 2 other compounds in development. Well, you know what we're pursuing. Maybe I should answer this more generally. So we're pursuing 3 approaches to hepatitis B cure. The one is adding another different mechanism to the nucleosides because there's the observation that despite being undetectable with hepatitis B therapies like Viread or TAF, there was always a little bit of virus left, HBV there may detectable if you look at very sensitive PCR methods. So by adding another mechanism, so actually, we could completely suppress virus replication down to 0, would that lead to an eventual cure or hepatitis S conversion? The second thing we're pursuing is immune therapy, so that belongs to the vaccine and the TLR7 that I've talked about already. And we have a TLR8 agonist currently that is working its way towards an IND. And then the third possibility, that's the most hopeful but also the one that's least scientifically proven that's going directly after cccDNA, and that's really too early to talk about at this point. It's still in the research stages."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Michael Yee of RBC Capital Markets.",12,"And our next question comes from Michael Yee of RBC Capital Markets."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","You talked a lot about volume and demand in the different buckets. But can you talk about the payer mix shift? Specifically, I wanted to ask on Medicaid. Can you just help us out with what percent of sales Medicaid is? And what is going on in that bucket?",98,"You talked a lot about volume and demand in the different buckets. But can you talk about the payer mix shift? Specifically, I wanted to ask on Medicaid. Can you just help us out with what percent of sales Medicaid is? And what is going on in that bucket? I presume it's a state-by-state negotiation. Can you talk about what's going on there? Is there a state-by-state negotiation you have to go through? Is that pretty much done? Walk us through that bucket and what percent of hep C that is in U.S.A. so I can understand them."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Michael, it's Kevin. Thank you for the question. I prefer not to break out specifically the percentage of the public payers in terms of Medicaid. As I said, all our public payers lumped together for the quarter were about 45%. That's an increase from the",177,"Michael, it's Kevin. Thank you for the question. I prefer not to break out specifically the percentage of the public payers in terms of Medicaid. As I said, all our public payers lumped together for the quarter were about 45%. That's an increase from the previous quarter, but as I said, that's all driven by VA. We've seen very little change, really, in our -- in the scale and size of our Medicaid business. I think it would be true to say that Medicaid's -- the states are slowly progressively opening up. 40% of Medicaid patients come from the 5 largest states. Two of those, New York and Florida, now have no fibrosis score. So as states do progressively consider opening up, they typically come to us for a contract. We think about those contracts very carefully. Depending on the size of Medicaid, we obviously put our submission in. Realistically, I think we may win, we hope, the majority of those, but there may be occasions when, occasionally, a Medicare -- Medicaid stake goes to the competition."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Matthew Harrison of Morgan Stanley.",11,"And our next question comes from Matthew Harrison of Morgan Stanley."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Robin, if you could just address the $279 million onetime swing. We obviously saw a swing in the first quarter and then a swing this quarter again. Can you just give us some insight into what's going on with those changes in chargebacks and if we should c",72,"Robin, if you could just address the $279 million onetime swing. We obviously saw a swing in the first quarter and then a swing this quarter again. Can you just give us some insight into what's going on with those changes in chargebacks and if we should continue to expect to see some of those numbers? And then just separately on PrEP, any plans to get a TAF-based regimen approved for PrEP?"
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Sure. I'll take the first part, and then Norbert will take the second. Matt, first of all, there are 2 separate things that we're talking about here Q2 versus Q1. First, let me address Q2. We did have a sales return reserve adjustment really related to th",360,"Sure. I'll take the first part, and then Norbert will take the second. Matt, first of all, there are 2 separate things that we're talking about here Q2 versus Q1. First, let me address Q2. We did have a sales return reserve adjustment really related to the fact that as we introduce our new hep C product, we're required to go out and get an external proxy related to sales return reserves. And just recently, just this past quarter, we closed several of the lots related to our products, which means that no further returns are accepted. So that gives us a triggering event by which we can look at returns versus how we had been accruing. The other key thing about the timing is just related to the Epclusa lot. So as we bring on a new product, we want to kind of want to rebase the level of returns that we are expecting to see. So that's really the adjustment there. For the most part, you could -- it's onetime in nature. We may have small adjustments going forward, but as long as returns continue where they are, then that $279 million is kind of a onetime event. Last quarter, we had a different issue, and that related to the rebate claims for hepatitis C. And as I said on the call last time, we always have a situation where we're constantly truing up claims around HCV rebate because we get those claims 1 to 2 quarters in arrears. This quarter was a bit different than last quarters that we saw a modernization of the level of those claims relative to the prior quarter. So it wasn't -- it didn't reverse the other way. It was just a slowing of what we saw in Q1. So we're, for lack of better words, maybe a little bit more caught up relative to returns this quarter than we were at the end of Q1. So 2 different items, but we caught up at $279 million because that was the onetime event. So we ensured -- we wanted to ensure that you understood relative to the future projection of HCV sales."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Matt, so to your question about F/TAF or PrEP, so we and also the outside medical community believes that, obviously, discovery of F/TAF would have advantages in terms of use for PrEP versus Truvada for all the obvious data that were published already. An",148,"Matt, so to your question about F/TAF or PrEP, so we and also the outside medical community believes that, obviously, discovery of F/TAF would have advantages in terms of use for PrEP versus Truvada for all the obvious data that were published already. And also, we have data now in human -- in animal models that show that that has the same efficacy. The thing we're debating internally and also we have had early discussions with FDA is what clinical study would need to be done that leads to approval. It would have to be, in almost all likelihood, a comparative study and tend to seek which is what would be the sample size and what would be the powering. And that's currently a discussion we're having with FDA. We hope we can come to some conclusion within the next months or so and then let you know."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Brian Abrahams with Jefferies.",10,"And our next question comes from Brian Abrahams with Jefferies."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Kevin, good to hear your voice again. With the list pricing and label established for Epclusa, I'm just wondering. What's the right way to think about Epclusa's potential impact on the genotype 2/3 franchise, particularly with respect to the net price per",75,"Kevin, good to hear your voice again. With the list pricing and label established for Epclusa, I'm just wondering. What's the right way to think about Epclusa's potential impact on the genotype 2/3 franchise, particularly with respect to the net price per patient treatment duration relative to Sovaldi and just how we should be thinking about the overall market dynamics there? I'm just wondering if you could also quantify the inventory build this quarter there."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. Great question, Brian. Nice to hear your voice as well. Brian, the majority of the revenues in the second quarter, which is right at the end, the majority of that was inventory that Robin called out. So we've really only just begun the introduction,",303,"Yes. Great question, Brian. Nice to hear your voice as well. Brian, the majority of the revenues in the second quarter, which is right at the end, the majority of that was inventory that Robin called out. So we've really only just begun the introduction, both the promotion and the education around Epclusa. I'm really pleased that the response has been excellent. In our advisory boards and our speaker programs there's been good acceptance. Whilst we have obviously a pan-genotypic label, I think the reality is that physicians are very, very comfortable, as are payers, with Harvoni for genotype 1. Obviously, there's a mix of 12-week treatments and 8-week. Just for your information, the 8-week course of Harvoni is now 45% of patients treated in the United States. So I think people are just really comfortable with the clinical effect and the value proposition of Harvoni in GT1, which therefore means that the slot that people see Epclusa is in the 2 and 3 patient. And as I highlighted, it's something like in the order of 20% to 25% of patients in the United States. I think the obvious advantage, both clinically and from a payer point of view, is you really do have a 12-week single-tablet regimen. You don't have to extend the treatment duration. You don't have to use ribavirin. There was quite a number of patients treated with Sovaldi, Daclatasvir, certainly, in United States. So really, in some ways, it takes away that regimen and is an excellent slot. So we've had very good reception to Epclusa. It's extremely early days. It'll take us 3 to 6 months to get payer approval. Physicians can apply based on medical need, and they're doing that. So just very early days and weeks. It seems to have found a very nice entry point."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from the line of Cory Kasimov of JPMorgan.",13,"And our next question comes from the line of Cory Kasimov of JPMorgan."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I have a bigger picture question for you. Really, just following the latest management shuffle back in 2Q, I'm wondering if these changes portend any material shift or consideration of a shift in, I guess, your commercial or pricing strategy, or really, t",76,"I have a bigger picture question for you. Really, just following the latest management shuffle back in 2Q, I'm wondering if these changes portend any material shift or consideration of a shift in, I guess, your commercial or pricing strategy, or really, the overall strategy for the business or any of the key businesses. And is this playing into the bump in anticipated R&D with the associated downtick in SG&A as illustrated by your updated guidance?"
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","I think there were a couple of questions there. So it's John Milligan. So in terms of -- let me get to the last bit. You said there was a bump in R&D. That is true, relating somewhat to our acquisition of Nimbus. So there were charges associated with that",246,"I think there were a couple of questions there. So it's John Milligan. So in terms of -- let me get to the last bit. You said there was a bump in R&D. That is true, relating somewhat to our acquisition of Nimbus. So there were charges associated with that and there are also charges associated -- I should say expenses associated with the purchase of an FDA priority review voucher. So we're very pleased to get that onboard, and we'll look forward to explaining when we're going to use that. Above and beyond that, actually, R&D expenses were slightly down what we -- beneath what we had forecasted because we continue to hold the cost of centers to -- accountable and continue to drive good value through our clinical teams in getting studies done at a very cost-effective way. So in terms of that, there's no difference. The SG&A line came down a little bit because of some onetime charges that were lower than we -- sorry, the IRS charge which was lower than we anticipated, so kind of what we would expect. In terms of signaling about pricing or changes in management about structures, I don't really think there's anything to signal there in terms of our pricing strategy. We're highly competitive. We think we have a very good differentiated product, and we'll continue to do the best for the company and for patients when coming to the right level of price and access."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. And I would just add, Cory, that the Gilead way is always to lead with the science around our product. Nothing's changed. In my eyes, as I have come back into the company, we lead with science. That's what you do in specialist markets. It is a realit",113,"Yes. And I would just add, Cory, that the Gilead way is always to lead with the science around our product. Nothing's changed. In my eyes, as I have come back into the company, we lead with science. That's what you do in specialist markets. It is a reality that there is more contracting. I think we've got a phenomenal team working on this. I met with them 2 weeks ago, and I think they're highly professional. And we always lead with value. That's the key thing. We think we've got tremendous products that either control disease or cure disease, and they are terrific value. And that's the course we're going to stay."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Phil Nadeau of Cowen.",10,"And our next question comes from Phil Nadeau of Cowen."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Kevin, it's great to have you back. I have a question on capital allocation. In the prepared remarks, I think you mentioned in regards to cash flows being lower in the second half of the year, that part of that was investment in R&D. And as you just discu",105,"Kevin, it's great to have you back. I have a question on capital allocation. In the prepared remarks, I think you mentioned in regards to cash flows being lower in the second half of the year, that part of that was investment in R&D. And as you just discussed, the R&D expenses aren't really changing that much in the guidance. So kind of curious whether you have on your list of things to do in the second half of the year more deals, whether M&A or in-licensing. And maybe you could give us some thoughts on how aggressive you're likely to be in those areas."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Well, Phil, I'll start. I think relative to the cash flow, what I was messaging was really just related to the dynamics of payments, right. So we have accrued rebates and other things that kind of caused volatility to quarterly cash flows. So overall, our",115,"Well, Phil, I'll start. I think relative to the cash flow, what I was messaging was really just related to the dynamics of payments, right. So we have accrued rebates and other things that kind of caused volatility to quarterly cash flows. So overall, our cash flows remain strong, but we definitely expect a sequential decrease in cash flows second half. Relative to overall capital allocation, it's no different than what we've been messaging, again, more focused on our BMD opportunities, but I'll let John speak of a little bit more and just, again, focus there. And that additional focus has meant we're somewhat less focused on share repurchases the second half of the year."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","And as a follow-up on what Robin said, Phil, we were very aggressive in the first quarter of this year. That's why we back off a little bit from where we are in the second half of the year. Mostly, you get the full year effect or a greater effect of repur",195,"And as a follow-up on what Robin said, Phil, we were very aggressive in the first quarter of this year. That's why we back off a little bit from where we are in the second half of the year. Mostly, you get the full year effect or a greater effect of repurchasing the almost 100 million shares through Robin's program. With regard to business development, obviously, we're a company that has been very open about being interested in doing more deals, especially deals of a certain size where we think we can get some leverage and we can use our organization to effectively accelerate or expand indications. We've done some good deals both with Galapagos and Nimbus recently. We are very interested in continuing that to add more things to our pipeline, especially in the non-antiviral area where we continue to see growth in franchises. It's our hope that as we exit this year, we'll have a better, more complete story of programs internally and externally that we can use to talk about why the long-term prospects for growth are as good as we believe they are, and that's what we'll be focused on."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Robyn Karnauskas of Citi.",10,"And our next question comes from Robyn Karnauskas of Citi."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I guess, the question for me after hearing some of the comments about like thinking about volumes slowing or coming down and then thinking about growth and that changing over time is how do you -- how are you comfortable that you can provide guidance with",102,"I guess, the question for me after hearing some of the comments about like thinking about volumes slowing or coming down and then thinking about growth and that changing over time is how do you -- how are you comfortable that you can provide guidance with these 2 variables? Or do you have any bookends for how low we can go that give you the comfort? And then the question is you affirmed guidance last quarter and lowered it this quarter. What was the one thing you think that really changed your view over the last 3 months that led to that?"
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Sure. You want to start, Kevin?",6,"Sure. You want to start, Kevin?"
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","I'll start and then hand the question to Robin. Robyn, it's really hard. We've got markets in different stages of development, whether it be U.S., parts of the U.S., different countries in Europe and obviously, interesting and profound dynamics in Japan.",130,"I'll start and then hand the question to Robin. Robyn, it's really hard. We've got markets in different stages of development, whether it be U.S., parts of the U.S., different countries in Europe and obviously, interesting and profound dynamics in Japan. So they're partly made up of patient flows and partly made up of sort of payer flows. I think the big thing this quarter, from the point of view of the U.S., was very much a payer kind of mix with the large addition of patients from the VA. So I think in the last 3 months, that was probably the biggest thing. We have not changed our prices in the U.S. Q2 versus Q1. It was largely we're seeing this dramatic but incredibly successful program from VA."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. Robyn, so I'll add to that. I agree with Kevin. I think the heavier percentage of more discounted payers, along with the fact that on the commercial side, right, we're seeing slight decreases in the U.S. And Kevin mentioned earlier about what we're a",184,"Yes. Robyn, so I'll add to that. I agree with Kevin. I think the heavier percentage of more discounted payers, along with the fact that on the commercial side, right, we're seeing slight decreases in the U.S. And Kevin mentioned earlier about what we're also seeing relative to the mix shift in countries in Europe; less of Northern Europe, Germany and France and more of Italy and Spain. To your other part of your question and to what you were [ph] earlier throughout the call, this is a really difficult area to predict. It's unlike any other. It's a curative market, and it's very large relative to Gilead's total revenues. And so it's a question we're asking ourselves as we think in the outer years how can we continue or can we really guide around HCV revenues. So we've guided this year, but it's definitely something we're giving a lot of thought to as we kind of think about the trends of HCV going forward and all the dynamics that we're trying to deal with. It's very complex, so more to follow on that."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Ying Huang of Bank of America Merrill Lynch.",14,"And our next question comes from Ying Huang of Bank of America Merrill Lynch."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I have a quick one on also the pricing environment. So if you look at VA sector and also the commercial sector, what kind of impacts are you seeing from competition, particularly Merck's Zepatier, from the pricing perspective? And then quickly on R&D side",74,"I have a quick one on also the pricing environment. So if you look at VA sector and also the commercial sector, what kind of impacts are you seeing from competition, particularly Merck's Zepatier, from the pricing perspective? And then quickly on R&D side. Do you plan to develop a doublet maintenance regimen? For example, recently, Tivicay plus EDURANT, the combination showed actually good results in heavily protruded [ph] patients in the near conference."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","So I'll take the first part in terms of kind of pricing and competitive impact. Very little in terms of our commercial payer areas because the contracts essentially were set up at the end of last year for the full year, so very little change in market sha",144,"So I'll take the first part in terms of kind of pricing and competitive impact. Very little in terms of our commercial payer areas because the contracts essentially were set up at the end of last year for the full year, so very little change in market share within the commercial payer segment. We still have a very strong position in VA with Harvoni and Sovaldi, particularly Harvoni. I think probably where we're seeing increased competitive activity is in the Medicaid setting where, as I described earlier, some of the smaller states are requesting contracts as they open up access. So I think that's probably where we see the competition. And again, because of our very strong value proposition, we hope we can be successful in the majority of those. But again, on occasions, we may find that they go to the competition."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. Ying, you asked a question about the ViiV, the expansion [ph] of the BCI in FIV. So we're, of course, aware of the data that were presented at EASL; they looked fairly impressive. They had a number of genotypes with high SVR rates. However, what they",205,"Yes. Ying, you asked a question about the ViiV, the expansion [ph] of the BCI in FIV. So we're, of course, aware of the data that were presented at EASL; they looked fairly impressive. They had a number of genotypes with high SVR rates. However, what they're doing right now in Phase III is not looking at the 8-weak treatment duration or genotypes enrolled patients. I would like to contrast this with our own triple combination, SOF/VEL/VOX, that John Milligan mentioned. We are looking essentially at 2-patient population of 1-patient population's experience that had previously failed other DAAs, that treatment duration is for 12 weeks; and then we're looking at all genotypes, cirrhotic and non-cirrhotic patients for 8-week treatment duration. And we had 1 study, in particular, that only looks at 8 weeks of treatment duration in the most difficult to treat genotype 3 cirrhotic patients because that's still a population where SVR rates are still in the low 90s. And if we could push that up into the high 90s, that would be a step forward. So I think our -- if our Phase III program, the data, support our Phase II results, then we will be a step ahead of all the competition."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Ian Somaiya of BMO Capital Markets.",12,"And our next question comes from Ian Somaiya of BMO Capital Markets."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I just wanted to follow up on the triplet opportunity within hep C. Specifically, Norbert, just I don't know if you could describe the proportion of patients that have maybe failed the -- in the first round -- sort of round of antivirals, whether it be do",91,"I just wanted to follow up on the triplet opportunity within hep C. Specifically, Norbert, just I don't know if you could describe the proportion of patients that have maybe failed the -- in the first round -- sort of round of antivirals, whether it be doublet therapy or SOF alone. So I don't know if there's a prevalent pool that you can speak to. And then maybe, I guess, it's more a question for Kevin. Just how do you think about the triplet and its impact on margin price share?"
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","So Ian, we -- as you know, we are doing essentially 4 studies with the triplets, what we call it the triplets, SOF/VEL/VOX. Two of them are in treatment-experienced patients, and what we would aspire to is to have this compound BD universal salvage regime",165,"So Ian, we -- as you know, we are doing essentially 4 studies with the triplets, what we call it the triplets, SOF/VEL/VOX. Two of them are in treatment-experienced patients, and what we would aspire to is to have this compound BD universal salvage regimen. Now, Kevin, maybe you could comment on what the proportion of patients is that would qualify for this. But something I can tell you, in Japan, there's a fairly large number of patients had been treated with the Bristol-Myers GI NS5A regimen. I think if I remember this correctly, they have SVR rates in the Phase III study of about 80% or thereabouts, and there are about 9,000 patients now that we heard of that are treatment experienced at that field. And those 9,000 would immediately be candidates for our own studies. And as I said, I want to say it again, the other 2 studies is 8 weeks treatment duration for all patients, all genotypes, cirrhotics and noncirrhotics. Kevin?"
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. It's a good question, Ian. We're waiting to see some of the clinical -- obviously, emerging clinical data. Right now, we've -- I think we've got a situation, certainly in the U.S. and Japan is -- Japan, with this resistant situation, I think is perha",193,"Yes. It's a good question, Ian. We're waiting to see some of the clinical -- obviously, emerging clinical data. Right now, we've -- I think we've got a situation, certainly in the U.S. and Japan is -- Japan, with this resistant situation, I think is perhaps quite unique in terms of the original use of the Bristol-Myers regimen. But I think we got patients being cured to an incredibly high level with Harvoni, and now we've got the right treatment, I think in Epclusa for the 2s and 3s. So I think in the U.S., perhaps in Europe, it will be far more modest, the opportunity. Having said that, it depends where we are with those products, our products with where the competition is obviously, what we decide to do in terms of the pricing strategy. I think most importantly, from a company point of view, we think this is the right thing to do and probably the last step in the whole story around hepatitis C to help treatment experience of failure patients. So I think, first and foremost, we think this is the right thing to do for patients in need."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Alethia Young of Crdit Suisse.",11,"And our next question comes from Alethia Young of Crdit Suisse."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Let me be the thousandth person, Kevin, to say welcome back and it's great to have you here. Two kind of questions in kind of the same vein. Just one on oncology. Has this remained a focus for you guys as far as building assets there and building out that",93,"Let me be the thousandth person, Kevin, to say welcome back and it's great to have you here. Two kind of questions in kind of the same vein. Just one on oncology. Has this remained a focus for you guys as far as building assets there and building out that business as much as it was in the past when you talk about it? And secondarily, just, Norbert, with NASH, can you just talk about some of the data points coming up and like, what's going on with the FXR program as well?"
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. So Alethia, let me start off by -- firstly and then John Milligan will afterwards comment on it, too. We are in oncology. We have now momelotinib is at the end of the Phase III program. We should have data this year. If the data is positive and going",246,"Yes. So Alethia, let me start off by -- firstly and then John Milligan will afterwards comment on it, too. We are in oncology. We have now momelotinib is at the end of the Phase III program. We should have data this year. If the data is positive and going fine, the NDA track, right application next year. We have that MMP9 in gastric cancer in Phase III. We're looking at other solid tumors. And we're now finally, after sorting out the dosing, starting the first study in combination of a PI3K inhibitor with BTK in CLL. So with regards to NASH, yes, we have now very interesting 4 modalities or 4 mechanisms that we're evaluating in NASH, and at least with 3 of them, we know that they are doing what they're supposed to do pharmacologically. We will have data this year on the ASK inhibitor that will include liver fat analyses along with histology. The FXR agonist is currently in a Phase I, Phase IIa study. And by the way, we know about that compound already that it has minimal systemic absorption, but there are systemic levels of FGF19. That was always our idea to have a compound that acts in the GI; that releases FGF19; the FGF19 has the efficacy. And by that, the rationale we won't get the side effect that other FXR agonists have. And then finally, we have -- oh the -- wait a moment -- ASK inhibitor, OC --"
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","ACC.",1,"ACC."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","ACC inhibitor, the Nimbus compound. And we know those data were presented at EASL, that it reduces the novel lipogenesis. So what we're going to do based on these data is [indiscernible] asking if we could go into Phase III next year and we have a compoun",63,"ACC inhibitor, the Nimbus compound. And we know those data were presented at EASL, that it reduces the novel lipogenesis. So what we're going to do based on these data is [indiscernible] asking if we could go into Phase III next year and we have a compound with the Phase II with the FXR and the ACC inhibitor or even this year. John?"
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. I just would follow up with Norbert's comment by saying, yes, we are committed to oncology. We continue to be interested in assets, collaborations and partnerships where we could enhance our ability to continue to sell these products, right. Where we",100,"Yes. I just would follow up with Norbert's comment by saying, yes, we are committed to oncology. We continue to be interested in assets, collaborations and partnerships where we could enhance our ability to continue to sell these products, right. Where we are seeing good progress, as Norbert mentioned, our BTK inhibitor, which is -- we're developing with our partner from ONO, is now making its way to the clinic, and we've overcome some formulation challenges to allow us to go ahead. So that will be very, very -- I think, an interesting avenue for us to continue to explore."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our final question comes from Terence Flynn of Goldman Sachs.",11,"And our final question comes from Terence Flynn of Goldman Sachs."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Just wondering a kind of 2-parter. The first is just any opportunity to broaden your prescriber base on hep C? Kevin, would love your thoughts on that. And the second question relates to Genvoya. Can you just give us what percentage of the switches were f",48,"Just wondering a kind of 2-parter. The first is just any opportunity to broaden your prescriber base on hep C? Kevin, would love your thoughts on that. And the second question relates to Genvoya. Can you just give us what percentage of the switches were from Atripla?"
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Terence, first of all, in terms of sort of like any future waves of market, I did mention Australia earlier. And that's an incredible story of treating and curing patients and amazing commitment by the government there. We are seeing more patients treated",152,"Terence, first of all, in terms of sort of like any future waves of market, I did mention Australia earlier. And that's an incredible story of treating and curing patients and amazing commitment by the government there. We are seeing more patients treated in Brazil. It's a lower-price market, but we are seeing more. We are just beginning our launch in Mexico. So yes, these are smaller markets. Typically, they are lower price. But those -- if you like, those smaller waves are starting to work through. We are thinking carefully about China and how we launch there, probably in a very modest or very focused way -- a very efficient way should I say. So we -- our expectations, I think, are very reasonable around China. So the second question, in terms of switch, about 18% of the switch patients is from Atripla. So I hope that gives you the number."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And that concludes our question-and-answer session for today. I'd like to turn the conference back over to Mr. Lee for closing remarks.",23,"And that concludes our question-and-answer session for today. I'd like to turn the conference back over to Mr. Lee for closing remarks."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Great. Thank you, Candace, and thank you all for joining us today. We appreciate your continued interest in Gilead, and the team here looks forward to providing you with updates on our future progress.",34,"Great. Thank you, Candace, and thank you all for joining us today. We appreciate your continued interest in Gilead, and the team here looks forward to providing you with updates on our future progress."
29002,369689622,1011625,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Have a great day, everyone.",25,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Have a great day, everyone."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Second Quarter 2016 Earnings Conference Call. My name is Candace, and I'll be your conference operator today. [Operator Instructions] And as a reminder, this conference ca",63,"Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Second Quarter 2016 Earnings Conference Call. My name is Candace, and I'll be your conference operator today. [Operator Instructions] And as a reminder, this conference call is being recorded. 
I would now like to turn the call over to Sung Lee, Vice President of Investor Relations. Please go ahead."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Great. Thank you, Candace, and good afternoon, everyone. Just after market closed today, a press release was issued with earnings results for the second quarter of 2016. The press release and detailed slides are available on the Investor Relations section",221,"Great. Thank you, Candace, and good afternoon, everyone. Just after market closed today, a press release was issued with earnings results for the second quarter of 2016. The press release and detailed slides are available on the Investor Relations section of the Gilead website. 
Joining today's call will be John Milligan, President and Chief Executive Officer; Robin Washington, Executive Vice President and Chief Financial Officer; Kevin Young, Chief Operating Officer; and Norbert Bischofberger, Executive Vice President of Research and Development and Chief Scientific Officer. 
Before we begin formal remarks, let me remind you that we will be making forward-looking statements, including plans and expectations with respect to products, product candidates, financial projections and the use of capital, all of which involve certain assumptions, risks and uncertainties that are beyond our control and could cause the actual results to differ materially from these statements. A description of these risks can be found in the latest SEC disclosures documents and recent press releases. In addition, Gilead does not undertake any obligation to update any forward-looking statements made during this call.
Non-GAAP financial measures will be used to help you understand the company's underlying business performance. The GAAP to non-GAAP reconciliations are provided in the earnings press release, as well as on the Gilead website. 
I will now turn the call over to Robin."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, Sung, and good afternoon, everyone. We are pleased to share results for the second quarter of 2016. I'll first review our financials, and Kevin and John will then make a few comments. Total revenues for the second quarter were $7.8 billion, wi",1045,"Thanks, Sung, and good afternoon, everyone. 
We are pleased to share results for the second quarter of 2016. I'll first review our financials, and Kevin and John will then make a few comments. 
Total revenues for the second quarter were $7.8 billion, with non-GAAP diluted earnings per share of $3.08. This compares to revenues of $8.2 billion and non-GAAP earnings per share of $3.15 for the same period last year. Product sales for the second quarter were $7.7 billion, down 6% year-over-year and flat sequentially. The year-over-year decline was driven by lower HCV sales, partially offset by increased sales in HIV and other therapeutic areas. Sequentially, we saw an increase in HIV, U.S. HCV and other product sales that were offset by a decline in HCV sales in Japan and Europe. 
Turning to the U.S. Product sales for the second quarter were $4.9 billion, down 12% year-over-year. HCV product sales were $2.3 billion, down 33% year-over-year, driven by lower revenues per patient as a result of increased rebates and discounts due primarily to payer mix and lower patient starts for Harvoni, as the initial group of warehouse patients was treated in 2015. Sequentially, our HCV product sales were up 13%, driven by a $270 million adjustment to our HCV sales returns reserves rate and the initial inventory build for Epclusa. Strong uptake of our TAF-based regimens drove 23% year-over-year and 11% sequential growth of our HIV product sales. The quarterly revenues of $2.2 billion were also positively impacted by the upward trajectory of Truvada used for PrEP.
Turning to Europe. Product sales for the second quarter were $1.6 billion, down 18% year-over-year, primarily driven by lower HCV patient starts and a higher proportion of patient starts from countries that have a lower net average price. Sequentially, sales in Europe were flat, excluding the impact of currency movements, with HIV sales growth offset by lower HCV sales. 
In Japan, product sales for the second quarter were $619 million, down 43% sequentially as a result of lower patient starts on Harvoni and the full quarter effect of the mandatory price reductions for both Sovaldi and Harvoni, which were discussed during our last call. 
Moving to gross margin. Our non-GAAP product gross margin for the second quarter of 2016 was 92%, and benefited from the reversal of a $200 million litigation charge recorded in the first quarter of 2016, following a favorable decision in the Merck case. 
Now turning to expenses. Non-GAAP R&D expenses were $1 billion for the second quarter, up 48% compared to the same period last year, primarily due to the purchase of a U.S. Food and Drug Administration priority review voucher and the progression of clinical studies. Non-GAAP SG&A expenses for the second quarter were up 10% compared to the same period last year, primarily due to higher costs to support new product launches and our geographic expansion. 
From a balance sheet perspective, during the second quarter, we generated cash flow from operations of $4.9 billion and ended the quarter with $24.6 billion in cash and investments. While our cash flows will remain strong in the second half of the year, we anticipate a sequential decrease in Q3 2016 due to required cash payments related to our current government rebates in the U.S. and abroad, as well as milestone payments associated with our R&D pipeline progression. 
We continue to return capital to our shareholders through dividends and share repurchases. During the second quarter, we repurchased 10.5 million shares for $1 billion under the $12 billion 2016 share repurchase program, and we received an additional 8.1 million shares in April 2016 from the final settlement of the accelerated share repurchase program announced in February 2016. The total share repurchases in the first half of the year were 98.2 million at a cost of $9 billion. As previously communicated, we anticipate share repurchases in the second half of 2016 to be lower than the first half of 2016, as we focus our capital allocation on advancing our R&D opportunities. 
Finally, we are updating full year 2016 guidance, which is outlined on Slide 21. The changes are as follows: We are lowering net product sales guidance to a range of $29.5 billion to $30.5 billion. While we are seeing continued strength in non-HCV product sales, given the current trends in payer and patient flow dynamics for HCV, our updated models for just net product sales will range from being slightly above to slightly below $30 billion for the year. As such, we believe it is prudent to update our full year 2016 guidance. 
The factors contributing to this conclusion include: Lower HCV revenue per patient as a result of a mix shift towards more heavily discounted payer segments in the U.S. and companies with a lower net average price in Europe; a trend towards slowing patient starts in the U.S. Commercial segment and some earlier launch markets of Europe; the continued gradual trends towards shorter duration and loss of some market share to competition. 
This guidance is subject to a number of uncertainties, including: potential changes in the global macroeconomic environment; adoption of additional pricing measures to reduce HCV spending; volatility in foreign currency exchange rates; inaccuracy in our HCV patient start estimates; additional competitive launches in HCV; an increase in discounts, chargebacks and rebates due to ongoing commercial payer contract negotiations; and a larger-than-anticipated shift in payer mix to more highly discounted payer segments, such as PHS, FFS, Medicaid and the VA. 
We are increasing our R&D expense guidance to a range of $3.6 billion to $3.8 billion, driven by acquisition-related expenses for Nimbus Apollo, Inc. and the purchase of a U.S. Food and Drug Administration priority review voucher, slightly offset by lower-than-anticipated clinical trial expenses. 
We are lowering SG&A expense guidance to a range of $3.1 billion to $3.3 billion, primarily driven by the favorable onetime adjustment to the expected invoice from the IRS for the Branded Prescription Drug fee, which lowered Q1 2016 SG&A expense. 
Diluted EPS impact of acquisition-related upfront collaboration, stock-based compensation and other expenses increases to a new range of $1.47 to $1.53 as a result of our recent M&A activity. All other components of our 2016 guidance remain unchanged. 
I would like to now turn the call over to Kevin."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Robin, and good afternoon, everyone. Let me say immediately how terrific it is to be back at Gilead in a full-time capacity. Working with exceptional executive colleagues around the table here in Foster City, interacting with my senior operat",1693,"Thank you, Robin, and good afternoon, everyone. 
Let me say immediately how terrific it is to be back at Gilead in a full-time capacity. Working with exceptional executive colleagues around the table here in Foster City, interacting with my senior operating management team and seeing the dedication of the thousands of Gilead employees around the world leaves me in no doubt as to the long-term prospects for this outstanding company. 
Whilst early days, over the last 2 months in my new role, I've had the opportunity to reflect on Gilead's recent product introductions, the evolving health care landscape and the operating challenges on our near-term horizon. I'd like to share 3 general observations with you today. 
First, I am struck by the commitment that is shared by physicians, payers and governments around the world to reduce the prevalence of hepatitis C. Even countries with challenging economic circumstances are finding ways to prioritize the treatment of HCV patients. 
In the 2.5 years since the launch of Sovaldi, more than 1 million patients have been treated on a sofosbuvir-based regimen. Beneath this aggregated number are several landmark statistics. The United States has already treated nearly 0.5 million patients to date with Sovaldi and Harvoni. Equally, over 200,000 patients in Europe have been treated with Gilead regimens. Japan has treated approximately 100,000 patients in a little over a year. And just this year, Australia has treated an estimated 70,000 patients in a matter of months. Health care systems have demonstrably mobilized to reach those patients most in need. These are remarkable facts that clearly underscore the profile of the products we have introduced. Equally, they have implications to longer-term treatment dynamics and portfolio life cycles. 
Secondly, in the area of HIV, I'm impressed by how the clinical data for TAF-based regimens are resonating with the many constituents who tirelessly drive for better patient care. The understanding that these regimens can help address a growing need for highly effective and safer treatment options for lifelong HIV therapy is evidenced by the early success of Genvoya. I will highlight some impressive data points later.
Thirdly, I'm reminded just how complex the delivery of health care continues to be. Gilead's focus on flawless execution, on controlling the variables that we can control with the highest levels of conduct and compliance is critical and is my top priority. 
Now I'll get into the details of the commercial performance for the second quarter, starting with HCV. In the U.S., total HCV revenue was $2.3 billion, up 13% sequentially and down 33% year-over-year. Since the beginning of the year, access has improved and almost all major commercial payers have removed fibrosis score criteria, joining Medicare and the VA in this regard. Medicaid remains the only payer segment where use is still generally restrict it to the sicker patients. There are other significant barriers to access, but we are encouraged that some states have recently moved away from fibrosis restrictions towards more open access.
In terms of patient starts, approximately 59,000 people began HCV therapy in the second quarter, and an estimated 90% of these patients started on a sofosbuvir-based regimen. Importantly, third-party databases suggest that new patients are being identified through increased screening efforts. As evidenced, approximately 14 million people were screened for HCV for the period of 2014 through 2015, and approximately 280,000 were confirmed RNA positive in that 2-year period. These figures represent a significant increase from the years prior to the launch of Sovaldi. We estimate that 3 million individuals remain infected with HCV in the U.S., approximately half of whom are diagnosed.
Although patient starts increased for the second consecutive quarter and patient inflows into care remained recently steady at around 30,000 patients a month, the dynamics vary by patient segment. Within the commercial and Medicare segment, some larger payers have recently opened up access. We now estimate that up to 90% of all commercial covered lives have access without regard to fibrosis score. While the payers that recently opened up access are bringing in more patients, we are seeing a modest downward trend in patient starts among payers that have had full access in place for longer periods of time. The sickest patients have largely been treated, and the movement we are seeing is towards treating genotype 1 patients with lower fibrosis scores and thus greater use of the 8-week treatment regimen for Harvoni. 
In terms of all new HCV treatment starts in the second quarter, approximately 45% came from within the public payer systems. We anticipate this percentage will remain largely the same through the remainder of the year. The VA is one example of a payer within this segment, and their commitment to treating and curing veterans who have HCV using budget allocated by Congress to do so is truly groundbreaking. We are aware that in some cities, extra clinics have been scheduled to help shoulder the workload. However, we also expect that in the longer term, socially disadvantaged patients within the VA system will be harder to reach and bring into care and that the rate of treatment will decline.
Turning to Europe. Total HCV revenue in the second quarter was $775 million, down 32% year-over-year and down 7% sequentially. Overall, Gilead patient starts decreased to around 28,000 for the quarter. We observed steady treatment rates in Italy and Spain, but lower numbers in early launch markets like Germany and France. Patient starts in the U.K. continue to be limited by NHS England budget restrictions. Additionally, we saw a slight decline in average treatment duration, as countries like Germany are treating more patients with low fibrosis scores, who qualify for an 8-week treatment duration.
In several European markets, locally documented cure rates are equal to, if not better than, what was demonstrated in Sovaldi and Harvoni clinical studies. This has resonated with governments and payer bodies. And some countries such as France are considering removing all fibrosis score criteria. We will watch this picture closely and share evolving news with you in the future. 
Moving to Japan. As Robin mentioned, revenue was $619 million, down 43% sequentially. We believe this was related to 2 factors: First, the decline in genotype 1 new patient starts following the Q1 2016 peak when a very large number of individuals with advanced disease initiated therapy; and second, the full 3-month effect of a mandatory price reduction previously described on last quarter's call.
Finally, for HCV, Epclusa was recently approved in the U.S., the EU and Canada. These approvals are true milestones in patient care since Epclusa is the first pan-genotypic, once-daily, single-tablet option. Epclusa will be an important treatment option in the U.S. as an estimated 20% to 25% of HCV patients have genotypes 2 and 3. And equally, across Europe, there are some countries that have up to 30% of patients with genotype 3 alone. 
In concluding my remarks on hepatitis C, I will return to my earlier comments. Gilead is proud to be part of a fundamental disease paradigm shift, delivering disease cures to virtually all patients treated. That's why we developed Sovaldi, Harvoni and Epclusa and have a third single-tablet regimen in clinical testing. 
Whilst the pace of new patient treatment may slow in coming years and quantifying that pace is incredibly hard, there is still an opportunity to identify and cure many HCV infected people around the globe. 
Moving to HIV. We are pleased with the launch of our TAF-based products in the U.S. and in the European markets where we have already achieved reimbursement. In the U.S., total HIV and other antiviral revenue was $2.2 billion, up 11% sequentially, and Genvoya revenue nearly doubled in Q2 versus Q1. The product represents the most successful HIV launch since the introduction of Atripla, the first single-tablet regimen, a decade ago. After its first 6 months of availability, Genvoya is already the most prescribed regimen for both treatment-nave and switch patients. 
78% of all Genvoya prescriptions have come from switches. Half of the switches have come from Stribild, and importantly, 10% of switches have come from non-Gilead therapies. Among all patients who switched, we have seen an increase in our ability to retain patients on a Gilead product. 
Whilst still in the early stages of the Odefsey and Descovy launches, we are seeing similar patient dynamic to Genvoya. Over 90% of all Odefsey and Descovy prescriptions have come from switches. And 6% and 11% of switches, respectively, have come from non-Gilead therapies. 
Finally, in the U.S., I would like to highlight the growing use of Truvada for PrEP. We estimate somewhere in the order of 60,000 to 70,000 patients were using Truvada for PrEP in the second quarter. This number accounts for approximately 1/3 of Truvada demand. This is encouraging, as we know Truvada has an important role to play as part of comprehensive HIV prevention for many at-risk individuals.
Turning to Europe. Total HIV and other antiviral revenue was $755 million, up 5% sequentially, driven by the launches of Genvoya and Descovy. Genvoya has gained pricing approval in 11 countries and is now the market leader in Germany for both treatment-nave and switch patients after only 6 months of availability. We anticipate additional launches in France, Italy and the U.K. in the second half of the year. 
Genvoya is the preferred regimen in several HIV treatment guidelines, including Italy, where it was added before pricing and reimbursement. Preferred listings are anticipated in other EU guidelines later this year and into 2017. EACS guidelines are expected to be updated following the HIV Glasgow 2016 Conference in October.
Finally, I would like to briefly update you on the outstanding performance of the Gilead U.S. cardiovascular team. Letairis and Ranexa together generated $356 million in revenue during the quarter, representing a 12% year-over-year increase. Today, over 0.25 million people in the United States regularly receive Ranexa. And Letairis remains the overall ERA market leader in PAH. 
In closing, Gilead achieved a great deal across our operations during the quarter, and I am confident that we will continue to make significant progress in the second half of 2016. 
I would now like to turn the call over to John."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, Kevin. Before I get started, I just wanted to say it's great to have you back on the Gilead full team -- full time as our new Chief Operating Officer. Today, in addition to the remarks of Robin and Kevin regarding the quarter, I'd like to make a",1165,"Thanks, Kevin. Before I get started, I just wanted to say it's great to have you back on the Gilead full team -- full time as our new Chief Operating Officer. 
Today, in addition to the remarks of Robin and Kevin regarding the quarter, I'd like to make a few comments of my own. Over the last 2.5 years, we've made great progress in helping provide access to Sovaldi and Harvoni for HCV patients. Throughout the world, more than 1 million HCV sufferers have now been treated with nearly half of those coming from the U.S. While lots of these drugs were unprecedented in our industry, and patients were treated at a much faster initial rate than we, or anyone else, thought possible, looking back, we can now say that in every country, the peak number of patients treated was achieved within 2 or 3 quarters of the launch of Harvoni, but that peak number was far higher than what we had -- what had ever been achieved before; about 3x that seen with the launch of the HCV protease inhibitors in 2011.
As we've reached the mid-point of this year, we now see the market maturing to a slower rate of treatment for HCV-infected individuals. And as we think about this more normal patient starts, there are a few things to keep in mind. As Kevin mentioned, there are about 3 million people who are infected in the U.S., and slightly more than half of those have been diagnosed. Many of these diagnosed patients have less advanced liver disease upon reentering care. For example, in the United States in the second quarter this year, we estimated that only 13% of patients starting treatment had F4 fibrosis scores compared with more than 21% the year prior to that. With less severely ill patients, there is less urgency to immediately treat patients. And this may explain the slower rate of treatment versus last year. However, we do believe these patients will eventually benefit from treatment, and this means the flow of patients will continue for many years to come.
There's also an opportunity to diagnose patients and bring them into care. As Kevin mentioned, we estimated that about 280,000 HCV patients were diagnosed in the U.S. within the last 2 years, showing the value and importance of the U.S. CDC and CMS recommendations for HCV testing. So while there has been a slowing of treatment compared with the rush of patients when Sovaldi and Harvoni were first approved, the HCV market is attractive over the longer term, providing good revenues, strong cash flow and earnings per share, on top of our base business of chronic therapies. 
Because of this, our focus on improving care for HCV and infected individuals has not wavered. Beyond the recent approvals of Epclusa, we are actively working on a third single-tablet regimen that combines the 2 active ingredients in Epclusa with a third investigational compound, voxilaprevir. This combination, known as SOF/VEL/VOX, is being evaluated at 4 Phase III clinical trials among patients who have previously failed direct-acting antiviral treatments. It's also being studied for its potential to offer an 8-week treatment duration for treatment-nave patients of all genotypes. We expect to have top line data available for SOF/VEL/VOX by the end of the year. 
We're making tremendous headway in HIV as well; both of our portfolio of newer products and our pipeline. We've had several key approvals with Descovy approved in the U.S. and Europe last quarter and Odefsey approved in Europe earlier this month. It's clear these medications offer a significant advance for patients, and that advance has been recognized now by multiple professionals and public health groups, including the International Antiviral Society of the U.S.A. and the Department of Health and Human Services, both of which were released updated guidelines supporting the use of TAF-based regimens for initial HIV therapy. 
We continue to generate clinical data that support the favorable scientific and medical profile of our TAF-based products. Last week, we announced the results of 2 Phase IIIb switch studies, evaluating Odefsey in virologically suppressed adults switching from Complera or Atripla. Odefsey achieved similar rates of virological suppression as the TDF-based regimens. These studies reinforce the efficacy of Odefsey as well as the renal and bone safety advantages, and we plan to present full data sets later this year. 
Last month, we presented the first human data on bictegravir, our investigational, unboosted integrase inhibitor, at the American Society for Microbiology. Data from 4 preclinical and Phase I studies examined the antiviral potency, resistance profile, pharmacokinetics and safety of bictegravir, providing the rationale to further evaluate the compound. Bictegravir, as part of a single-tablet regimen, in combination with TAF and emtricitabine, is currently in Phase III trials. Enrollment of more than 2,300 patients across 4 registrational studies was completed earlier this month. The 48-week endpoints for these studies will be reached in the second quarter of next year, and if the data play out as we hope, NDA and MAA filings could occur in the third quarter of 2017.
With the approval and rapid adoption of our TAF-based regimens, an exciting new STR and Phase III development and an active HIV research pipeline, I'm confident that we will be able to extend our leadership position in the HIV market and broaden our ability to help even more patients around the world. 
Outside of our working antivirals, Gilead is focused on solving some of the biggest health challenges today. Several important data sets that are anticipated in the second half of this year may help us to find a strategy and pathway forward for tackling these challenges. 
In our NASH program, where we have 4 active clinical programs, we'll have data from the Phase II studies of GS-4997, our ASK-1 inhibitor, and simtuzumab, our monoclonal antibody against LOXL2. The Phase II study of simtuzumab for primary sclerosing cholangitis will also conclude. And we'll also have data from the Phase II studies of GS-4997 in diabetic nephropathy and pulmonary arterial hypertension, or PAH. And finally, we expect data from 2 Phase III studies for myelofibrosis before the end of the year. If these data are positive, these studies will form the basis for an MDA filing in the first quarter of 2017. 
These are important milestones and represent a great deal of work across the organization to enroll and advance these studies and analyze complex data sets as they become available. Gilead continues to innovate at every level and every part of the organization. Next month, we will publish our first corporate social responsibility report that looks at access, sustainability, grant making and other positive contributions to the communities we serve, and I urge each of you to read it. 
I'm proud of the work that's been led by our employees and extend my many thanks to them for all the ways they are making a difference around the world. 
Thank you, and let's now open up the call for questions. Operator?"
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Geoff Meacham of Barclays.",15,"[Operator Instructions] And our first question comes from the line of Geoff Meacham of Barclays."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Kevin, good to have you back on the call, and in the seat, of course. So I want to dig into your comments and also John's comments on the hep C new starts. And just, I guess I'm curious here because you have better F0, F1 Access. You have positive impact",121,"Kevin, good to have you back on the call, and in the seat, of course. So I want to dig into your comments and also John's comments on the hep C new starts. And just, I guess I'm curious here because you have better F0, F1 Access. You have positive impact theoretically from the CDC guidelines and very low penetration in markets such as the prison population. I'm just curious why, could you put your finger on maybe 1 or 2 things that you feel like could ultimately be a -- become a growth driver to get us back to better sequential growth? I'm just trying to figure out what the tipping point is, on some of these different volume drivers."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Geoff, nice to hear your voice as well. Thank you for your comments. I'm not at all pessimistic about the long-term prospects for hepatitis C. In fact, I'm rather optimistic. I think what we have seen 2014, 2015 is an enormous group of the less well patie",337,"Geoff, nice to hear your voice as well. Thank you for your comments. I'm not at all pessimistic about the long-term prospects for hepatitis C. In fact, I'm rather optimistic. I think what we have seen 2014, 2015 is an enormous group of the less well patients treated, particularly by specialist hepatitis C treaters. It's really quite amazing. I think this quarter and we've highlighted perhaps going forward is really sort of a payer mix situation that we've got. The VA has definitely increased in terms of its contribution to the 59,000 total HCV starts, which, of course, was an increase on quarter 1. So a lot of VA patients are coming through, and the VA is very, very motivated to try to essentially eradicate the virus from that population. I think, yes, we did see pickup in 2 of the large players that came on stream with open fibrosis scores from the beginning of the year, but we did see some downtick in other commercial payers. So net-net, it was slightly a decrease in overall commercial patients. What I feel about the long term and as we go into years further forward and we kind of hit an equilibrium of patients is all around what I mentioned, and John mentioned, around diagnoses. There's been a considerable pickup in the number of HCV tests; 2014, 2015, about a 65% increase in the number of HCV tests. 280,000 in that 2-year period were HCV RNA positive. So as John said, they will eventually work their way through to treatment. But still over 1/4 of the population being diagnosed is at 4. So there's still a lot of sickness out there in patients. So whilst the health care system here and in some of the European markets have done heroic things in treating patients in the last 2 years, I still think, with 1.5 million diagnosed patients in the United States that we are going to see a continued healthy flow of patients that can benefit from our products."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Geoffrey Porges of Leerink.",10,"And our next question comes from Geoffrey Porges of Leerink."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","For Kevin, welcome back, and good to hear you. So following up on this somewhat vexing issue of the HCV outlook. Historically, in this category after each market has peaked, it's begun a steady slow, sometimes slow, anyway, decline. We certainly saw a rap",152,"For Kevin, welcome back, and good to hear you. So following up on this somewhat vexing issue of the HCV outlook. Historically, in this category after each market has peaked, it's begun a steady slow, sometimes slow, anyway, decline. We certainly saw a rapid decline after the protease inhibitors, more slow decline after we went to ribavirin and with the introduction of pegylated interferon. Are you suggesting to us that you think that there is a stable outlook for the HCV revenue on a market-by-market basis from these levels? Or are you suggesting that we should see more like an orderly and steady decline? And could you particularly comment about Europe, where I think it was surprising to see patient numbers in the big early markets roll over so quickly, particularly Germany and Japan? Is that a onetime step-down? Or are we going to continue at or below this level going forward?"
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. Thanks for the question, Geoff. I think it is encouraging that patient starts in the U.S. and Europe have been reasonably steady over the past 3 quarters. Japan's a different story, I can certainly, at some point, comment on that this afternoon. I th",298,"Yes. Thanks for the question, Geoff. I think it is encouraging that patient starts in the U.S. and Europe have been reasonably steady over the past 3 quarters. Japan's a different story, I can certainly, at some point, comment on that this afternoon. I think, from my perspective and Robin, Norbert, John around the table here, I think it's more of the latter comment; that there will continue to be a gradual decline in new patient starts, but an equilibrium will be eventually hit. Quite the timing of that, Geoff, it's really, really, really hard to peg. I've just got to believe that with the amount of testing, with the amount of diagnoses with the CDC guidelines, Gilead itself in Q3, Q4 of this year are going do some more educational programs around the need to test and treat that. We will eventually hit an equilibrium. In terms of Europe, Italy and Spain are very steady. I should tell you that in Italy, there are still 200,000 quite sick individuals, people to be treated, and they're in treated care. And the Italian government do want to go ahead and try and mobilize providers to do that treating. So it's still an enormous number in Italy. I think the more -- the markets that are more akin to the U.S., like, first and foremost, Germany and to a slightly lesser extent, France, are starting to see that sort of turnover of patients. We've got full access in terms of fibrosis score in Germany, and we're hoping, as I said, that we get broader access in France. The U.K. is a different situation, and that's largely due to payer restrictions. But again, still an enthusiasm to treat, but 1 or 2 of those markets, there is some maturing going on."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Mark Schoenebaum of Evercore ISI.",11,"And our next question comes from Mark Schoenebaum of Evercore ISI."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","This is Regina Grebla in for Mark. I actually wanted to change topics and shift to hepatitis B. On your Q1 call, you mentioned your hep B program included a vaccine, the TLR7 agonist, and 2 other internal preclinical candidates. When will we see any data",73,"This is Regina Grebla in for Mark. I actually wanted to change topics and shift to hepatitis B. On your Q1 call, you mentioned your hep B program included a vaccine, the TLR7 agonist, and 2 other internal preclinical candidates. When will we see any data on the internal candidates? And also, you mentioned taking a look at external opportunities for hepatitis B. Is hep B still potential area of interest for acquisition?"
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. So Regina, you asked a question about what our pipeline is for hepatitis B. So we have, as you know, 2 compounds currently in clinical development. One is an active vaccine, 4779, the collaboration with GlobeImmune. That's currently in the later stag",323,"Yes. So Regina, you asked a question about what our pipeline is for hepatitis B. So we have, as you know, 2 compounds currently in clinical development. One is an active vaccine, 4779, the collaboration with GlobeImmune. That's currently in the later stages of being evaluated in non-suppressed hep B patients. The suppressed hep B patients, those data have been released, I think, maybe a year ago that they did not show any activity, so we don't have high hopes that the compound will work. Then, the TLR7 agonist is that's just finishing the first cohort, which is in suppressed patients, and we are currently initiating. The second cohort quarter is ongoing. We hope that we'll have the presentation of the first cohort ready by AASLD. Hopefully, we'll make that -- the abstract deadline. Then, you said that -- you asked the question about we had 2 other compounds in development. Well, you know what we're pursuing. Maybe I should answer this more generally. So we're pursuing 3 approaches to hepatitis B cure. The one is adding another different mechanism to the nucleosides because there's the observation that despite being undetectable with hepatitis B therapies like Viread or TAF, there was always a little bit of virus left, HBV there may detectable if you look at very sensitive PCR methods. So by adding another mechanism, so actually, we could completely suppress virus replication down to 0, would that lead to an eventual cure or hepatitis S conversion? The second thing we're pursuing is immune therapy, so that belongs to the vaccine and the TLR7 that I've talked about already. And we have a TLR8 agonist currently that is working its way towards an IND. And then the third possibility, that's the most hopeful but also the one that's least scientifically proven that's going directly after cccDNA, and that's really too early to talk about at this point. It's still in the research stages."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Michael Yee of RBC Capital Markets.",12,"And our next question comes from Michael Yee of RBC Capital Markets."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","You talked a lot about volume and demand in the different buckets. But can you talk about the payer mix shift? Specifically, I wanted to ask on Medicaid. Can you just help us out with what percent of sales Medicaid is? And what is going on in that bucket?",98,"You talked a lot about volume and demand in the different buckets. But can you talk about the payer mix shift? Specifically, I wanted to ask on Medicaid. Can you just help us out with what percent of sales Medicaid is? And what is going on in that bucket? I presume it's a state-by-state negotiation. Can you talk about what's going on there? Is there a state-by-state negotiation you have to go through? Is that pretty much done? Walk us through that bucket and what percent of hep C that is in U.S.A. so I can understand them."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Michael, it's Kevin. Thank you for the question. I prefer not to break out specifically the percentage of the public payers in terms of Medicaid. As I said, all our public payers lumped together for the quarter were about 45%. That's an increase from the",177,"Michael, it's Kevin. Thank you for the question. I prefer not to break out specifically the percentage of the public payers in terms of Medicaid. As I said, all our public payers lumped together for the quarter were about 45%. That's an increase from the previous quarter, but as I said, that's all driven by VA. We've seen very little change, really, in our -- in the scale and size of our Medicaid business. I think it would be true to say that Medicaid's -- the states are slowly progressively opening up. 40% of Medicaid patients come from the 5 largest states. Two of those, New York and Florida, now have no fibrosis score. So as states do progressively consider opening up, they typically come to us for a contract. We think about those contracts very carefully. Depending on the size of Medicaid, we obviously put our submission in. Realistically, I think we may win, we hope, the majority of those, but there may be occasions when, occasionally, a Medicare -- Medicaid stake goes to the competition."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Matthew Harrison of Morgan Stanley.",11,"And our next question comes from Matthew Harrison of Morgan Stanley."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Robin, if you could just address the $279 million onetime swing. We obviously saw a swing in the first quarter and then a swing this quarter again. Can you just give us some insight into what's going on with those changes in chargebacks and if we should c",72,"Robin, if you could just address the $279 million onetime swing. We obviously saw a swing in the first quarter and then a swing this quarter again. Can you just give us some insight into what's going on with those changes in chargebacks and if we should continue to expect to see some of those numbers? And then just separately on PrEP, any plans to get a TAF-based regimen approved for PrEP?"
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Sure. I'll take the first part, and then Norbert will take the second. Matt, first of all, there are 2 separate things that we're talking about here Q2 versus Q1. First, let me address Q2. We did have a sales return reserve adjustment really related to th",360,"Sure. I'll take the first part, and then Norbert will take the second. Matt, first of all, there are 2 separate things that we're talking about here Q2 versus Q1. First, let me address Q2. We did have a sales return reserve adjustment really related to the fact that as we introduce our new hep C product, we're required to go out and get an external proxy related to sales return reserves. And just recently, just this past quarter, we closed several of the lots related to our products, which means that no further returns are accepted. So that gives us a triggering event by which we can look at returns versus how we had been accruing. The other key thing about the timing is just related to the Epclusa lot. So as we bring on a new product, we want to kind of want to rebase the level of returns that we are expecting to see. So that's really the adjustment there. For the most part, you could -- it's onetime in nature. We may have small adjustments going forward, but as long as returns continue where they are, then that $279 million is kind of a onetime event. Last quarter, we had a different issue, and that related to the rebate claims for hepatitis C. And as I said on the call last time, we always have a situation where we're constantly truing up claims around HCV rebate because we get those claims 1 to 2 quarters in arrears. This quarter was a bit different than last quarters that we saw a modernization of the level of those claims relative to the prior quarter. So it wasn't -- it didn't reverse the other way. It was just a slowing of what we saw in Q1. So we're, for lack of better words, maybe a little bit more caught up relative to returns this quarter than we were at the end of Q1. So 2 different items, but we caught up at $279 million because that was the onetime event. So we ensured -- we wanted to ensure that you understood relative to the future projection of HCV sales."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Matt, so to your question about F/TAF or PrEP, so we and also the outside medical community believes that, obviously, discovery of F/TAF would have advantages in terms of use for PrEP versus Truvada for all the obvious data that were published already. An",148,"Matt, so to your question about F/TAF or PrEP, so we and also the outside medical community believes that, obviously, discovery of F/TAF would have advantages in terms of use for PrEP versus Truvada for all the obvious data that were published already. And also, we have data now in human -- in animal models that show that that has the same efficacy. The thing we're debating internally and also we have had early discussions with FDA is what clinical study would need to be done that leads to approval. It would have to be, in almost all likelihood, a comparative study and tend to seek which is what would be the sample size and what would be the powering. And that's currently a discussion we're having with FDA. We hope we can come to some conclusion within the next months or so and then let you know."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Brian Abrahams with Jefferies.",10,"And our next question comes from Brian Abrahams with Jefferies."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Kevin, good to hear your voice again. With the list pricing and label established for Epclusa, I'm just wondering. What's the right way to think about Epclusa's potential impact on the genotype 2/3 franchise, particularly with respect to the net price per",75,"Kevin, good to hear your voice again. With the list pricing and label established for Epclusa, I'm just wondering. What's the right way to think about Epclusa's potential impact on the genotype 2/3 franchise, particularly with respect to the net price per patient treatment duration relative to Sovaldi and just how we should be thinking about the overall market dynamics there? I'm just wondering if you could also quantify the inventory build this quarter there."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. Great question, Brian. Nice to hear your voice as well. Brian, the majority of the revenues in the second quarter, which is right at the end, the majority of that was inventory that Robin called out. So we've really only just begun the introduction,",303,"Yes. Great question, Brian. Nice to hear your voice as well. Brian, the majority of the revenues in the second quarter, which is right at the end, the majority of that was inventory that Robin called out. So we've really only just begun the introduction, both the promotion and the education around Epclusa. I'm really pleased that the response has been excellent. In our advisory boards and our speaker programs there's been good acceptance. Whilst we have obviously a pan-genotypic label, I think the reality is that physicians are very, very comfortable, as are payers, with Harvoni for genotype 1. Obviously, there's a mix of 12-week treatments and 8-week. Just for your information, the 8-week course of Harvoni is now 45% of patients treated in the United States. So I think people are just really comfortable with the clinical effect and the value proposition of Harvoni in GT1, which therefore means that the slot that people see Epclusa is in the 2 and 3 patient. And as I highlighted, it's something like in the order of 20% to 25% of patients in the United States. I think the obvious advantage, both clinically and from a payer point of view, is you really do have a 12-week single-tablet regimen. You don't have to extend the treatment duration. You don't have to use ribavirin. There was quite a number of patients treated with Sovaldi, Daclatasvir, certainly, in United States. So really, in some ways, it takes away that regimen and is an excellent slot. So we've had very good reception to Epclusa. It's extremely early days. It'll take us 3 to 6 months to get payer approval. Physicians can apply based on medical need, and they're doing that. So just very early days and weeks. It seems to have found a very nice entry point."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from the line of Cory Kasimov of JPMorgan.",13,"And our next question comes from the line of Cory Kasimov of JPMorgan."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I have a bigger picture question for you. Really, just following the latest management shuffle back in 2Q, I'm wondering if these changes portend any material shift or consideration of a shift in, I guess, your commercial or pricing strategy, or really, t",76,"I have a bigger picture question for you. Really, just following the latest management shuffle back in 2Q, I'm wondering if these changes portend any material shift or consideration of a shift in, I guess, your commercial or pricing strategy, or really, the overall strategy for the business or any of the key businesses. And is this playing into the bump in anticipated R&D with the associated downtick in SG&A as illustrated by your updated guidance?"
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","I think there were a couple of questions there. So it's John Milligan. So in terms of -- let me get to the last bit. You said there was a bump in R&D. That is true, relating somewhat to our acquisition of Nimbus. So there were charges associated with that",246,"I think there were a couple of questions there. So it's John Milligan. So in terms of -- let me get to the last bit. You said there was a bump in R&D. That is true, relating somewhat to our acquisition of Nimbus. So there were charges associated with that and there are also charges associated -- I should say expenses associated with the purchase of an FDA priority review voucher. So we're very pleased to get that onboard, and we'll look forward to explaining when we're going to use that. Above and beyond that, actually, R&D expenses were slightly down what we -- beneath what we had forecasted because we continue to hold the cost of centers to -- accountable and continue to drive good value through our clinical teams in getting studies done at a very cost-effective way. So in terms of that, there's no difference. The SG&A line came down a little bit because of some onetime charges that were lower than we -- sorry, the IRS charge which was lower than we anticipated, so kind of what we would expect. In terms of signaling about pricing or changes in management about structures, I don't really think there's anything to signal there in terms of our pricing strategy. We're highly competitive. We think we have a very good differentiated product, and we'll continue to do the best for the company and for patients when coming to the right level of price and access."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. And I would just add, Cory, that the Gilead way is always to lead with the science around our product. Nothing's changed. In my eyes, as I have come back into the company, we lead with science. That's what you do in specialist markets. It is a realit",113,"Yes. And I would just add, Cory, that the Gilead way is always to lead with the science around our product. Nothing's changed. In my eyes, as I have come back into the company, we lead with science. That's what you do in specialist markets. It is a reality that there is more contracting. I think we've got a phenomenal team working on this. I met with them 2 weeks ago, and I think they're highly professional. And we always lead with value. That's the key thing. We think we've got tremendous products that either control disease or cure disease, and they are terrific value. And that's the course we're going to stay."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Phil Nadeau of Cowen.",10,"And our next question comes from Phil Nadeau of Cowen."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Kevin, it's great to have you back. I have a question on capital allocation. In the prepared remarks, I think you mentioned in regards to cash flows being lower in the second half of the year, that part of that was investment in R&D. And as you just discu",105,"Kevin, it's great to have you back. I have a question on capital allocation. In the prepared remarks, I think you mentioned in regards to cash flows being lower in the second half of the year, that part of that was investment in R&D. And as you just discussed, the R&D expenses aren't really changing that much in the guidance. So kind of curious whether you have on your list of things to do in the second half of the year more deals, whether M&A or in-licensing. And maybe you could give us some thoughts on how aggressive you're likely to be in those areas."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Well, Phil, I'll start. I think relative to the cash flow, what I was messaging was really just related to the dynamics of payments, right. So we have accrued rebates and other things that kind of caused volatility to quarterly cash flows. So overall, our",115,"Well, Phil, I'll start. I think relative to the cash flow, what I was messaging was really just related to the dynamics of payments, right. So we have accrued rebates and other things that kind of caused volatility to quarterly cash flows. So overall, our cash flows remain strong, but we definitely expect a sequential decrease in cash flows second half. Relative to overall capital allocation, it's no different than what we've been messaging, again, more focused on our BMD opportunities, but I'll let John speak of a little bit more and just, again, focus there. And that additional focus has meant we're somewhat less focused on share repurchases the second half of the year."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","And as a follow-up on what Robin said, Phil, we were very aggressive in the first quarter of this year. That's why we back off a little bit from where we are in the second half of the year. Mostly, you get the full year effect or a greater effect of repur",195,"And as a follow-up on what Robin said, Phil, we were very aggressive in the first quarter of this year. That's why we back off a little bit from where we are in the second half of the year. Mostly, you get the full year effect or a greater effect of repurchasing the almost 100 million shares through Robin's program. With regard to business development, obviously, we're a company that has been very open about being interested in doing more deals, especially deals of a certain size where we think we can get some leverage and we can use our organization to effectively accelerate or expand indications. We've done some good deals both with Galapagos and Nimbus recently. We are very interested in continuing that to add more things to our pipeline, especially in the non-antiviral area where we continue to see growth in franchises. It's our hope that as we exit this year, we'll have a better, more complete story of programs internally and externally that we can use to talk about why the long-term prospects for growth are as good as we believe they are, and that's what we'll be focused on."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Robyn Karnauskas of Citi.",10,"And our next question comes from Robyn Karnauskas of Citi."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I guess, the question for me after hearing some of the comments about like thinking about volumes slowing or coming down and then thinking about growth and that changing over time is how do you -- how are you comfortable that you can provide guidance with",102,"I guess, the question for me after hearing some of the comments about like thinking about volumes slowing or coming down and then thinking about growth and that changing over time is how do you -- how are you comfortable that you can provide guidance with these 2 variables? Or do you have any bookends for how low we can go that give you the comfort? And then the question is you affirmed guidance last quarter and lowered it this quarter. What was the one thing you think that really changed your view over the last 3 months that led to that?"
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Sure. You want to start, Kevin?",6,"Sure. You want to start, Kevin?"
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","I'll start and then hand the question to Robin. Robyn, it's really hard. We've got markets in different stages of development, whether it be U.S., parts of the U.S., different countries in Europe and obviously, interesting and profound dynamics in Japan.",130,"I'll start and then hand the question to Robin. Robyn, it's really hard. We've got markets in different stages of development, whether it be U.S., parts of the U.S., different countries in Europe and obviously, interesting and profound dynamics in Japan. So they're partly made up of patient flows and partly made up of sort of payer flows. I think the big thing this quarter, from the point of view of the U.S., was very much a payer kind of mix with the large addition of patients from the VA. So I think in the last 3 months, that was probably the biggest thing. We have not changed our prices in the U.S. Q2 versus Q1. It was largely we're seeing this dramatic but incredibly successful program from VA."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. Robyn, so I'll add to that. I agree with Kevin. I think the heavier percentage of more discounted payers, along with the fact that on the commercial side, right, we're seeing slight decreases in the U.S. And Kevin mentioned earlier about what we're a",184,"Yes. Robyn, so I'll add to that. I agree with Kevin. I think the heavier percentage of more discounted payers, along with the fact that on the commercial side, right, we're seeing slight decreases in the U.S. And Kevin mentioned earlier about what we're also seeing relative to the mix shift in countries in Europe; less of Northern Europe, Germany and France and more of Italy and Spain. To your other part of your question and to what you were [ph] earlier throughout the call, this is a really difficult area to predict. It's unlike any other. It's a curative market, and it's very large relative to Gilead's total revenues. And so it's a question we're asking ourselves as we think in the outer years how can we continue or can we really guide around HCV revenues. So we've guided this year, but it's definitely something we're giving a lot of thought to as we kind of think about the trends of HCV going forward and all the dynamics that we're trying to deal with. It's very complex, so more to follow on that."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Ying Huang of Bank of America Merrill Lynch.",14,"And our next question comes from Ying Huang of Bank of America Merrill Lynch."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I have a quick one on also the pricing environment. So if you look at VA sector and also the commercial sector, what kind of impacts are you seeing from competition, particularly Merck's Zepatier, from the pricing perspective? And then quickly on R&D side",74,"I have a quick one on also the pricing environment. So if you look at VA sector and also the commercial sector, what kind of impacts are you seeing from competition, particularly Merck's Zepatier, from the pricing perspective? And then quickly on R&D side. Do you plan to develop a doublet maintenance regimen? For example, recently, Tivicay plus EDURANT, the combination showed actually good results in heavily protruded [ph] patients in the near conference."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","So I'll take the first part in terms of kind of pricing and competitive impact. Very little in terms of our commercial payer areas because the contracts essentially were set up at the end of last year for the full year, so very little change in market sha",144,"So I'll take the first part in terms of kind of pricing and competitive impact. Very little in terms of our commercial payer areas because the contracts essentially were set up at the end of last year for the full year, so very little change in market share within the commercial payer segment. We still have a very strong position in VA with Harvoni and Sovaldi, particularly Harvoni. I think probably where we're seeing increased competitive activity is in the Medicaid setting where, as I described earlier, some of the smaller states are requesting contracts as they open up access. So I think that's probably where we see the competition. And again, because of our very strong value proposition, we hope we can be successful in the majority of those. But again, on occasions, we may find that they go to the competition."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. Ying, you asked a question about the ViiV, the expansion [ph] of the BCI in FIV. So we're, of course, aware of the data that were presented at EASL; they looked fairly impressive. They had a number of genotypes with high SVR rates. However, what they",205,"Yes. Ying, you asked a question about the ViiV, the expansion [ph] of the BCI in FIV. So we're, of course, aware of the data that were presented at EASL; they looked fairly impressive. They had a number of genotypes with high SVR rates. However, what they're doing right now in Phase III is not looking at the 8-weak treatment duration or genotypes enrolled patients. I would like to contrast this with our own triple combination, SOF/VEL/VOX, that John Milligan mentioned. We are looking essentially at 2-patient population of 1-patient population's experience that had previously failed other DAAs, that treatment duration is for 12 weeks; and then we're looking at all genotypes, cirrhotic and non-cirrhotic patients for 8-week treatment duration. And we had 1 study, in particular, that only looks at 8 weeks of treatment duration in the most difficult to treat genotype 3 cirrhotic patients because that's still a population where SVR rates are still in the low 90s. And if we could push that up into the high 90s, that would be a step forward. So I think our -- if our Phase III program, the data, support our Phase II results, then we will be a step ahead of all the competition."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Ian Somaiya of BMO Capital Markets.",12,"And our next question comes from Ian Somaiya of BMO Capital Markets."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I just wanted to follow up on the triplet opportunity within hep C. Specifically, Norbert, just I don't know if you could describe the proportion of patients that have maybe failed the -- in the first round -- sort of round of antivirals, whether it be do",91,"I just wanted to follow up on the triplet opportunity within hep C. Specifically, Norbert, just I don't know if you could describe the proportion of patients that have maybe failed the -- in the first round -- sort of round of antivirals, whether it be doublet therapy or SOF alone. So I don't know if there's a prevalent pool that you can speak to. And then maybe, I guess, it's more a question for Kevin. Just how do you think about the triplet and its impact on margin price share?"
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","So Ian, we -- as you know, we are doing essentially 4 studies with the triplets, what we call it the triplets, SOF/VEL/VOX. Two of them are in treatment-experienced patients, and what we would aspire to is to have this compound BD universal salvage regime",165,"So Ian, we -- as you know, we are doing essentially 4 studies with the triplets, what we call it the triplets, SOF/VEL/VOX. Two of them are in treatment-experienced patients, and what we would aspire to is to have this compound BD universal salvage regimen. Now, Kevin, maybe you could comment on what the proportion of patients is that would qualify for this. But something I can tell you, in Japan, there's a fairly large number of patients had been treated with the Bristol-Myers GI NS5A regimen. I think if I remember this correctly, they have SVR rates in the Phase III study of about 80% or thereabouts, and there are about 9,000 patients now that we heard of that are treatment experienced at that field. And those 9,000 would immediately be candidates for our own studies. And as I said, I want to say it again, the other 2 studies is 8 weeks treatment duration for all patients, all genotypes, cirrhotics and noncirrhotics. Kevin?"
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. It's a good question, Ian. We're waiting to see some of the clinical -- obviously, emerging clinical data. Right now, we've -- I think we've got a situation, certainly in the U.S. and Japan is -- Japan, with this resistant situation, I think is perha",193,"Yes. It's a good question, Ian. We're waiting to see some of the clinical -- obviously, emerging clinical data. Right now, we've -- I think we've got a situation, certainly in the U.S. and Japan is -- Japan, with this resistant situation, I think is perhaps quite unique in terms of the original use of the Bristol-Myers regimen. But I think we got patients being cured to an incredibly high level with Harvoni, and now we've got the right treatment, I think in Epclusa for the 2s and 3s. So I think in the U.S., perhaps in Europe, it will be far more modest, the opportunity. Having said that, it depends where we are with those products, our products with where the competition is obviously, what we decide to do in terms of the pricing strategy. I think most importantly, from a company point of view, we think this is the right thing to do and probably the last step in the whole story around hepatitis C to help treatment experience of failure patients. So I think, first and foremost, we think this is the right thing to do for patients in need."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Alethia Young of Crdit Suisse.",11,"And our next question comes from Alethia Young of Crdit Suisse."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Let me be the thousandth person, Kevin, to say welcome back and it's great to have you here. Two kind of questions in kind of the same vein. Just one on oncology. Has this remained a focus for you guys as far as building assets there and building out that",93,"Let me be the thousandth person, Kevin, to say welcome back and it's great to have you here. Two kind of questions in kind of the same vein. Just one on oncology. Has this remained a focus for you guys as far as building assets there and building out that business as much as it was in the past when you talk about it? And secondarily, just, Norbert, with NASH, can you just talk about some of the data points coming up and like, what's going on with the FXR program as well?"
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. So Alethia, let me start off by -- firstly and then John Milligan will afterwards comment on it, too. We are in oncology. We have now momelotinib is at the end of the Phase III program. We should have data this year. If the data is positive and going",246,"Yes. So Alethia, let me start off by -- firstly and then John Milligan will afterwards comment on it, too. We are in oncology. We have now momelotinib is at the end of the Phase III program. We should have data this year. If the data is positive and going fine, the NDA track, right application next year. We have that MMP9 in gastric cancer in Phase III. We're looking at other solid tumors. And we're now finally, after sorting out the dosing, starting the first study in combination of a PI3K inhibitor with BTK in CLL. So with regards to NASH, yes, we have now very interesting 4 modalities or 4 mechanisms that we're evaluating in NASH, and at least with 3 of them, we know that they are doing what they're supposed to do pharmacologically. We will have data this year on the ASK inhibitor that will include liver fat analyses along with histology. The FXR agonist is currently in a Phase I, Phase IIa study. And by the way, we know about that compound already that it has minimal systemic absorption, but there are systemic levels of FGF19. That was always our idea to have a compound that acts in the GI; that releases FGF19; the FGF19 has the efficacy. And by that, the rationale we won't get the side effect that other FXR agonists have. And then finally, we have -- oh the -- wait a moment -- ASK inhibitor, OC --"
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","ACC.",1,"ACC."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","ACC inhibitor, the Nimbus compound. And we know those data were presented at EASL, that it reduces the novel lipogenesis. So what we're going to do based on these data is [indiscernible] asking if we could go into Phase III next year and we have a compoun",63,"ACC inhibitor, the Nimbus compound. And we know those data were presented at EASL, that it reduces the novel lipogenesis. So what we're going to do based on these data is [indiscernible] asking if we could go into Phase III next year and we have a compound with the Phase II with the FXR and the ACC inhibitor or even this year. John?"
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. I just would follow up with Norbert's comment by saying, yes, we are committed to oncology. We continue to be interested in assets, collaborations and partnerships where we could enhance our ability to continue to sell these products, right. Where we",100,"Yes. I just would follow up with Norbert's comment by saying, yes, we are committed to oncology. We continue to be interested in assets, collaborations and partnerships where we could enhance our ability to continue to sell these products, right. Where we are seeing good progress, as Norbert mentioned, our BTK inhibitor, which is -- we're developing with our partner from ONO, is now making its way to the clinic, and we've overcome some formulation challenges to allow us to go ahead. So that will be very, very -- I think, an interesting avenue for us to continue to explore."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our final question comes from Terence Flynn of Goldman Sachs.",11,"And our final question comes from Terence Flynn of Goldman Sachs."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Just wondering a kind of 2-parter. The first is just any opportunity to broaden your prescriber base on hep C? Kevin, would love your thoughts on that. And the second question relates to Genvoya. Can you just give us what percentage of the switches were f",48,"Just wondering a kind of 2-parter. The first is just any opportunity to broaden your prescriber base on hep C? Kevin, would love your thoughts on that. And the second question relates to Genvoya. Can you just give us what percentage of the switches were from Atripla?"
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Terence, first of all, in terms of sort of like any future waves of market, I did mention Australia earlier. And that's an incredible story of treating and curing patients and amazing commitment by the government there. We are seeing more patients treated",152,"Terence, first of all, in terms of sort of like any future waves of market, I did mention Australia earlier. And that's an incredible story of treating and curing patients and amazing commitment by the government there. We are seeing more patients treated in Brazil. It's a lower-price market, but we are seeing more. We are just beginning our launch in Mexico. So yes, these are smaller markets. Typically, they are lower price. But those -- if you like, those smaller waves are starting to work through. We are thinking carefully about China and how we launch there, probably in a very modest or very focused way -- a very efficient way should I say. So we -- our expectations, I think, are very reasonable around China. So the second question, in terms of switch, about 18% of the switch patients is from Atripla. So I hope that gives you the number."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","And that concludes our question-and-answer session for today. I'd like to turn the conference back over to Mr. Lee for closing remarks.",23,"And that concludes our question-and-answer session for today. I'd like to turn the conference back over to Mr. Lee for closing remarks."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Executives","Great. Thank you, Candace, and thank you all for joining us today. We appreciate your continued interest in Gilead, and the team here looks forward to providing you with updates on our future progress.",34,"Great. Thank you, Candace, and thank you all for joining us today. We appreciate your continued interest in Gilead, and the team here looks forward to providing you with updates on our future progress."
29002,369689622,1011750,"Gilead Sciences Inc., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Have a great day, everyone.",25,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Have a great day, everyone."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Third Quarter 2016 Earnings Conference Call. My name is Candace, and I'll be your conference operator today. [Operator Instructions] And as a reminder, this conference cal",63,"Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Third Quarter 2016 Earnings Conference Call. My name is Candace, and I'll be your conference operator today. [Operator Instructions] And as a reminder, this conference call is being recorded. I would now like to turn the call over to Sung Lee, Vice President of Investor Relations. Please go ahead."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Candace, and good afternoon, everyone. Just after market close today, a press release was issued with earnings results for the third quarter of 2016. The press release and detailed slides are available on the Investor Relations section of the G",219,"Thank you, Candace, and good afternoon, everyone. Just after market close today, a press release was issued with earnings results for the third quarter of 2016. The press release and detailed slides are available on the Investor Relations section of the Gilead website.
Joining today's call will be John Milligan, President and Chief Executive Officer; Robin Washington, Executive Vice President and Chief Financial Officer; Kevin Young, Chief Operating Officer; and Norbert Bischofberger, Executive Vice President of Research and Development and Chief Scientific Officer.
Before we begin formal remarks, let me remind you that we will be making forward-looking statements, including plans and expectations with respect to products, product candidates, financial projections and the use of capital, all of which involve certain assumptions, risks and uncertainties that are beyond our control and could cause actual results to differ materially from these statements. A description of these risks can be found in the latest SEC disclosure documents and recent press releases. In addition, Gilead does not undertake any obligation to update any forward-looking statements made during this call.
Non-GAAP financial measures will be used to help you understand the company's underlying business performance. The GAAP to non-GAAP reconciliations are provided in the earnings press release as well as on the Gilead website.
I will now turn the call over to Robin."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, Sung, and good afternoon, everyone. We are pleased to share our results for the third quarter of 2016. I'll first review our financials, and Kevin, Norbert and John will then make a few comments.Total revenues for the third quarter were $7.5 bil",779,"Thanks, Sung, and good afternoon, everyone. We are pleased to share our results for the third quarter of 2016. I'll first review our financials, and Kevin, Norbert and John will then make a few comments.
Total revenues for the third quarter were $7.5 billion with non-GAAP diluted earnings per share of $2.75. This compares to revenues of $8.3 billion and non-GAAP earnings per share of $3.22 for the same period last year.
Product sales for the third quarter were $7.4 billion, down 10% year-over-year and down 3% sequentially. These declines were due to lower HCV sales, partially offset by increased sales in HIV and other therapeutic areas. Sequentially, declines in our HCV sales in the U.S., Japan and Europe were partially offset by increases in U.S. HIV and other product sales.
Turning to the U.S. Product sales for the third quarter were $5.1 billion, down 9% year-over-year. HCV product sales were $2 billion, down 37% year-over-year, driven primarily by lower patient starts for Harvoni and lower revenues per patient, primarily due to a higher percentage of sales to more deeply discounted segments. The decline was partially offset by demand for Epclusa, which was launched at the end of Q2 2016 and generated $593 million in its first full quarter of sales.
Sequentially, our HCV product sales were down 12%. These sales were essentially flat compared to the second quarter, excluding the favorable adjustment to our HCV sales return of $279 million that we made last quarter. HIV and other anti-viral sales increased 32% year-over-year and 19% sequentially. The quarterly revenues of $2.6 billion were positively impacted by strong uptake of our TAF-based regimens and a onetime favorable adjustment of $332 million to our rebate reserves, primarily related to our TDF-based regimens. Without the adjustment, U.S. HIV and other anti-viral sales grew 15% year-over-year and 4% sequentially.
Turning to Europe. Product sales for the third quarter were $1.4 billion, down 16% year-over-year, primarily due to lower HCV patient starts and unfavorable currency movements. Sequentially, sales were down 12%, primarily driven by lower HCV patient starts and summer seasonality, consistent with the usual decreases in demand during the European summer holiday months.
In Japan, product sales for the third quarter were $452 million, flat year-over-year, driven by higher sales of Harvoni, which was launched in September 2015, offset by mandatory price reductions for both Sovaldi and Harvoni, which we discussed during our last call. Sequentially, sales were down 27% as a result of lower Harvoni and Sovaldi patient starts.
Now turning to expenses. Non-GAAP R&D expenses were $981 million for the third quarter, up 38% compared to the same period last year, primarily due to the progression of our clinical studies, which included a $200 million milestone expense associated with our purchase of Nimbus. Non-GAAP SG&A expenses for the third quarter were down 8% compared to the same period last year, primarily due to lower branded prescription drug fee expense.
From a balance sheet perspective, during the third quarter, we generated cash flows from operation of $4.3 billion and ended the quarter with $31.6 billion in cash and investments, which is inclusive of the issuance of $5 billion of senior unsecured notes. We have a healthy balance sheet to invest in our pipeline and external opportunities.  While our cash flows will remain strong, we do anticipate a sequential decrease in Q4 2016 due to required cash payments related to accrued government rebates as well as milestone payments associated with our R&D pipeline.
Shareholder return via dividends and share repurchases year-to-date remains strong. In the third quarter, we repurchased 11.7 million shares for $1 billion under the $12 billion 2016 share repurchase program. For 2016, the total share repurchases through the third quarter were 110 million shares at a cost of $10 billion. Year-over-year, we have seen an 11% decline in our diluted shares, primarily driven by our share repurchases.
Finally, we are reiterating our full year 2016 guidance, which was revised on July 25, 2016, and summarized on Slide 27 in the earnings results presentation available on our corporate website. As a reminder, guidance for product sales is subject to a number of uncertainties, including an uncertain global macroeconomic environment; adoption of additional pricing measurement -- measures to reduce HCV spending; volatility in foreign currency exchange rates; inaccuracy in HCV patient start estimates; additional competitive launches in HCV; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; and a larger-than-anticipated shift in payer mix to more highly discounted payer segments such as PHS [ph] , FFS, Medicaid and the VA.
I would like to turn the call over to Kevin now."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Robin, and good afternoon, everyone. I am very pleased to take you through a solid set of operating results for the third quarter.Starting with HIV. Gilead continues to make significant steps in delivering improved single-tablet regimens to p",1395,"Thank you, Robin, and good afternoon, everyone. I am very pleased to take you through a solid set of operating results for the third quarter.
Starting with HIV. Gilead continues to make significant steps in delivering improved single-tablet regimens to patients around the world. We have seen strong adoption of our TAF-based regimens in the U.S. and in the European markets, where we have achieved reimbursement.
In the U.S., of the nearly 840,000 people on anti-retroviral therapy, approximately 80% received a Gilead regimen. Genvoya is now the most prescribed regimen for both treatment-nave and switch patients. This month, we expect cumulative prescriptions of Genvoya to surpass Atripla's prescription at the same point in time post approval. This will make Genvoya the all-time most successful product [ph] adoption in its first year in the 30-year history of HIV therapy in this country.
The uptake of Genvoya, Odefsey and Descovy have largely been driven by the switch from Gilead's old STRs due to the improved safety profile of TAF. It is also encouraging to see a notable number of patients from non-Gilead therapies moving to TAF-based regimens. Approximately 10% of Genvoya switches are incremental to the Gilead HIV franchise.
Turning to Europe. Total HIV and other anti-viral revenue was $728 million, up 1% year-over-year and down 4% sequentially. Third quarter European pharmaceutical revenues are typically affected by summer seasonality. In Italy, Spain and Portugal, we saw lower prescribing rates consistent with prior years. Genvoya has been launched in 18 markets in the U.K. -- in the EU, including Spain and Germany, while we have seen rapid uptake similar to the U.S. Descovy has been launched in 9 markets, and Odefsey has been launched in 8 markets, the largest being Germany in both cases. We expect our TAF-based therapies to continue to grow in Europe with Spain still early in its commercial launch of Genvoya.  Pricing and reimbursement discussions are ongoing in France and Italy with the goal of having these complete by year-end.
Guidelines historically have had a significant impact on prescribing patterns [ph] . Genvoya is already listed as a preferred regimen in several HIV treatment guidelines, including the European AIDS Clinical Society as well as country guidelines in Germany, the U.K., Spain and Italy.
I would like to make a few comments about HIV prevention and the use of Truvada for PrEP. The growth in people starting Truvada points to the valuable role that therapeutical can play when used as part of a comprehensive strategy to prevent transmission. We estimate that in the U.S., approximately 80,000 to 90,000 people were using Truvada for this indication in the third quarter.  We are also starting to see usage of PrEP in France, where approximately 2,000 people have begun -- have been prescribed Truvada since it received reimbursement in January this year. We expect PrEP to continue to be a significant part of Gilead's growth in HIV going forward, particularly in the U.S.
With the rapid adoption of TAF-based regimens, the potential of PrEP and our exciting pipeline programs, especially bictegravir, I'm very positive about the long-term life cycle potential we have in HIV.
Turning to HCV. Approximately 61,000 people in total began HCV therapy in the U.S. in the third quarter 2016. This represents the fourth consecutive 3-month period where patient starts have been in the 50,000 to 60,000 range. We estimate that more than 85% of treated patients in the most recent quarter received a sofosbuvir-based regimen.
The uptake of Epclusa has been most encouraging in its first full quarter post launch, although it is important to point out that we have observed a small yet noticeable warehousing effect. As expected, the vast majority of Epclusa is being used in genotype 2 and 3 patients according to our 12-week label. In terms of payer coverage, formulary reviews for Epclusa are on track. 11-state Medicaid programs have already added Epclusa to genotype -- for genotype 2 and 3 patients, and most commercial and Medicare Part D plans are providing interim coverage for Epclusa based on medical need. Finally, the VA has added Epclusa to their national formulary and have begun ordering.
The 2017 commercial and Medicare Part D contracting cycle is now essentially complete. And whilst I cannot share with you plan-by-plan details, suffice to say that we are pleased with the picture for the coming year. Discussions with all major PBMs and MCOs prove to be productive and recognize the clinical leadership of Gilead's HCV options, especially as demonstrated in real-life settings.  But barriers to access still remain as Medicaid continues to be the outlier in terms of access, restricting coverage to only the more advanced patients.
Turning to Europe. Total HCV revenue in the third quarter was $604 million, down 30% year-over-year and down 22% sequentially. This was driven by lower HCV patient starts. While overall patient starts declined, our market share remained largely unchanged across the major markets with the exception of the U.K., which was slightly down for the quarter.
We estimate that 21,000 patients started on a sofosbuvir-based regimen in the third quarter compared to 27,000 in the second quarter. At our last earnings, I described how we were observing lower patient starts in the early EU launch markets of Germany and France. Took simply, many of the high-need patients have been treated and cured. We are now starting to see this trend unfold in southern European countries, particularly in Italy and in Spain. Performance in the region is also likely somewhat affected by summer seasonality similar to the dynamics we observed in HIV.
Epclusa has now been launched in Germany, Sweden, Norway, Finland and Denmark. I'm pleased to say that there have been the same positive reception as in the U.S. We expect to launch in the other large EU markets once pricing and reimbursement is in place by the second half of 2017.
Not only does 12 weeks of Epclusa deliver incredibly high cure rates, but as a new standard of care, it is considerably cheaper than previously used interferon-free regimens, especially treating genotype 3.
As I conclude my remarks on hepatitis C, it is very important to reiterate that more work needs to be done to identify and cure HCV-infected people around the globe. A key objective for Gilead is to appropriately raise disease awareness, highlight the importance of age-related testing and encourage linkage to specialty care. To help with this effort, we recently launched new educational campaigns in the U.S. and Japan to urge all individuals at risk for or living with HCV to talk to their health care provider.
You may have seen our new advertisement on television here in the U.S. It debuted last week, and I am very pleased with the positive and responsible tone it takes to [ph] emphasize to people the need to be screened for a disease that can now be cured in as little as 8 weeks. We have received numerous positive comments from advocacy groups, providers and not least, the many people already cured of hepatitis C who want others like them to benefit.
Moving on. One of the liver disease that warrants a mention today is hepatitis B, for which we are well prepared for the launch of TAF. With our PDUFA date coming, we are hopeful that we will have the opportunity to speak to physicians at the AASLD meeting and in the field about the strong data for this product as soon as next week.
Finally, as I highlighted last quarter, we have a very strong U.S. cardiovascular team that continues to deliver impressive results. Letairis and Ranexa revenues totaled $385 million for the quarter and surpassed $1 billion in the year-to-date.
In closing, I'd like to reiterate the positive progress Gilead is making in addressing viral diseases. We will soon have treated 1.2 million HCV-infected individuals around the world, most of whom are now cured. By any measure, this is a profound contribution to global health care delivery.
And in the field of HIV, not only are we effectively managing the disease with our new TAF-based regimens, but Truvada is helping more and more people avoid infection. I am confident that we will close out the year with continued strong financial performance underpinned by a passion for operational excellence and our focus on putting the patient first.
I will now hand the call over to Norbert."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Kevin. During the third quarter, a number of Phase II and Phase III studies concluded, providing insights into efficacy and safety of both approved and experimental Gilead [ph] in the areas of HIV, liver disease, inflammation, oncology and card",1389,"Thank you, Kevin. During the third quarter, a number of Phase II and Phase III studies concluded, providing insights into efficacy and safety of both approved and experimental Gilead [ph] in the areas of HIV, liver disease, inflammation, oncology and cardiovascular disease. Some of these results were disappointments. Some were exciting successes.
To start off with the disappointments. We now have the final analyses from 3 96-week studies of the anti-LOXL2 monoclonal antibody, simtuzumab. The data indicate that while safe and well tolerated, there is no evidence of efficacy in 1 study in primary sclerosing cholangitis and in 2 studies in NASH. One NASH study was in patients with cirrhosis, and one was in patients with bridging fibrosis. Consequently, we will not develop simtuzumab any further in these or any other indications. We will present this data at future conferences.
As for GS-5745, an anti-MMP9 antibody, we stopped a Phase II/III study in patients with ulcerative colitis because of a lack of efficacy. This decision followed a planned interim DSMB analysis after the first 150 patients had been enrolled and the study met predefined futility criteria. Also, and not unexpectedly, there was no evidence of benefit of GS-5745 in a Phase II study in patients with Crohn's disease. Consequently, we will not further pursue GS-5745 for ulcerative colitis or Crohn's. In these studies, GS-5745 were safe and well tolerated, and we're continuing to evaluate GS-5745 in rheumatoid arthritis as an add on to anti-TNFs or other therapies.
Meclizine, or SG&A 6615, failed to meet its primary endpoint in a study of patients with ventricular tachycardia, ventricular fibrillation, or VTVF, and implanted cardioverter defibrillators. Patients were randomized to 2 doses of the meclizine or placebo. The primary endpoint was the number of electrical interventions, including shocks and pacing by the implanted device, and there was no evidence of efficacy of meclizine compared to placebo. Consequently, we will not develop meclizine any further for VTVF evaluation in long QT-3 syndrome, and hypertrophic cardiomyopathy is continuing. 
But now to the excitement. Starting with HCV. The pan-genotypic single-pill, triple-combination regimen of sofosbuvir, [indiscernible], or I'll call it [indiscernible], has been studied in 4 Phase IIb facilities for Polaris 1, 2, 3 and 4. Polaris 1 and 4 evaluated the regimen in patients with the fille direct acting antiviral and included patients with cirrhosis. Treatment of these salvage patients with soft [indiscernible] resulted in SVR rates of 96% and 97%. 
The 2 other studies, Polaris 2 and 3, compared the triple-combination regimen in treatment-naive patients given for 8 weeks to Epclusa given for 12 weeks. Polaris 2 was open to all genotypes, whereas Polaris 3 enrolled only genotype 3 infected individuals with compensated cirrhosis where the unmet need is the greatest. In Polaris 2, the SVR rate of 10 to 12 weeks of Epclusa were numerically higher than those obtained with 8 weeks of the triple combination, whereas in Polaris 3, the SVR rates were comparable. Particularly in Polaris 3, which involved the most difficult-to-treat genotype 3 infected cirrhotic patients, Epclusa for 12 weeks resulted in 96% SVR rate. These results underscore the value of Epclusa as an excellent treatment option for patients across all genotypes and also suggest that the future role of SOF/VEL DLX will be for patients who previously filled an antiviral regimen. The full data from these studies will be presented at ASOD in a few weeks, and we will submit Marketing Authorization Application to regulatory authorities imminently. 
Another exciting result was the anti-fibrotic effect observed with GS-4997 and investigational small molecule inhibitor of a proptosis signal regulating kinase 1 or S1. GS-4997 was a shown to inhibit inflammation a proptosis in fibrosis in settings of increased oxidative stress associated with NASH in preclinical models. This Phase II clinical study involved 72 patients. 2/3 had F-3 stage fibrosis and 1/3 had F2 stage fibrosis. There was evidence that treatment of GS-4997 for only 24 weeks resulted in fibrosis reversal and decreased fibrosis progression in a dose-dependent manner. At the highest dose tested, which was 18 milligrams, 43% of patients showed at least a 1-point decrease in their fibrosis score compared to only 20% in the simtuzumab control arm. At the same time, 20% of the simtuzumab-treated patients progressed to cirrhosis compared to only 3% or 1 out of 30 at the 18-milligram dose. The full data from these studies will be presented at ASOD in a few weeks. 
Based on these exciting data, we will initiate discussions with regulatory authorities and plan to launch GS-4997 into Phase III clinical development in patients with NASH. Based on the Phase II results, we intend to evaluate GS-4997 in patients with the highest unmet need, that means those with F3 and F4 stages of fibrosis. 
At the same time, we have 2 other compounds with different mechanisms currently in 2 Phase II studies in patients with NASH and fibrosis, and that is GS-9674, an FXR agonist; and GS-0976, an ACC inhibitor. And the studies or 24- and 12-week duration, respectively. Pending demonstration of single agent efficacy and safety in these 2 Phase II studies, we plan to initiate combination studies with 3 agents towards the middle of next year.
In HIV, we're continuing to explore the utility of TAF-containing regimens in various uses in different populations. Last week, data from 3 Phase III studies were presented at the HRV Conference in Glasgow. 96-week data were disclosed from 1 study or 663 biologically suppress patients were randomized to either continue to the TAF-based regimen or switch to a Descovy-based regimen. In 2 other studies, 630 and 875 are largely suppressed patients on COMPLERA and Atripla, respectively, were randomized to switch to Odefsey or stay on their current regimen. In all studies, switching to a TAF-based regimen was noninferior with regards to efficacy but were superior with regards to renal and bone laboratory safety parameters. 
The Phase III development of the single-tablet regimen of bictegravir F/TAF is continuing. Four Phase III studies for now fully enrolled, and we anticipate ublinding these studies towards the middle of next year with regulatory submissions plan for the third quarter of 2017. We also plan to present 48-week Phase II data on bictegravir F/TAF at the Scientific Meeting in the first quarter of 2017.
In oncology, a Phase III study of GS-5745 in patients with gastric cancer is ongoing as well as a Phase II study in patients with gastric cancer in combination with [indiscernible]. We're also evaluating GS-5745 in other solid tumors. 
In addition, we have now completed 2 Phase I safety studies of our combination kinase inhibitors. We were able to establish safe doses of our PI3K inhibitor, idelalisib, in combination with our BTK inhibitor, GS-4059, and our Syk inhibitor, [indiscernible], in combination with the BTK inhibitor, GS-4059. Consequently, we will now first evaluate the PI3K/BTK combination with and without anti-CD-20 therapy in relapsed/refractory CLL patients in collaboration with the CLL study group.
We will also be announcing initial Phase Ib/II data on our Syk inhibitor, entospletinib, in acute myeloid leukemia at the upcoming ASH Conference in San Diego. We've entered into a collaboration with the Leukemia and Lymphoma Society to provide entospletinib for their beat AML master trial. This trial will employ the latest genomic technology to match specific AML mutations in newly diagnosed patients over age of 60 with an appropriate investigational drug or drug combination.
In summary, great progress has been made with some of our programs. The very nature of R&D is that you often face foreclosures and progress. Going forward, I am pleased we now have the ability to focus our attention on development programs in NASH, inflammation oncology and HIV. We now have 7 new molecules in advanced clinical development. The PDUFA date for TAF for HPV is coming up in a few weeks, and we plan to file an NDA before the end of the year on SOF/VEL DLX for use as therapy for patients who have built a previous direct-acting antiviral. 
Four molecules are continuing in Phase III. That is momelotinib for myelofibrosis; dolutegravir F/TAF, the single-tablet regimen for HIV infection; [indiscernible] for 3 separate indication, rheumatoid arthritis, ulcerative colitis and Crohn's; and GS-5745 in gastric cancer. 
Finally, we plan to advance GS-4997 for NASH to Phase III. 
I would now like to turn the call over to John."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, Norbert. I want to make a few closing remarks before we get to your questions. We continue to have success with important work we're doing in HIV and hepatitis. There's still a great need for innovation in these deals. Both of these include pati",831,"Thanks, Norbert. I want to make a few closing remarks before we get to your questions. 
We continue to have success with important work we're doing in HIV and hepatitis. There's still a great need for innovation in these deals. Both of these include patients whose needs remain unaddressed, and both represent global epidemics. 
Our researchers are working now options to wider range of patients than ever before. This includes people with HIV who've been on therapy for decades and may need to change their medication due to side effects or patients who may be failing to post suppressor balance due to the present resistance. 
Approaches our research teams are pursuing include new molecules from our system environments, now in formulations and combinations that we maybe those frequently and opportunities to care HIV patients by clearing of the viral reservoir from their bodies.
Our innovative work, in conjunction with our many partners, has already allowed us our [indiscernible] reach million of patients worldwide. Practically excited about the role that TAF will play. With a small daily dose and improved side effect profile, this ideal for resource string areas of the world empires only 1/10 of the manufacturing capacity to supply the same number of patient. 
In the area of viral hepatitis, the data now is Epclusa suggested we have an excellent option for the many parts of the developing world for genotypic HCV and the stage of disease could be difficult, if not impossible. With Epclusa, there's no difference in dosing for the different genotypes or is a liver disease, and so there's no need for these diagnostic procedures. We're working around the globe to rapidly introduce Epclusa as well as Sovaldi and Harvoni.
Finally, in hepatitis B, as Kevin and Norbert mentioned, we are approaching the launch of TAF. HCV continues to be an undertreated disease despite the long-term data showing improvement of liver for people who will remain unaffected therapy. TAF provides an important new option for patients with chronic HBV, and we'll have the opportunity to introduce the product at the liver meeting the next coming weeks in Boston. 
We also recognize that treating such a prevalent disease chronically is a major global challenge, and we continue to seek ways to provide finite durations of treatment such as the patient they control or eliminate the virus without having to endure a lifetime of treatment. Gilead's largest research effort is in the area of HPV care. 
Antivirals, we are making progress in your disease areas through Gilead. We are pleased to be able to share you today our top line data for GS-4997 and NASH. GS-4997 targets ASK1, a previously unexplored target for NASH. The data very suggests of the strong anti-fibrotic activity after only a 24-week period of treatment, and we look forward to future in-depth discussions once the data are presented at ASLD. 
We think about GS-4997 as a potential backbone molecule, one that can be used alone or in combination. NASH is an understudied but increasingly prevalent disease and Gilead's liver disease team now has 3 exciting molecule to move forward in the clinical studies. We understand that there's a lot of work to do in providing the rationale for the patient and to the payer after the benefits of treating NASH. An active compound such as GS-4997 could really move the deal forward, and we are in the process of designing comprehensive studies to demonstrate that health system benefits of treating such a prevalent and growing disease. 
In the area of inflammation, we're executing the build on plan. Phase III studies of the company been up and running and study is in Crohn's and ulcerative colitis have just begun screening patients in the first of these studies. I'm pleased with the progress we're making and we're our collaborators at the store up and running as quickly as possible. We're also looking forward to exploratory studies of about the name in a wider variety of inflammatory diseases that can fully understand the potential for this specific inhibitor. 
As you know, we are also focused on our augmenting our portfolio with external opportunities to take in the field of oncology. However, our interests in partnerships of potential acquisitions to not limited to oncology, and we are considering opportunities for strong science and where we see the possibility of developing a truly differentiated product.
We have going to extensive maternal programs and opportunities, and an important aspect of our approach is that we remain open-minded but disciplined. So while we have the balance sheet to execute a multi-opportunities, we will keep the bar high. 
With 2 months of the year remaining I want to take the opportunity to think the 9,000 employees of Gilead for their hard work and dedication. Everyday, more than 10 million individuals around the world take a Gilead medication, and everyday, our teams come to work to improve upon that number. 
Thank you for your time. But to open the call to questions. Operator?"
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Geoff Meacham of Barclays.",15,"[Operator Instructions] 
And our first question comes from the line of Geoff Meacham of Barclays."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","John or Kevin, I got one for you. Just want to ask about hep C but in a broader context. So you guys have had flat patient numbers despite better access in the U.S. and revenues down sequentially but on payer mix. So the question is, how do you think abou",78,"John or Kevin, I got one for you. Just want to ask about hep C but in a broader context. So you guys have had flat patient numbers despite better access in the U.S. and revenues down sequentially but on payer mix. So the question is, how do you think about the return on investing continually in hep C? Are there commercial or new products versus, say, looking outwards and be more aggressive in a new therapeutic category?"
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Jeff, it's Kevin. Let me just take maybe half a step back from your question, just a few more observations. I've got to tell you that I think we're really executing well in the area of hepatitis C. I spent a lot of time this quarter with many Gilead's and",421,"Jeff, it's Kevin. Let me just take maybe half a step back from your question, just a few more observations. I've got to tell you that I think we're really executing well in the area of hepatitis C. I spent a lot of time this quarter with many Gilead's and with several providers. And I think the variables that we can directly influence, we're really doing a good job on. Our market share is staying incredibly strong. We're ensuring access whilst preserving the value of our hepatitis C drugs. And we're executing on new versions coming to the market. I think you've seen that with Epclusa. And the area that we can less control but we can influence, you're now seeing some new activities from us in terms of unbranded awareness campaigns. And you may have seen our advertisement that came on the television just over a week ago. So I think, from my point of view, in terms of operational excellence, we're doing a very nice job. It is true that the treatments are staying about the same. Actually, I've considered that very positive. Let's not forget that where treatment levels that are 2.5x the treatment levels that were there before, the Gilead regimens came to the market. So I take at the level of 50,000 to 60,000 patients as very good. The vast proportion of those are Gilead patients. Epclusa had a very big effect in this quarter. So it goes to show that there's still room for new patients, albeit we're entering a high level of satisfaction. But with Harvoni for genotype 1, both 12 weeks and now at high proportion of 8 weeks and now Epclusa for the 2 and 3 patients, yes, we have got patients being cured at very high levels. In terms of our triple, I do agree that could be a relatively small proportion of patients, but it's the right thing to do and it completes our whole picture for hepatitis C. So I think to have the range of products that we have, to have the efficacy that we have is the right offering for health care. So we continue to move forward, and I think we have a healthy franchise. And we are getting better access from, particularly the commercial payers, although, as I pointed out and I often discussed with the team here, the Medicaid is still a little bit on the slow side in terms of access. But great progress as far as I'm concerned in the third quarter."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","And Jeff, it's John. The second part of your question was something about investing in this area versus other areas. I would say, from a pipeline perspective, with SOF/VEL/VOX being our fourth generation of HCV products now being approved, there really is",110,"And Jeff, it's John. The second part of your question was something about investing in this area versus other areas. I would say, from a pipeline perspective, with SOF/VEL/VOX being our fourth generation of HCV products now being approved, there really isn't much less in terms of unmatched medical need. And so from a pipeline perspective, this is really the end of what we will be developing in terms of HCV molecules, and that will allow us then to turn our attention to the important aspects in our fibrosis and NASH franchises and our oncology franchises. So we've really largely turned our attention away from HCV to those areas already."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Brian Abraham with Jefferies.",10,"And our next question comes from Brian Abraham with Jefferies."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Norbert, a question on 4997. Wondering if you could talk a little bit more about the go-forward plan there, particularly with respect to potential Phase III trial duration and whether or not a fibrosis endpoint might be acceptable, just given the effects",90,"Norbert, a question on 4997. Wondering if you could talk a little bit more about the go-forward plan there, particularly with respect to potential Phase III trial duration and whether or not a fibrosis endpoint might be acceptable, just given the effects that you saw in such a short time period in Phase II and the plan to target more severe progressive patients. And then can you confirm that there were no baseline imbalances in the Phase II that might have influenced the fibrosis data or progression to cirrhosis data?"
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes, Brian, so the second question, yes, I can confirm that there were no baseline imbalances. And regarding the Phase III study, no, we are going to make the proposal to regulatory authorities to use just fibrosis as the endpoint. We feel very convinced",231,"Yes, Brian, so the second question, yes, I can confirm that there were no baseline imbalances. And regarding the Phase III study, no, we are going to make the proposal to regulatory authorities to use just fibrosis as the endpoint. We feel very convinced that, that's the right thing to do because as you may now, fibrosis is the only histological correlate to clinical outcomes. There was a large study published a few years ago where they looked at baseline histology, and they correlated histological variables with clinical outcomes, and [indiscernible] didn't correlate, inflammation didn't correlate, ballooning didn't correlate. The only thing that correlated was fibrosis. So we are going to propose 2 Phase III studies both looking at fibrosis 48-week as the endpoint. The other thing we're going to do the studies in F3, F4 patients, again, the rationale is that, that's where the unmet need is. And also since ultimately, for full approval, you will need some clinical endpoint, we think we can get there much faster maybe with a 96-week study even if we start off with F4 patients. But having all of that said, this all has to be agreed upon by regulatory authorities. We have a date for the FDA, but we have not discussed this with them yet. So stay tuned. Sometime early next year, I think we can update you on the exact plan."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Matthew Harrison of Morgan Stanley.",11,"And our next question comes from Matthew Harrison of Morgan Stanley."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Can I just ask, you made 2 comments related to HCV that I just wanted to get more color on. You talked about you're pleased with the 2017 payer cycle. Can you tell if we should expect any significant changes in pricing or not? And then can you describe wh",83,"Can I just ask, you made 2 comments related to HCV that I just wanted to get more color on. You talked about you're pleased with the 2017 payer cycle. Can you tell if we should expect any significant changes in pricing or not? And then can you describe what you think is the size of the Epclusa warehouse and if you think you've moved through that or you would expect to see some more of that through the end of the year?"
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Matt, it's Kevin Young. I'll take your second part first. Yes, there was a small warehousing effect. We think that this is anecdotal and qualitative. We think that providers probably held people for sort of a quarter or 2- to 3-month period. So this is no",176,"Matt, it's Kevin Young. I'll take your second part first. Yes, there was a small warehousing effect. We think that this is anecdotal and qualitative. We think that providers probably held people for sort of a quarter or 2- to 3-month period. So this is nothing like the warehousing that we saw with Sovaldi or with Harvoni. So we think it's largely a Q3 effect. It might go into the fourth quarter, into the quarter now. But we really think it's mostly a 2016 effect. In terms of our negotiations and contracts, I really can't make any specific comments. Obviously, they're confidential. But we are pleased with the outcome. We feel we're in a strong position for 2017. And most providers will have very, very good access in the private and Medicaid -- Medicare Part D setting to both Harvoni and Epclusa. So we think we're in good shape, and our providers will have the Gilead options to look forward to giving to their patients as we have done in 2016. So feel good about that."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from John Scotti of Evercore ISI.",11,"And our next question comes from John Scotti of Evercore ISI."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I wanted to ask one on capital allocation, if I may. So last quarter, you spoke about potentially having a more complete story of internal and also external progress by year-end. And you've continued to be relatively light on the buyback in 3Q. So a coupl",105,"I wanted to ask one on capital allocation, if I may. So last quarter, you spoke about potentially having a more complete story of internal and also external progress by year-end. And you've continued to be relatively light on the buyback in 3Q. So a couple of things. Can you characterize right now your current appetite for M&A and if that's changed the current thinking more along the lines of larger, transformative deals? Or should we expect the string of in-licensing deals than what [indiscernible] in Nimbus? And how should we think about the sense of urgency here, given your comments and going into year-end?"
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","John, it's John. I think you asked the capital allocation question and switched to strategy. I will try to answer that for you. As we said in our opening comets, we're still there actively evaluating opportunities. We're actively evaluating a series of di",126,"John, it's John. I think you asked the capital allocation question and switched to strategy. I will try to answer that for you. As we said in our opening comets, we're still there actively evaluating opportunities. We're actively evaluating a series of different partnerships. But as I said in my comments, we're going to remain indisciplined, and we're going to keep the bar high. You don't want the sense of urgency to overwhelm your discipline because then you'll do things that don't make long-term sense, and that's in the history of all businesses, and that's one we apply here. So we're currently very, very active. We'll do things when they make sense for us and not before that. That's really as much as I could say."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Geoffrey  Porges of Leerink Partners.",11,"And our next question comes from Geoffrey  Porges of Leerink Partners."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Robin, just a couple for you, if we may. First, operating margin, down by 200 to 300 basis points a quarter. Is that something that we should anticipate going continuing or there's some variables in there? Secondly, just on Epclusa. Was there any channel",99,"Robin, just a couple for you, if we may. First, operating margin, down by 200 to 300 basis points a quarter. Is that something that we should anticipate going continuing or there's some variables in there? Secondly, just on Epclusa. Was there any channel inventory build in the reported number? And then lastly, how are you judging the sort of share buyback? You spent $10 billion, as you pointed out this year, and the average cost is sort of around 90. Compared to other things that you might have invested in, how are you feeling about buyback going forward?"
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Sure, Jeff. I'll start with this quarter and address the buyback first. I mean, we really look at buybacks on a long-term perspective, which is pretty much what I committed or mentioned during the last quarter call. But we're still very comfortable where",314,"Sure, Jeff. I'll start with this quarter and address the buyback first. I mean, we really look at buybacks on a long-term perspective, which is pretty much what I committed or mentioned during the last quarter call. But we're still very comfortable where we are. We did front-load a significant component of our share buybacks. As a matter of fact, I think just in the first quarter, we did more than the entire 3 quarters for 2015. And we messaged [ph] very early on that we see those declines towards the second half of this year, very much aligned with John's comets around here for M&A. It's still fairly part of our capital allocation strategy, along with dividends. But I think balancing that with overall looking for growth is something that we're still focused on doing. And as John mentioned, these things take time to buy themselves out. I'll let Kevin answer the inventory question but I think your question of operating margin. Yes, but quarterization of our margins do get impacted by revenue dynamics as well as expenses. Keep in mind, R&D had a $200 million milestone payment this quarter included in that. But overall, our margins still remain high, high relative to overall industry. And we're comfortable with where we're very prudent with expense management use our SG&A spend is down. I think the other thing your slightly seeing is that mix changes between HCV and HIV. That has a little bit of an impact in our growth margin. But overall, with the continued conversion of TAF, long term, you'll continue to see that go down. But it will be impacted relative to HCV becoming a smaller component of our total revenue. I can't really give guidance on our gross margins, but I think at the Barstow remains high for them and we still remain a very disciplined pending type of organization."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Geoff, just a comment on Epclusa. We launched Epclusa last week and quarter to so that's when our opening inventory went in. Like any green products, major wholesalers take up their inventory basically because they got a stand the calculation for days on",104,"Geoff, just a comment on Epclusa. We launched Epclusa last week and quarter to so that's when our opening inventory went in. Like any green products, major wholesalers take up their inventory basically because they got a stand the calculation for days on hand. So basically that just ticks up as a product grows R&D comes down as a product, comes down as likely Sovaldi because it's now becoming Epclusa well in the future. So there was nothing unnatural about inventory for Epclusa in the third quarter. But as I've said, we did get a very nice bump in usage from small warehousing patients."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Cory Asimov of JPMorgan.",10,"And our next question comes from Cory Asimov of JPMorgan."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","John, I wanted to go back to your comments on the strategic question you just got. When you talk about having a high bar in the M&A front, does that mean you see a lack of interesting opportunities out there than just don't meet that bar? Or is this more",61,"John, I wanted to go back to your comments on the strategic question you just got. When you talk about having a high bar in the M&A front, does that mean you see a lack of interesting opportunities out there than just don't meet that bar? Or is this more of a price disconnect given the continued volatility of the market?"
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Discipline has both components to it. There are a number of things that, I think, are probably too early for us to take part in. There are a number of things that, I think, are just overpriced. And so it's been a combination of those 2 things going forwar",73,"Discipline has both components to it. There are a number of things that, I think, are probably too early for us to take part in. There are a number of things that, I think, are just overpriced. And so it's been a combination of those 2 things going forward looking backwards. Going forward, we'll have to see what makes sense for us and where we're willing to go to bring in new products."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Michael Yee of RBC Capital Markets.",12,"And our next question comes from Michael Yee of RBC Capital Markets."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I want to ask a question on patient volumes in hep C, specifically as it relates to Slide 41, I guess. Previously, I would have thought that changes in payer access would have opened up the availability of these drugs get reimbursed for [indiscernible] F1",134,"I want to ask a question on patient volumes in hep C, specifically as it relates to Slide 41, I guess. Previously, I would have thought that changes in payer access would have opened up the availability of these drugs get reimbursed for [indiscernible] F1s. I guess, with patient volumes flattish, are you seeing these hep C and F1s coming in? Are They getting treated? Or is your bottleneck there that comment and it don't get treated? Just want to understand your dynamic on that and what do you think that's going to for have [indiscernible] volumes. And then in Europe, the same question. Europe declined from 27 down to 21. Just do you think that how do you think that plays out, I guess, going forward? What are the dynamics there for volumes?"
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Michael, 2 great questions. Let would try and deal with those in the order. So first, the U.S. If you look at our slide, actually, the percentage of F0s to F2s has increased over time. It was sort of 50% a little while ago, and now it's up to 60%. So clea",412,"Michael, 2 great questions. Let would try and deal with those in the order. So first, the U.S. If you look at our slide, actually, the percentage of F0s to F2s has increased over time. It was sort of 50% a little while ago, and now it's up to 60%. So clearly, fitter patients there, less sick of being as a result of coverage. But I want to say that the patient journey, I think, is becoming longer in the U.S. now. If you think about it, patients are really starting further back because they are healthier. We are continuing to see approximately 30,000 patients coming into specialty scare, so in other words, 90,000 patients a quarter. 60,000 of those are coming out to the other side and being treated and cured. That's probably not a bad ratio in itself. Not every patient is treated, and not every patient is immediately treated. Now we shouldn't forget that sometimes, patients drift in and out of a specialist's care. Some patients have compounding factors that complicates the start of therapy, most notably, drug use or alcohol use. And the patients who are just less sick have less motivation themselves, and the physician has less motivation to very push those therapy. And lastly, the paperwork and the administrative process for authorization is still there, likely within specialist products. So I think those are mostly the dynamics, and it's mostly around the patients being less time in the physician's practice. They're not patients that have been held for a long time. They are not patients that are failed 1 or 2 prior therapies and great urgency by the physician. In terms of Europe, as I said, we did see a downtick in the patients treated in the Southern European markets, primarily Italy and Spain. And I think that's because they are working through the sicker patients and are becoming more like France and Germany. There still are more patients in the Southern European markets, but I do think they are clearing -- do think they are clearing the most obvious patients to treat and cure. Now I would emphasize that market share is very, very solid in those markets. And whilst it's not an obvious mechanism through advertising, television advertising, in the European markets, we are doing a lot of partnership with KOLs, WITH societies, with patient groups to, again, try to encourage the right screening practices and the right transfer of patients into specialist's care."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Robyn Karnauskas with Citi.",10,"And our next question comes from Robyn Karnauskas with Citi."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","So just to ask the HCV question from a fourth quarter perspective. And last fourth quarter, you started changes in HCV. So given that looks like you also stabilized, are you seeing anything that hints that payers could change how they're viewing early cha",110,"So just to ask the HCV question from a fourth quarter perspective. And last fourth quarter, you started changes in HCV. So given that looks like you also stabilized, are you seeing anything that hints that payers could change how they're viewing early changes in the fourth quarter that you're seeing that can influence 2017? And then given you've been guided, how do you think now about providing what kinds of guidance you might provide in '17 to help investors feel comfortable that you can predict going forward? I know you can't guidance, but you give any hint of how you're thinking about giving us some color on next year."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Robyn, I'll take the first part. I think, again, come back to the quality of the discussions that we had for 2017 contracting, and I think they were very good. Let's not forget the fact that Gilead are in a very strong place by virtue of Harvoni being in",231,"Robyn, I'll take the first part. I think, again, come back to the quality of the discussions that we had for 2017 contracting, and I think they were very good. Let's not forget the fact that Gilead are in a very strong place by virtue of Harvoni being in a good proportion of patients and 8-week therapy. So that's a very big advantage for us, and I think that's really appreciated from a point of view of managing costs from a commercial payer. We didn't see much change in the ratio of the public to private payer in the third quarter. It was still about 45% of patients who were covered as a public patient as opposed to a commercial or Medicare Part D plan. Part of the commercial part of the market is, of course, the VA. The VA was a little bit lower in the third quarter versus the second quarter. They still seem to be very enthusiastic, very engaged in recalling patients. But I think that's, perhaps, one of the variables that will kind of unfold in 2017 is the VA and their continuing ability to recall and treat patients. I think with our efforts around highlighting the CDC, need to treat the baby boomers and the activity of all the companies involved in hepatitis C, I'd like to think that we can continue our progress in 2017."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","So Robyn, it's Robin. I'll take the second part of that question. Yes, I think, as we said, this is a curative market, HCV, and it's difficult to predict. And Kevin just outlined this kind of patient journey taking a longer bit of time and just changing d",132,"So Robyn, it's Robin. I'll take the second part of that question. Yes, I think, as we said, this is a curative market, HCV, and it's difficult to predict. And Kevin just outlined this kind of patient journey taking a longer bit of time and just changing dynamics. And we can spent a lot of time this fall working through the planning cycle figuring out what that means around '17 and beyond. Obviously, I can't give the answer yet, but it's how we guide will again depend on our ability to bracket the risk and opportunities around those dynamics and what those mean. It continues to change and it's something that we monitor very closely. But that patient flow, as Kevin said, is something that's just very difficult for us to control."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. I'd also add, Robyn, if I might, that how solid and good we feel about HIV going into next year with that chronic model and the uptick of our TAF-based regimens.",32,"Yes. I'd also add, Robyn, if I might, that how solid and good we feel about HIV going into next year with that chronic model and the uptick of our TAF-based regimens."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Ying Huang of Bank of America Merrill Lynch.",14,"And our next question comes from Ying Huang of Bank of America Merrill Lynch."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","The first one maybe is for Kevin. Our channel check's indicating that VA is paying about $15,000 to $17,000 per patient. Do you think that's the absolute floor for HCV pricing? And then another question for John and Robin. Sounds like you guys have really",82,"The first one maybe is for Kevin. Our channel check's indicating that VA is paying about $15,000 to $17,000 per patient. Do you think that's the absolute floor for HCV pricing? And then another question for John and Robin. Sounds like you guys have really high acquisitions. If you don't deploy capital in acquisitions, would you consider hiking dividend to a much higher level like 5% to 6% so that's a lot of investors would be willing to take the dividend payment?"
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Ying, it's Kevin. I apologize, but in terms of commenting on net pricing to the various channels to the various constituents, it's not something that we directly comment on. So I couldn't go any further than that at this time.",40,"Ying, it's Kevin. I apologize, but in terms of commenting on net pricing to the various channels to the various constituents, it's not something that we directly comment on. So I couldn't go any further than that at this time."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes, Ying, I'll take the second half. I mean, I think, as we said, the bar is side, but we are very encouraged and remain engaged in M&A. And when we think about our overall capital allocation, we wouldn't want it to do anything that would constrain us wi",98,"Yes, Ying, I'll take the second half. I mean, I think, as we said, the bar is side, but we are very encouraged and remain engaged in M&A. And when we think about our overall capital allocation, we wouldn't want it to do anything that would constrain us with -- an reduce our flexibility to purchase if we found something that we thought could really grow our top line. So we talk with our board all the time about dividends increases and dividends in general as well as share repurchases, and that's something that we'll continue to do."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes Phil Nadeau of Cowen and Company.",11,"And our next question comes Phil Nadeau of Cowen and Company."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Kevin, you mentioned kind of 2 factors that impact the average per patient price that have been changing. One is the public versus private payer mix, which is a change over the last year but maybe stabilized now; and then also the rebates given to private",153,"Kevin, you mentioned kind of 2 factors that impact the average per patient price that have been changing. One is the public versus private payer mix, which is a change over the last year but maybe stabilized now; and then also the rebates given to private payers. You didn't really discuss those too much in this call, but in the past, you predecessors said that you expect the rebates actually increase in the enter the market next year. Some of your comments could suggest the opposite. So I guess, kind of just curious for 2017, how should we think about those 2 factors? Do you think public versus private has plateaued? Is 45% the number we should be thinking about for 2017? And then on the rebates to the private payers, should we continue to expect those to tick up in 2017? Or is your feeling different now that you've through negotiation cycles?"
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Difficult for me to comment in any great detail, fill, on either of those questions. I'll take the commercial first. They have gone well. I think, as I keep emphasizing, the advantage we have, the 8 weeks, we think about it, 45% right now of Harvoni patie",274,"Difficult for me to comment in any great detail, fill, on either of those questions. I'll take the commercial first. They have gone well. I think, as I keep emphasizing, the advantage we have, the 8 weeks, we think about it, 45% right now of Harvoni patients, genotype 1 patients, are receiving 8 weeks. So if you think about 45% of genotype 1 with just 8 weeks, that's a very good economic offering for our payers that they really appreciate. So we've -- I believe we've done very well in our position going into 2017. In terms of the ratio between public and private, again, very difficult for me to make a prediction. VA did come down a little bit, but there was an increase, just a tick-up, to replace that by Medicaid. I made a comment that the Medicaid opening is really slower than we would like, but I think there may be that change in mix going forward. Difficult to predict VA. VA is still a big part of the public, and we'll just have to see. It's very impressive what they've done, and I know they're very committed. And they feel that they haven't done their job yet. We, and that's Gilead, we estimate that between 35% and 40% of the patients in the VA system have been treated to date. So there's still a lot of work to do, and I think they want to do it. So 45 -- 55 seems to have been the level for the last couple of quarters. And not entirely clear that, that's going to be maintained into 2017, but seems reasonable to me."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Olivia Young of Credit Suisse.",11,"And our next question comes from Olivia Young of Credit Suisse."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Just I wanted to talk a little bit about like Genvoya launch and like maybe how it's faster than even Atripla. It was obviously a very good launch. Maybe if you could just frame like what's been kind of how doctors are looking at this are they looking at",81,"Just I wanted to talk a little bit about like Genvoya launch and like maybe how it's faster than even Atripla. It was obviously a very good launch. Maybe if you could just frame like what's been kind of how doctors are looking at this are they looking at it more like just kind of for everyone that needs to come to the doctor, they're just going at this drug. Or just give us some more flavor on the dynamics."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Alethia, thanks for the HIV question. I was at our International Advisory Board a couple of weeks ago, and we had some of the foremost HIV doctors from around the world. And it was absolutely unanimous. The commitment to switching patients, all things bei",244,"Alethia, thanks for the HIV question. I was at our International Advisory Board a couple of weeks ago, and we had some of the foremost HIV doctors from around the world. And it was absolutely unanimous. The commitment to switching patients, all things being equal, particularly in terms of pricing, physicians see the benefit in terms of bone and kidney from the point the view of TAF. So I think there's an awful strong commitment. Let's not forget that in most practices now, half the patients are over the age of 50. And they've been on long-term therapy, and physicians just see a natural and fairly straightforward switch going on. I really didn't think I'd ever see on uptake quicker than Atripla. As you remember, there were the components of Atripla that could just be put together and the patients switched. These are slightly different with Genvoya because it's a switch of regimen. So I'm delighted with the way it's going. 80% of Genvoya comes from switches. And right now, half of those switches are from Stribild, which is the natural TAF to TDF to TAF switch. So my expectation is that we will continue to convert patients and [indiscernible] about it. And once we get more countries online in Europe, I think we can have that same expectation. Germany is going great, Spain is going great, and we're on the threshold of getting the most important market up and running, and that's France."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Terence Flynn of Goldman Sachs.",11,"And our next question comes from Terence Flynn of Goldman Sachs."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Maybe just wondering if you guys can comment around the GSKV doublets for HIV. And maybe just help frame for us how to think about that, if those are successful and either treatment or maintenance setting. Would you look to explore your own doublet regime",57,"Maybe just wondering if you guys can comment around the GSKV doublets for HIV. And maybe just help frame for us how to think about that, if those are successful and either treatment or maintenance setting. Would you look to explore your own doublet regimen? Or do you think you've already set a high enough bar there?"
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Terence, so the debates in our -- with bictegravir is not doublet or triplet. We're developing dolutegravir F/TAF because it has 3 excellent components that have proven safety and enormously high efficacy. If you look at the [indiscernible] compound, of c",137,"Terence, so the debates in our -- with bictegravir is not doublet or triplet. We're developing dolutegravir F/TAF because it has 3 excellent components that have proven safety and enormously high efficacy. If you look at the [indiscernible] compound, of course, that contains bictegravir. So in that scenario, this is an incentive to get rid of the back of their in go to a doublet as you call it but in our case, that's absolutely we have no incentive whatsoever to do that. I would like to point out that it's an interesting strategy. It's a potential competitor. The only thing I would like to point out is safety efficacy has to be still proven in a larger patient population, number one; and number two, and you might ignore diverse patient population, particularly in patients with [indiscernible]."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Anne of from BMO Capital Markets.",12,"And our next question comes from Anne of from BMO Capital Markets."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Just question for you, maybe Robin, on just R&D spending going forward. The filgotinib program 3 Phase III programs may have cost about $1 billion or about embark on a fairly sizable NASH program. Just how should we think about R&D spend going forward? Ar",67,"Just question for you, maybe Robin, on just R&D spending going forward. The filgotinib program 3 Phase III programs may have cost about $1 billion or about embark on a fairly sizable NASH program. Just how should we think about R&D spend going forward? Are there any trials that are completing that might provide an offset? Just if you could just give more color related to that."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","So maybe, Ian, I'll answer the first question, and Robin can join in. So as we indicated before, our hepatitis C research is winding down or the development is winding down. Really, with this SOF/VEL/VOX, this will be our last development candidate. And w",109,"So maybe, Ian, I'll answer the first question, and Robin can join in. So as we indicated before, our hepatitis C research is winding down or the development is winding down. Really, with this SOF/VEL/VOX, this will be our last development candidate. And we have spent over the last 3 years, probably most of our money, on hepatitis C. So that's winding down, and also in HIV are coming down because of dolutegravir F/TAF is going to be our last single-tablet regimen for a broad single population. And that I think the loss of the increased spending in the other areas, as you pointed out, filgotinib and also oncology."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. I think, Norbert, [indiscernible]. I think the rigor remains very high internally within Gilead as well. We're always making the various trade-offs, and we look to do the right thing scientifically. So you can see variability in costs. But overall, t",80,"Yes. I think, Norbert, [indiscernible]. I think the rigor remains very high internally within Gilead as well. We're always making the various trade-offs, and we look to do the right thing scientifically. So you can see variability in costs. But overall, there's a lot high [indiscernible] how we allocate our research spend. But a lot of our projects ongoing, as mentioned, will be paid for with the decline in some of the larger products we have with HIV and HCV."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our final question comes from the line of Jim Brichenough of Wells Fargo.",14,"And our final question comes from the line of Jim Brichenough of Wells Fargo."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","I think that's it, Candace.",6,"I think that's it, Candace."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","There are no further questions of something out of the conference back over to Sony for closing remarks.",18,"There are no further questions of something out of the conference back over to Sony for closing remarks."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Com 25 great thanks Candace. Thanks, everyone for joining us today. We appreciate your continued interest in Gilead and the team here looks forward to providing you with updates in our future progress.",33,"Com 25 great thanks Candace. Thanks, everyone for joining us today. We appreciate your continued interest in Gilead and the team here looks forward to providing you with updates in our future progress."
29002,403467286,1068913,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program and you may all disconnect. Have a great day, everyone.",25,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program and you may all disconnect. Have a great day, everyone."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Third Quarter 2016 Earnings Conference Call. My name is Candace, and I'll be your conference operator today. [Operator Instructions] And as a reminder, this conference cal",63,"Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Third Quarter 2016 Earnings Conference Call. My name is Candace, and I'll be your conference operator today. [Operator Instructions] And as a reminder, this conference call is being recorded. I would now like to turn the call over to Sung Lee, Vice President of Investor Relations. Please go ahead."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Candace, and good afternoon, everyone. Just after market close today, a press release was issued with earnings results for the third quarter of 2016. The press release and detailed slides are available on the Investor Relations section of the G",219,"Thank you, Candace, and good afternoon, everyone. Just after market close today, a press release was issued with earnings results for the third quarter of 2016. The press release and detailed slides are available on the Investor Relations section of the Gilead website.
Joining today's call will be John Milligan, President and Chief Executive Officer; Robin Washington, Executive Vice President and Chief Financial Officer; Kevin Young, Chief Operating Officer; and Norbert Bischofberger, Executive Vice President of Research and Development and Chief Scientific Officer.
Before we begin formal remarks, let me remind you that we will be making forward-looking statements, including plans and expectations with respect to products, product candidates, financial projections and the use of capital, all of which involve certain assumptions, risks and uncertainties that are beyond our control and could cause actual results to differ materially from these statements. A description of these risks can be found in the latest SEC disclosure documents and recent press releases. In addition, Gilead does not undertake any obligation to update any forward-looking statements made during this call.
Non-GAAP financial measures will be used to help you understand the company's underlying business performance. The GAAP to non-GAAP reconciliations are provided in the earnings press release as well as on the Gilead website.
I will now turn the call over to Robin."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, Sung, and good afternoon, everyone. We are pleased to share our results for the third quarter of 2016. I'll first review our financials, and Kevin, Norbert and John will then make a few comments.Total revenues for the third quarter were $7.5 bil",777,"Thanks, Sung, and good afternoon, everyone. We are pleased to share our results for the third quarter of 2016. I'll first review our financials, and Kevin, Norbert and John will then make a few comments.
Total revenues for the third quarter were $7.5 billion with non-GAAP diluted earnings per share of $2.75. This compares to revenues of $8.3 billion and non-GAAP earnings per share of $3.22 for the same period last year.
Product sales for the third quarter were $7.4 billion, down 10% year-over-year and down 3% sequentially. These declines were due to lower HCV sales, partially offset by increased sales in HIV and other therapeutic areas. Sequentially, declines in our HCV sales in the U.S., Japan and Europe were partially offset by increases in U.S. HIV and other product sales.
Turning to the U.S. Product sales for the third quarter were $5.1 billion, down 9% year-over-year. HCV product sales were $2 billion, down 37% year-over-year, driven primarily by lower patient starts for Harvoni and lower revenues per patient, primarily due to a higher percentage of sales to more deeply discounted segments. The decline was partially offset by demand for Epclusa, which was launched at the end of Q2 2016 and generated $593 million in its first full quarter of sales.
Sequentially, our HCV product sales were down 12%. These sales were essentially flat compared to the second quarter, excluding the favorable adjustment to our HCV sales return of $279 million that we made last quarter. HIV and other anti-viral sales increased 32% year-over-year and 19% sequentially. The quarterly revenues of $2.6 billion were positively impacted by strong uptake of our TAF-based regimens and a onetime favorable adjustment of $332 million to our rebate reserves, primarily related to our TDF-based regimens. Without the adjustment, U.S. HIV and other anti-viral sales grew 15% year-over-year and 4% sequentially.
Turning to Europe. Product sales for the third quarter were $1.4 billion, down 16% year-over-year, primarily due to lower HCV patient starts and unfavorable currency movements. Sequentially, sales were down 12%, primarily driven by lower HCV patient starts and summer seasonality, consistent with the usual decreases in demand during the European summer holiday months.
In Japan, product sales for the third quarter were $452 million, flat year-over-year, driven by higher sales of Harvoni, which was launched in September 2015, offset by mandatory price reductions for both Sovaldi and Harvoni, which we discussed during our last call. Sequentially, sales were down 27% as a result of lower Harvoni and Sovaldi patient starts.
Now turning to expenses. Non-GAAP R&D expenses were $981 million for the third quarter, up 38% compared to the same period last year, primarily due to the progression of our clinical studies, which included a $200 million milestone expense associated with our purchase of Nimbus. Non-GAAP SG&A expenses for the third quarter were down 8% compared to the same period last year, primarily due to lower branded prescription drug fee expense.
From a balance sheet perspective, during the third quarter, we generated cash flows from operation of $4.3 billion and ended the quarter with $31.6 billion in cash and investments, which is inclusive of the issuance of $5 billion of senior unsecured notes. We have a healthy balance sheet to invest in our pipeline and external opportunities.  While our cash flows will remain strong, we do anticipate a sequential decrease in Q4 2016 due to required cash payments related to accrued government rebates as well as milestone payments associated with our R&D pipeline.
Shareholder return via dividends and share repurchases year-to-date remains strong. In the third quarter, we repurchased 11.7 million shares for $1 billion under the $12 billion 2016 share repurchase program. For 2016, the total share repurchases through the third quarter were 110 million shares at a cost of $10 billion. Year-over-year, we have seen an 11% decline in our diluted shares, primarily driven by our share repurchases.
Finally, we are reiterating our full year 2016 guidance, which was revised on July 25, 2016, and summarized on Slide 27 in the earnings results presentation available on our corporate website. As a reminder, guidance for product sales is subject to a number of uncertainties, including an uncertain global macroeconomic environment; adoption of additional pricing measurement -- measures to reduce HCV spending; volatility in foreign currency exchange rates; inaccuracy in HCV patient start estimates; additional competitive launches in HCV; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; and a larger-than-anticipated shift in payer mix to more highly discounted payer segments such as PHS, FFS, Medicaid and the VA.
I would like to turn the call over to Kevin now."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Robin, and good afternoon, everyone. I am very pleased to take you through a solid set of operating results for the third quarter.Starting with HIV. Gilead continues to make significant steps in delivering improved single-tablet regimens to p",1391,"Thank you, Robin, and good afternoon, everyone. I am very pleased to take you through a solid set of operating results for the third quarter.
Starting with HIV. Gilead continues to make significant steps in delivering improved single-tablet regimens to patients around the world. We have seen strong adoption of our TAF-based regimens in the U.S. and in the European markets, where we have achieved reimbursement.
In the U.S., of the nearly 840,000 people on anti-retroviral therapy, approximately 80% received a Gilead regimen. Genvoya is now the most prescribed regimen for both treatment-nave and switch patients. This month, we expect cumulative prescriptions of Genvoya to surpass Atripla's prescription at the same point in time post approval. This will make Genvoya the all-time most successful product adoption in its first year in the 30-year history of HIV therapy in this country.
The uptake of Genvoya, Odefsey and Descovy have largely been driven by the switch from Gilead's old STRs due to the improved safety profile of TAF. It is also encouraging to see a notable number of patients from non-Gilead therapies moving to TAF-based regimens. Approximately 10% of Genvoya switches are incremental to the Gilead HIV franchise.
Turning to Europe. Total HIV and other anti-viral revenue was $728 million, up 1% year-over-year and down 4% sequentially. Third quarter European pharmaceutical revenues are typically affected by summer seasonality. In Italy, Spain and Portugal, we saw lower prescribing rates consistent with prior years. Genvoya has been launched in 18 markets in the U.K. -- in the EU, including Spain and Germany, while we have seen rapid uptake similar to the U.S. Descovy has been launched in 9 markets, and Odefsey has been launched in 8 markets, the largest being Germany in both cases. We expect our TAF-based therapies to continue to grow in Europe with Spain still early in its commercial launch of Genvoya.  Pricing and reimbursement discussions are ongoing in France and Italy with the goal of having these complete by year-end.
Guidelines historically have had a significant impact on prescribing patterns. Genvoya is already listed as a preferred regimen in several HIV treatment guidelines, including the European AIDS Clinical Society as well as country guidelines in Germany, the U.K., Spain and Italy.
I would like to make a few comments about HIV prevention and the use of Truvada for PrEP. The growth in people starting Truvada points to the valuable role that therapy can play when used as part of a comprehensive strategy to prevent transmission. We estimate that in the U.S., approximately 80,000 to 90,000 people were using Truvada for this indication in the third quarter.  We are also starting to see usage of PrEP in France, where approximately 2,000 people have begun -- have been prescribed Truvada since it received reimbursement in January this year. We expect PrEP to continue to be a significant part of Gilead's growth in HIV going forward, particularly in the U.S.
With the rapid adoption of TAF-based regimens, the potential of PrEP and our exciting pipeline programs, especially bictegravir, I'm very positive about the long-term life cycle potential we have in HIV.
Turning to HCV. Approximately 61,000 people in total began HCV therapy in the U.S. in the third quarter 2016. This represents the fourth consecutive 3-month period where patient starts have been in the 50,000 to 60,000 range. We estimate that more than 85% of treated patients in the most recent quarter received a sofosbuvir-based regimen.
The uptake of Epclusa has been most encouraging in its first full quarter post launch, although it is important to point out that we have observed a small yet noticeable warehousing effect. As expected, the vast majority of Epclusa is being used in genotype 2 and 3 patients according to our 12-week label. In terms of payer coverage, formulary reviews for Epclusa are on track. 11-state Medicaid programs have already added Epclusa to genotype -- for genotype 2 and 3 patients, and most commercial and Medicare Part D plans are providing interim coverage for Epclusa based on medical need. Finally, the VA has added Epclusa to their national formulary and have begun ordering.
The 2017 commercial and Medicare Part D contracting cycle is now essentially complete. And whilst I cannot share with you plan-by-plan details, suffice to say that we are pleased with the picture for the coming year. Discussions with all major PBMs and MCOs prove to be productive and recognize the clinical leadership of Gilead's HCV options, especially as demonstrated in real-life settings.  But barriers to access still remain as Medicaid continues to be the outlier in terms of access, restricting coverage to only the more advanced patients.
Turning to Europe. Total HCV revenue in the third quarter was $604 million, down 30% year-over-year and down 22% sequentially. This was driven by lower HCV patient starts. While overall patient starts declined, our market share remained largely unchanged across the major markets with the exception of the U.K., which was slightly down for the quarter.
We estimate that 21,000 patients started on a sofosbuvir-based regimen in the third quarter compared to 27,000 in the second quarter. At our last earnings, I described how we were observing lower patient starts in the early EU launch markets of Germany and France. Took simply, many of the high-need patients have been treated and cured. We are now starting to see this trend unfold in southern European countries, particularly in Italy and in Spain. Performance in the region is also likely somewhat affected by summer seasonality similar to the dynamics we observed in HIV.
Epclusa has now been launched in Germany, Sweden, Norway, Finland and Denmark. I'm pleased to say that there have been the same positive reception as in the U.S. We expect to launch in the other large EU markets once pricing and reimbursement is in place by the second half of 2017.
Not only does 12 weeks of Epclusa deliver incredibly high cure rates, but as a new standard of care, it is considerably cheaper than previously used interferon-free regimens, especially treating genotype 3.
As I conclude my remarks on hepatitis C, it is very important to reiterate that more work needs to be done to identify and cure HCV-infected people around the globe. A key objective for Gilead is to appropriately raise disease awareness, highlight the importance of age-related testing and encourage linkage to specialty care. To help with this effort, we recently launched new educational campaigns in the U.S. and Japan to urge all individuals at risk for or living with HCV to talk to their health care provider.
You may have seen our new advertisement on television here in the U.S. It debuted last week, and I am very pleased with the positive and responsible tone it takes to emphasize to people the need to be screened for a disease that can now be cured in as little as 8 weeks. We have received numerous positive comments from advocacy groups, providers and not least, the many people already cured of hepatitis C who want others like them to benefit.
Moving on. One of the liver disease that warrants a mention today is hepatitis B, for which we are well prepared for the launch of TAF. With our PDUFA date coming, we are hopeful that we will have the opportunity to speak to physicians at the AASLD meeting and in the field about the strong data for this product as soon as next week.
Finally, as I highlighted last quarter, we have a very strong U.S. cardiovascular team that continues to deliver impressive results. Letairis and Ranexa revenues totaled $385 million for the quarter and surpassed $1 billion in the year-to-date.
In closing, I'd like to reiterate the positive progress Gilead is making in addressing viral diseases. We will soon have treated 1.2 million HCV-infected individuals around the world, most of whom are now cured. By any measure, this is a profound contribution to global health care delivery.
And in the field of HIV, not only are we effectively managing the disease with our new TAF-based regimens, but Truvada is helping more and more people avoid infection. I am confident that we will close out the year with continued strong financial performance underpinned by a passion for operational excellence and our focus on putting the patient first.
I will now hand the call over to Norbert."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Kevin. During the third quarter, a number of Phase II and Phase III studies concluded, providing insights into efficacy and safety of both approved and experimental Gilead agents in the areas of HIV, liver disease, inflammation, oncology and ca",1377,"Thank you, Kevin. During the third quarter, a number of Phase II and Phase III studies concluded, providing insights into efficacy and safety of both approved and experimental Gilead agents in the areas of HIV, liver disease, inflammation, oncology and cardiovascular disease. Some of these results were disappointments. Some were exciting successes.
To start off with the disappointments. We now have the final analyses from 3 96-week studies of the anti-LOXL2 monoclonal antibody, simtuzumab. The data indicate that while safe and well tolerated, there is no evidence of efficacy in 1 study in primary sclerosing cholangitis and in 2 studies in NASH. One NASH study was in patients with cirrhosis, and one was in patients with bridging fibrosis. Consequently, we will not develop simtuzumab any further in these or any other indications. We will present this data at future conferences.
As for GS-5745, an anti-MMP9 antibody, we stopped a Phase II/III study in patients with ulcerative colitis because of a lack of efficacy. This decision followed a planned interim DSMB analysis after the first 150 patients had been enrolled and the study met predefined futility criteria. Also, and not unexpectedly, there was no evidence of benefit of GS-5745 in a Phase II study in patients with Crohn's disease. Consequently, we will not further pursue GS-5745 for ulcerative colitis or Crohn's. In these studies, GS-5745 were safe and well tolerated, and we're continuing to evaluate GS-5745 in rheumatoid arthritis as an add on to anti-TNFs or other therapies.
Eleclazine or GS-6615 failed to meet its primary endpoint in a study of patients with ventricular tachycardia/ventricular fibrillation or VTVF and implanted cardioverter defibrillators. Patients were randomized to 2 doses of eleclazine or placebo. The primary endpoint was the number of electrical interventions, including shocks and pacing by the implanted device, and there was no evidence of efficacy of eleclazine compared to placebo. Consequently, we will not develop eleclazine any further for VTVF evaluation in long QT-3 syndrome and that hypertrophic cardiomyopathy is continuing. 
But now to the excitement. Starting with HCV. The pan-genotypic single-pill, triple-combination regimen of sofosbuvir, velpatasvir, voxilaprevir or, I'll call it, SOF/VEL/VOX has been studied in 4 Phase III studies called POLARIS-1, -2, -3 and -4. POLARIS-1 and -4 evaluated the regimen in patients who have previously failed a direct acting antiviral and included patients with cirrhosis. Treatment of these salvage patients with SOF/VEL/VOX resulted in SVR rates of 96% and 97%.
The 2 other studies, POLARIS-2 and -3, compared the triple-combination regimen in treatment-naive patients given for 8 weeks to Epclusa given for 12 weeks. POLARIS-2 was open to all genotypes, whereas POLARIS-3 enrolled only genotype-3-infected individuals with compensated cirrhosis, where the unmet need is the greatest. In POLARIS-2, the SVR rates obtained with 10 to 12 weeks of Epclusa were numerically higher than those obtained with 8 weeks of the triple combination, whereas in POLARIS-3, the SVR rates were comparable.
Particularly in POLARIS-3, which involved the most difficult-to-treat genotype-3-infected cirrhotic patients, Epclusa for 12 weeks resulted in 96% SVR rate. These results underscore the value of Epclusa as an excellent treatment option for patients across all genotypes, and they also suggest that the future role of SOF/VEL/VOX will be for patients who previously failed an anti-viral regimen. The full data from these studies will be presented at AASLD in a few weeks, and we will submit Marketing Authorization Applications to regulatory authorities imminently.
Another exciting result was the anti-fibrotic effect observed with GS-4997, an investigational small molecule inhibitor of apoptosis signal-regulating kinase 1 or ASK1. GS-4997 was a shown to inhibit inflammation apoptosis and fibrosis in settings of increased oxidative stress associated with NASH in preclinical models. This Phase II clinical study involved 72 patients. 2/3 had F3-stage fibrosis, and 1/3 had F2-stage fibrosis. There was evidence that treatment with GS-4997 for only 24 weeks resulted in fibrosis reversal and decreased fibrosis progression in a dose-dependent manner. At the highest dose tested, which was 18 milligrams, 43% of patients showed at least a 1 point decrease in their fibrosis score compared to only 20% in the simtuzumab control arm. At the same time, 20% of the simtuzumab-treated patients progressed to cirrhosis compared to only 3% or 1 out of 30 at the 18-milligram dose. The full data from these studies will be presented at AASLD in a few weeks.
Based on these exciting data, we will initiate discussions with regulatory authorities and plan to move GS-4997 into Phase III clinical development in patients with NASH. Based on the Phase II results, we intend to evaluate GS-4997 in patients with the highest unmet need. That means those with F3 and F4 stages of fibrosis.
At the same time, we have 2 other compounds with different mechanisms currently in 2 Phase II studies in patients with NASH and fibrosis, and that is GS-9674, an FXR agonist; and GS-0976, an ACC inhibitor. And the studies are of 24- and 12-week duration, respectively. Pending demonstration of single-agent efficacy and safety in these 2 Phase II studies, we plan to initiate combination studies with the 3 agents towards the middle of next year.
In HIV, we're continuing to explore the utility of TAF-containing regimens in various uses in different populations. Last week, data from 3 Phase III studies were presented at the HIV Conference in Glasgow. 96-week data were disclosed from 1 study where 663 biologically suppressed patients were randomized to either continue on their Truvada-based regimen or to switch to a Descovy-based regimen. In 2 other studies, 630 and 875 of largely suppressed patients on Complera and Atripla, respectively, were randomized to switch to Odefsey or stay on their current regimen. In all studies, switching to a TAF-based regimen was noninferior with regards to efficacy but were superior with regards to renal and bone laboratory safety parameters.
The Phase III development of the single-tablet regimen of bictegravir F/TAF is continuing. Four Phase III studies are now fully enrolled, and we anticipate unblinding these studies towards the middle of next year with regulatory submissions planned for the third quarter of 2017. We also plan to present 48-week Phase II data on bictegravir F/TAF at the Scientific Meeting in the first quarter of 2017.
In oncology, a Phase III study of GS-5745 in patients with gastric cancer is ongoing as well as a Phase II study in patients with gastric cancer in combination with nivolumab. We're also evaluating GS-5745 in other solid tumors.
In addition, we have now completed 2 Phase I safety studies of our combination kinase inhibitors. We were able to establish safe doses of our PI3K inhibitor, idelalisib, in combination with our BTK inhibitor, GS-4059, and our Syk inhibitor, entospletinib, in combination with the BTK inhibitor, GS-4059. Consequently, we will now first evaluate the PI3K/BTK combination with and without anti-CD20 therapy in relapsed/refractory CLL patients in collaboration with the German CLL study group.
We will also be announcing initial Phase Ib/II data on our Syk inhibitor, entospletinib, in acute myeloid leukemia at the upcoming ASH Conference in San Diego. We've entered into a collaboration with the Leukemia & Lymphoma Society to provide entospletinib for their Beat AML Master Trial. This trial will employ the latest genomic technology to match specific AML mutations in newly diagnosed patients over age of 60 with an appropriate investigational drug or drug combination.
In summary, great progress has been made with some of our programs. The very nature of R&D is that you often face both closures and progress. Going forward, I'm pleased we now have the ability to focus our attention on development programs in NASH, inflammation oncology and HIV. We now have 7 new molecules in advanced clinical development. The PDUFA date for TAF for HBV is coming up in a few weeks, and we plan to file an NDA before the end of the year on SOF/VEL/VOX for use as salvage therapy for patients who have failed a previous direct acting antiviral. 
Four molecules are continuing in Phase III. That is momelotinib for myelofibrosis; bictegravir/F/TAF, the single-tablet regimen for HIV infection; filgotinib for 3 separate indication, rheumatoid arthritis, ulcerative colitis and Crohn's; and GS-5745 in gastric cancer. Finally, we plan to advance GS-4997 for NASH to Phase III.
I would now like to turn the call over to John."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, Norbert. I want to make a few closing remarks before we get to your question.We continue to have success with the important work we do in HIV and viral hepatitis. There's still a great need for innovation in these deals. Both diseases include pa",868,"Thanks, Norbert. I want to make a few closing remarks before we get to your question.
We continue to have success with the important work we do in HIV and viral hepatitis. There's still a great need for innovation in these deals. Both diseases include patients whose needs remain unaddressed, and both represent global epidemics.
Our researchers are working to bring new options to a wider range of patients than ever before. This includes people with HIV who've been on therapy for decades and may need to change their medication due to side effects or patients who may be failing to fully suppress their virus due to the presence of resistance.  Approaches our research teams are pursuing include new molecules for treating resistant virus now in formulations and combinations that may be dosed infrequently and opportunities to cure HIV patients by clearing out viral reservoir from their bodies.
Our innovative work, in conjunction with our many partners, has already allowed our HIV medicines to reach millions of patients worldwide. We're particularly excited about the role that TAF will play. With a small daily dose and improved side effect profile, it is ideal for resource-constrained areas of the world and requires only 1/10 of the manufacturing capacity to supply the same number of patients.
In the area of viral hepatitis, the data now obtained with Epclusa suggest that we have an excellent option for the many parts of the developing world for genotyping HCV in determining the stage of disease can be difficult, if not, impossible. With Epclusa, there's no difference in dosing for the different genotypes or stages of liver disease, and so there's no need for these diagnostic procedures. We're working around the globe to rapidly introduce Epclusa as well as Sovaldi and Harvoni.
Finally, in hepatitis B, as Kevin and Norbert mentioned, we are approaching the launch of TAF. HBV continues to be an under-treated disease despite the long-term data showing improvement of liver for people who remain on effective therapy. TAF provides an important new option for patients with chronic HBV, and we'll have the opportunity to introduce the product at the liver meeting in the next -- coming weeks at Boston.
We also recognize that treating such a prevalent disease chronically is a major global challenge, and we continue to seek ways to provide finite duration of treatment that the patients can control or eliminate the virus without having to endure a lifetime of treatment. Gilead's largest research effort is in the area of HBV care.
Beyond our work in antivirals, we are making great progress in new disease areas for Gilead. We are pleased to be able to share with you today our top line data for GS-4997 in NASH. GS-4997 targets ASK1, a previously unexplored target for NASH. The data are suggestive of a strong anti-fibrotic -- of strong anti-fibrotic activity after only a 24-week period of treatment, and we look forward to future in-depth discussions once the data are presented at AASLD.
We think about GS-4997 as a potential backbone molecule, one that can be used alone or in combination. NASH is an understudied but increasingly prevalent disease, and Gilead's liver disease team now has 3 exciting molecule to move forward in the clinical studies. We understand that there's a lot of work to do in providing both the rationale for the patient and to the payer as to the benefits of treating NASH. An active compound such as GS-4997 could really move the field forward, and we are in the process of designing comprehensive studies to demonstrate that health system benefits of treating such a prevalent and growing disease.
In the area of inflammation, we're executing nicely on our development plan. Phase III studies of filgotinib in RA are up and running, and studies in Crohn's and ulcerative colitis have just begun screening patients in the first of these studies. I'm pleased with the progress we are making, and the work of our teams and collaborators get these trials up and running as quickly as possible. We're also looking forward to exploratory studies of filgotinib in a wider variety of inflammatory diseases so that we can fully understand the potential of this specific JAK1 inhibitor.
As you know, we are also focused on our -- augmenting our portfolio with external opportunities, particularly in the field of oncology. However, our interest in partnerships or potential acquisitions is not limited to oncology, and we are considering opportunities for strong science and where we see the possibility of developing a truly differentiated product.
We have been going through an extensive internal review of programs and opportunities, and an important aspect of our approach is that we remain open minded but disciplined. So while we have the balance sheet to execute on multiple opportunities, we will keep the bar high.
With 2 months of the year remaining, I want to take the opportunity to thank the 9,000 employees of Gilead for their hard work and dedication. Everyday, more than 10 million individuals around the world take a Gilead medication, and everyday, our teams come to work to improve upon that number.
Thank you for your time. Let's now open the call to questions. Operator?"
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Geoff Meacham of Barclays.",15,"[Operator Instructions] And our first question comes from the line of Geoff Meacham of Barclays."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","John or Kevin, I got one for you. Just wanted to ask about hep C but in a broader context. So you guys have had flat patient numbers despite better access in the U.S., and revenue's down sequentially but on payer mix. So the question is how do you think a",78,"John or Kevin, I got one for you. Just wanted to ask about hep C but in a broader context. So you guys have had flat patient numbers despite better access in the U.S., and revenue's down sequentially but on payer mix. So the question is how do you think about the return on investing continually in hep C either commercially or in new products versus, say, looking outwards and being more aggressive in a new therapeutic category."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Jeff, it's Kevin. Let me just take maybe half a step back from your question, just a few more observations. I've got to tell you that I think we're really executing well in the area of hepatitis C. I've spent a lot of time this quarter with many Gileads a",423,"Jeff, it's Kevin. Let me just take maybe half a step back from your question, just a few more observations. I've got to tell you that I think we're really executing well in the area of hepatitis C. I've spent a lot of time this quarter with many Gileads and with several providers, and I think the variables that we can directly influence, we're really doing a good job on. Our market share is staying incredibly strong. We're ensuring access whilst preserving the value of our hepatitis C drugs. And we're executing on new versions coming to the market. I think you've seen that with Epclusa. And the area that we can less control but we can influence, you're now seeing some new activities from us in terms of unbranded awareness campaigns, and you may have seen our advertisement that came on the television just over a week ago. So I think, from my point of view, in terms of operational excellence, we're doing a very nice job. It is true that the treatments are staying about the same. Actually, I've considered that very positive. Let's not forget that we're at treatment levels that are 2.5x the treatment levels that were there before the Gilead regimens came to the market. So I take at the level of 50,000 to 60,000 patients as very good. The vast proportion of those are Gilead patients. Epclusa had a very big effect in this quarter, so it goes to show that there's still room for new patients, albeit that we're entering a high level of satisfaction. But with Harvoni for genotype 1, both 12 weeks and now a high proportion of 8 weeks and now Epclusa for the 2 and 3 patients, yes, we have got patients being cured at very high levels. In terms of our triple, I do agree that will be a relatively small proportion of patients, but it's the right thing to do. And it completes our whole picture for hepatitis C. So I think to have the range of products that we have, to have the efficacy that we have is the right offering for health care. So we continue to move forward, and I think we have a healthy franchise. And we are getting better access from particularly the commercial payers, although, as I pointed out and I often discuss with the team here, the Medicaid is still a little bit on the slow side in terms of access. But great progress as far as I'm concerned in the third quarter."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","And Jeff, it's John. The second part of your question is -- was something about investing in this area versus other areas. So I would say, from a pipeline perspective, with SOF/VEL/VOX being our fourth generation of HCV products now being approved, there",113,"And Jeff, it's John. The second part of your question is -- was something about investing in this area versus other areas. So I would say, from a pipeline perspective, with SOF/VEL/VOX being our fourth generation of HCV products now being approved, there really isn't much less in terms of unmatched medical need. And so from a pipeline perspective, this is really the end of what we will be developing in terms of HCV molecules, and that will allow us then to turn our attention to the important aspects in our fibrosis and NASH franchises and our oncology franchises. So we've really largely turned our attention away from HCV to those areas already."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Brian Abrahams of Jefferies.",10,"And our next question comes from Brian Abrahams of Jefferies."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Norbert, a question on 4997. Wondering if you could talk a little bit more about the go-forward plan there, particularly with respect to potential Phase III trial duration and whether or not a fibrosis endpoint might be acceptable just given the effects t",90,"Norbert, a question on 4997. Wondering if you could talk a little bit more about the go-forward plan there, particularly with respect to potential Phase III trial duration and whether or not a fibrosis endpoint might be acceptable just given the effects that you saw in such a short time period in Phase II and the plan to target more severe progressive patients. And then can you confirm that there were no baseline imbalances in the Phase II that might have influenced the fibrosis data or progression to cirrhosis data?"
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","So the second question, yes, I can confirm that there were no baseline imbalances. And regarding the Phase III study, no, we are going to make the proposal to regulatory authorities to use just fibrosis as the endpoint. We feel very convinced that, that's",230,"So the second question, yes, I can confirm that there were no baseline imbalances. And regarding the Phase III study, no, we are going to make the proposal to regulatory authorities to use just fibrosis as the endpoint. We feel very convinced that, that's the right thing to do because, as you may know, fibrosis is the only histological correlate to clinical outcomes. There was a large study published a few years ago where they looked at baseline histology and they correlated histological variables with clinical outcomes. And steatosis didn't correlate. Inflammation didn't correlate. Ballooning didn't correlate. The only thing that correlated was fibrosis. So we are going to propose 2 Phase III studies, both looking at fibrosis 48 week as the endpoint. The other thing, we're going to do the studies in F3, F4 patients. Again, the rationale is that, that's where the unmet need is. And also since ultimately for full approval you will need some clinical endpoint, we think we can get there much faster maybe with a 96-week study even if we start off with F4 patients. But having all of that said, this all has to be agreed upon by regulatory authorities. We have a date with the FDA, but we have not discussed this with them yet. So stay tuned. Sometime early next year, I think we can update you on the exact plan."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Matthew Harrison of Morgan Stanley.",11,"And our next question comes from Matthew Harrison of Morgan Stanley."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Can I just ask, you made 2 comments related to HCV that I just want to get some more color on. You talked about you're pleased with the 2017 payer cycle. Can you just tell us if we should expect any significant changes in pricing or not? And then can you",86,"Can I just ask, you made 2 comments related to HCV that I just want to get some more color on. You talked about you're pleased with the 2017 payer cycle. Can you just tell us if we should expect any significant changes in pricing or not? And then can you describe what you think is the size of the Epclusa warehouse and if you think you've moved through that or you would expect to see some more of that through the end of the year?"
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Matt, it's Kevin Young. I'll take your second part first. Yes, there was a small warehousing effect. We think that this is anecdotal and qualitative. We think that providers probably held people for sort of a quarter, 2- to 3-month period. So this is noth",177,"Matt, it's Kevin Young. I'll take your second part first. Yes, there was a small warehousing effect. We think that this is anecdotal and qualitative. We think that providers probably held people for sort of a quarter, 2- to 3-month period. So this is nothing like the warehousing that we saw with Sovaldi or with Harvoni. So I -- we think it's largely a Q3 effect. It might going to the fourth quarter, into the quarter now. But we really think it's mostly a 2016 effect. In terms of our negotiations and contracts, I really can't make any specific comments. Obviously, they're confidential. But we are pleased with the outcome. We feel we're in a strong position for 2017, and most providers will have very, very good access in the private and Medicaid -- Medicare Part D setting to both Harvoni and Epclusa. So we think we're in good shape, and our providers will have the Gilead options to look forward to giving to their patients as we have done in 2016. So feel good about that."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from John Scotti of Evercore ISI.",11,"And our next question comes from John Scotti of Evercore ISI."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I wanted to ask one on capital allocation if I may. So last quarter, you spoke about potentially having a more complete story of internal and also external progress by year-end, and you've continued to be relatively light on the buyback in 3Q. So couple t",107,"I wanted to ask one on capital allocation if I may. So last quarter, you spoke about potentially having a more complete story of internal and also external progress by year-end, and you've continued to be relatively light on the buyback in 3Q. So couple things. Can you characterize right now your current appetite for M&A and if that's changed the current thinking more along the lines of larger, transformative deals? Or should we expect a string of in-licensing deals similar to what we saw with filgotinib and Nimbus? And how should we think about the sense of urgency here given your comments and going into year-end?"
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","John, it's John. I think you asked the capital allocation question and switched to strategy. I will try to answer that for you. We -- so as we said in our opening comments, we're still very actively evaluating opportunities. We're actively evaluating a se",129,"John, it's John. I think you asked the capital allocation question and switched to strategy. I will try to answer that for you. We -- so as we said in our opening comments, we're still very actively evaluating opportunities. We're actively evaluating a series of different partnerships. But as I said in my comments, we're going to remain disciplined. We're going to keep the bar high. You don't want the sense of urgency to overwhelm your discipline because then you'll do things that don't make long-term sense. And that's in the history in all businesses, and that's one we apply here. So we're currently very, very active. We'll do things when they make sense for us and not before that. And that's really as much as I can say."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Geoffrey Porges of Leerink Partners.",11,"And our next question comes from Geoffrey Porges of Leerink Partners."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Appreciate the question. Robin, just a couple for you if we may. First, operating margin, trending down by 200 to 300 basis points a quarter. Is that something that we should anticipate continuing or there are some variables in there? Secondly, just on Ep",104,"Appreciate the question. Robin, just a couple for you if we may. First, operating margin, trending down by 200 to 300 basis points a quarter. Is that something that we should anticipate continuing or there are some variables in there? Secondly, just on Epclusa. Was there any channel inventory build in the reported number? And then lastly, how are you judging the sort of share buyback? You spent $10 billion, as you pointed out, this year, and the average cost is sort of around $90. Compared to other things that you might have invested in, how are you feeling about that buyback going forward?"
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Sure, Geoff. I'll start on the reverse quarter and address the buyback first. I mean, we really look at buybacks on a long-term perspective, which is pretty much what I committed or mentioned during the last quarter call. So we're still very comfortable w",327,"Sure, Geoff. I'll start on the reverse quarter and address the buyback first. I mean, we really look at buybacks on a long-term perspective, which is pretty much what I committed or mentioned during the last quarter call. So we're still very comfortable where we are. We did front load a significant component of our share buybacks. As a matter of fact, I think, just in the first quarter, we did more than the entire 3 quarters of 2015. And we messaged very early on that we would see those declines towards the second half of this year, very much in alignment with John's comments around being prepared for M&A. It's still fairly a part of our capital allocation strategy along with dividends. But I think balancing that with overall, looking for growth is something that we're still focused on doing. And as John mentioned, these things take time to play their selves out. I'll let Kevin answer the inventory question, but I think to your question of operating margins, yes, but quarterization of our margins do get impacted by revenue dynamics as well as expenses. Keep in mind, R&D had a $200 million milestone payment this quarter included in that. But overall, I think our margins still remain high, high relative to overall industry, much better and we're comfortable with them. We're very prudent with expense management. You saw SG&A expense is down. I think the other thing you're slightly seeing is as the that mix changes between HCV and HIV, that has a little bit of an impact on our growth margin. But overall, with the continued conversion of TAF, long term, you'll continue to see that go down. But it will be impacted relative to HCV becoming a smaller component of our total revenue. I can't really give guidance on our gross margins, but I think the bar still remains high for them, and we still remain a very disciplined spending type of organization."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. And Geoff, just to comment on Epclusa. If you recall, we launched Epclusa in the last week in quarter 2, so that's when our opening inventory went in. Like any growing products, major wholesalers tick up their inventory basically because they got a s",112,"Yes. And Geoff, just to comment on Epclusa. If you recall, we launched Epclusa in the last week in quarter 2, so that's when our opening inventory went in. Like any growing products, major wholesalers tick up their inventory basically because they got a standard calculation for days on hand. So basically, that just ticks up as a product grows or indeed comes down, as a product comes down as likely Sovaldi because it's now becoming Epclusa well in the future. So there was nothing unnatural about inventory for Epclusa in the third quarter, but as I've said, we did get a very nice bump in usage from small warehousing of patients."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Cory Kasimov of JPMorgan.",10,"And our next question comes from Cory Kasimov of JPMorgan."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","John, I wanted to go back to your comments on the strategic question you just got. When you talk about having a high bar in the M&A front, does that mean you see a lack of interesting opportunities out there that just don't meet that bar? Is this more of",60,"John, I wanted to go back to your comments on the strategic question you just got. When you talk about having a high bar in the M&A front, does that mean you see a lack of interesting opportunities out there that just don't meet that bar? Is this more of a price disconnect given the continued volatility in the market?"
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Discipline has both components to it. There are a number of things that, I think, are probably too early for us to take part in. There are a number of things that, I think, are just overpriced. And so it's been a combination of those 2 things going forwar",75,"Discipline has both components to it. There are a number of things that, I think, are probably too early for us to take part in. There are a number of things that, I think, are just overpriced. And so it's been a combination of those 2 things going forward -- or looking backwards. Going forward, we'll have to see what makes sense for us and where we're willing to go to bring in new products."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Michael Yee of RBC Capital Markets.",12,"And our next question comes from Michael Yee of RBC Capital Markets."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I want to ask a question on patient volumes in hep C, specifically as it relates to Slide 41, I guess. Previously, I would have thought that changes in payer access would have opened up the availability of these drugs to get reimbursed for the health care",144,"I want to ask a question on patient volumes in hep C, specifically as it relates to Slide 41, I guess. Previously, I would have thought that changes in payer access would have opened up the availability of these drugs to get reimbursed for the health care [ph] your F0s and F1s. I guess, with patient volumes flattish, are you seeing these F0s and F1s coming in? Are They getting treated? Or is your bottleneck there? They come in, and they don't get treated. Just wanted to understand your dynamic on that and whether you think that, that's going to drive some positive development of volumes. And then in Europe, the same question. Europe declined from 27,000 down to 21,000. Just do you think that -- how do you think that plays out, I guess, going forward? What are the dynamics there for volumes?"
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Two great questions. Let me try and deal with those in the order. So first, the U.S. If you look at our slide, actually, the percentage of F0s to F2s has increased over time. It was sort of 50% a little while ago. Now it's up to 60%. So clearly, fitter pa",418,"Two great questions. Let me try and deal with those in the order. So first, the U.S. If you look at our slide, actually, the percentage of F0s to F2s has increased over time. It was sort of 50% a little while ago. Now it's up to 60%. So clearly, fitter patients there, the less sick are being treated, and of course, that's as result of coverage. But I want to say that the patient journey, I think, is becoming longer in the U.S. now. If you think about it, patients are really starting further back because they are healthier. We are continuing to see approximately 30,000 patients coming into specialist care so in other words, 90,000 patients a quarter. 60,000 of those are coming out of the other side and are being treated and cured. That's probably not a bad ratio in itself. Not every patient is treated, and not every patient is immediately treated. Now we shouldn't forget that, sometimes, patients drift in and out of a specialist's care. Some patients have compounding factors that complicates the start of therapy, most notably, drug use or alcohol use. And the patients who are just less sick have less motivation themselves, and the physician has less motivation to really push those sort of therapy. And lastly, the paperwork and the administrative process for authorization is still there with -- likely there as with any specialist product. So I think those are mostly the dynamics, and it's mostly around the patients being less time in the physician's practice. They're not patients that have been held for a long time. They're not patients that failed 1 or 2 prior therapies and a great urgency by the physician. In terms of Europe, as I said, we did see a downtick in the patients treated in the southern European markets, primarily Italy and Spain, and I think that's because they are working through the sicker patients and are becoming more like France and Germany. There still are more patients in the southern European markets, but I do think they are clearing the most obvious patients to treat and cure. Now I want to emphasize that market share has stayed very, very solid in those markets. And whilst it's not an obvious mechanism through advertising, television advertising in the European markets, we are doing a lot of partnership with KOLs, with societies, with patient groups to, again, try to encourage the right screening practices and the right transfer of patients into specialist care."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Robyn Karnauskas of Citi.",10,"And our next question comes from Robyn Karnauskas of Citi."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","So just to ask the HCV question from a fourth quarter impair perspective. Remember, last fourth quarter, you started to see tens of [ph] changes in HCV. So given that looks like you have stabilized, are you seeing anything that hints that payers could cha",123,"So just to ask the HCV question from a fourth quarter impair perspective. Remember, last fourth quarter, you started to see tens of [ph] changes in HCV. So given that looks like you have stabilized, are you seeing anything that hints that payers could change how they're viewing the -- or any changes in fourth quarter that you're seeing that can influence 2017? And then given you've maintained guidance, how are you thinking now about providing what kinds of guidance you might provide in '17 to help investors feel comfortable that you can predict going forward? If any -- I know you can't give guidance but if you can give any hints on how you're thinking about giving us some color next year."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","I'll take the first part. I think, again, come back to the quality of the discussions that we had for 2017 contracting, and I think they were very good. Let's not forget the fact that Gilead are in a very strong place by virtue of Harvoni being in a good",233,"I'll take the first part. I think, again, come back to the quality of the discussions that we had for 2017 contracting, and I think they were very good. Let's not forget the fact that Gilead are in a very strong place by virtue of Harvoni being in a good proportion of patients in an 8-week therapy. So that's a very big advantage for us, and I think that's really appreciated from a point of view of managing costs from a commercial payer. We didn't see much change in the ratio of the public to private payer in the third quarter. It was still about 45% of patients who were covered as a public patient as opposed to a commercial or Medicare Part D plan. Part of the commercial part of the market is, of course, the VA. The VA was a little bit lower in the third quarter versus the second quarter. They still seem to be very enthusiastic, very engaged in recalling patients. But I think that's, perhaps, one of the variables that will kind of unfold in 2017, is the VA and their continuing ability to recall and treat patients. But I think with our efforts around highlighting the CDC, need to treat the baby boomers and the activity of all the companies involved in hepatitis C, I'd like to think that we can continue our progress in 2017."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","So Robyn, it's Robin. I'll take the second part of that question. Yes, I think, as we said, this is a curative market, HCV, and it's difficult to predict. And Kevin just outlined this kind of patient journey taking a longer bit of time and just changing d",132,"So Robyn, it's Robin. I'll take the second part of that question. Yes, I think, as we said, this is a curative market, HCV, and it's difficult to predict. And Kevin just outlined this kind of patient journey taking a longer bit of time and just changing dynamics. And we spent a lot of time this fall working through the planning cycle, figuring out what that means around '17 and beyond. Obviously, I can't give the answer yet, but it's -- how we guide will, again, depend on our ability to bracket the risk and opportunities around those dynamics and what those mean. It continues to change, and it's something that we monitor very closely. But that patient flow, as Kevin said, is something that's just very difficult for us to control."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. I'd also add, Robyn, if I might, that -- how solid and good we feel about HIV going into next year with that chronic model and the uptick of our TAF-based regimens.",33,"Yes. I'd also add, Robyn, if I might, that -- how solid and good we feel about HIV going into next year with that chronic model and the uptick of our TAF-based regimens."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Ying Huang of Bank of America Merrill Lynch.",14,"And our next question comes from Ying Huang of Bank of America Merrill Lynch."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","The first one maybe is for Kevin. Our channel checks indicated that VA is paying about $15,000 to $17,000 per patient. Do you think that's the absolute floor for HCV pricing? And then another question for John and Robin. Sounds like you guys have really h",85,"The first one maybe is for Kevin. Our channel checks indicated that VA is paying about $15,000 to $17,000 per patient. Do you think that's the absolute floor for HCV pricing? And then another question for John and Robin. Sounds like you guys have really high bar for acquisitions. If you don't deploy capital in acquisitions, would you consider hiking dividend to a much higher level like 5% to 6% so that a lot of investors would be willing to take the [indiscernible] dividend payment?"
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","It's Kevin. I apologize, but in terms of commenting on net our pricing to the various channels, to the various constituents, it's not something that we directly comment on. So I couldn't go any further than that at this time.",41,"It's Kevin. I apologize, but in terms of commenting on net our pricing to the various channels, to the various constituents, it's not something that we directly comment on. So I couldn't go any further than that at this time."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes, Ying, and I'll take the second half. I mean, I think, as we said, the bar is side, but we're very engaged and remain engaged in M&A. And when we think about our overall capital allocation, we wouldn't want to do anything that would constrain us with",97,"Yes, Ying, and I'll take the second half. I mean, I think, as we said, the bar is side, but we're very engaged and remain engaged in M&A. And when we think about our overall capital allocation, we wouldn't want to do anything that would constrain us with -- and reduce our flexibility to purchase if we found something that we thought could really grow our top line. So we talk with our board all the time about dividend increases and dividends in general as well as share repurchases, and that's something that we'll continue to do."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes Phil Nadeau of Cowen and Company.",11,"And our next question comes Phil Nadeau of Cowen and Company."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Unfortunately, it's another one on HCV pricing for you Kevin. You mentioned kind of 2 factors that impact the average per patient price that have been changing. One is the public versus private payer mix, which is a change over last year but maybe stabili",164,"Unfortunately, it's another one on HCV pricing for you Kevin. You mentioned kind of 2 factors that impact the average per patient price that have been changing. One is the public versus private payer mix, which is a change over last year but maybe stabilized now and then also the rebates given to private payers. You didn't really discuss those too much in this call, but in the past, your predecessor said that he expected the rebates to actually increase when Merck entered the market next year. Some of your comments today could suggest the opposite. So I guess, kind of just curious, for 2017, how should we think about those 2 factors. Do you think public versus private has plateaued? Is 45% the number we should be thinking about for 2017? And then on the rebates to the private payers, should we continue to expect those to tick up in 2017? Or is your feeling different now that you've gone through negotiation cycles?"
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Difficult for me to comment in any great detail, Phil, on either of those questions. I'll take the commercial first. They have gone well. I think, as I keep emphasizing, the advantage we have in 8 weeks, we think about it, 45% right now of Harvoni patient",274,"Difficult for me to comment in any great detail, Phil, on either of those questions. I'll take the commercial first. They have gone well. I think, as I keep emphasizing, the advantage we have in 8 weeks, we think about it, 45% right now of Harvoni patients, genotype 1 patients are receiving 8 weeks. So if you think about 45% of genotype 1 with just that 8 weeks, that's a very good economic offering for our payers that they really appreciate. So we've -- I believe we've done very well in our position going into 2017. In terms of the ratio between public and private, again, very difficult for me to make a prediction. VA did come down a little bit, but there was an increase, just a tick-up, to replace that by Medicaid. I made the comment that the Medicaid opening is really slower than we would like, but I think there may be that change in mix going forward. Difficult to predict VA. VA is still a big part of the public, and we'll just have to see. It's very impressive what they've done, and I know they're very committed. And they feel that they haven't done their job yet. We, and that's Gilead, we estimate that between 35% and 40% of the patients in the VA system have been treated to date. So still a lot of work to do, and I think they want to do it. So 45% -- 55% seems to have been the level for the last couple of quarters and not entirely clear if that's going to be maintained into 2017, but seems reasonable to me."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Alethia Young of Crdit Suisse.",11,"And our next question comes from Alethia Young of Crdit Suisse."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Just, I wanted to talk a little bit about like Genvoya launch and like maybe how it's faster than even the Atripla launch. It was obviously a very good launch. Maybe if you can just frame like what's been kind of how doctors are looking at this. Are they",83,"Just, I wanted to talk a little bit about like Genvoya launch and like maybe how it's faster than even the Atripla launch. It was obviously a very good launch. Maybe if you can just frame like what's been kind of how doctors are looking at this. Are they looking at it more as like just kind of for everyone that needs to come to the doctor, they're just going at this drug? Or just give us some more flavor on the dynamics."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Alethia, thanks for an HIV question. I really appreciate it. Alethia, I was at our international advisory board couple of weeks ago, and we had some of the foremost HIV doctors from around the world. And it was absolutely unanimous. The commitment to swit",252,"Alethia, thanks for an HIV question. I really appreciate it. Alethia, I was at our international advisory board couple of weeks ago, and we had some of the foremost HIV doctors from around the world. And it was absolutely unanimous. The commitment to switching patients, all things being equal, particularly in terms of pricing, physicians see the benefit in terms of bone and kidney from the point the view of TAF. So I think there's an awful strong commitment. Let's not forget that in most practices now half the patients are over the age of 50, and they've been on long-term therapy. And physicians just see a natural and fairly straightforward switch going on. I'm really -- I really didn't think I'd ever see an uptake quicker than Atripla. As you remember, there were the components of Atripla that could just be put together and the patients switched. These are slightly different with Genvoya because it's a switch of regimen. So I'm delighted with the way it's going. 80% of Genvoya comes from switches, and right now half of those switches are from Stribild, which is the natural TAF to -- TDF-to-TAF switch. So my expectation is that we will continue to convert patients, and I'm super enthusiastic about it. And once we get more countries online in Europe, I think we can have that same expectation. Germany is going great. Spain is going great. And we're on the threshold of getting the most important market up and running, and that's France."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Terence Flynn of Goldman Sachs.",11,"And our next question comes from Terence Flynn of Goldman Sachs."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Maybe just wondering if you guys can comment about the GSK ViiV doublets for HIV. Maybe just help frame for us how to think about that, if those are successful and either treatment or maintenance setting. Would you look to explore your own doublet regimen",57,"Maybe just wondering if you guys can comment about the GSK ViiV doublets for HIV. Maybe just help frame for us how to think about that, if those are successful and either treatment or maintenance setting. Would you look to explore your own doublet regimen? Or do you think you've already set a high enough bar there?"
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Terence, so the debates in our -- with bictegravir is not doublet or triplet. We're developing bictegravir/F/TAF because it has 3 excellent components that have proven safety and enormously high efficacy. If you look at the ViIV Triumeq compound, of cours",135,"Terence, so the debates in our -- with bictegravir is not doublet or triplet. We're developing bictegravir/F/TAF because it has 3 excellent components that have proven safety and enormously high efficacy. If you look at the ViIV Triumeq compound, of course, that contains abacavir. So in that scenario, there is an incentive to get rid of abacavir and go to a doublet as you call it. But in our case, that's -- absolutely, we have no incentive whatsoever to do that. I would like to point out it's an interesting strategy. It's a potential competitor. The only thing I would like to point out is the safety efficacy has to be still proven in a larger patient population, number one; and number two, in more diverse patient population, particularly in patients with high viral load."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Ian Somaiya of BMO Capital Markets.",12,"And our next question comes from Ian Somaiya of BMO Capital Markets."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Just a question for you maybe, Robin, on just the R&D spend going forward. The filgotinib program, the 3 Phase III programs may, in aggregate, cost about $1 billion. You're about to embark on a -- in a fairly sizable NASH program. Just how should we think",75,"Just a question for you maybe, Robin, on just the R&D spend going forward. The filgotinib program, the 3 Phase III programs may, in aggregate, cost about $1 billion. You're about to embark on a -- in a fairly sizable NASH program. Just how should we think about R&D spend going forward? Are there any trials that are completing that might provide an offset? Just if you could give us some color related to that."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","So maybe, Ian, I'm going to answer the first question, and Robin can join in. So as we indicated before, our hepatitis C research is winding down, or the development is winding down. Really, with this SOF/VEL/VOX, this will be our last development candida",109,"So maybe, Ian, I'm going to answer the first question, and Robin can join in. So as we indicated before, our hepatitis C research is winding down, or the development is winding down. Really, with this SOF/VEL/VOX, this will be our last development candidate, and we have spent, over the last 3 years, probably most of our money on hepatitis C. So that's winding down and also, in HIV are coming down because of bictegravir/F/TAF is going to be our last single-tablet regimen for a broad patient population. And that, I think, will offset the increased spending in the other areas, as you pointed out, filgotinib and also oncology."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes, yes. I think, Norbert, summed it up. Ian. I'll only add that I think the rigor remains very high internally within Gilead as well, right? We're always making the various tradeoffs, and we look to do the right thing scientifically. So you could see va",92,"Yes, yes. I think, Norbert, summed it up. Ian. I'll only add that I think the rigor remains very high internally within Gilead as well, right? We're always making the various tradeoffs, and we look to do the right thing scientifically. So you could see variability in costs. But overall, there's still a high bar internally relative to how we allocate our research spend, but a lot of our projects ongoing, as mentioned, will be paid for with the decline in some of the larger products we have with HIV and HCV."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our final question comes from the line of Jim Birchenough of Wells Fargo.",14,"And our final question comes from the line of Jim Birchenough of Wells Fargo."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Jim, are you there?",4,"Jim, are you there?"
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","You're on mute.",4,"You're on mute."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","I think that's it, Candace.",6,"I think that's it, Candace."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","There are no further questions at this time. I'd like to turn the conference back over to Sung Lee for closing remarks.",22,"There are no further questions at this time. I'd like to turn the conference back over to Sung Lee for closing remarks."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Great. Thanks, Candace. Thanks, everyone, for joining us today. We appreciate your continued interest in Gilead, and the team here looks forward to providing you with updates on our future progress.",31,"Great. Thanks, Candace. Thanks, everyone, for joining us today. We appreciate your continued interest in Gilead, and the team here looks forward to providing you with updates on our future progress."
29002,403467286,1069207,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Have a great day, everyone.",25,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Have a great day, everyone."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Third Quarter 2016 Earnings Conference Call. My name is Candace, and I'll be your conference operator today. [Operator Instructions] And as a reminder, this conference cal",63,"Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Third Quarter 2016 Earnings Conference Call. My name is Candace, and I'll be your conference operator today. [Operator Instructions] And as a reminder, this conference call is being recorded. I would now like to turn the call over to Sung Lee, Vice President of Investor Relations. Please go ahead."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Candace, and good afternoon, everyone. Just after market close today, a press release was issued with earnings results for the third quarter of 2016. The press release and detailed slides are available on the Investor Relations section of the G",219,"Thank you, Candace, and good afternoon, everyone. Just after market close today, a press release was issued with earnings results for the third quarter of 2016. The press release and detailed slides are available on the Investor Relations section of the Gilead website.
Joining today's call will be John Milligan, President and Chief Executive Officer; Robin Washington, Executive Vice President and Chief Financial Officer; Kevin Young, Chief Operating Officer; and Norbert Bischofberger, Executive Vice President of Research and Development and Chief Scientific Officer.
Before we begin formal remarks, let me remind you that we will be making forward-looking statements, including plans and expectations with respect to products, product candidates, financial projections and the use of capital, all of which involve certain assumptions, risks and uncertainties that are beyond our control and could cause actual results to differ materially from these statements. A description of these risks can be found in the latest SEC disclosure documents and recent press releases. In addition, Gilead does not undertake any obligation to update any forward-looking statements made during this call.
Non-GAAP financial measures will be used to help you understand the company's underlying business performance. The GAAP to non-GAAP reconciliations are provided in the earnings press release as well as on the Gilead website.
I will now turn the call over to Robin."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, Sung, and good afternoon, everyone. We are pleased to share our results for the third quarter of 2016. I'll first review our financials, and Kevin, Norbert and John will then make a few comments.Total revenues for the third quarter were $7.5 bil",777,"Thanks, Sung, and good afternoon, everyone. We are pleased to share our results for the third quarter of 2016. I'll first review our financials, and Kevin, Norbert and John will then make a few comments.
Total revenues for the third quarter were $7.5 billion with non-GAAP diluted earnings per share of $2.75. This compares to revenues of $8.3 billion and non-GAAP earnings per share of $3.22 for the same period last year.
Product sales for the third quarter were $7.4 billion, down 10% year-over-year and down 3% sequentially. These declines were due to lower HCV sales, partially offset by increased sales in HIV and other therapeutic areas. Sequentially, declines in our HCV sales in the U.S., Japan and Europe were partially offset by increases in U.S. HIV and other product sales.
Turning to the U.S. Product sales for the third quarter were $5.1 billion, down 9% year-over-year. HCV product sales were $2 billion, down 37% year-over-year, driven primarily by lower patient starts for Harvoni and lower revenues per patient, primarily due to a higher percentage of sales to more deeply discounted segments. The decline was partially offset by demand for Epclusa, which was launched at the end of Q2 2016 and generated $593 million in its first full quarter of sales.
Sequentially, our HCV product sales were down 12%. These sales were essentially flat compared to the second quarter, excluding the favorable adjustment to our HCV sales return of $279 million that we made last quarter. HIV and other anti-viral sales increased 32% year-over-year and 19% sequentially. The quarterly revenues of $2.6 billion were positively impacted by strong uptake of our TAF-based regimens and a onetime favorable adjustment of $332 million to our rebate reserves, primarily related to our TDF-based regimens. Without the adjustment, U.S. HIV and other anti-viral sales grew 15% year-over-year and 4% sequentially.
Turning to Europe. Product sales for the third quarter were $1.4 billion, down 16% year-over-year, primarily due to lower HCV patient starts and unfavorable currency movements. Sequentially, sales were down 12%, primarily driven by lower HCV patient starts and summer seasonality, consistent with the usual decreases in demand during the European summer holiday months.
In Japan, product sales for the third quarter were $452 million, flat year-over-year, driven by higher sales of Harvoni, which was launched in September 2015, offset by mandatory price reductions for both Sovaldi and Harvoni, which we discussed during our last call. Sequentially, sales were down 27% as a result of lower Harvoni and Sovaldi patient starts.
Now turning to expenses. Non-GAAP R&D expenses were $981 million for the third quarter, up 38% compared to the same period last year, primarily due to the progression of our clinical studies, which included a $200 million milestone expense associated with our purchase of Nimbus. Non-GAAP SG&A expenses for the third quarter were down 8% compared to the same period last year, primarily due to lower branded prescription drug fee expense.
From a balance sheet perspective, during the third quarter, we generated cash flows from operation of $4.3 billion and ended the quarter with $31.6 billion in cash and investments, which is inclusive of the issuance of $5 billion of senior unsecured notes. We have a healthy balance sheet to invest in our pipeline and external opportunities.  While our cash flows will remain strong, we do anticipate a sequential decrease in Q4 2016 due to required cash payments related to accrued government rebates as well as milestone payments associated with our R&D pipeline.
Shareholder return via dividends and share repurchases year-to-date remains strong. In the third quarter, we repurchased 11.7 million shares for $1 billion under the $12 billion 2016 share repurchase program. For 2016, the total share repurchases through the third quarter were 110 million shares at a cost of $10 billion. Year-over-year, we have seen an 11% decline in our diluted shares, primarily driven by our share repurchases.
Finally, we are reiterating our full year 2016 guidance, which was revised on July 25, 2016, and summarized on Slide 27 in the earnings results presentation available on our corporate website. As a reminder, guidance for product sales is subject to a number of uncertainties, including an uncertain global macroeconomic environment; adoption of additional pricing measurement -- measures to reduce HCV spending; volatility in foreign currency exchange rates; inaccuracy in HCV patient start estimates; additional competitive launches in HCV; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; and a larger-than-anticipated shift in payer mix to more highly discounted payer segments such as PHS, FFS, Medicaid and the VA.
I would like to turn the call over to Kevin now."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Robin, and good afternoon, everyone. I am very pleased to take you through a solid set of operating results for the third quarter.Starting with HIV. Gilead continues to make significant steps in delivering improved single-tablet regimens to p",1393,"Thank you, Robin, and good afternoon, everyone. I am very pleased to take you through a solid set of operating results for the third quarter.
Starting with HIV. Gilead continues to make significant steps in delivering improved single-tablet regimens to patients around the world. We have seen strong adoption of our TAF-based regimens in the U.S. and in the European markets, where we have achieved reimbursement.
In the U.S., of the nearly 840,000 people on anti-retroviral therapy, approximately 80% receive a Gilead regimen. Genvoya is now the most prescribed regimen for both treatment-nave and switch patients. This month, we expect cumulative prescriptions of Genvoya to surpass Atripla's prescription at the same point in time post approval. This will make Genvoya the all-time most successful product adoption in its first year in the 30-year history of HIV therapy in this country.
The uptake of Genvoya, Odefsey and Descovy have largely been driven by the switch from Gilead's old STRs due to the improved safety profile of TAF. It is also encouraging to see a notable number of patients from non-Gilead therapies moving to TAF-based regimens. Approximately 10% of Genvoya switches are incremental to the Gilead HIV franchise.
Turning to Europe. Total HIV and other anti-viral revenue was $728 million, up 1% year-over-year and down 4% sequentially. Third quarter European pharmaceutical revenues are typically affected by summer seasonality. In Italy, Spain and Portugal, we saw lower prescribing rates consistent with prior years. Genvoya has been launched in 18 markets in the U.K. -- in the EU, including Spain and Germany, while we have seen rapid uptake similar to the U.S. Descovy has been launched in 9 markets, and Odefsey has been launched in 8 markets, the largest being Germany in both cases. We expect our TAF-based therapies to continue to grow in Europe with Spain still early in its commercial launch of Genvoya.  Pricing and reimbursement discussions are ongoing in France and Italy with the goal of having these complete by year-end.
Guidelines historically have had a significant impact on prescribing patterns. Genvoya is already listed as a preferred regimen in several HIV treatment guidelines, including the European AIDS Clinical Society as well as country guidelines in Germany, the U.K., Spain and Italy.
I would like to make a few comments about HIV prevention and the use of Truvada for PrEP. The growth in people starting Truvada points to the valuable role that therapy can play when used as part of a comprehensive strategy to prevent transmission. We estimate that in the U.S., approximately 80,000 to 90,000 people were using Truvada for this indication in the third quarter.  We are also starting to see usage of PrEP in France, where approximately 2,000 people have begun -- have been prescribed Truvada since it received reimbursement in January this year. We expect PrEP to continue to be a significant part of Gilead's growth in HIV going forward, particularly in the U.S.
With the rapid adoption of TAF-based regimens, the potential of PrEP and our exciting pipeline programs, especially bictegravir, I'm very positive about the long-term life cycle potential we have in HIV.
Turning to HCV. Approximately 61,000 people in total began HCV therapy in the U.S. in the third quarter 2016. This represents the fourth consecutive 3-month period where patient starts have been in the 50,000 to 60,000 range. We estimate that more than 85% of treated patients in the most recent quarter received a sofosbuvir-based regimen.
The uptake of Epclusa has been most encouraging in its first full quarter post launch, although it is important to point out that we have observed a small yet noticeable warehousing effect. As expected, the vast majority of Epclusa is being used in genotype 2 and 3 patients according to our 12-week label. In terms of payer coverage, formulary reviews for Epclusa are on track. 11 state Medicaid programs have already added Epclusa to genotype -- for genotype 2 and 3 patients, and most commercial and Medicare Part D plans are providing interim coverage for Epclusa based on medical need. Finally, the VA has added Epclusa to their national formulary and have begun ordering.
The 2017 commercial and Medicare Part D contracting cycle is now essentially complete. And whilst I cannot share with you plan-by-plan details, suffice to say that we are pleased with the picture for the coming year. Discussions with all major PBMs and MCOs prove to be productive and recognize the clinical leadership of Gilead's HCV options, especially as demonstrated in real-life settings.  But barriers to access still remain as Medicaid continues to be the outlier in terms of access, restricting coverage to only the more advanced patients.
Turning to Europe. Total HCV revenue in the third quarter was $604 million, down 30% year-over-year and down 22% sequentially. This was driven by lower HCV patient starts. While overall patient starts declined, our market share remained largely unchanged across the major markets with the exception of the U.K., which was slightly down for the quarter.
We estimate that 21,000 patients started on a sofosbuvir-based regimen in the third quarter compared to 27,000 in the second quarter. At our last earnings, I described how we were observing lower patient starts in the early EU launch markets of Germany and France. To put simply, many of the high-need patients have been treated and cured. We are now starting to see this trend unfold in southern European countries, particularly in Italy and in Spain. Performance in the region is also likely somewhat affected by summer seasonality similar to the dynamics we observed in HIV.
Epclusa has now been launched in Germany, Sweden, Norway, Finland and Denmark. I'm pleased to say that there have been the same positive reception as in the U.S. We expect to launch in the other large EU markets once pricing and reimbursement is in place by the second half of 2017.
Not only does 12 weeks of Epclusa deliver incredibly high cure rates, but as a new standard of care, it is considerably cheaper than previously used interferon-free regimens, especially treating genotype 3.
As I conclude my remarks on hepatitis C, it is very important to reiterate that more work needs to be done to identify and cure HCV-infected people around the globe. A key objective for Gilead is to appropriately raise disease awareness, highlight the importance of age-related testing and encourage linkage to specialty care. To help with this effort, we recently launched new educational campaigns in the U.S. and Japan to urge all individuals at risk for or living with HCV to talk to their health care provider.
You may have seen our new advertisement on television here in the U.S. It debuted last week, and I am very pleased with the positive and responsible tone it takes to emphasize to people the need to be screened for a disease that can now be cured in as little as 8 weeks. We have received numerous positive comments from advocacy groups, providers and not least, the many people already cured of hepatitis C who want others like them to benefit.
Moving on. One other liver disease that warrants a mention today is hepatitis B, for which we are well prepared for the launch of TAF. With our PDUFA date coming up, we are hopeful that we will have the opportunity to speak to physicians at the AASLD meeting and in the field about the strong data for this product as soon as next week.
Finally, as I highlighted last quarter, we have a very strong U.S. cardiovascular team that continues to deliver impressive results. Letairis and Ranexa revenues totaled $385 million for the quarter and surpassed $1 billion in the year-to-date.
In closing, I'd like to reiterate the positive progress Gilead is making in addressing viral diseases. We will soon have treated 1.2 million HCV-infected individuals around the world, most of whom are now cured. By any measure, this is a profound contribution to global health care delivery.
And in the field of HIV, not only are we effectively managing the disease with our new TAF-based regimens, but Truvada is helping more and more people avoid infection. I am confident that we will close out the year with continued strong financial performance underpinned by a passion for operational excellence and our focus on putting the patient first.
I will now hand the call over to Norbert."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Kevin. During the third quarter, a number of Phase II and Phase III studies concluded, providing insights into efficacy and safety of both approved and experimental Gilead agents in the areas of HIV, liver disease, inflammation, oncology and ca",1379,"Thank you, Kevin. During the third quarter, a number of Phase II and Phase III studies concluded, providing insights into efficacy and safety of both approved and experimental Gilead agents in the areas of HIV, liver disease, inflammation, oncology and cardiovascular disease. Some of these results were disappointments. Some were exciting successes.
To start off with the disappointments. We now have the final analyses from 3 96-week studies of the anti-LOXL2 monoclonal antibody, simtuzumab. The data indicate that while safe and well tolerated, there is no evidence of efficacy in 1 study in primary sclerosing cholangitis and in 2 studies in NASH. One NASH study was in patients with cirrhosis, and one was in patients with bridging fibrosis. Consequently, we will not develop simtuzumab any further in these or any other indications. We will present these data at future conferences.
As for GS-5745, an anti-MMP9 antibody, we stopped a Phase II/III study in patients with ulcerative colitis because of a lack of efficacy. This decision followed a planned interim DSMB analysis after the first 150 patients had been enrolled and the study met predefined futility criteria. Also, and not unexpectedly, there was no evidence of benefit of GS-5745 in a Phase II study in patients with Crohn's disease. Consequently, we will not further pursue GS-5745 for ulcerative colitis or Crohn's. In these studies, GS-5745 were safe and well tolerated, and we're continuing to evaluate GS-5745 in rheumatoid arthritis as an add on to anti-TNFs or other therapies.
Eleclazine or GS-6615 failed to meet its primary endpoint in a study of patients with ventricular tachycardia/ventricular fibrillation or VTVF and implanted cardioverter defibrillators. Patients were randomized to 2 doses of eleclazine or placebo. The primary endpoint was the number of electrical interventions, including shocks and pacing by the implanted device, and there was no evidence of efficacy of eleclazine compared to placebo. Consequently, we will not develop eleclazine any further for VTVF evaluation in long QT-3 syndrome and that hypertrophic cardiomyopathy is continuing. 
But now to the excitement. Starting with HCV. The pan-genotypic single-pill, triple-combination regimen of sofosbuvir, velpatasvir, voxilaprevir or, I'll call it, SOF/VEL/VOX has been studied in 4 Phase III studies called POLARIS-1, -2, -3 and -4. POLARIS-1 and -4 evaluated the regimen in patients who have previously failed a direct acting antiviral and included patients with cirrhosis. Treatment of these salvage patients with SOF/VEL/VOX resulted in SVR rates of 96% and 97%.
The 2 other studies, POLARIS-2 and -3, compared the triple-combination regimen in treatment-naive patients given for 8 weeks to Epclusa given for 12 weeks. POLARIS-2 was open to all genotypes, whereas POLARIS-3 enrolled only genotype-3-infected individuals with compensated cirrhosis, where the unmet need is the greatest. In POLARIS-2, the SVR rates obtained with 12 weeks of Epclusa were numerically higher than those obtained with 8 weeks of the triple combination, whereas in POLARIS-3, the SVR rates were comparable.
Particularly in POLARIS-3, which involved the most difficult to treat, genotype 3 infected cirrhotic patients, Epclusa for 12 weeks resulted in 96% SVR rate. These results underscore the value of Epclusa as an excellent treatment option for patients across all genotypes, and they also suggest that the future role of SOF/VEL/VOX will be for patients who previously failed an anti-viral regimen. The full data from these studies will be presented at AASLD in a few weeks, and we will submit Marketing Authorization Applications to regulatory authorities imminently.
Another exciting result was the anti-fibrotic effect observed with GS-4997, an investigational small molecule inhibitor of apoptosis signal-regulating kinase 1 or ASK1. GS-4997 was a shown to inhibit inflammation apoptosis and fibrosis in settings of increased oxidative stress associated with NASH in preclinical models. This Phase II clinical study involved 72 patients. 2/3 had F3-stage fibrosis, and 1/3 had F2-stage fibrosis. There was evidence that treatment with GS-4997 for only 24 weeks resulted in fibrosis reversal and decreased fibrosis progression in a dose-dependent manner. At the highest dose tested, which was 18 milligrams, 43% of patients showed at least a 1 point decrease in their fibrosis score compared to only 20% in the simtuzumab control arm. At the same time, 20% of the simtuzumab-treated patients progressed to cirrhosis compared to only 3% or 1 out of 30 at the 18-milligram dose. The full data from these studies will be presented at AASLD in a few weeks.
Based on these exciting data, we will initiate discussions with regulatory authorities and plan to move GS-4997 into Phase III clinical development in patients with NASH. Based on the Phase II results, we intend to evaluate GS-4997 in patients with the highest unmet need. That means those with F3 and F4 stages of fibrosis.
At the same time, we have 2 other compounds with different mechanisms currently in 2 Phase II studies in patients with NASH and fibrosis, and that is GS-9674, an FXR agonist; and GS-0976, an ACC inhibitor. And the studies are of 24- and 12-week duration, respectively. Pending demonstration of single-agent efficacy and safety in these 2 Phase II studies, we plan to initiate combination studies with the 3 agents towards the middle of next year.
In HIV, we're continuing to explore the utility of TAF-containing regimens in various uses in different populations. Last week, data from 3 Phase III studies were presented at the HIV Conference in Glasgow. 96-week data were disclosed from 1 study where 663 biologically suppressed patients were randomized to either continue on their Truvada-based regimen or to switch to a Descovy-based regimen. In 2 other studies, 630 and 875 of largely suppressed patients on Complera and Atripla, respectively, were randomized to switch to Odefsey or stay on their current regimen. In all studies, switching to a TAF-based regimen was noninferior with regards to efficacy but were superior with regards to renal and bone laboratory safety parameters.
The Phase III development of the single-tablet regimen of bictegravir F/TAF is continuing. Four Phase III studies are now fully enrolled, and we anticipate unblinding these studies towards the middle of next year with regulatory submissions planned for the third quarter of 2017. We also plan to present 48-week Phase II data on bictegravir F/TAF at the Scientific Meeting in the first quarter of 2017.
In oncology, a Phase III study of GS-5745 in patients with gastric cancer is ongoing as well as a Phase II study in patients with gastric cancer in combination with nivolumab. We're also evaluating GS-5745 in other solid tumors.
In addition, we have now completed 2 Phase I safety studies of our combination kinase inhibitors. We were able to establish safe doses of our PI3K inhibitor, idelalisib, in combination with our BTK inhibitor, GS-4059, and our Syk inhibitor, entospletinib, in combination with the BTK inhibitor, GS-4059. Consequently, we will now first evaluate the PI3K/BTK combination with and without anti-CD20 therapy in relapsed/refractory CLL patients in collaboration with the German CLL study group.
We will also be announcing initial Phase Ib/II data on our Syk inhibitor, entospletinib, in acute myeloid leukemia at the upcoming ASH Conference in San Diego. We've entered into a collaboration with the Leukemia & Lymphoma Society to provide entospletinib for their Beat AML Master Trial. This trial will employ the latest genomic technology to match specific AML mutations in newly diagnosed patients over age of 60 with an appropriate investigational drug or drug combination.
In summary, great progress has been made with some of our programs. The very nature of R&D is that you often face both closures and progress. Going forward, I'm pleased we now have the ability to focus our attention on development programs in NASH, inflammation oncology and HIV. We now have 7 new molecules in advanced clinical development. The PDUFA date for TAF for HBV is coming up in a few weeks, and we plan to file an NDA before the end of the year on SOF/VEL/VOX for use as salvage therapy for patients who have failed a previous direct acting antiviral. 
Four molecules are continuing in Phase III. That is momelotinib for myelofibrosis; bictegravir/F/TAF, the single-tablet regimen for HIV infection; filgotinib for 3 separate indications, rheumatoid arthritis, ulcerative colitis and Crohn's; and GS-5745 in gastric cancer. Finally, we plan to advance GS-4997 for NASH to Phase III.
I would now like to turn the call over to John."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, Norbert. I want to make a few closing remarks before we get to your question.We continue to have success with the important work we do in HIV and viral hepatitis. There's still a great need for innovation in these deals. Both diseases include pa",869,"Thanks, Norbert. I want to make a few closing remarks before we get to your question.
We continue to have success with the important work we do in HIV and viral hepatitis. There's still a great need for innovation in these deals. Both diseases include patients whose needs remain unaddressed, and both represent global epidemics.
Our researchers are working to bring new options to a wider range of patients than ever before. This includes people with HIV who've been on therapy for decades and may need to change their medication due to side effects or patients who may be failing to fully suppress their virus due to the presence of resistance.  Approaches our research teams are pursuing include new molecules for treating resistant virus now in formulations and combinations that may be dosed infrequently and opportunities to cure HIV patients by clearing out viral reservoir from their bodies.
Our innovative work, in conjunction with our many partners, has already allowed our HIV medicines to reach millions of patients worldwide. We're particularly excited about the role that TAF will play. With a small daily dose and improved side effect profile, it is ideal for resource-constrained areas of the world and requires only 1/10 of the manufacturing capacity to supply the same number of patients.
In the area of viral hepatitis, the data now obtained with Epclusa suggests that we have an excellent option for the many parts of the developing world for genotyping HCV in determining the stage of disease can be difficult, if not, impossible. With Epclusa, there's no difference in dosing for the different genotypes or stages of liver disease, and so there's no need for these diagnostic procedures. We're working around the globe to rapidly introduce Epclusa as well as Sovaldi and Harvoni.
Finally, in hepatitis B, as Kevin and Norbert mentioned, we are approaching the launch of TAF. HBV continues to be an under-treated disease despite the long-term data showing improvement of liver for people who remain on effective therapy. TAF provides an important new option for patients with chronic HBV, and we'll have the opportunity to introduce the product at the liver meeting in the next -- coming weeks at Boston.
We also recognize that treating such a prevalent disease chronically is a major global challenge, and we continue to seek ways to provide finite duration of treatment that the patients can control or eliminate the virus without having to endure a lifetime of treatment. Gilead's largest research effort is in the area of HBV care.
Beyond our work in antivirals, we are making great progress in new disease areas for Gilead. We are pleased to be able to share with you today our top line data for GS-4997 in NASH. GS-4997 targets ASK1, a previously unexplored target for NASH. The data are suggestive of a strong anti-fibrotic -- of strong anti-fibrotic activity after only a 24-week period of treatment, and we look forward to future in-depth discussions once the data are presented at AASLD.
We think about GS-4997 as a potential backbone molecule, one that can be used alone or in combination. NASH is an understudied but increasingly prevalent disease, and Gilead's liver disease team now has 3 exciting molecule to move forward in the clinical studies. We understand that there's a lot of work to do in providing both the rationale for the patient and to the payer as to the benefits of treating NASH. An active compound such as GS-4997 could really move the field forward, and we are in the process of designing comprehensive studies to demonstrate that health system benefits of treating such a prevalent and growing disease.
In the area of inflammation, we're executing nicely on our development plan. Phase III studies of filgotinib in RA are up and running, and studies in Crohn's and ulcerative colitis have just begun screening patients in the first of these studies. I'm pleased with the progress we are making, and the work of our teams and collaborators get these trials up and running as quickly as possible. We're also looking forward to exploratory studies of filgotinib in a wider variety of inflammatory diseases so that we can fully understand the potential of this specific JAK1 inhibitor.
As you know, we are also focused on our -- augmenting our portfolio with external opportunities, particularly in the field of oncology. However, our interest in partnerships or potential acquisitions is not limited to oncology, and we are considering opportunities where there's strong science and where we see the possibility of developing a truly differentiated product.
We have been going through an extensive internal review of programs and opportunities, and an important aspect of our approach is that we remain open minded but disciplined. So while we have the balance sheet to execute on multiple opportunities, we will keep the bar high.
With 2 months of the year remaining, I want to take the opportunity to thank the 9,000 employees of Gilead for their hard work and dedication. Everyday, more than 10 million individuals around the world take a Gilead medication, and everyday, our teams come to work to improve upon that number.
Thank you for your time. Let's now open the call to questions. Operator?"
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Geoff Meacham of Barclays.",15,"[Operator Instructions] And our first question comes from the line of Geoff Meacham of Barclays."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","John or Kevin, I got one for you. Just wanted to ask about hep C but in a broader context. So you guys have had flat patient numbers despite better access in the U.S., and revenue's down sequentially but on payer mix. So the question is how do you think a",78,"John or Kevin, I got one for you. Just wanted to ask about hep C but in a broader context. So you guys have had flat patient numbers despite better access in the U.S., and revenue's down sequentially but on payer mix. So the question is how do you think about the return on investing continually in hep C either commercially or in new products versus, say, looking outwards and being more aggressive in a new therapeutic category."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Jeff, it's Kevin. Let me just take maybe half a step back from your question, just a few more observations. I've got to tell you that I think we're really executing well in the area of hepatitis C. I've spent a lot of time this quarter with many Gileads a",423,"Jeff, it's Kevin. Let me just take maybe half a step back from your question, just a few more observations. I've got to tell you that I think we're really executing well in the area of hepatitis C. I've spent a lot of time this quarter with many Gileads and with several providers, and I think the variables that we can directly influence, we're really doing a good job on. Our market share is staying incredibly strong. We're ensuring access whilst preserving the value of our hepatitis C drugs. And we're executing on new versions coming to the market. I think you've seen that with Epclusa. And the area that we can less control but we can influence, you're now seeing some new activities from us in terms of unbranded awareness campaigns, and you may have seen our advertisement that came on the television just over a week ago. So I think, from my point of view, in terms of operational excellence, we're doing a very nice job. It is true that the treatments are staying about the same. Actually, I've considered that very positive. Let's not forget that we're at treatment levels that are 2.5x the treatment levels that were there before the Gilead regimens came to the market. So I take at the level of 50,000 to 60,000 patients as very good. The vast proportion of those are Gilead patients. Epclusa had a very big effect in this quarter, so it goes to show that there's still room for new patients, albeit that we're entering a high level of satisfaction. But with Harvoni for genotype 1, both 12 weeks and now a high proportion at 8 weeks and now Epclusa for the 2 and 3 patients. Yes, we have got patients being cured at very high levels. In terms of our triple, I do agree that will be a relatively small proportion of patients, but it's the right thing to do. And it completes our whole picture for hepatitis C. So I think to have the range of products that we have, to have the efficacy that we have is the right offering for health care. So we continue to move forward, and I think we have a healthy franchise. And we are getting better access from particularly the commercial payers, although, as I pointed out and I often discuss with the team here, the Medicaid is still a little bit on the slow side in terms of access. But great progress as far as I'm concerned in the third quarter."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","And Jeff, it's John. The second part of your question is -- was something about investing in this area versus other areas. So I would say, from a pipeline perspective, with SOF/VEL/VOX being our fourth generation of HCV products now being approved, there",113,"And Jeff, it's John. The second part of your question is -- was something about investing in this area versus other areas. So I would say, from a pipeline perspective, with SOF/VEL/VOX being our fourth generation of HCV products now being approved, there really isn't much left in terms of unmatched medical need. And so from a pipeline perspective, this is really the end of what we will be developing in terms of HCV molecules, and that will allow us then to turn our attention to the important aspects in our fibrosis and NASH franchises and our oncology franchises. So we've really largely turned our attention away from HCV to those areas already."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Brian Abrahams of Jefferies.",10,"And our next question comes from Brian Abrahams of Jefferies."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Norbert, a question on 4997. Wondering if you could talk a little bit more about the go-forward plan there, particularly with respect to potential Phase III trial duration and whether or not a fibrosis endpoint might be acceptable just given the effects t",90,"Norbert, a question on 4997. Wondering if you could talk a little bit more about the go-forward plan there, particularly with respect to potential Phase III trial duration and whether or not a fibrosis endpoint might be acceptable just given the effects that you saw in such a short time period in Phase II and the plan to target more severe progressive patients. And then can you confirm that there were no baseline imbalances in the Phase II that might have influenced the fibrosis data or progression to cirrhosis data?"
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","So the second question, yes, I can confirm that there were no baseline imbalances. And regarding the Phase III study, no, we are going to make the proposal to regulatory authorities to use just fibrosis as the endpoint. We feel very convinced that, that's",231,"So the second question, yes, I can confirm that there were no baseline imbalances. And regarding the Phase III study, no, we are going to make the proposal to regulatory authorities to use just fibrosis as the endpoint. We feel very convinced that, that's the right thing to do because, as you may know, fibrosis is the only histological correlate to clinical outcomes. There was a large study published a few years ago where they looked at baseline histology and they correlated histological variables with clinical outcomes. And steatosis didn't correlate. Inflammation didn't correlate. Ballooning didn't correlate. The only thing that correlated was fibrosis. So we are going to propose 2 Phase III studies, both looking at fibrosis 48 week as the endpoint. The other thing, we're going to do with the studies in F3, F4 patients. Again, the rationale is that, that's where the unmet need is. And also since ultimately for full approval you will need some clinical endpoint, we think we can get there much faster maybe with a 96-week study even if we start off with F4 patients. But having all of that said, this all has to be agreed upon by regulatory authorities. We have a date with the FDA, but we have not discussed this with them yet. So stay tuned. Sometime early next year, I think we can update you on the exact plan."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Matthew Harrison of Morgan Stanley.",11,"And our next question comes from Matthew Harrison of Morgan Stanley."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Can I just ask, you made 2 comments related to HCV that I just want to get some more color on. You talked about you're pleased with the 2017 payer cycle. Can you just tell us if we should expect any significant changes in pricing or not? And then can you",86,"Can I just ask, you made 2 comments related to HCV that I just want to get some more color on. You talked about you're pleased with the 2017 payer cycle. Can you just tell us if we should expect any significant changes in pricing or not? And then can you describe what you think is the size of the Epclusa warehouse and if you think you've moved through that or you would expect to see some more of that through the end of the year?"
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Matt, it's Kevin Young. I'll take your second part first. Yes, there was a small warehousing effect. We think that this is anecdotal and qualitative. We think that providers probably held people for sort of a quarter, 2- to 3-month period. So this is noth",177,"Matt, it's Kevin Young. I'll take your second part first. Yes, there was a small warehousing effect. We think that this is anecdotal and qualitative. We think that providers probably held people for sort of a quarter, 2- to 3-month period. So this is nothing like the warehousing that we saw with Sovaldi or with Harvoni. So I -- we think it's largely a Q3 effect. It might go into the fourth quarter, into the quarter now. But we really think it's mostly a 2016 effect. In terms of our negotiations and contracts, I really can't make any specific comments. Obviously, they're confidential. But we are pleased with the outcome. We feel we're in a strong position for 2017, and most providers will have very, very good access in the private and Medicaid -- Medicare Part D setting to both Harvoni and Epclusa. So we think we're in good shape, and our providers will have the Gilead options to look forward to giving to their patients as we have done in 2016. So feel good about that."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from John Scotti of Evercore ISI.",11,"And our next question comes from John Scotti of Evercore ISI."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I wanted to ask one on capital allocation if I may. So last quarter, you spoke about potentially having a more complete story of internal and also external progress by year-end, and you've continued to be relatively light on the buyback in 3Q. So couple t",107,"I wanted to ask one on capital allocation if I may. So last quarter, you spoke about potentially having a more complete story of internal and also external progress by year-end, and you've continued to be relatively light on the buyback in 3Q. So couple things. Can you characterize right now your current appetite for M&A and if that's changed the current thinking more along the lines of larger, transformative deals? Or should we expect a string of in-licensing deals similar to what we saw with filgotinib and Nimbus? And how should we think about the sense of urgency here given your comments and going into year-end?"
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","John, it's John. I think you asked the capital allocation question and switched to strategy. I will try to answer that for you. We -- so as we said in our opening comments, we're still very actively evaluating opportunities. We're actively evaluating a se",129,"John, it's John. I think you asked the capital allocation question and switched to strategy. I will try to answer that for you. We -- so as we said in our opening comments, we're still very actively evaluating opportunities. We're actively evaluating a series of different partnerships. But as I said in my comments, we're going to remain disciplined. We're going to keep the bar high. You don't want the sense of urgency to overwhelm your discipline because then you'll do things that don't make long-term sense. And that's been the history in all businesses, and that's one we apply here. So we're currently very, very active. We'll do things when they make sense for us and not before that. And that's really as much as I can say."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Geoffrey Porges of Leerink Partners.",11,"And our next question comes from Geoffrey Porges of Leerink Partners."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Appreciate the question. Robin, just a couple for you if we may. First, operating margin, trending down by 200 to 300 basis points a quarter. Is that something that we should anticipate continuing or are there some variables in there? Secondly, just on Ep",104,"Appreciate the question. Robin, just a couple for you if we may. First, operating margin, trending down by 200 to 300 basis points a quarter. Is that something that we should anticipate continuing or are there some variables in there? Secondly, just on Epclusa. Was there any channel inventory build in the reported number? And then lastly, how are you judging the sort of share buyback? You spent $10 billion, as you pointed out, this year, and the average cost is sort of around $90. Compared to other things that you might have invested in, how are you feeling about that buyback going forward?"
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Sure, Geoff. I'll start on the reverse quarter and address the buyback first. I mean, we really look at buybacks on a long-term perspective, which is pretty much what I committed or mentioned during the last quarter call. So we're still very comfortable w",327,"Sure, Geoff. I'll start on the reverse quarter and address the buyback first. I mean, we really look at buybacks on a long-term perspective, which is pretty much what I committed or mentioned during the last quarter call. So we're still very comfortable where we are. We did front load a significant component of our share buybacks. As a matter of fact, I think, just in the first quarter, we did more than the entire 3 quarters of 2015. And we messaged very early on that we would see those declines towards the second half of this year, very much in alignment with John's comments around being prepared for M&A. It's still clearly a part of our capital allocation strategy along with dividends. But I think balancing that with overall, looking for growth is something that we're still focused on doing. And as John mentioned, these things take time to play their selves out. I'll let Kevin answer the inventory question, but I think to your question of operating margins, yes, but quarterization of our margins do get impacted by revenue dynamics as well as expenses. Keep in mind, R&D had a $200 million milestone payment this quarter included in that. But overall, I think our margins still remain high, high relative to overall industry, much better and we're comfortable with them. We're very prudent with expense management. You saw SG&A expense is down. I think the other thing you're slightly seeing is as the that mix changes between HCV and HIV, that has a little bit of an impact on our growth margin. But overall, with the continued conversion of TAF, long term, you'll continue to see that go down. But it will be impacted relative to HCV becoming a smaller component of our total revenue. I can't really give guidance on our gross margins, but I think the bar still remains high for them, and we still remain a very disciplined spending type of organization."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. And Geoff, just to comment on Epclusa. If you recall, we launched Epclusa in the last week in quarter 2, so that's when our opening inventory went in. Like any growing products, major wholesalers tick up their inventory basically because they got a s",113,"Yes. And Geoff, just to comment on Epclusa. If you recall, we launched Epclusa in the last week in quarter 2, so that's when our opening inventory went in. Like any growing products, major wholesalers tick up their inventory basically because they got a standard calculation for days on hand. So basically, that just ticks up as a product grows or indeed comes down, as a product comes down as likely Sovaldi because it's now becoming Epclusa will in the future. So there was nothing unnatural about inventory for Epclusa in the third quarter, but as I've said, we did get a very nice bump in usage from a small warehousing of patients."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Cory Kasimov of JPMorgan.",10,"And our next question comes from Cory Kasimov of JPMorgan."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","John, I wanted to go back to your comments on the strategic question you just got. When you talk about having a high bar in the M&A front, does that mean you see a lack of interesting opportunities out there that just don't meet that bar? Is this more of",60,"John, I wanted to go back to your comments on the strategic question you just got. When you talk about having a high bar in the M&A front, does that mean you see a lack of interesting opportunities out there that just don't meet that bar? Is this more of a price disconnect given the continued volatility in the market?"
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Discipline has both components to it. There are a number of things that, I think, are probably too early for us to take part in. There are a number of things that I think are just overpriced. And so it's been a combination of those 2 things going forward",75,"Discipline has both components to it. There are a number of things that, I think, are probably too early for us to take part in. There are a number of things that I think are just overpriced. And so it's been a combination of those 2 things going forward -- or looking backwards. Going forward, we'll have to see what makes sense for us and where we're willing to go to bring in new products."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Michael Yee of RBC Capital Markets.",12,"And our next question comes from Michael Yee of RBC Capital Markets."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I want to ask a question on patient volumes in hep C, specifically as it relates to Slide 41, I guess. Previously, I would have thought that changes in payer access would have opened up the availability of these drugs to get reimbursed for the healthier F",141,"I want to ask a question on patient volumes in hep C, specifically as it relates to Slide 41, I guess. Previously, I would have thought that changes in payer access would have opened up the availability of these drugs to get reimbursed for the healthier F0s and F1s. I guess, with patient volumes flattish, are you seeing these F0s and F1s coming in? Are they getting treated? Or is your bottleneck there? They come in, and they don't get treated. Just wanted to understand your dynamic on that and whether you think that, that's going to drive some positive development of volumes. And then in Europe, the same question. Europe declined from 27,000 down to 21,000. Just do you think that -- how do you think that plays out, I guess, going forward? What are the dynamics there for volumes?"
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Two great questions. Let me try and deal with those in the order. So first, the U.S. If you look at our slide, actually, the percentage of F0s to F2s has increased over time. It was sort of 50% a little while ago. Now it's up to 60%. So clearly, fitter pa",417,"Two great questions. Let me try and deal with those in the order. So first, the U.S. If you look at our slide, actually, the percentage of F0s to F2s has increased over time. It was sort of 50% a little while ago. Now it's up to 60%. So clearly, fitter patients there, the less sick are being treated, and of course, that's as result of coverage. But I want to say that the patient journey, I think, is becoming longer in the U.S. now. If you think about it, patients are really starting further back because they are healthier. We are continuing to see approximately 30,000 patients coming into specialist care so in other words, 90,000 patients a quarter. 60,000 of those are coming out of the other side and are being treated and cured. That's probably not a bad ratio in itself. Not every patient is treated, and not every patient is immediately treated. Now we shouldn't forget that, sometimes, patients drift in and out of a specialist's care. Some patients have compounding factors that complicates the start of therapy, most notably, drug use or alcohol use. And the patients who are just less sick have less motivation themselves, and the physician has less motivation to really push those through therapy. And lastly, the paperwork and the administrative process for authorization is still there with -- like it is with any specialist product. So I think those are mostly the dynamics, and it's mostly around the patients being less time in the physician's practice. They're not patients that have been held for a long time. They're not patients that failed 1 or 2 prior therapies and a great urgency by the physician. In terms of Europe, as I said, we did see a downtick in the patients treated in the southern European markets, primarily Italy and Spain, and I think that's because they are working through the sicker patients and are becoming more like France and Germany. There still are more patients in the southern European markets, but I do think they are clearing the most obvious patients to treat and cure. Now I want to emphasize that market share has stayed very, very solid in those markets. And whilst it's not an obvious mechanism through advertising, television advertising in the European markets, we are doing a lot of partnership with KOLs, with societies, with patient groups to, again, try to encourage the right screening practices and the right transfer of patients into specialist care."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Robyn Karnauskas of Citi.",10,"And our next question comes from Robyn Karnauskas of Citi."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","So just to ask the HCV question from a fourth quarter impair perspective. Remember, last fourth quarter, you started to see tens of [ph] changes in HCV. So given that looks like you have stabilized, are you seeing anything that hints that payers could cha",123,"So just to ask the HCV question from a fourth quarter impair perspective. Remember, last fourth quarter, you started to see tens of [ph] changes in HCV. So given that looks like you have stabilized, are you seeing anything that hints that payers could change how they're viewing the -- or any changes in fourth quarter that you're seeing that can influence 2017? And then given you've maintained guidance, how are you thinking now about providing what kinds of guidance you might provide in '17 to help investors feel comfortable that you can predict going forward? If any -- I know you can't give guidance but if you can give any hints on how you're thinking about giving us some color next year."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","I'll take the first part. I think, again, come back to the quality of the discussions that we had for 2017 contracting, and I think they were very good. Let's not forget the fact that Gilead are in a very strong place by virtue of Harvoni being in a good",233,"I'll take the first part. I think, again, come back to the quality of the discussions that we had for 2017 contracting, and I think they were very good. Let's not forget the fact that Gilead are in a very strong place by virtue of Harvoni being in a good proportion of patients in an 8-week therapy. So that's a very big advantage for us, and I think that's really appreciated from a point of view of managing costs from a commercial payer. We didn't see much change in the ratio of the public to private payer in the third quarter. It was still about 45% of patients who were covered as a public patient as opposed to a commercial or Medicare Part D plan. Part of the commercial part of the market is, of course, the VA. The VA was a little bit lower in the third quarter versus the second quarter. They still seem to be very enthusiastic, very engaged in recalling patients. But I think that's, perhaps, one of the variables that will kind of unfold in 2017, is the VA and their continuing ability to recall and treat patients. But I think with our efforts around highlighting the CDC, need to treat the baby boomers and the activity of all the companies involved in hepatitis C, I'd like to think that we can continue our progress in 2017."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","So Robyn, it's Robin. I'll take the second part of that question. Yes, I think, as we said, this is a curative market, HCV, and it's difficult to predict. And Kevin just outlined this kind of patient journey taking a longer bit of time and just changing d",132,"So Robyn, it's Robin. I'll take the second part of that question. Yes, I think, as we said, this is a curative market, HCV, and it's difficult to predict. And Kevin just outlined this kind of patient journey taking a longer bit of time and just changing dynamics. And we spent a lot of time this fall working through the planning cycle, figuring out what that means around '17 and beyond. Obviously, I can't give the answer yet, but it's -- how we guide will, again, depend on our ability to bracket the risk and opportunities around those dynamics and what those mean. It continues to change, and it's something that we monitor very closely. But that patient flow, as Kevin said, is something that's just very difficult for us to control."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. I'd also add, Robyn, if I might, that -- how solid and good we feel about HIV going into next year with that chronic model and the uptick of our TAF-based regimens.",33,"Yes. I'd also add, Robyn, if I might, that -- how solid and good we feel about HIV going into next year with that chronic model and the uptick of our TAF-based regimens."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Ying Huang of Bank of America Merrill Lynch.",14,"And our next question comes from Ying Huang of Bank of America Merrill Lynch."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","The first one maybe is for Kevin. Our channel checks indicated that VA is paying about $15,000 to $17,000 per patient. Do you think that's the absolute floor for HCV pricing? And then another question for John and Robin. Sounds like you guys have really h",85,"The first one maybe is for Kevin. Our channel checks indicated that VA is paying about $15,000 to $17,000 per patient. Do you think that's the absolute floor for HCV pricing? And then another question for John and Robin. Sounds like you guys have really high bar for acquisitions. If you don't deploy capital in acquisitions, would you consider hiking dividend to a much higher level like 5% to 6% so that a lot of investors would be willing to take the [indiscernible] dividend payment?"
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","It's Kevin. I apologize, but in terms of commenting on our net pricing to the various channels, to the various constituents, it's not something that we directly comment on. So I couldn't go any further than that at this time.",41,"It's Kevin. I apologize, but in terms of commenting on our net pricing to the various channels, to the various constituents, it's not something that we directly comment on. So I couldn't go any further than that at this time."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes, Ying, and I'll take the second half. I mean, I think, as we said, the bar is side, but we're very engaged and remain engaged in M&A. And when we think about our overall capital allocation, we wouldn't want to do anything that would constrain us with",97,"Yes, Ying, and I'll take the second half. I mean, I think, as we said, the bar is side, but we're very engaged and remain engaged in M&A. And when we think about our overall capital allocation, we wouldn't want to do anything that would constrain us with -- and reduce our flexibility to purchase if we found something that we thought could really grow our top line. So we talk with our board all the time about dividend increases and dividends in general as well as share repurchases, and that's something that we'll continue to do."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes Phil Nadeau of Cowen and Company.",11,"And our next question comes Phil Nadeau of Cowen and Company."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Unfortunately, it's another one on HCV pricing for you Kevin. You mentioned kind of 2 factors that impact the average per patient price that have been changing. One is the public versus private payer mix, which as you said, changed over last year but mayb",165,"Unfortunately, it's another one on HCV pricing for you Kevin. You mentioned kind of 2 factors that impact the average per patient price that have been changing. One is the public versus private payer mix, which as you said, changed over last year but maybe stabilized now and then also the rebates given to private payers. You didn't really discuss those too much in this call, but in the past, your predecessor said that he expected the rebates to actually increase when Merck entered the market next year. Some of your comments today could suggest the opposite. So I guess, kind of just curious, for 2017, how should we think about those 2 factors. Do you think public versus private has plateaued? Is 45% the number we should be thinking about for 2017? And then on the rebates to the private payers, should we continue to expect those to tick up in 2017? Or is your feeling different now that you've gone through negotiation cycles?"
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Difficult for me to comment in any great detail, Phil, on either of those questions. I'll take the commercial first. They have gone well. I think, as I keep emphasizing, the advantage we have in 8 weeks, we think about it, 45% right now of Harvoni patient",274,"Difficult for me to comment in any great detail, Phil, on either of those questions. I'll take the commercial first. They have gone well. I think, as I keep emphasizing, the advantage we have in 8 weeks, we think about it, 45% right now of Harvoni patients, genotype 1 patients are receiving 8 weeks. So if you think about 45% of genotype 1 with just that 8 weeks, that's a very good economic offering for our payers that they really appreciate. So we've -- I believe we've done very well in our position going into 2017. In terms of the ratio between public and private, again, very difficult for me to make a prediction. VA did come down a little bit, but there was an increase, just a tick-up, to replace that by Medicaid. I made the comment that the Medicaid opening is really slower than we would like, but I think there may be that change in mix going forward. Difficult to predict VA. VA is still a big part of the public, and we'll just have to see. It's very impressive what they've done, and I know they're very committed. And they feel that they haven't done their job yet. We, and that's Gilead, we estimate that between 35% and 40% of the patients in the VA system have been treated to date. So still a lot of work to do, and I think they want to do it. So 45% -- 55% seems to have been the level for the last couple of quarters and not entirely clear if that's going to be maintained into 2017, but seems reasonable to me."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Alethia Young of Crdit Suisse.",11,"And our next question comes from Alethia Young of Crdit Suisse."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Just, I wanted to talk a little bit about like Genvoya launch and like maybe how it's faster than even the Atripla launch. It was obviously a very good launch. Maybe if you can just frame like what's been kind of how doctors are looking at this. Are they",84,"Just, I wanted to talk a little bit about like Genvoya launch and like maybe how it's faster than even the Atripla launch. It was obviously a very good launch. Maybe if you can just frame like what's been kind of how doctors are looking at this. Are they looking at it more as like just kind of for everyone that needs to come to the doctor, they're just go and get this drug? Or just give us some more flavor on the dynamics."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Alethia, thanks for an HIV question. I really appreciate it. Alethia, I was at our international advisory board couple of weeks ago, and we had some of the foremost HIV doctors from around the world. And it was absolutely unanimous. The commitment to swit",252,"Alethia, thanks for an HIV question. I really appreciate it. Alethia, I was at our international advisory board couple of weeks ago, and we had some of the foremost HIV doctors from around the world. And it was absolutely unanimous. The commitment to switching patients, all things being equal, particularly in terms of pricing, physicians see the benefit in terms of bone and kidney from the point the view of TAF. So I think there's an awful strong commitment. Let's not forget that in most practices now half the patients are over the age of 50, and they've been on long-term therapy. And physicians just see a natural and fairly straightforward switch going on. I'm really -- I really didn't think I'd ever see an uptake quicker than Atripla. As you remember, there were the components of Atripla that could just be put together and the patients switched. These are slightly different with Genvoya because it's a switch of regimen. So I'm delighted with the way it's going. 80% of Genvoya comes from switches, and right now half of those switches are from Stribild, which is the natural TAF to -- TDF-to-TAF switch. So my expectation is that we will continue to convert patients, and I'm super enthusiastic about it. And once we get more countries online in Europe, I think we can have that same expectation. Germany is going great. Spain is going great. And we're on the threshold of getting the most important market up and running, and that's France."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Terence Flynn of Goldman Sachs.",11,"And our next question comes from Terence Flynn of Goldman Sachs."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Maybe just wondering if you guys can comment about the GSK ViiV doublets for HIV. Maybe just help frame for us how to think about that, if those are successful and either treatment or maintenance setting. Would you look to explore your own doublet regimen",57,"Maybe just wondering if you guys can comment about the GSK ViiV doublets for HIV. Maybe just help frame for us how to think about that, if those are successful and either treatment or maintenance setting. Would you look to explore your own doublet regimen? Or do you think you've already set a high enough bar there?"
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Terence, so the debates in our -- with bictegravir is not doublet or triplet. We're developing bictegravir/F/TAF because it has 3 excellent components that have proven safety and enormously high efficacy. If you look at the ViIV Triumeq compound, of cours",135,"Terence, so the debates in our -- with bictegravir is not doublet or triplet. We're developing bictegravir/F/TAF because it has 3 excellent components that have proven safety and enormously high efficacy. If you look at the ViIV Triumeq compound, of course, that contains abacavir. So in that scenario, there is an incentive to get rid of abacavir and go to a doublet as you call it. But in our case, that's -- absolutely, we have no incentive whatsoever to do that. I would like to point out it's an interesting strategy. It's a potential competitor. The only thing I would like to point out is the safety efficacy has to be still proven in a larger patient population, number one; and number two, in more diverse patient population, particularly in patients with high viral load."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Ian Somaiya of BMO Capital Markets.",12,"And our next question comes from Ian Somaiya of BMO Capital Markets."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Just a question for you maybe, Robin, on just the R&D spend going forward. The filgotinib program, the 3 Phase III programs may, in aggregate, cost about $1 billion. You're about to embark on a -- in a fairly sizable NASH program. Just how should we think",75,"Just a question for you maybe, Robin, on just the R&D spend going forward. The filgotinib program, the 3 Phase III programs may, in aggregate, cost about $1 billion. You're about to embark on a -- in a fairly sizable NASH program. Just how should we think about R&D spend going forward? Are there any trials that are completing that might provide an offset? Just if you could give us some color related to that."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","So maybe, Ian, I'm going to answer the first question, and Robin can join in. So as we indicated before, our hepatitis C research is winding down, or the development is winding down. Really, with this SOF/VEL/VOX, this will be our last development candida",109,"So maybe, Ian, I'm going to answer the first question, and Robin can join in. So as we indicated before, our hepatitis C research is winding down, or the development is winding down. Really, with this SOF/VEL/VOX, this will be our last development candidate, and we have spent, over the last 3 years, probably most of our money on hepatitis C. So that's winding down and also, in HIV are coming down because of bictegravir/F/TAF is going to be our last single-tablet regimen for a broad patient population. And that, I think, will offset the increased spending in the other areas, as you pointed out, filgotinib and also oncology."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes, yes. I think, Norbert, summed it up. Ian. I'll only add that I think the rigor remains very high internally within Gilead as well, right? We're always making the various tradeoffs, and we look to do the right thing scientifically. So you could see va",92,"Yes, yes. I think, Norbert, summed it up. Ian. I'll only add that I think the rigor remains very high internally within Gilead as well, right? We're always making the various tradeoffs, and we look to do the right thing scientifically. So you could see variability in costs. But overall, there's still a high bar internally relative to how we allocate our research spend. But a lot of our projects ongoing, as mentioned, will be paid for with the decline in some of the larger products we have with HIV and HCV."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our final question comes from the line of Jim Birchenough of Wells Fargo.",14,"And our final question comes from the line of Jim Birchenough of Wells Fargo."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Jim, are you there?",4,"Jim, are you there?"
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","You're on mute.",4,"You're on mute."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","I think that's it, Candace.",6,"I think that's it, Candace."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","There are no further questions at this time. I'd like to turn the conference back over to Sung Lee for closing remarks.",22,"There are no further questions at this time. I'd like to turn the conference back over to Sung Lee for closing remarks."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Great. Thanks, Candace. Thanks, everyone, for joining us today. We appreciate your continued interest in Gilead, and the team here looks forward to providing you with updates on our future progress.",31,"Great. Thanks, Candace. Thanks, everyone, for joining us today. We appreciate your continued interest in Gilead, and the team here looks forward to providing you with updates on our future progress."
29002,403467286,1069328,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Have a great day, everyone.",25,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Have a great day, everyone."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Third Quarter 2016 Earnings Conference Call. My name is Candace, and I'll be your conference operator today. [Operator Instructions] And as a reminder, this conference cal",63,"Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Third Quarter 2016 Earnings Conference Call. My name is Candace, and I'll be your conference operator today. [Operator Instructions] And as a reminder, this conference call is being recorded. I would now like to turn the call over to Sung Lee, Vice President of Investor Relations. Please go ahead."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Candace, and good afternoon, everyone. Just after market close today, a press release was issued with earnings results for the third quarter of 2016. The press release and detailed slides are available on the Investor Relations section of the G",219,"Thank you, Candace, and good afternoon, everyone. Just after market close today, a press release was issued with earnings results for the third quarter of 2016. The press release and detailed slides are available on the Investor Relations section of the Gilead website.
Joining today's call will be John Milligan, President and Chief Executive Officer; Robin Washington, Executive Vice President and Chief Financial Officer; Kevin Young, Chief Operating Officer; and Norbert Bischofberger, Executive Vice President of Research and Development and Chief Scientific Officer.
Before we begin formal remarks, let me remind you that we will be making forward-looking statements, including plans and expectations with respect to products, product candidates, financial projections and the use of capital, all of which involve certain assumptions, risks and uncertainties that are beyond our control and could cause actual results to differ materially from these statements. A description of these risks can be found in the latest SEC disclosure documents and recent press releases. In addition, Gilead does not undertake any obligation to update any forward-looking statements made during this call.
Non-GAAP financial measures will be used to help you understand the company's underlying business performance. The GAAP to non-GAAP reconciliations are provided in the earnings press release as well as on the Gilead website.
I will now turn the call over to Robin."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, Sung, and good afternoon, everyone. We are pleased to share our results for the third quarter of 2016. I'll first review our financials, and Kevin, Norbert and John will then make a few comments.Total revenues for the third quarter were $7.5 bil",777,"Thanks, Sung, and good afternoon, everyone. We are pleased to share our results for the third quarter of 2016. I'll first review our financials, and Kevin, Norbert and John will then make a few comments.
Total revenues for the third quarter were $7.5 billion with non-GAAP diluted earnings per share of $2.75. This compares to revenues of $8.3 billion and non-GAAP earnings per share of $3.22 for the same period last year.
Product sales for the third quarter were $7.4 billion, down 10% year-over-year and down 3% sequentially. These declines were due to lower HCV sales, partially offset by increased sales in HIV and other therapeutic areas. Sequentially, declines in our HCV sales in the U.S., Japan and Europe were partially offset by increases in U.S. HIV and other product sales.
Turning to the U.S. Product sales for the third quarter were $5.1 billion, down 9% year-over-year. HCV product sales were $2 billion, down 37% year-over-year, driven primarily by lower patient starts for Harvoni and lower revenues per patient, primarily due to a higher percentage of sales to more deeply discounted segments. The decline was partially offset by demand for Epclusa, which was launched at the end of Q2 2016 and generated $593 million in its first full quarter of sales.
Sequentially, our HCV product sales were down 12%. These sales were essentially flat compared to the second quarter, excluding the favorable adjustment to our HCV sales return of $279 million that we made last quarter. HIV and other anti-viral sales increased 32% year-over-year and 19% sequentially. The quarterly revenues of $2.6 billion were positively impacted by strong uptake of our TAF-based regimens and a onetime favorable adjustment of $332 million to our rebate reserves, primarily related to our TDF-based regimens. Without the adjustment, U.S. HIV and other anti-viral sales grew 15% year-over-year and 4% sequentially.
Turning to Europe. Product sales for the third quarter were $1.4 billion, down 16% year-over-year, primarily due to lower HCV patient starts and unfavorable currency movements. Sequentially, sales were down 12%, primarily driven by lower HCV patient starts and summer seasonality, consistent with the usual decreases in demand during the European summer holiday months.
In Japan, product sales for the third quarter were $452 million, flat year-over-year, driven by higher sales of Harvoni, which was launched in September 2015, offset by mandatory price reductions for both Sovaldi and Harvoni, which we discussed during our last call. Sequentially, sales were down 27% as a result of lower Harvoni and Sovaldi patient starts.
Now turning to expenses. Non-GAAP R&D expenses were $981 million for the third quarter, up 38% compared to the same period last year, primarily due to the progression of our clinical studies, which included a $200 million milestone expense associated with our purchase of Nimbus. Non-GAAP SG&A expenses for the third quarter were down 8% compared to the same period last year, primarily due to lower branded prescription drug fee expense.
From a balance sheet perspective, during the third quarter, we generated cash flows from operation of $4.3 billion and ended the quarter with $31.6 billion in cash and investments, which is inclusive of the issuance of $5 billion of senior unsecured notes. We have a healthy balance sheet to invest in our pipeline and external opportunities.  While our cash flows will remain strong, we do anticipate a sequential decrease in Q4 2016 due to required cash payments related to accrued government rebates as well as milestone payments associated with our R&D pipeline.
Shareholder return via dividends and share repurchases year-to-date remains strong. In the third quarter, we repurchased 11.7 million shares for $1 billion under the $12 billion 2016 share repurchase program. For 2016, the total share repurchases through the third quarter were 110 million shares at a cost of $10 billion. Year-over-year, we have seen an 11% decline in our diluted shares, primarily driven by our share repurchases.
Finally, we are reiterating our full year 2016 guidance, which was revised on July 25, 2016, and summarized on Slide 27 in the earnings results presentation available on our corporate website. As a reminder, guidance for product sales is subject to a number of uncertainties, including an uncertain global macroeconomic environment; adoption of additional pricing measurement -- measures to reduce HCV spending; volatility in foreign currency exchange rates; inaccuracy in HCV patient start estimates; additional competitive launches in HCV; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; and a larger-than-anticipated shift in payer mix to more highly discounted payer segments such as PHS, FFS, Medicaid and the VA.
I would like to turn the call over to Kevin now."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Robin, and good afternoon, everyone. I am very pleased to take you through a solid set of operating results for the third quarter.Starting with HIV. Gilead continues to make significant steps in delivering improved single-tablet regimens to p",1393,"Thank you, Robin, and good afternoon, everyone. I am very pleased to take you through a solid set of operating results for the third quarter.
Starting with HIV. Gilead continues to make significant steps in delivering improved single-tablet regimens to patients around the world. We have seen strong adoption of our TAF-based regimens in the U.S. and in the European markets, where we have achieved reimbursement.
In the U.S., of the nearly 840,000 people on anti-retroviral therapy, approximately 80% receive a Gilead regimen. Genvoya is now the most prescribed regimen for both treatment-nave and switch patients. This month, we expect cumulative prescriptions of Genvoya to surpass Atripla's prescription at the same point in time post approval. This will make Genvoya the all-time most successful product adoption in its first year in the 30-year history of HIV therapy in this country.
The uptake of Genvoya, Odefsey and Descovy have largely been driven by the switch from Gilead's old STRs due to the improved safety profile of TAF. It is also encouraging to see a notable number of patients from non-Gilead therapies moving to TAF-based regimens. Approximately 10% of Genvoya switches are incremental to the Gilead HIV franchise.
Turning to Europe. Total HIV and other anti-viral revenue was $728 million, up 1% year-over-year and down 4% sequentially. Third quarter European pharmaceutical revenues are typically affected by summer seasonality. In Italy, Spain and Portugal, we saw lower prescribing rates consistent with prior years. Genvoya has been launched in 18 markets in the U.K. -- in the EU, including Spain and Germany, while we have seen rapid uptake similar to the U.S. Descovy has been launched in 9 markets, and Odefsey has been launched in 8 markets, the largest being Germany in both cases. We expect our TAF-based therapies to continue to grow in Europe with Spain still early in its commercial launch of Genvoya.  Pricing and reimbursement discussions are ongoing in France and Italy with the goal of having these complete by year-end.
Guidelines historically have had a significant impact on prescribing patterns. Genvoya is already listed as a preferred regimen in several HIV treatment guidelines, including the European AIDS Clinical Society as well as country guidelines in Germany, the U.K., Spain and Italy.
I would like to make a few comments about HIV prevention and the use of Truvada for PrEP. The growth in people starting Truvada points to the valuable role that therapy can play when used as part of a comprehensive strategy to prevent transmission. We estimate that in the U.S., approximately 80,000 to 90,000 people were using Truvada for this indication in the third quarter.  We are also starting to see usage of PrEP in France, where approximately 2,000 people have begun -- have been prescribed Truvada since it received reimbursement in January this year. We expect PrEP to continue to be a significant part of Gilead's growth in HIV going forward, particularly in the U.S.
With the rapid adoption of TAF-based regimens, the potential of PrEP and our exciting pipeline programs, especially bictegravir, I'm very positive about the long-term life cycle potential we have in HIV.
Turning to HCV. Approximately 61,000 people in total began HCV therapy in the U.S. in the third quarter 2016. This represents the fourth consecutive 3-month period where patient starts have been in the 50,000 to 60,000 range. We estimate that more than 85% of treated patients in the most recent quarter received a sofosbuvir-based regimen.
The uptake of Epclusa has been most encouraging in its first full quarter post launch, although it is important to point out that we have observed a small yet noticeable warehousing effect. As expected, the vast majority of Epclusa is being used in genotype 2 and 3 patients according to our 12-week label. In terms of payer coverage, formulary reviews for Epclusa are on track. 11 state Medicaid programs have already added Epclusa to genotype -- for genotype 2 and 3 patients, and most commercial and Medicare Part D plans are providing interim coverage for Epclusa based on medical need. Finally, the VA has added Epclusa to their national formulary and have begun ordering.
The 2017 commercial and Medicare Part D contracting cycle is now essentially complete. And whilst I cannot share with you plan-by-plan details, suffice to say that we are pleased with the picture for the coming year. Discussions with all major PBMs and MCOs prove to be productive and recognize the clinical leadership of Gilead's HCV options, especially as demonstrated in real-life settings.  But barriers to access still remain as Medicaid continues to be the outlier in terms of access, restricting coverage to only the more advanced patients.
Turning to Europe. Total HCV revenue in the third quarter was $604 million, down 30% year-over-year and down 22% sequentially. This was driven by lower HCV patient starts. While overall patient starts declined, our market share remained largely unchanged across the major markets with the exception of the U.K., which was slightly down for the quarter.
We estimate that 21,000 patients started on a sofosbuvir-based regimen in the third quarter compared to 27,000 in the second quarter. At our last earnings, I described how we were observing lower patient starts in the early EU launch markets of Germany and France. To put simply, many of the high-need patients have been treated and cured. We are now starting to see this trend unfold in southern European countries, particularly in Italy and in Spain. Performance in the region is also likely somewhat affected by summer seasonality similar to the dynamics we observed in HIV.
Epclusa has now been launched in Germany, Sweden, Norway, Finland and Denmark. I'm pleased to say that there have been the same positive reception as in the U.S. We expect to launch in the other large EU markets once pricing and reimbursement is in place by the second half of 2017.
Not only does 12 weeks of Epclusa deliver incredibly high cure rates, but as a new standard of care, it is considerably cheaper than previously used interferon-free regimens, especially treating genotype 3.
As I conclude my remarks on hepatitis C, it is very important to reiterate that more work needs to be done to identify and cure HCV-infected people around the globe. A key objective for Gilead is to appropriately raise disease awareness, highlight the importance of age-related testing and encourage linkage to specialty care. To help with this effort, we recently launched new educational campaigns in the U.S. and Japan to urge all individuals at risk for or living with HCV to talk to their health care provider.
You may have seen our new advertisement on television here in the U.S. It debuted last week, and I am very pleased with the positive and responsible tone it takes to emphasize to people the need to be screened for a disease that can now be cured in as little as 8 weeks. We have received numerous positive comments from advocacy groups, providers and not least, the many people already cured of hepatitis C who want others like them to benefit.
Moving on. One other liver disease that warrants a mention today is hepatitis B, for which we are well prepared for the launch of TAF. With our PDUFA date coming up, we are hopeful that we will have the opportunity to speak to physicians at the AASLD meeting and in the field about the strong data for this product as soon as next week.
Finally, as I highlighted last quarter, we have a very strong U.S. cardiovascular team that continues to deliver impressive results. Letairis and Ranexa revenues totaled $385 million for the quarter and surpassed $1 billion in the year-to-date.
In closing, I'd like to reiterate the positive progress Gilead is making in addressing viral diseases. We will soon have treated 1.2 million HCV-infected individuals around the world, most of whom are now cured. By any measure, this is a profound contribution to global health care delivery.
And in the field of HIV, not only are we effectively managing the disease with our new TAF-based regimens, but Truvada is helping more and more people avoid infection. I am confident that we will close out the year with continued strong financial performance underpinned by a passion for operational excellence and our focus on putting the patient first.
I will now hand the call over to Norbert."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thank you, Kevin. During the third quarter, a number of Phase II and Phase III studies concluded, providing insights into efficacy and safety of both approved and experimental Gilead agents in the areas of HIV, liver disease, inflammation, oncology and ca",1379,"Thank you, Kevin. During the third quarter, a number of Phase II and Phase III studies concluded, providing insights into efficacy and safety of both approved and experimental Gilead agents in the areas of HIV, liver disease, inflammation, oncology and cardiovascular disease. Some of these results were disappointments. Some were exciting successes.
To start off with the disappointments. We now have the final analyses from 3 96-week studies of the anti-LOXL2 monoclonal antibody, simtuzumab. The data indicate that while safe and well tolerated, there is no evidence of efficacy in 1 study in primary sclerosing cholangitis and in 2 studies in NASH. One NASH study was in patients with cirrhosis, and one was in patients with bridging fibrosis. Consequently, we will not develop simtuzumab any further in these or any other indications. We will present these data at future conferences.
As for GS-5745, an anti-MMP9 antibody, we stopped a Phase II/III study in patients with ulcerative colitis because of a lack of efficacy. This decision followed a planned interim DSMB analysis after the first 150 patients had been enrolled and the study met predefined futility criteria. Also, and not unexpectedly, there was no evidence of benefit of GS-5745 in a Phase II study in patients with Crohn's disease. Consequently, we will not further pursue GS-5745 for ulcerative colitis or Crohn's. In these studies, GS-5745 were safe and well tolerated, and we're continuing to evaluate GS-5745 in rheumatoid arthritis as an add on to anti-TNFs or other therapies.
Eleclazine or GS-6615 failed to meet its primary endpoint in a study of patients with ventricular tachycardia/ventricular fibrillation or VTVF and implanted cardioverter defibrillators. Patients were randomized to 2 doses of eleclazine or placebo. The primary endpoint was the number of electrical interventions, including shocks and pacing by the implanted device, and there was no evidence of efficacy of eleclazine compared to placebo. Consequently, we will not develop eleclazine any further for VTVF evaluation in long QT-3 syndrome and that hypertrophic cardiomyopathy is continuing. 
But now to the excitement. Starting with HCV. The pan-genotypic single-pill, triple-combination regimen of sofosbuvir, velpatasvir, voxilaprevir or, I'll call it, SOF/VEL/VOX has been studied in 4 Phase III studies called POLARIS-1, -2, -3 and -4. POLARIS-1 and -4 evaluated the regimen in patients who have previously failed a direct acting antiviral and included patients with cirrhosis. Treatment of these salvage patients with SOF/VEL/VOX resulted in SVR rates of 96% and 97%.
The 2 other studies, POLARIS-2 and -3, compared the triple-combination regimen in treatment-naive patients given for 8 weeks to Epclusa given for 12 weeks. POLARIS-2 was open to all genotypes, whereas POLARIS-3 enrolled only genotype-3-infected individuals with compensated cirrhosis, where the unmet need is the greatest. In POLARIS-2, the SVR rates obtained with 12 weeks of Epclusa were numerically higher than those obtained with 8 weeks of the triple combination, whereas in POLARIS-3, the SVR rates were comparable.
Particularly in POLARIS-3, which involved the most difficult to treat, genotype 3 infected cirrhotic patients, Epclusa for 12 weeks resulted in 96% SVR rate. These results underscore the value of Epclusa as an excellent treatment option for patients across all genotypes, and they also suggest that the future role of SOF/VEL/VOX will be for patients who previously failed an anti-viral regimen. The full data from these studies will be presented at AASLD in a few weeks, and we will submit Marketing Authorization Applications to regulatory authorities imminently.
Another exciting result was the anti-fibrotic effect observed with GS-4997, an investigational small molecule inhibitor of apoptosis signal-regulating kinase 1 or ASK1. GS-4997 was a shown to inhibit inflammation apoptosis and fibrosis in settings of increased oxidative stress associated with NASH in preclinical models. This Phase II clinical study involved 72 patients. 2/3 had F3-stage fibrosis, and 1/3 had F2-stage fibrosis. There was evidence that treatment with GS-4997 for only 24 weeks resulted in fibrosis reversal and decreased fibrosis progression in a dose-dependent manner. At the highest dose tested, which was 18 milligrams, 43% of patients showed at least a 1 point decrease in their fibrosis score compared to only 20% in the simtuzumab control arm. At the same time, 20% of the simtuzumab-treated patients progressed to cirrhosis compared to only 3% or 1 out of 30 at the 18-milligram dose. The full data from these studies will be presented at AASLD in a few weeks.
Based on these exciting data, we will initiate discussions with regulatory authorities and plan to move GS-4997 into Phase III clinical development in patients with NASH. Based on the Phase II results, we intend to evaluate GS-4997 in patients with the highest unmet need. That means those with F3 and F4 stages of fibrosis.
At the same time, we have 2 other compounds with different mechanisms currently in 2 Phase II studies in patients with NASH and fibrosis, and that is GS-9674, an FXR agonist; and GS-0976, an ACC inhibitor. And the studies are of 24- and 12-week duration, respectively. Pending demonstration of single-agent efficacy and safety in these 2 Phase II studies, we plan to initiate combination studies with the 3 agents towards the middle of next year.
In HIV, we're continuing to explore the utility of TAF-containing regimens in various uses in different populations. Last week, data from 3 Phase III studies were presented at the HIV Conference in Glasgow. 96-week data were disclosed from 1 study where 663 biologically suppressed patients were randomized to either continue on their Truvada-based regimen or to switch to a Descovy-based regimen. In 2 other studies, 630 and 875 of largely suppressed patients on Complera and Atripla, respectively, were randomized to switch to Odefsey or stay on their current regimen. In all studies, switching to a TAF-based regimen was noninferior with regards to efficacy but were superior with regards to renal and bone laboratory safety parameters.
The Phase III development of the single-tablet regimen of bictegravir F/TAF is continuing. Four Phase III studies are now fully enrolled, and we anticipate unblinding these studies towards the middle of next year with regulatory submissions planned for the third quarter of 2017. We also plan to present 48-week Phase II data on bictegravir F/TAF at the Scientific Meeting in the first quarter of 2017.
In oncology, a Phase III study of GS-5745 in patients with gastric cancer is ongoing as well as a Phase II study in patients with gastric cancer in combination with nivolumab. We're also evaluating GS-5745 in other solid tumors.
In addition, we have now completed 2 Phase I safety studies of our combination kinase inhibitors. We were able to establish safe doses of our PI3K inhibitor, idelalisib, in combination with our BTK inhibitor, GS-4059, and our Syk inhibitor, entospletinib, in combination with the BTK inhibitor, GS-4059. Consequently, we will now first evaluate the PI3K/BTK combination with and without anti-CD20 therapy in relapsed/refractory CLL patients in collaboration with the German CLL study group.
We will also be announcing initial Phase Ib/II data on our Syk inhibitor, entospletinib, in acute myeloid leukemia at the upcoming ASH Conference in San Diego. We've entered into a collaboration with the Leukemia & Lymphoma Society to provide entospletinib for their Beat AML Master Trial. This trial will employ the latest genomic technology to match specific AML mutations in newly diagnosed patients over age of 60 with an appropriate investigational drug or drug combination.
In summary, great progress has been made with some of our programs. The very nature of R&D is that you often face both closures and progress. Going forward, I'm pleased we now have the ability to focus our attention on development programs in NASH, inflammation oncology and HIV. We now have 7 new molecules in advanced clinical development. The PDUFA date for TAF for HBV is coming up in a few weeks, and we plan to file an NDA before the end of the year on SOF/VEL/VOX for use as salvage therapy for patients who have failed a previous direct acting antiviral. 
Four molecules are continuing in Phase III. That is momelotinib for myelofibrosis; bictegravir/F/TAF, the single-tablet regimen for HIV infection; filgotinib for 3 separate indications, rheumatoid arthritis, ulcerative colitis and Crohn's; and GS-5745 in gastric cancer. Finally, we plan to advance GS-4997 for NASH to Phase III.
I would now like to turn the call over to John."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Thanks, Norbert. I want to make a few closing remarks before we get to your question.We continue to have success with the important work we do in HIV and viral hepatitis. There's still a great need for innovation in these deals. Both diseases include pa",869,"Thanks, Norbert. I want to make a few closing remarks before we get to your question.
We continue to have success with the important work we do in HIV and viral hepatitis. There's still a great need for innovation in these deals. Both diseases include patients whose needs remain unaddressed, and both represent global epidemics.
Our researchers are working to bring new options to a wider range of patients than ever before. This includes people with HIV who've been on therapy for decades and may need to change their medication due to side effects or patients who may be failing to fully suppress their virus due to the presence of resistance.  Approaches our research teams are pursuing include new molecules for treating resistant virus now in formulations and combinations that may be dosed infrequently and opportunities to cure HIV patients by clearing out viral reservoir from their bodies.
Our innovative work, in conjunction with our many partners, has already allowed our HIV medicines to reach millions of patients worldwide. We're particularly excited about the role that TAF will play. With a small daily dose and improved side effect profile, it is ideal for resource-constrained areas of the world and requires only 1/10 of the manufacturing capacity to supply the same number of patients.
In the area of viral hepatitis, the data now obtained with Epclusa suggests that we have an excellent option for the many parts of the developing world for genotyping HCV in determining the stage of disease can be difficult, if not, impossible. With Epclusa, there's no difference in dosing for the different genotypes or stages of liver disease, and so there's no need for these diagnostic procedures. We're working around the globe to rapidly introduce Epclusa as well as Sovaldi and Harvoni.
Finally, in hepatitis B, as Kevin and Norbert mentioned, we are approaching the launch of TAF. HBV continues to be an under-treated disease despite the long-term data showing improvement of liver for people who remain on effective therapy. TAF provides an important new option for patients with chronic HBV, and we'll have the opportunity to introduce the product at the liver meeting in the next -- coming weeks at Boston.
We also recognize that treating such a prevalent disease chronically is a major global challenge, and we continue to seek ways to provide finite duration of treatment that the patients can control or eliminate the virus without having to endure a lifetime of treatment. Gilead's largest research effort is in the area of HBV care.
Beyond our work in antivirals, we are making great progress in new disease areas for Gilead. We are pleased to be able to share with you today our top line data for GS-4997 in NASH. GS-4997 targets ASK1, a previously unexplored target for NASH. The data are suggestive of a strong anti-fibrotic -- of strong anti-fibrotic activity after only a 24-week period of treatment, and we look forward to future in-depth discussions once the data are presented at AASLD.
We think about GS-4997 as a potential backbone molecule, one that can be used alone or in combination. NASH is an understudied but increasingly prevalent disease, and Gilead's liver disease team now has 3 exciting molecule to move forward in the clinical studies. We understand that there's a lot of work to do in providing both the rationale for the patient and to the payer as to the benefits of treating NASH. An active compound such as GS-4997 could really move the field forward, and we are in the process of designing comprehensive studies to demonstrate that health system benefits of treating such a prevalent and growing disease.
In the area of inflammation, we're executing nicely on our development plan. Phase III studies of filgotinib in RA are up and running, and studies in Crohn's and ulcerative colitis have just begun screening patients in the first of these studies. I'm pleased with the progress we are making, and the work of our teams and collaborators get these trials up and running as quickly as possible. We're also looking forward to exploratory studies of filgotinib in a wider variety of inflammatory diseases so that we can fully understand the potential of this specific JAK1 inhibitor.
As you know, we are also focused on our -- augmenting our portfolio with external opportunities, particularly in the field of oncology. However, our interest in partnerships or potential acquisitions is not limited to oncology, and we are considering opportunities where there's strong science and where we see the possibility of developing a truly differentiated product.
We have been going through an extensive internal review of programs and opportunities, and an important aspect of our approach is that we remain open minded but disciplined. So while we have the balance sheet to execute on multiple opportunities, we will keep the bar high.
With 2 months of the year remaining, I want to take the opportunity to thank the 9,000 employees of Gilead for their hard work and dedication. Everyday, more than 10 million individuals around the world take a Gilead medication, and everyday, our teams come to work to improve upon that number.
Thank you for your time. Let's now open the call to questions. Operator?"
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Geoff Meacham of Barclays.",15,"[Operator Instructions] And our first question comes from the line of Geoff Meacham of Barclays."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","John or Kevin, I got one for you. Just wanted to ask about hep C but in a broader context. So you guys have had flat patient numbers despite better access in the U.S., and revenue's down sequentially but on payer mix. So the question is how do you think a",78,"John or Kevin, I got one for you. Just wanted to ask about hep C but in a broader context. So you guys have had flat patient numbers despite better access in the U.S., and revenue's down sequentially but on payer mix. So the question is how do you think about the return on investing continually in hep C either commercially or in new products versus, say, looking outwards and being more aggressive in a new therapeutic category."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Jeff, it's Kevin. Let me just take maybe half a step back from your question, just a few more observations. I've got to tell you that I think we're really executing well in the area of hepatitis C. I've spent a lot of time this quarter with many Gileads a",423,"Jeff, it's Kevin. Let me just take maybe half a step back from your question, just a few more observations. I've got to tell you that I think we're really executing well in the area of hepatitis C. I've spent a lot of time this quarter with many Gileads and with several providers, and I think the variables that we can directly influence, we're really doing a good job on. Our market share is staying incredibly strong. We're ensuring access whilst preserving the value of our hepatitis C drugs. And we're executing on new versions coming to the market. I think you've seen that with Epclusa. And the area that we can less control but we can influence, you're now seeing some new activities from us in terms of unbranded awareness campaigns, and you may have seen our advertisement that came on the television just over a week ago. So I think, from my point of view, in terms of operational excellence, we're doing a very nice job. It is true that the treatments are staying about the same. Actually, I've considered that very positive. Let's not forget that we're at treatment levels that are 2.5x the treatment levels that were there before the Gilead regimens came to the market. So I take at the level of 50,000 to 60,000 patients as very good. The vast proportion of those are Gilead patients. Epclusa had a very big effect in this quarter, so it goes to show that there's still room for new patients, albeit that we're entering a high level of satisfaction. But with Harvoni for genotype 1, both 12 weeks and now a high proportion at 8 weeks and now Epclusa for the 2 and 3 patients. Yes, we have got patients being cured at very high levels. In terms of our triple, I do agree that will be a relatively small proportion of patients, but it's the right thing to do. And it completes our whole picture for hepatitis C. So I think to have the range of products that we have, to have the efficacy that we have is the right offering for health care. So we continue to move forward, and I think we have a healthy franchise. And we are getting better access from particularly the commercial payers, although, as I pointed out and I often discuss with the team here, the Medicaid is still a little bit on the slow side in terms of access. But great progress as far as I'm concerned in the third quarter."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","And Jeff, it's John. The second part of your question is -- was something about investing in this area versus other areas. So I would say, from a pipeline perspective, with SOF/VEL/VOX being our fourth generation of HCV products now being approved, there",113,"And Jeff, it's John. The second part of your question is -- was something about investing in this area versus other areas. So I would say, from a pipeline perspective, with SOF/VEL/VOX being our fourth generation of HCV products now being approved, there really isn't much left in terms of unmatched medical need. And so from a pipeline perspective, this is really the end of what we will be developing in terms of HCV molecules, and that will allow us then to turn our attention to the important aspects in our fibrosis and NASH franchises and our oncology franchises. So we've really largely turned our attention away from HCV to those areas already."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Brian Abrahams of Jefferies.",10,"And our next question comes from Brian Abrahams of Jefferies."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Norbert, a question on 4997. Wondering if you could talk a little bit more about the go-forward plan there, particularly with respect to potential Phase III trial duration and whether or not a fibrosis endpoint might be acceptable just given the effects t",90,"Norbert, a question on 4997. Wondering if you could talk a little bit more about the go-forward plan there, particularly with respect to potential Phase III trial duration and whether or not a fibrosis endpoint might be acceptable just given the effects that you saw in such a short time period in Phase II and the plan to target more severe progressive patients. And then can you confirm that there were no baseline imbalances in the Phase II that might have influenced the fibrosis data or progression to cirrhosis data?"
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","So the second question, yes, I can confirm that there were no baseline imbalances. And regarding the Phase III study, no, we are going to make the proposal to regulatory authorities to use just fibrosis as the endpoint. We feel very convinced that, that's",231,"So the second question, yes, I can confirm that there were no baseline imbalances. And regarding the Phase III study, no, we are going to make the proposal to regulatory authorities to use just fibrosis as the endpoint. We feel very convinced that, that's the right thing to do because, as you may know, fibrosis is the only histological correlate to clinical outcomes. There was a large study published a few years ago where they looked at baseline histology and they correlated histological variables with clinical outcomes. And steatosis didn't correlate. Inflammation didn't correlate. Ballooning didn't correlate. The only thing that correlated was fibrosis. So we are going to propose 2 Phase III studies, both looking at fibrosis 48 week as the endpoint. The other thing, we're going to do with the studies in F3, F4 patients. Again, the rationale is that, that's where the unmet need is. And also since ultimately for full approval you will need some clinical endpoint, we think we can get there much faster maybe with a 96-week study even if we start off with F4 patients. But having all of that said, this all has to be agreed upon by regulatory authorities. We have a date with the FDA, but we have not discussed this with them yet. So stay tuned. Sometime early next year, I think we can update you on the exact plan."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Matthew Harrison of Morgan Stanley.",11,"And our next question comes from Matthew Harrison of Morgan Stanley."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Can I just ask, you made 2 comments related to HCV that I just want to get some more color on. You talked about you're pleased with the 2017 payer cycle. Can you just tell us if we should expect any significant changes in pricing or not? And then can you",86,"Can I just ask, you made 2 comments related to HCV that I just want to get some more color on. You talked about you're pleased with the 2017 payer cycle. Can you just tell us if we should expect any significant changes in pricing or not? And then can you describe what you think is the size of the Epclusa warehouse and if you think you've moved through that or you would expect to see some more of that through the end of the year?"
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Matt, it's Kevin Young. I'll take your second part first. Yes, there was a small warehousing effect. We think that this is anecdotal and qualitative. We think that providers probably held people for sort of a quarter, 2- to 3-month period. So this is noth",177,"Matt, it's Kevin Young. I'll take your second part first. Yes, there was a small warehousing effect. We think that this is anecdotal and qualitative. We think that providers probably held people for sort of a quarter, 2- to 3-month period. So this is nothing like the warehousing that we saw with Sovaldi or with Harvoni. So I -- we think it's largely a Q3 effect. It might go into the fourth quarter, into the quarter now. But we really think it's mostly a 2016 effect. In terms of our negotiations and contracts, I really can't make any specific comments. Obviously, they're confidential. But we are pleased with the outcome. We feel we're in a strong position for 2017, and most providers will have very, very good access in the private and Medicaid -- Medicare Part D setting to both Harvoni and Epclusa. So we think we're in good shape, and our providers will have the Gilead options to look forward to giving to their patients as we have done in 2016. So feel good about that."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from John Scotti of Evercore ISI.",11,"And our next question comes from John Scotti of Evercore ISI."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I wanted to ask one on capital allocation if I may. So last quarter, you spoke about potentially having a more complete story of internal and also external progress by year-end, and you've continued to be relatively light on the buyback in 3Q. So couple t",107,"I wanted to ask one on capital allocation if I may. So last quarter, you spoke about potentially having a more complete story of internal and also external progress by year-end, and you've continued to be relatively light on the buyback in 3Q. So couple things. Can you characterize right now your current appetite for M&A and if that's changed the current thinking more along the lines of larger, transformative deals? Or should we expect a string of in-licensing deals similar to what we saw with filgotinib and Nimbus? And how should we think about the sense of urgency here given your comments and going into year-end?"
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","John, it's John. I think you asked the capital allocation question and switched to strategy. I will try to answer that for you. We -- so as we said in our opening comments, we're still very actively evaluating opportunities. We're actively evaluating a se",129,"John, it's John. I think you asked the capital allocation question and switched to strategy. I will try to answer that for you. We -- so as we said in our opening comments, we're still very actively evaluating opportunities. We're actively evaluating a series of different partnerships. But as I said in my comments, we're going to remain disciplined. We're going to keep the bar high. You don't want the sense of urgency to overwhelm your discipline because then you'll do things that don't make long-term sense. And that's been the history in all businesses, and that's one we apply here. So we're currently very, very active. We'll do things when they make sense for us and not before that. And that's really as much as I can say."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Geoffrey Porges of Leerink Partners.",11,"And our next question comes from Geoffrey Porges of Leerink Partners."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Appreciate the question. Robin, just a couple for you if we may. First, operating margin, trending down by 200 to 300 basis points a quarter. Is that something that we should anticipate continuing or are there some variables in there? Secondly, just on Ep",104,"Appreciate the question. Robin, just a couple for you if we may. First, operating margin, trending down by 200 to 300 basis points a quarter. Is that something that we should anticipate continuing or are there some variables in there? Secondly, just on Epclusa. Was there any channel inventory build in the reported number? And then lastly, how are you judging the sort of share buyback? You spent $10 billion, as you pointed out, this year, and the average cost is sort of around $90. Compared to other things that you might have invested in, how are you feeling about that buyback going forward?"
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Sure, Geoff. I'll start on the reverse quarter and address the buyback first. I mean, we really look at buybacks on a long-term perspective, which is pretty much what I committed or mentioned during the last quarter call. So we're still very comfortable w",327,"Sure, Geoff. I'll start on the reverse quarter and address the buyback first. I mean, we really look at buybacks on a long-term perspective, which is pretty much what I committed or mentioned during the last quarter call. So we're still very comfortable where we are. We did front load a significant component of our share buybacks. As a matter of fact, I think, just in the first quarter, we did more than the entire 3 quarters of 2015. And we messaged very early on that we would see those declines towards the second half of this year, very much in alignment with John's comments around being prepared for M&A. It's still clearly a part of our capital allocation strategy along with dividends. But I think balancing that with overall, looking for growth is something that we're still focused on doing. And as John mentioned, these things take time to play their selves out. I'll let Kevin answer the inventory question, but I think to your question of operating margins, yes, but quarterization of our margins do get impacted by revenue dynamics as well as expenses. Keep in mind, R&D had a $200 million milestone payment this quarter included in that. But overall, I think our margins still remain high, high relative to overall industry, much better and we're comfortable with them. We're very prudent with expense management. You saw SG&A expense is down. I think the other thing you're slightly seeing is as the that mix changes between HCV and HIV, that has a little bit of an impact on our growth margin. But overall, with the continued conversion of TAF, long term, you'll continue to see that go down. But it will be impacted relative to HCV becoming a smaller component of our total revenue. I can't really give guidance on our gross margins, but I think the bar still remains high for them, and we still remain a very disciplined spending type of organization."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. And Geoff, just to comment on Epclusa. If you recall, we launched Epclusa in the last week in quarter 2, so that's when our opening inventory went in. Like any growing products, major wholesalers tick up their inventory basically because they got a s",113,"Yes. And Geoff, just to comment on Epclusa. If you recall, we launched Epclusa in the last week in quarter 2, so that's when our opening inventory went in. Like any growing products, major wholesalers tick up their inventory basically because they got a standard calculation for days on hand. So basically, that just ticks up as a product grows or indeed comes down, as a product comes down as likely Sovaldi because it's now becoming Epclusa will in the future. So there was nothing unnatural about inventory for Epclusa in the third quarter, but as I've said, we did get a very nice bump in usage from a small warehousing of patients."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Cory Kasimov of JPMorgan.",10,"And our next question comes from Cory Kasimov of JPMorgan."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","John, I wanted to go back to your comments on the strategic question you just got. When you talk about having a high bar in the M&A front, does that mean you see a lack of interesting opportunities out there that just don't meet that bar? Is this more of",60,"John, I wanted to go back to your comments on the strategic question you just got. When you talk about having a high bar in the M&A front, does that mean you see a lack of interesting opportunities out there that just don't meet that bar? Is this more of a price disconnect given the continued volatility in the market?"
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Discipline has both components to it. There are a number of things that, I think, are probably too early for us to take part in. There are a number of things that I think are just overpriced. And so it's been a combination of those 2 things going forward",75,"Discipline has both components to it. There are a number of things that, I think, are probably too early for us to take part in. There are a number of things that I think are just overpriced. And so it's been a combination of those 2 things going forward -- or looking backwards. Going forward, we'll have to see what makes sense for us and where we're willing to go to bring in new products."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Michael Yee of RBC Capital Markets.",12,"And our next question comes from Michael Yee of RBC Capital Markets."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","I want to ask a question on patient volumes in hep C, specifically as it relates to Slide 41, I guess. Previously, I would have thought that changes in payer access would have opened up the availability of these drugs to get reimbursed for the healthier F",141,"I want to ask a question on patient volumes in hep C, specifically as it relates to Slide 41, I guess. Previously, I would have thought that changes in payer access would have opened up the availability of these drugs to get reimbursed for the healthier F0s and F1s. I guess, with patient volumes flattish, are you seeing these F0s and F1s coming in? Are they getting treated? Or is your bottleneck there? They come in, and they don't get treated. Just wanted to understand your dynamic on that and whether you think that, that's going to drive some positive development of volumes. And then in Europe, the same question. Europe declined from 27,000 down to 21,000. Just do you think that -- how do you think that plays out, I guess, going forward? What are the dynamics there for volumes?"
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Two great questions. Let me try and deal with those in the order. So first, the U.S. If you look at our slide, actually, the percentage of F0s to F2s has increased over time. It was sort of 50% a little while ago. Now it's up to 60%. So clearly, fitter pa",417,"Two great questions. Let me try and deal with those in the order. So first, the U.S. If you look at our slide, actually, the percentage of F0s to F2s has increased over time. It was sort of 50% a little while ago. Now it's up to 60%. So clearly, fitter patients there, the less sick are being treated, and of course, that's as result of coverage. But I want to say that the patient journey, I think, is becoming longer in the U.S. now. If you think about it, patients are really starting further back because they are healthier. We are continuing to see approximately 30,000 patients coming into specialist care so in other words, 90,000 patients a quarter. 60,000 of those are coming out of the other side and are being treated and cured. That's probably not a bad ratio in itself. Not every patient is treated, and not every patient is immediately treated. Now we shouldn't forget that, sometimes, patients drift in and out of a specialist's care. Some patients have compounding factors that complicates the start of therapy, most notably, drug use or alcohol use. And the patients who are just less sick have less motivation themselves, and the physician has less motivation to really push those through therapy. And lastly, the paperwork and the administrative process for authorization is still there with -- like it is with any specialist product. So I think those are mostly the dynamics, and it's mostly around the patients being less time in the physician's practice. They're not patients that have been held for a long time. They're not patients that failed 1 or 2 prior therapies and a great urgency by the physician. In terms of Europe, as I said, we did see a downtick in the patients treated in the southern European markets, primarily Italy and Spain, and I think that's because they are working through the sicker patients and are becoming more like France and Germany. There still are more patients in the southern European markets, but I do think they are clearing the most obvious patients to treat and cure. Now I want to emphasize that market share has stayed very, very solid in those markets. And whilst it's not an obvious mechanism through advertising, television advertising in the European markets, we are doing a lot of partnership with KOLs, with societies, with patient groups to, again, try to encourage the right screening practices and the right transfer of patients into specialist care."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Robyn Karnauskas of Citi.",10,"And our next question comes from Robyn Karnauskas of Citi."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","So just to ask the HCV question from a fourth quarter impair perspective. Remember, last fourth quarter, you started to see tens of [ph] changes in HCV. So given that looks like you have stabilized, are you seeing anything that hints that payers could cha",123,"So just to ask the HCV question from a fourth quarter impair perspective. Remember, last fourth quarter, you started to see tens of [ph] changes in HCV. So given that looks like you have stabilized, are you seeing anything that hints that payers could change how they're viewing the -- or any changes in fourth quarter that you're seeing that can influence 2017? And then given you've maintained guidance, how are you thinking now about providing what kinds of guidance you might provide in '17 to help investors feel comfortable that you can predict going forward? If any -- I know you can't give guidance but if you can give any hints on how you're thinking about giving us some color next year."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","I'll take the first part. I think, again, come back to the quality of the discussions that we had for 2017 contracting, and I think they were very good. Let's not forget the fact that Gilead are in a very strong place by virtue of Harvoni being in a good",233,"I'll take the first part. I think, again, come back to the quality of the discussions that we had for 2017 contracting, and I think they were very good. Let's not forget the fact that Gilead are in a very strong place by virtue of Harvoni being in a good proportion of patients in an 8-week therapy. So that's a very big advantage for us, and I think that's really appreciated from a point of view of managing costs from a commercial payer. We didn't see much change in the ratio of the public to private payer in the third quarter. It was still about 45% of patients who were covered as a public patient as opposed to a commercial or Medicare Part D plan. Part of the commercial part of the market is, of course, the VA. The VA was a little bit lower in the third quarter versus the second quarter. They still seem to be very enthusiastic, very engaged in recalling patients. But I think that's, perhaps, one of the variables that will kind of unfold in 2017, is the VA and their continuing ability to recall and treat patients. But I think with our efforts around highlighting the CDC, need to treat the baby boomers and the activity of all the companies involved in hepatitis C, I'd like to think that we can continue our progress in 2017."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","So Robyn, it's Robin. I'll take the second part of that question. Yes, I think, as we said, this is a curative market, HCV, and it's difficult to predict. And Kevin just outlined this kind of patient journey taking a longer bit of time and just changing d",132,"So Robyn, it's Robin. I'll take the second part of that question. Yes, I think, as we said, this is a curative market, HCV, and it's difficult to predict. And Kevin just outlined this kind of patient journey taking a longer bit of time and just changing dynamics. And we spent a lot of time this fall working through the planning cycle, figuring out what that means around '17 and beyond. Obviously, I can't give the answer yet, but it's -- how we guide will, again, depend on our ability to bracket the risk and opportunities around those dynamics and what those mean. It continues to change, and it's something that we monitor very closely. But that patient flow, as Kevin said, is something that's just very difficult for us to control."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes. I'd also add, Robyn, if I might, that -- how solid and good we feel about HIV going into next year with that chronic model and the uptick of our TAF-based regimens.",33,"Yes. I'd also add, Robyn, if I might, that -- how solid and good we feel about HIV going into next year with that chronic model and the uptick of our TAF-based regimens."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Ying Huang of Bank of America Merrill Lynch.",14,"And our next question comes from Ying Huang of Bank of America Merrill Lynch."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","The first one maybe is for Kevin. Our channel checks indicated that VA is paying about $15,000 to $17,000 per patient. Do you think that's the absolute floor for HCV pricing? And then another question for John and Robin. Sounds like you guys have really h",85,"The first one maybe is for Kevin. Our channel checks indicated that VA is paying about $15,000 to $17,000 per patient. Do you think that's the absolute floor for HCV pricing? And then another question for John and Robin. Sounds like you guys have really high bar for acquisitions. If you don't deploy capital in acquisitions, would you consider hiking dividend to a much higher level like 5% to 6% so that a lot of investors would be willing to take the [indiscernible] dividend payment?"
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","It's Kevin. I apologize, but in terms of commenting on our net pricing to the various channels, to the various constituents, it's not something that we directly comment on. So I couldn't go any further than that at this time.",41,"It's Kevin. I apologize, but in terms of commenting on our net pricing to the various channels, to the various constituents, it's not something that we directly comment on. So I couldn't go any further than that at this time."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes, Ying, and I'll take the second half. I mean, I think, as we said, the bar is side, but we're very engaged and remain engaged in M&A. And when we think about our overall capital allocation, we wouldn't want to do anything that would constrain us with",97,"Yes, Ying, and I'll take the second half. I mean, I think, as we said, the bar is side, but we're very engaged and remain engaged in M&A. And when we think about our overall capital allocation, we wouldn't want to do anything that would constrain us with -- and reduce our flexibility to purchase if we found something that we thought could really grow our top line. So we talk with our board all the time about dividend increases and dividends in general as well as share repurchases, and that's something that we'll continue to do."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes Phil Nadeau of Cowen and Company.",11,"And our next question comes Phil Nadeau of Cowen and Company."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Unfortunately, it's another one on HCV pricing for you Kevin. You mentioned kind of 2 factors that impact the average per patient price that have been changing. One is the public versus private payer mix, which as you said, changed over last year but mayb",165,"Unfortunately, it's another one on HCV pricing for you Kevin. You mentioned kind of 2 factors that impact the average per patient price that have been changing. One is the public versus private payer mix, which as you said, changed over last year but maybe stabilized now and then also the rebates given to private payers. You didn't really discuss those too much in this call, but in the past, your predecessor said that he expected the rebates to actually increase when Merck entered the market next year. Some of your comments today could suggest the opposite. So I guess, kind of just curious, for 2017, how should we think about those 2 factors. Do you think public versus private has plateaued? Is 45% the number we should be thinking about for 2017? And then on the rebates to the private payers, should we continue to expect those to tick up in 2017? Or is your feeling different now that you've gone through negotiation cycles?"
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Difficult for me to comment in any great detail, Phil, on either of those questions. I'll take the commercial first. They have gone well. I think, as I keep emphasizing, the advantage we have in 8 weeks, we think about it, 45% right now of Harvoni patient",274,"Difficult for me to comment in any great detail, Phil, on either of those questions. I'll take the commercial first. They have gone well. I think, as I keep emphasizing, the advantage we have in 8 weeks, we think about it, 45% right now of Harvoni patients, genotype 1 patients are receiving 8 weeks. So if you think about 45% of genotype 1 with just that 8 weeks, that's a very good economic offering for our payers that they really appreciate. So we've -- I believe we've done very well in our position going into 2017. In terms of the ratio between public and private, again, very difficult for me to make a prediction. VA did come down a little bit, but there was an increase, just a tick-up, to replace that by Medicaid. I made the comment that the Medicaid opening is really slower than we would like, but I think there may be that change in mix going forward. Difficult to predict VA. VA is still a big part of the public, and we'll just have to see. It's very impressive what they've done, and I know they're very committed. And they feel that they haven't done their job yet. We, and that's Gilead, we estimate that between 35% and 40% of the patients in the VA system have been treated to date. So still a lot of work to do, and I think they want to do it. So 45% -- 55% seems to have been the level for the last couple of quarters and not entirely clear if that's going to be maintained into 2017, but seems reasonable to me."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Alethia Young of Crdit Suisse.",11,"And our next question comes from Alethia Young of Crdit Suisse."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Just, I wanted to talk a little bit about like Genvoya launch and like maybe how it's faster than even the Atripla launch. It was obviously a very good launch. Maybe if you can just frame like what's been kind of how doctors are looking at this. Are they",84,"Just, I wanted to talk a little bit about like Genvoya launch and like maybe how it's faster than even the Atripla launch. It was obviously a very good launch. Maybe if you can just frame like what's been kind of how doctors are looking at this. Are they looking at it more as like just kind of for everyone that needs to come to the doctor, they're just go and get this drug? Or just give us some more flavor on the dynamics."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Alethia, thanks for an HIV question. I really appreciate it. Alethia, I was at our international advisory board couple of weeks ago, and we had some of the foremost HIV doctors from around the world. And it was absolutely unanimous. The commitment to swit",252,"Alethia, thanks for an HIV question. I really appreciate it. Alethia, I was at our international advisory board couple of weeks ago, and we had some of the foremost HIV doctors from around the world. And it was absolutely unanimous. The commitment to switching patients, all things being equal, particularly in terms of pricing, physicians see the benefit in terms of bone and kidney from the point the view of TAF. So I think there's an awful strong commitment. Let's not forget that in most practices now half the patients are over the age of 50, and they've been on long-term therapy. And physicians just see a natural and fairly straightforward switch going on. I'm really -- I really didn't think I'd ever see an uptake quicker than Atripla. As you remember, there were the components of Atripla that could just be put together and the patients switched. These are slightly different with Genvoya because it's a switch of regimen. So I'm delighted with the way it's going. 80% of Genvoya comes from switches, and right now half of those switches are from Stribild, which is the natural TAF to -- TDF-to-TAF switch. So my expectation is that we will continue to convert patients, and I'm super enthusiastic about it. And once we get more countries online in Europe, I think we can have that same expectation. Germany is going great. Spain is going great. And we're on the threshold of getting the most important market up and running, and that's France."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Terence Flynn of Goldman Sachs.",11,"And our next question comes from Terence Flynn of Goldman Sachs."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Maybe just wondering if you guys can comment about the GSK ViiV doublets for HIV. Maybe just help frame for us how to think about that, if those are successful and either treatment or maintenance setting. Would you look to explore your own doublet regimen",57,"Maybe just wondering if you guys can comment about the GSK ViiV doublets for HIV. Maybe just help frame for us how to think about that, if those are successful and either treatment or maintenance setting. Would you look to explore your own doublet regimen? Or do you think you've already set a high enough bar there?"
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Terence, so the debates in our -- with bictegravir is not doublet or triplet. We're developing bictegravir/F/TAF because it has 3 excellent components that have proven safety and enormously high efficacy. If you look at the ViIV Triumeq compound, of cours",135,"Terence, so the debates in our -- with bictegravir is not doublet or triplet. We're developing bictegravir/F/TAF because it has 3 excellent components that have proven safety and enormously high efficacy. If you look at the ViIV Triumeq compound, of course, that contains abacavir. So in that scenario, there is an incentive to get rid of abacavir and go to a doublet as you call it. But in our case, that's -- absolutely, we have no incentive whatsoever to do that. I would like to point out it's an interesting strategy. It's a potential competitor. The only thing I would like to point out is the safety efficacy has to be still proven in a larger patient population, number one; and number two, in more diverse patient population, particularly in patients with high viral load."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our next question comes from Ian Somaiya of BMO Capital Markets.",12,"And our next question comes from Ian Somaiya of BMO Capital Markets."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Analysts","Just a question for you maybe, Robin, on just the R&D spend going forward. The filgotinib program, the 3 Phase III programs may, in aggregate, cost about $1 billion. You're about to embark on a -- in a fairly sizable NASH program. Just how should we think",75,"Just a question for you maybe, Robin, on just the R&D spend going forward. The filgotinib program, the 3 Phase III programs may, in aggregate, cost about $1 billion. You're about to embark on a -- in a fairly sizable NASH program. Just how should we think about R&D spend going forward? Are there any trials that are completing that might provide an offset? Just if you could give us some color related to that."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","So maybe, Ian, I'm going to answer the first question, and Robin can join in. So as we indicated before, our hepatitis C research is winding down, or the development is winding down. Really, with this SOF/VEL/VOX, this will be our last development candida",109,"So maybe, Ian, I'm going to answer the first question, and Robin can join in. So as we indicated before, our hepatitis C research is winding down, or the development is winding down. Really, with this SOF/VEL/VOX, this will be our last development candidate, and we have spent, over the last 3 years, probably most of our money on hepatitis C. So that's winding down and also, in HIV are coming down because of bictegravir/F/TAF is going to be our last single-tablet regimen for a broad patient population. And that, I think, will offset the increased spending in the other areas, as you pointed out, filgotinib and also oncology."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Yes, yes. I think, Norbert, summed it up. Ian. I'll only add that I think the rigor remains very high internally within Gilead as well, right? We're always making the various tradeoffs, and we look to do the right thing scientifically. So you could see va",92,"Yes, yes. I think, Norbert, summed it up. Ian. I'll only add that I think the rigor remains very high internally within Gilead as well, right? We're always making the various tradeoffs, and we look to do the right thing scientifically. So you could see variability in costs. But overall, there's still a high bar internally relative to how we allocate our research spend. But a lot of our projects ongoing, as mentioned, will be paid for with the decline in some of the larger products we have with HIV and HCV."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","And our final question comes from the line of Jim Birchenough of Wells Fargo.",14,"And our final question comes from the line of Jim Birchenough of Wells Fargo."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Jim, are you there?",4,"Jim, are you there?"
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","You're on mute.",4,"You're on mute."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","I think that's it, Candace.",6,"I think that's it, Candace."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","There are no further questions at this time. I'd like to turn the conference back over to Sung Lee for closing remarks.",22,"There are no further questions at this time. I'd like to turn the conference back over to Sung Lee for closing remarks."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Executives","Great. Thanks, Candace. Thanks, everyone, for joining us today. We appreciate your continued interest in Gilead, and the team here looks forward to providing you with updates on our future progress.",31,"Great. Thanks, Candace. Thanks, everyone, for joining us today. We appreciate your continued interest in Gilead, and the team here looks forward to providing you with updates on our future progress."
29002,403467286,1069814,"Gilead Sciences Inc., Q3 2016 Earnings Call, Nov 01, 2016",2016-11-01,"Earnings Calls","Gilead Sciences, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Have a great day, everyone.",25,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Have a great day, everyone."
